HISTORY OF THE INTERNATIONAL THYROID CONGRESS

- International Conference on Goitre
  Berne, Switzerland – August 24-26, 1927
- 2nd International Conference on Goitre
  Berne, Switzerland – August, 1933
- 3rd International Goiter Conference & American Association for the Study of Goiter
  Washington, DC, United States – September 12-14, 1938
- 4th International Goitre Conference
  London, United Kingdom – July 5-8, 1960
- 5th International Thyroid Conference
  Rome, Italy – May 23-27, 1970
- 6th International Thyroid Conference
  Rome, Italy – May 23-27, 1970
- 7th International Thyroid Conference
  Boston, Massachusetts, United States – June 9-13, 1975
- 8th International Thyroid Congress
  Sydney, Australia – February 3-8, 1980
- 9th International Thyroid Congress
  Sao Paulo, Brazil – September 1-4, 1985
- 10th International Thyroid Congress
  The Hague, The Netherlands – February 3-8, 1991
- 11th International Thyroid Congress
  Toronto, Ontario, Canada – September 10-13, 1995
- 12th International Thyroid Congress
  Kyoto, Japan – October 22-27, 2000
- 13th International Thyroid Congress
  Buenos Aires, Argentina – October 30 – November 4, 2003
COMMITTEES

LOCAL ORGANISING COMMITTEE

President
Martin Schlumberger
Villejuif, France

Vice-President
Jacques Orgiazzi
Pierre Bénite, France

PROGRAMME ORGANISING COMMITTEE

Chairman
Wilmar Wiersinga
Amsterdam, The Netherlands

Members
Marcos Abalovich
Buenos Aires, Argentina

Antonio Bianco
Miami, United States

Denise Carvalho
Rio de Janeiro, Brazil

Sabine Costagliola
Brussels, Belgium

Josef Kührle
Berlin, Germany

Teofil O.L. San Luis
Manila, Philippines

Steven Sherman
Houston, United States

Young Kee Shong
Seoul, Korea

Yaron Tomer
New-York, United States

Laura Ward
Sao Paulo, Brazil

Shunichi Yamashita
Nagasaki, Japan

PATRONAGE COMMITTEE

Jean-François Bach, Académie des Sciences
Jacques-Louis Binet, Académie Nationale de Médecine
Guy Couarraze, Université Paris-Sud XI
Philippe Darterelle, Hôpital Marie Lannelongue
Anne Dejean, Institut Pasteur
Benoît Leclercq, Assistance Publique-Hôpitaux de Paris

René Mornex, Hospices Civils de Lyon
Maurice Tubiana, Institut Gustave Roussy
Jacques Dumont, Université Libre de Bruxelles
Sebastiano Filetti, Università La Sapienza, Rome
GianCarlo Vecchio, Università Federico II, Naples
Sir Dillwyn Williams, Università de Cambridge
WELCOME MESSAGE

Dear Colleagues, dear Friends,

On behalf of the Local Organizing Committee and the Program Organizing Committee, it is a privilege and pleasure to welcome you to the 14th International Thyroid Congress to be held from 11th to 14th September 2010 in Paris, at the Palais des Congrès.

Thanks to all committee members and with the cooperation of the 4 sister societies, we are confident that the Paris Congress will gain a great success, at least equivalent to that of the Buenos Aires Congress five years ago. We believe that the final result will be absolutely unforgettable!

The extremely high percentage of acceptance to lecture invitations in the scientific sessions represents a strong evidence of approval of the general programme from our scientific community.

We have received a total of 1300 abstracts that is 50% more than in Buenos Aires. The POC and LOC met in Paris during the last week end of May to finalize the program.

In addition to prestigious Plenary Prize Lectures scheduled each morning, a large number of sessions covering all aspects of the thyroid research and treatment (3 Implementing Guidelines sessions, 2 Debates, 28 Symposia, 24 Meet the Experts sessions) will be proposed.

Futhermore, for the first time, as a short cut to significant very recent data, two innovative “late breaking communication” oral sessions have been organised thanks to the enthusiastic submission of more than 50 abstracts after the special call circulated all over the four sister Associations.

Selected abstracts will be presented either as oral or poster discussion sessions and talented young investigators will be rewarded during the congress. Overall, the POC has selected 24 abstracts for 4 highlight sessions, 168 abstracts for 28 oral sessions (including one complete session on prospective trials in thyroid cancer patients) and 156 abstracts for 26 poster discussion sessions, 6 abstracts being presented during each session. The other accepted abstracts will be presented as posters.

Our field of research exists in close cooperation with the pharmaceutical companies and we are very grateful for the generous support that we have already received from these companies. The industrial exhibits and sponsored symposia will be a major attraction.

We have also allotted room for the 4 sister societies, for other academic societies and for association of patients.

Paris is a city of majestic beauty and charm and all the famous places and attractions of the « City of Lights » are easily reachable from the Palais des Congrès. The accompanying person programme will include a wide variety of tours and even post-tours. The weather is usually fair at that time of the year. Besides the Opening Ceremony and Reception at the Palais des Congrès, please join us for the Congress dinner, a unique Evening in the Château de Versailles on Tuesday 14th of September. This was permitted by the President of the Sénat to whom we would like to express our gratitude.

Wishing you a memorable ITC 2010 in Paris!

Martin Schlumberger and Jacques Orgiazzi
President and Co-President of the Local Organising Committee

Wilmar Wiersinga
President of the Program Organising Committee
The European Thyroid Association (ETA) was founded in 1965 and has met each year since then, with the exception of the years in which the International Thyroid Congress has been held. Membership of the Association consists of over 550 members (honorary, ordinary, junior, corresponding and senior).

The ETA’s aims are to promote knowledge in the thyroid field (fundamental and clinical) and improve knowledge of the thyroid gland and its diseases. The Executive Committee has established several Boards to assist in the organization and management of the ETA and its activities in order to reach the goals delineated in the statutes. The Public Affairs Board responds to all matters relating to the study of the thyroid in medicine and life science as they may occur in any country or region served by the ETA. The Membership Board is aimed at increasing the service and relation to ETA members. The Website Board intends to update the ETA website building up an internet area for ETA members which among others will allow scientific exchange between members and provide a ‘shop-window’ for the ETA. The Educational Board initiates and organizes educational activities in the field of thyroidology in various European and non-European countries. The Public Health Board is aimed at evaluating and advising on thyroid-related issues which are of concern to public health (such as iodine deficiency, radioactive fallout, endocrine disruptors, screening programs). The Board should also serve as a stand-by emergency board. The Archives Board records the history of the ETA and contributes historical vignettes to the ETA newsletter and website (Milestones in European Thyroidology, MET). The Guidelines Board is to generate and prioritize new proposals for guidelines and identify the need to update existing guidelines. There are working groups within the ETA, including the European Group on Graves’ Orbitopathy (EUGOGO) and the ETA-Cancer Research Network (ETA-CRN). The ETA publishes a Newsletter twice a year and runs its own online Journal, Hot Thyroidology.

Executive Committee

President
Peter Laurberg, Denmark

Secretary
Luigi Bartalena, Italy

Treasurer
George J. Kahaly, Germany

Ana Aranda, Spain
Leonidas Duntas, Greece
Agnieszka Piekielko-Witkowska, Poland
Robin Peeters, The Netherlands
Kris Poppe, Belgium
Martin Schlumberger, France
Graham Williams, England
Mariastella Zannini, Italy
Founded in 1923 as the American Goiter Association, the ATA is a nonprofit professional medical society comprised of physicians and scientists dedicated to enhancing the understanding of thyroid physiology and pathophysiology, improving diagnosis and treatment of thyroid diseases, and promoting the education of physicians, patients, and the public about thyroid disorders. In the 87 years of its existence, the ATA has grown to more than 1300 clinicians and research scientists in the field of thyrology.

NOTE: All meetings are located in the Palais des Congrès unless otherwise noted.

ATA Business Meeting (Open to all Active Members) Tuesday, September 14, 2010 8:45 – 6:15 pm (Level 3, Amphithéâtre Bordeaux)
ATA Board of Directors’ Meeting: Saturday, September 11, 2010, 4:00 – 6:30 pm (Level 3, Room 304-305)
ATA Anaplastic Thyroid Cancer Guidelines Task Force: Sunday, September 12, 2010, 7:00 – 8:30 am (Level 3, Room 304-305)
ATA Pediatric Thyroid Cancer Guidelines Task Force: Wednesday, September 15, 2010, 1:00 – 3:00 pm (Level 3, Room 304-305)
ATA Thyroid and Pregnancy Guidelines Task Force: Thursday-Friday, September 16-17, 2010 (Hôtel Concorde La Fayette, Renoir Room)
History and Current Activities

The Asia and Oceania Thyroid Association (AOTA) fosters scientific and educational activities relating to the thyroid, from basic science to clinical investigation and new therapies. The association was founded in 1975 and the first meeting of AOTA was held in Singapore in 1978. Subsequent meetings were held in Tokyo (1982), Bangkok (1986), Seoul (1989), Osaka (1997), Singapore (2003), Manila (2007) and Nagoya (2009). In 1980, AOTA hosted the 8th International Thyroid Congress (ITC) in Sydney, Australia and in year 2000 it hosted 12th ITC in Kyoto, Japan.

At the Manila meeting a new AOTA Prize, the Nagataki Prize, was launched in addition to the traditional Daiichi Prize (currently FUJIFILM Prize) to honor a distinguished scientist from its region. Furthermore, decisions were made by Council to further strengthen AOTA, including increasing the frequency of regular scientific meetings and expanding its membership. Accordingly, it was decided to have AOTA meeting every two years following each ITC. Recruitment of representatives from west Asian and Arab countries is one of the issues to be discussed.

Office bearers (from November, 2005 to September, 2010)

**Honorary President**  
Shigenobu Nagataki, Japan

**President**  
Junji Konishi, Japan

**Secretary/Treasurer**  
Yoshiharu Murata, Japan

**Vice Presidents**  
Duncan Topliss, Australia  
Zupei Chen, China  
Kwangwoon Lee, Korea

**Program Organizing Committee**  
Shunichi Yamashita, Japan  
Youngkoo Shong, Korea  
Teofilo San Luis, Philippines

**Council**  
Fereidoun Azizi, Iran  
Tien Shiang Huang, Taiwan  
Daphne Khoo, Singapore  
Annie W. Kung, China  
Kwangwon Kim, Korea  
Johan S. Masjhur, Indonesia  
Bruce Robinson, Australia  
Co-opted member:  
Creswell J. Eastman, Australia

Future Meeting

**10th AOTA Congress**

**Date:** October 24-27, 2012  
**Venue:** Discovery Kartika Plaza Hotel, Bali, Indonesia  
http://www.discoverykartikaplaza.com/

**Overall Chair:** Professor Johan S. Masjhur (Bandung, Indonesia)
The Latin American Thyroid Society (LATS) is an association interested in promoting research in the thyroid field which brings together basic and clinical specialists and scientists from Latin American countries. LATS was founded in 1974 in Buenos Aires, Argentina. In the International Thyroid Congress, Boston, 1975, LATS was recognized as a new sister of the already chartered thyroid associations ATA and ETA. The aims of LATS are to encourage research on thyroid physiology and biochemistry as well as nuclear medicine, cellular and molecular biology and clinical science to improve knowledge in diagnosis, management and treatment of thyroid diseases.

Membership of LATS consists of Active, Corresponding, Honorary and Associate members. The society has now around 850 members in Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Panama, Paraguay, Peru and Mexico, among other countries.

The Scientific Meeting of LATS is regularly held every two years and usually attracts over 1000 active participants including physicians and basic researchers. Outstanding fundamental and clinical scientists are invited from Latin American and other countries to share new knowledge on thyroid function and disease. At each Congress the LATS Prize is awarded to an Active member of the Society who has made outstanding contributions to thyroid research over a considerable period of time. Besides, two young researchers receive the Merck Prize Young Investigator (one Clinical and one Basic). At least 30 to 50 Travel Grants are distributed to young investigators for the best Oral and Poster presentations.

The last XIII LATS Meeting was held in Gramado, Brazil, from April 30 to May 3, 2009. The number of registered attendees was 1415. The scientific program comprised 7 Conferences, 6 Oral Sessions (Basic and Clinic), 13 parallel Symposia (Basic and Clinic), 5 Meet the Expert Sessions, and 4 Thyroid Debate Sessions. Important topics were reviewed which dealt with new insights in thyroid biology and pathophysiology as well as molecular diagnosis and clinical management of thyroid diseases.

The LATS General Assembly, held during the last meeting, elected the LATS Executive Council for the 2009-2011 period. The next XIV LATS Congress will take place in Lima, Peru, August 4-7, 2011. The Local Organizing Committee and the Scientific Committee are working hard to make this event a great success. Many relevant scientists have already agreed to participate in the meeting.

The LATS website (http://www.lats.org) is constantly updated to announce upcoming events and to provide new materials with important information on the thyroid field. The LATS directory maintains regular contact with its members through periodic Newsletters and communications. On the other hand, LATS website allows foreign colleagues to be updated with the society activities.

Several LATS task force groups have been set up to address particular issues and to develop clinical practice guidelines for diagnosis and management of thyroid diseases.

**LATS Executive Council 2009-2011**

**President**
Hans Graf, Curitiba, Brazil

**President-Elect**
Marcos Abalovich, Buenos Aires, Argentina

**Secretary**
Ana Maria Masini-Repiso, Córdoba, Argentina

**Treasurer**
Eduardo K. Tomimori, São Paulo, Brazil

**Directors**
Claudia Pellizas, Córdoba, Argentina
Erivelto Volpi, São Paulo, Brazil
José Luis Novelli, Rosario, Argentina
Mario Vaisman, Rio de Janeiro, Brazil
Sonia Iorcansky, Buenos Aires, Argentina
Egberto Moura, Rio de Janeiro, Brazil
Jannete Cerutti, São Paulo, Brazil
Laura Ward, Campinas, Brazil
Mirta Corino, Buenos Aires, Argentina
AT A GLANCE

TUESDAY 14 SEPTEMBER 2010

7:00 am - LATS PRIZE LECTURE
PL04

9:00 am - ORAL COMMUNICATIONS
OC15 - OC17

10:00 am - DEBATES
DB01

12:00 pm - POSTER VIEWING
(in the exhibition area)

12:30 pm - MEET THE EXPERT
ME13 - ME14

2:00 pm - POSTER DISCUSSIONS
PD13 - PD17

3:00 pm - ORAL COMMUNICATIONS
OC18 - OC21

5:00 pm - BUSINESS MEETINGS
ATA
AOTA
LATS

7:00 pm - CONGRESS DINNER
ROYAL EVENING IN VERSAILLES

WEDNESDAY 15 SEPTEMBER 2010

7:00 am - ATA PRIZE LECTURE
PL05

9:00 am - ORAL COMMUNICATIONS
OC22 - OC24

10:00 am - IMPLEMENTING GUIDELINES
IG03

12:00 pm - POSTER VIEWING
(in the exhibition area)

12:00 pm - MEET THE EXPERT
ME19 - ME24

2:00 pm - POSTER DISCUSSIONS
PD20 - PD26

3:00 pm - ORAL COMMUNICATIONS
OC25 - OC28

5:00 pm - SYMPOSIA
SY25 - SY28

THURSDAY 16 SEPTEMBER 2010

7:00 am - AOTA PRIZE LECTURE
PL06

9:00 am - SYMPOSIA
SY15 - SY17

10:00 am - DEBATES
DB02

12:00 pm - POSTER VIEWING
(in the exhibition area)

12:30 pm - MEET THE EXPERT
ME19 - ME24

2:00 pm - POSTER DISCUSSIONS
PD13 - PD17

3:00 pm - ORAL COMMUNICATIONS
OC18 - OC21

5:00 pm - SYMPOSIA
SY25 - SY28

DAILY PROGRAMME OVERVIEW

Saturday 11th September . . . Page 11 to 16
Sunday 12th September . . . . Page 17 to 28
Monday 13th September . . . Page 29 to 42
Tuesday 14th September . . . Page 43 to 54
Wednesday 15th September . Page 55 to 66
Thursday 16th September . . . Page 67 to 69

Posters . . . . . . . . . . . . . . . . . . . . Page 70 to 117
SATURDAY 11th SEPTEMBER 2010

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Session Type</th>
<th>Session Time</th>
<th>Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-congress session</td>
<td>08:00 - 13:15</td>
<td>10th MEETING OF ETA-CRN</td>
<td>Irradiation and carcinomas: lessons of Chernobyl for thyroid, implications for the diagnosis and prevention of thyroid carcinoma</td>
<td>Room 351</td>
</tr>
<tr>
<td>Pre-congress session</td>
<td>08:15 - 13:00</td>
<td>ULTRASONOGRAPHY COURSE</td>
<td>Diagnostic thyroid and parathyroid ultrasonography course</td>
<td>Room 353</td>
</tr>
<tr>
<td></td>
<td>11:00 - 13:00</td>
<td>Patient information meeting</td>
<td></td>
<td>Room 32A8</td>
</tr>
<tr>
<td>Satellite Symposium</td>
<td>14:00 - 18:00</td>
<td>CME SATELLITE SYMPOSIUM</td>
<td>Practical management of thyroid cancer</td>
<td>Grand Amphitheatre</td>
</tr>
</tbody>
</table>

PL01 Plenary Lecture 18:30 - 19:30 OPENING CEREMONY AND PLENARY LECTURE Grand Amphitheatre
19:30 - 21:00 Welcome reception Exhibition Area
SATURDAY 11th SEPTEMBER
MORNING

ETA-CRN MEETING
10th MEETING OF ETA-CRN (ETA Cancer Research Network)
Irradiation and carcinomas: lessons of Chernobyl for thyroid,
implications for the diagnosis and prevention of thyroid carcinoma

Chairpersons: Ulla Feldt-Rasmussen, Jacques Dumont, Mike Atkinson

08:00 INTRODUCTION
Maurice Tubiana
A tribute to Professor J. Nauman on the occasion of his action to introduce stable iodine prophylaxis after Chernobyl-related contamination in 1986 in Poland

08:15 CHERNOBYL CANCERS
Michael Tuttle (New York, United States)

08:45 GENE EXPRESSION IN PAPILLARY THYROID CARCINOMAS AND CONTRA-LATERAL TISSUES FROM PATIENTS EXPOSED AND NOT EXPOSED TO THE CHERNOBYL FALLOUT
C. Maenhaut, V. Detours (Brussels, Belgium)

09:15 IS THERE A GENE EXPRESSION SIGNATURE SPECIFIC OF IRRADIATION INDUCED THYROID CARCINOMA?
B. Jarzab, D. Handkiewicz-Junak (Gliwice, Poland)

09:45 GENE EXPRESSION IN X RAY INDUCED THYROID CARCINOMAS
S. Chevillard (Saclay, France)

10:15 - 10:45 Coffee break

10:45 THYROID CANCER AND LOW DOSE RADIATION
D. Williams (Cambridge, United Kingdom)

11:15 GENE COPY NUMBER (CGH) IN CHERNOBYL CANCERS
H. Zitzelsberger (Munich, Germany)

11:45 GENOMICS OF CHERNOBYL RELATED THYROID CANCER
K. Unger, G. Thomas (London, United Kingdom)

12:15 RET/PTC IN THYROID CANCER
F. Carlomagno (Naples, Italy)

12:45 GENERAL DISCUSSION

Symposium kindly sponsored by Genrisk-T Consortium

ETA-CRN is sponsored by
### ULTRASONOGRAPHY COURSE

**Diagnostic thyroid and parathyroid ultrasonography course**

*Course kindly sponsored by Siemens*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15 - 08:30</td>
<td><strong>INTRODUCTION</strong>&lt;br&gt;Laurence Leenhardt (Paris, France)</td>
</tr>
<tr>
<td>08:30 - 10:30</td>
<td><strong>NORMAL THYROID GLAND AND THYROID NODULES</strong>&lt;br&gt;Chairpersons: Murat Faik Erdogan (Ankara, Turkey), Laurence Leenhardt (Paris, France)</td>
</tr>
<tr>
<td>08:30</td>
<td><strong>NECK ANATOMY, BASICS OF ULTRASONOGRAPHY, HOW TO PERFORM NECK ULTRASONOGRAPHY ?</strong>&lt;br&gt;Jean Tramalloni (Paris, France)</td>
</tr>
<tr>
<td>09:00</td>
<td><strong>ULTRASONOGRAPHY IN THYROID NODULE, SONOGRAPHIC RISK ASSESSMENT OF THYROID NODULES</strong>&lt;br&gt;Susan Mandel (Philadelphia, United States)</td>
</tr>
<tr>
<td>09:30</td>
<td><strong>DOPPLER SONOGRAPHY AND ELASTOGRAPHY IN NODULAR DISEASE</strong>&lt;br&gt;Paolo Vitti (Pisa, Italy)</td>
</tr>
<tr>
<td>10:00</td>
<td><strong>FINE NEEDLE ASPIRATION BIOPSY (FNAB) AND ULTRASONOGRAPHY GUIDANCE</strong>&lt;br&gt;Eun Kyung Kim (Seoul, Korea)</td>
</tr>
<tr>
<td>10:30 - 10:50</td>
<td><strong>Coffee break</strong></td>
</tr>
<tr>
<td>10:50 - 12:00</td>
<td><strong>THYROIDITIS, PARATHYROID GLANDS, FOLLOW UP OF THYROID CANCER</strong>&lt;br&gt;Chairpersons: Paolo Vitti (Pisa, Italy), Jean Tramalloni (Paris, France)</td>
</tr>
<tr>
<td>10:50</td>
<td><strong>GRAY SCALE AND DOPPLER SONOGRAPHY IN AUTO IMMUNE THYROIDITIS</strong>&lt;br&gt;Hervé Monpeyssen (Paris, France)</td>
</tr>
<tr>
<td>11:10</td>
<td><strong>PARATHYROID GLANDS</strong>&lt;br&gt;Murat Faik Erdogan (Ankara, Turkey)</td>
</tr>
<tr>
<td>11:40</td>
<td><strong>ULTRASONOGRAPHY IN THE FOLLOW UP OF THYROID CANCER, NECK LYMPH NODES</strong>&lt;br&gt;Laurence Leenhardt (Paris, France)</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td><strong>CASE ILLUSTRATIONS, PITFALLS QUESTIONS AND ANSWERS (USING THE VOTING-PAD SYSTEM) WITH REAL TIME PROJECTION OF THE ULTRASOUND EXAMINATION ON 3 VOLUNTEERS</strong>&lt;br&gt;Chairpersons: Susan Mandel (Philadelphia, United States), Theresa Rago (Pisa, Italy), Hervé Monpeyssen (Paris, France)</td>
</tr>
<tr>
<td>12:00</td>
<td><strong>CASE 1 : PATIENT WITH A NORMAL THYROID GLAND</strong>&lt;br&gt;Speaker/operator: MF. Erdogan (Ankara, Turkey)/G. Russ (Paris, France)</td>
</tr>
<tr>
<td>12:10</td>
<td><strong>CASE 2 : PATIENT WITH A THYROID NODULE</strong>&lt;br&gt;Speaker/operator: EK. Kim (Seoul, Korea)/J. Tramalloni (Paris, France)</td>
</tr>
<tr>
<td>12:20</td>
<td><strong>CASE 3 : PATIENT WITH GRAVES’ DISEASE</strong>&lt;br&gt;Speaker/operator: P. Vitti (Pisa, Italy)/H. Monpeyssen (Paris, France)</td>
</tr>
<tr>
<td>13:00 - 13:15</td>
<td><strong>CONCLUSION</strong>&lt;br&gt;Jean Tramalloni (Paris, France), Hervé Monpeyssen (Paris, France)</td>
</tr>
</tbody>
</table>

*Room 353  08:15 - 13:15  ULTRASONOGRAPHY COURSE  Diagnostic thyroid and parathyroid ultrasonography course*
SATURDAY 11th SEPTEMBER

AFTERNOON

Room 352AB 11:00 - 13:00

CONFERENCE Débat Grand Public / Patient information meeting

Organisée par / organised by

Orateurs / Speakers:

Dr Dana Hartl
Chirurgienne / Surgeon
Institut Gustave Roussy, Villejuif (France)

La chirurgie thyroïdienne dans tous ses états. Le cancer de la thyroïde : traitements en plein essor
Thyroid surgery, state of the art. Thyroid cancer, treatments in evolution

Pr Philippe Caron
Chef du service d’endocrinologie / head of the endocrine department
CHU Larrey, Toulouse (France)
Président du Groupe de Recherche sur la Thyroïde (France)
President of the Thyroid Research Group (France)

Pathologies thyroïdiennes et grossesse
Thyroid dysfunction and pregnancy

Réalisé avec le soutien de / with the support of

Entrée libre / Free entrance

www.ligue-cancer.net
www.thyroid-fed.org
www.forum-thyroide.net
CME SATELLITE SYMPOSIUM
Supported by an educational grant from Genzyme

Practical management of thyroid cancer: State of the art & perspectives

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15</td>
<td>WELCOME RECEPTION</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>WELCOME &amp; OPENING REMARKS</td>
<td>M. Schlumberger (France)</td>
</tr>
<tr>
<td>14:10</td>
<td>RADIOIODINE: AN HISTORICAL VIGNETTE</td>
<td>E. Mazzaferri (United States)</td>
</tr>
<tr>
<td>14:20</td>
<td>HIGH-RISK PATIENT: INTERACTIVE CASE STUDY</td>
<td>M. Tuttle (United States)</td>
</tr>
<tr>
<td>14:40</td>
<td>LOW-RISK PATIENT: INTERACTIVE CASE STUDY</td>
<td>M. Tuttle (United States)</td>
</tr>
<tr>
<td>15:00</td>
<td>LOW-RISK PATIENTS: TO ABLATE OR NOT TO ABLATE - AN INTERACTIVE DEBATE</td>
<td>G. Doherty, R. Kloos (United States)</td>
</tr>
<tr>
<td>15:30</td>
<td>SESSION 1 PANEL DISCUSSION/Q &amp; A</td>
<td>Expert Panel 1</td>
</tr>
<tr>
<td>15:50</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>DIAGNOSTIC FOLLOW UP: AN HISTORICAL VIGNETTE</td>
<td>E. Mazzaferri (United States)</td>
</tr>
<tr>
<td>16:25</td>
<td>DIAGNOSTIC FOLLOW UP AND MONITORING: BEST PRACTICE</td>
<td>F. Pacini (Italy)</td>
</tr>
<tr>
<td>16:40</td>
<td>LOW-RISK PATIENT: INTERACTIVE CASE STUDY</td>
<td>D. Cooper (United States)</td>
</tr>
<tr>
<td>16:55</td>
<td>SESSION 2 PANEL DISCUSSION/Q &amp; A</td>
<td>Expert Panel 2</td>
</tr>
<tr>
<td>17:15</td>
<td>RESULTS - THE PATIENT JOURNEY - DIAGNOSIS, TREATMENT, IMPACT</td>
<td>M. Luster (Germany), K. Farnell (United Kingdom)</td>
</tr>
<tr>
<td>17:30</td>
<td>Q &amp; A</td>
<td>M. Luster (Germany)</td>
</tr>
<tr>
<td>17:50</td>
<td>CLOSING REMARKS</td>
<td>M. Schlumberger (France)</td>
</tr>
<tr>
<td>18:00</td>
<td>CLOSE</td>
<td></td>
</tr>
</tbody>
</table>

Expert Panels
Panel 1: M. Tuttle (United States) – Chair, W.Y. Chung (Korea), G. Doherty (United States), R. Elisei (Italy), R. Kloos (United States), M. Luster (Germany), F. Pitoia (Argentina)
Panel 2: D. Cooper (United States) – Chair, G. Doherty (United States), M. Hoffmann (Austria), F. Pacini (Italy), F. Pitoia (Argentina), J.W.A. Sten (Netherlands), M. Tuttle (United States)
OPENING CEREMONY AND PLENARY LECTURE
Chairpersons: Martin Schlumberger (LOC President), Wilmar Wiersinga (POC Chairman)

18:30 OFFICIAL WELCOME ADDRESSES by
    Martin Schlumberger (LOC President)
    Wilmar Wiersinga (POC Chairman)

18:45 THE YEAR IN THE THYROID
    E. Chester Ridgway (United States)

WELCOME RECEPTION

Following the Opening Ceremony, a Welcome Reception will be offered to all attendees,
on Saturday 11 September, from 19:30 to 21:00 within the premises of the Palais des Congrès in the exhibition area, level 3

Do not miss this get together party. Delegates, spouses and exhibitors are most welcome.
<table>
<thead>
<tr>
<th>Session Code</th>
<th>Session Type</th>
<th>Session Time</th>
<th>Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>PL02</td>
<td>Plenary Lecture</td>
<td>08:30 - 09:20</td>
<td>SPECIAL PLenary LECTURE</td>
<td>Grand Amphitheatre</td>
</tr>
<tr>
<td>OC01</td>
<td>Oral communications</td>
<td>09:30 - 11:00</td>
<td>TOPIC HIGHLIGHTS 1</td>
<td>Grand Amphitheatre</td>
</tr>
<tr>
<td>OC02</td>
<td>Oral communications</td>
<td>09:30 - 11:00</td>
<td>THYROID CANCER BASIC (Part 1)</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>OC03</td>
<td>Oral communications</td>
<td>09:30 - 11:00</td>
<td>REGULATION OF DEIODINASE EXPRESSION</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11:00 - 11:30</td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
<tr>
<td>IG01</td>
<td>Implementing Guidelines</td>
<td>11:30 - 13:00</td>
<td>IMPLEMENTING GUIDELINES FOR DIFFERENTIATED THYROID CANCER</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>SY01</td>
<td>Symposium</td>
<td>11:30 - 13:00</td>
<td>THYROID IN THE FACE OF CHANGING IODINE INTAKE</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>SY02</td>
<td>Symposium</td>
<td>11:30 - 13:00</td>
<td>THE TSH RECEPTOR AND AUTOIMMUNE THYROID DISEASE</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>SY03</td>
<td>Symposium</td>
<td>11:30 - 13:00</td>
<td>NEW INSIGHTS INTO THE CONTROL OF THYROID HORMONE ACTION</td>
<td>Room 352AB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>13:00 - 14:00</td>
<td>LUNCH BREAK</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>13:00 - 14:00</td>
<td>POSTER VIEWING SESSION (P-0001 - P-0013)</td>
<td>Poster Zone</td>
</tr>
<tr>
<td>ME01</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>TREATMENT OF PEDIATRIC GRAVES’ DISEASE</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>ME02</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>THYROID AND MALE GONAD</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>ME03</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>CLINICAL IMPLICATIONS OF ANTI-TSH RECEPTOR ANTIBODIES</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>ME04</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>THYROTOXIC PERIODIC PARALYSIS</td>
<td>Room 352AB</td>
</tr>
<tr>
<td>ME05</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>ENIGMA IN THE LOW T3 SYNDROME (DEBATE) – DEIODINASE 1 VS DEIODINASE 3</td>
<td>Room 351</td>
</tr>
<tr>
<td>ME06</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>OMICS IN THYROID CANCER RESEARCH</td>
<td>Room 341</td>
</tr>
<tr>
<td>PD01</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>CLINICAL THYROIDOLOGY - HYPERTHYROIDISM</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>PD02</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>ENVIRONMENTAL FACTORS - IODINE</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>PD03</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>THYROID CANCER - CLINICAL 1</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>PD04</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>THYROID CANCER - BASIC</td>
<td>Room 352AB</td>
</tr>
<tr>
<td>PD05</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>AUTOIMMUNITY</td>
<td>Room 351</td>
</tr>
<tr>
<td>PD06</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>DEIODINASES</td>
<td>Room 341</td>
</tr>
<tr>
<td>OC04</td>
<td>Oral communications</td>
<td>14:45 - 16:15</td>
<td>PROSPECTIVE TRIALS IN REFRACTORY THYROID CANCERS</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>OC05</td>
<td>Oral communications</td>
<td>14:45 - 16:15</td>
<td>CLINICAL THYROIDOLOGY - SUBCLINICAL THYROID DISEASE</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>OC06</td>
<td>Oral communications</td>
<td>14:45 - 16:15</td>
<td>ENVIRONMENTAL FACTORS</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>OC07</td>
<td>Oral communications</td>
<td>14:45 - 16:15</td>
<td>MOLECULAR ASPECTS OF THE HYPOTHALAMUS-PITUITARY-THYROID AXIS</td>
<td>Room 352AB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16:35 - 16:45</td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
<tr>
<td>SY04</td>
<td>Symposium</td>
<td>16:45 - 18:15</td>
<td>THYROID NODULES</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>SY05</td>
<td>Symposium</td>
<td>16:45 - 18:15</td>
<td>NUCLEAR ACCIDENTS AND THYROID BLOCKADE ARE WE READY ? (Sponsored by ELECTRICITE DE FRANCE)</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>SY06</td>
<td>Symposium</td>
<td>16:45 - 18:15</td>
<td>ALLAN HEINON-FUTLEY SYNDROME AND THYROID HORMONE TRANSPORTERS</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>SY07</td>
<td>Symposium</td>
<td>16:45 - 18:15</td>
<td>NON-MAMMALIAN MODELS IN THYROID RESEARCH</td>
<td>Room 352AB</td>
</tr>
<tr>
<td></td>
<td>Satellite Symposium</td>
<td>18:30 - 19:30</td>
<td>AFFINITESICA SATELLITE SYMPOSIUM</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>Satellite Symposium</td>
<td>18:30 - 19:30</td>
<td>MERCK SERONO SATELLITE SYMPOSIUM</td>
<td>Amphitheatre Havane</td>
<td></td>
</tr>
</tbody>
</table>
### Sunday 12th September  
**Morning**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Grand Amphitheatre</td>
<td>SPECIAL PLENARY LECTURE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairpersons: J. Orgiazzi (France), D. Carvalho (Brazil)</td>
</tr>
<tr>
<td>08:30</td>
<td>Grand Amphitheatre</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>08:30</td>
<td>Amphitheatre Bordeaux</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
</tbody>
</table>

**Plenary Lecture**

**Special Plenary Lecture**

*Chairpersons: J. Orgiazzi (France), D. Carvalho (Brazil)*

**Introduction**

**Thyroid and Evolution**

*V. Laudet (France)*

**Oral Communications**

**Topic highlights 1**

*Chairpersons: J. Koehrle (Germany), Y. K. Shong (Korea)*

- **OC-001**
  - **09:30** EVEN A CAUTIOUS IODEIZATION PROGRAM BRINGING IODINE INTAKE TO A LOW RECOMMENDED LEVEL IS ASSOCIATED WITH AN INCREASE IN THE PREVALENCE OF TPO-AB AND TG-AB IN THE POPULATION

- **OC-002**
  - **09:45** MUTATION DATA-DRIVEN DIFFERENTIATION BETWEEN ACTIVATING AND INACTIVATING PHARMACOPHORE PATTERNS SURROUNDING THE ALLOSTERIC SMALL LIGAND BINDING POCKET OF THE THYROTROPIN RECEPTOR

- **OC-003**
  - **10:00** A COMPARISON OF A TSHR BLOCKING AUTOANTIBODY (K1-70), A THYROID STIMULATING AUTOANTIBODY (M22), AND TSH BINDING TO THE TSHR AT THE MOLECULAR LEVEL
  - R. Nunez Miguel, J. Sanders, P. Sanders, S. Young, M. Evans, J. Fermanakis, B. Rees Smith (Cardiff, United Kingdom)

- **OC-004**
  - **10:15** PLX4720 INHIBITS CELL PROLIFERATION AND MIGRATION/INVASION IN HUMAN THYROID CANCER CELLS, AND INHIBITS TUMOR GROWTH AND METASTASIS IN AN ORTHOTOPIC MOUSE MODEL OF ANAPLASTIC THYROID CANCER HARBOURING B-RAFV600E
  - C. Nucera, M. A. Nehs, S. Nagarkatti, P. Salerno, M. Meckel, A. H. Fischer, J. Lawler, R. A. Hodin, S. Parangi (Boston, United States)

- **OC-005**
  - **10:30** TOWARDS TREATING PATIENTS WITH MCT8 MUTATIONS WITH THE THYROID HORMONE ANALOGUE TETRAC
  - S. Horn, S. Mayer, C. Gobba, J. Müller, M. Trpkovic-Arsic, T. J. Visser, H. Heuer (Jena, Germany)

- **OC-006**
  - **10:45** MUTATION-SPECIFIC MITOCHONDRIAL LOCALIZATION OF BRAFV600E IN THYROID CANCER: CLINICALLY-USED BRAF INHIBITORS ARE UNABLE TO BLOCK THE MITOCHONDRIAL ACTIVITIES OF BRAFV600E

**Oral Communications**

**Thyroid Cancer Basic (Part 1)**

*Chairpersons: S. Y. Chen (United States), B. Robinson (Australia)*

- **OC-007**
  - **09:30** PROGRESSION OF BRAF-INDUCED THYROID CANCER IS ASSOCIATED WITH EPITHELIAL-MESENCHYMAL TRANSITION REQUIRING CONCOMITANT MAP KINASE AND TGFβ SIGNALING
  - J. A. Knudt, M. A. Sartor, M. Medvedovic, E. Lundsmith, Y. E. Nikiforov, Y. J. Gaither, R. A. Ghossein, J. A. Fagin (New York, United States)

- **OC-008**
  - **09:45** TWIST1 EXPRESSION PROMOTES MIGRATION AND INVASION IN HUMAN PAPILLARY THYROID CARCINOMA
  - Y. Gao, H. Guan, Z. Shan, X. Shi, J. Mao, W. Teng (Shenyang, China)

- **OC-009**
  - **10:00** CROSS-TALK BETWEEN NOTCH AND MAPK SIGNALING DURING RET/P75C AND BRAFI799A ONCOGENE ACTIVATION
  - A. S. Yamashita, E. K. Tenorio (São Paulo, Brazil)
SUNDAY 12th SEPTEMBER  MORNING

10:15  HYPOXIA-INDUCIBLE FACTOR-1A (HIF-1A): AN INTERACTING ROLE WITH THE PHOSPHOLIPID DEIODINASE PATHWAY IN THE DEVELOPMENT OF A METASTATIC PHENOTYPE IN THYROID CARCINOMAS?

10:30  ACTIVATION OF THE SONIC HEDGEHOG PATHWAY IN THYROID NEOPLASMS AND ITS ROLE IN TUMOR CELL PROLIFERATION

10:45  FOXO3 IS INHIBITED BY THE ONCOGENIC P110A MUTANT H1074R IN THYREOCYTES, BUT CAN BE REACTIVATED BY NSAIDS
C. Weidinger, K. Krause, A. Klugge, D. Fuhre (Leipzig, Germany)

Coffee break

Exhibition Area

11:00 - 11:30

IMPLEMENTING GUIDELINES

Implementing guidelines for differentiated thyroid cancer
Moderator: F. Pacini (Italy)

Case discussants: David Cooper (United States), Yasuhiro Ito (Japan), Nelson Wohllk (Chile)

Voting machines available
**SY01 SYMPOSIUM**

**Thyroid in the face of changing iodine intake**  
Chairpersons: G. Burrow (United States), C. Eastmann (Australia)

- **11:30** THE CHANGING EPIDEMIOLOGY OF IODINE DEFICIENCY  
  Mu Li (Australia)
- **11:52** WORLDWIDE CHANGES IN IODINE INTAKE  
  Eduardo Pretell (Peru)
- **12:14** NOVEL STRATEGIES FOR CONTROL OF IODINE DEFICIENCY  
  Michael Zimmermann (Switzerland)
- **12:36** CONSEQUENCES OF CHANGES IN IODINE INTAKE FOR THE OCCURRENCE OF THYROID DISORDERS  
  Peter Laurberg (Denmark)

**SY02 SYMPOSIUM**

**The TSH receptor and auto-immune thyroid disease**  
Chairpersons: P. Rodien (France), K. H. Yi (Korea)

- **11:30** POLYMORPHISMS IN THE TSH RECEPTOR  
  Stephen C.L. Gough (United Kingdom)
- **11:52** MODEL OF TSH RECEPTOR ACTIVATION BY LIGANDS AND AUTOANTIBODIES  
  Gilbert Vassart (Belgium)
- **12:14** THE ECTODOMAIN IS A KEY-DETERMINANT OF TSH RECEPTOR SIGNALLING MECHANISM  
  Gunnar Kleinau (Germany)
- **12:36** ANIMAL MODELS OF GRAVES' DISEASE  
  Yuji Nagayama (Japan)

**SY03 SYMPOSIUM**

**New insights into the control of thyroid hormone action**  
Chairpersons: C. Cabanelas Pazos Moura (Brazil), A. Pontecorvi (Italy)

- **11:30** ENTRY & EXIT OF THYROID HORMONE INTO/FROM TISSUES  
  Theo Visser (The Netherlands)
- **11:52** INTRACELLULAR THYROID HORMONE ACTIVATION AND INACTIVATION BY DEIODINASES  
  Domenico Salvatore (Italy)
- **12:14** MOLECULAR MODELS OF LIGAND-TR INTERACTIONS  
  Paul Webb (United States)
- **12:36** CO-ACTIVATORS AND CO-REPRESSORS FOR REGULATING THYROID HORMONE RECEPTORS  
  Fred Wondisford (United States)

**Lunch break** (Lunch bags distribution)

**Room 342AB 11:30 - 13:00**

**Room 352AB 11:30 - 13:00**

**Exhibition Area 13:00 - 14:00**

**Poster Zone 13:00 - 14:00**

**POSTER VIEWING SESSION**

**Group A1: P-0001-P-0313** (see page 72)

Authors will be present next to their poster in order to answer questions from delegates.
SUNDAY 12th SEPTEMBER

AMPHITHEATRE BORDEAUX 13:15 - 13:55

MEET THE EXPERT
Treatment of paediatric Graves’ disease
Scott Rivkees (United States)

AMPHITHEATRE HAVANE 13:15 - 13:55

MEET THE EXPERT
Thyroid and male gonad
Gerasimos Krassas (Greece)

ROOM 342AB 13:15 - 13:55

MEET THE EXPERT
Clinical implications of anti-TSH receptor antibodies
Keiichi Kamijo (Japan)

ROOM 352AB 13:15 - 13:55

MEET THE EXPERT
Thyrotoxic periodic paralysis
Annie C. Kung (China)

ROOM 351 13:15 - 13:55

MEET THE EXPERT
Enigma in the low T3- syndrome (debate)
Deiodinase 1 vs Deiodinase 3
Ronald J. Koenig (United States), Anita Boelen (The Netherlands)

ROOM 341 13:15 - 13:55

MEET THE EXPERT
“Omics” in thyroid cancer research
Barbara Jarzab (Poland)
SUNDAY 12th SEPTEMBER  

**Amphitheatre Bordeaux**  
14:00 - 14:40  

**POSTER DISCUSSIONS**  
Clinical thyroidology - Hyperthyroidism  
Chairperson: J. Stockigt (Australia)

14:00  
LACK OF IN VITRO CONSTITUTIVE ACTIVITY FOR FOUR PREVIOUSLY REPORTED TSH RECEPTOR MUTATIONS IDENTIFIED IN PATIENTS WITH NONAUTOIMMUNE HYPERTHYROIDISM AND HOT THYROID CARCINOMAS  
H. Jaeschke, S. Mueller, M. Eszlinger, R. Paschke (Leipzig, Germany) 
P-0001

14:06  
PERINATAL OUTCOME IN HYPOTHYROID WOMEN: THE IMPACT OF THYROID STATUS AT THE TIME OF THE FIRST OBSTETRICAL VISIT  
J. H. Nestman, M. Montoro, G. Hernandez, M. Wilson, P. Paghjou, B. Pathak, T. M. Goodwin (Los Angeles, United States) 
P-0002

14:12  
LEVELS OF NEONATAL THYROID HORMONE IN PRETERM INFANTS AND NEURODEVELOPMENTAL OUTCOME AT 5½ YEARS  
E. L. R. Williams, R. Hum (Dundee, United Kingdom) 
P-0003

14:18  
INDUCTION OF THE NUCLEAR RECEPTOR CAR AND ITS DOWNSTREAM TARGET GENES BY PROLONGED, BUT NOT ACUTE, CRITICAL ILLNESS IRRESPECTIVE OF FEEDING STATUS  
L. Mebis, S. Derde, E.-J. Ververs, G. Van den Berghen (Leuven, Belgium) 
P-0004

14:24  
THE IMPACT OF IODINE SUPPLEMENTATION ON THYROID DYSFUNCTION IN A POPULATION WITH MILD PRE-EXISTING IODINE DEFICIENCY  
J. R. Burgess, B. D. Owens, Z. Cao (Hobart, Australia) 
P-0005

14:30  
NO EFFECT OF PERCHLORATE ON SERUM THYROXINE FOR PREGNANT US WOMEN WITH LOW URINE IODINE  
S. H. Lamont, S. Robbins, J. Lu, R. Chen, J. G. Hollowell (Washington, United States) 
P-0006

**Amphitheatre Havane**  
14:00 - 14:40  

**POSTER DISCUSSIONS**  
Environmental factors - Iodine  
Chairperson: F. Azizi (Iran)

14:00  
The CCL21/CCR7 CHEMOKINE SYSTEM IS EXPRESSED IN THYROID FROM IODINE-INDUCED THYROIDITIS IN NOD MOUSE  
X. Y. Zang (Tianjin, China) 
P-0001

14:06  
IODINE LOSSES FROM IODIZED SALT DURING DIFFERENT COOKING METHODS  
R. Rana (Vadodara, India) 
P-0002

14:12  
IODINE EXCESS ACUTELY INCREASES THE RATE OF PENDRIN GENE TRANSCRIPTION: A POSSIBLE CONTRIBUTION FOR THE ESCAPE OF THE WOLFF-CHAIKOFF EFFECT  
A. M. Serrano-Nascimento, M. T. Nunes (Sao Paulo, Brazil) 
P-0003

14:18  
THE CLINICAL EFFECTS OF IODINE IN PREGNANCY AND INFANCY  
J. Lado-Abeal, A. Rimer, B. M. P. D. Pizzorno, J. Alvarez-Escudero (Lubbock, United States) 
P-0004

14:24  
IODINE EXCESS ACUTELY INCREASES THE RATE OF PENDRIN GENE TRANSCRIPTION: A POSSIBLE CONTRIBUTION FOR THE ESCAPE OF THE WOLFF-CHAIKOFF EFFECT  
F. L. R. Williams, R. Hum (Dundee, United Kingdom) 
P-0005

14:30  
IODINE DEFICIENCY AND HYPOTHYROIDISM IN PREGNANT WOMEN: A SYSTEMATIC REVIEW  
J. R. Burgess, B. D. Owens, Z. Cao (Hobart, Australia) 
P-0006
SUNDAY 12th SEPTEMBER  
AFTERNOON

**POSTER DISCUSSIONS**

**Thyroid cancer - Clinical I**

Chairperson: B. Haugen (United States)

**14:00**

RATIONAL AND DESIGN OF DECISION: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH LOCALIZED ADVANCED OR METASTATIC, RADIOACTIVE IODINE (RAI)-REFRACTORY, DIFFERENTIATED THYROID CANCER


**14:06**

ROLE OF CYTOTOXIC CHEMOTHERAPY IN ADVANCED DIFFERENTIATED THYROID CANCER: A REVIEW OF THE M.D. ANDERSON (MDACC) EXPERIENCE


**14:12**

DETECTION OF BONE METASTASES IN DIFFERENTIATED THYROID CANCER BY 18F NAF PET-CT


**14:18**

INTERVENTIONAL RADIOLOGIST: AN IMPORTANT ROLE IN THE TREATMENT OF RADIODOINE REFRACTORY THYROID CARCINOMAS


**14:24**

THE EFFECTIVENESS OF 124I PET/CT AND 18FDG-PET/CT IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA WITH NEGATIVE I-131 SCAN AND ELEVATED SERUM THYROGLOBULIN


**14:30**

CLINICO-PATHOLOGIC FEATURES AND OUTCOME OF METASTATIC FOLLICULAR THYROID CARCINOMA (FTC) IN YOUNG PATIENTS: IS IT DIFFERENT FROM THE OLD PATIENTS?


**POSTER DISCUSSIONS**

**Thyroid cancer - Basic**

Chairperson: A. Fusco (Italy)

**14:00**

DIFFERENCES IN THE EXPRESSION PROFILES OF NORMAL CONTRA-LATERAL TISSUES OF PATIENTS WITH LOCALIZED ADVANCED OR METASTATIC, RADIOACTIVE IODINE (RAI)-REFRACTORY, DIFFERENTIATED THYROID CANCER PATIENTS EXPOSED AND NOT EXPOSED TO THE CHERNOBYL FALLOUT

G. Dom, M. Tarabichi, B. Jarzab, J. Dumont, K. Unger, G. Thomas, V. Detours, C. Maenhaut (Brussels, Belgium)

**14:06**

IN-VITRO STUDY OF TYROSINE KINASE INHIBITORS, HISTONE DEACETYLASE INHIBITORS AND THEIR COMBINATION ON PRIMARY THYROID CANCER CELL LINES CHARACTERISED BY THEIR MUTATIONS

D. Chan, H. P. Koeffer, C.-Y. Tuang, T. D. Braulerstein (Singapore, Singapore)

**14:12**

REARRANGED ANAPLASTIC LYMPHOMA KINASE (ALK) GENE FOUND FOR THE FIRST TIME IN ADULT-ONSET PAPILLARY THYROID CANCER CASES AND ITS POSSIBLE ROLE IN ADOPTIVE T-LYMPHOCYTE INFUSIONS

K. Hamatani, M. Mukai, Y. Hayashi, K. Takahashi, K. Nakachi, Y. Kusunoki (Hiroshima, Japan)

**14:18**

PROTECTION AGAINST 131I-INDUCED DOUBLE STRAND DNA BREAKS IN THYROID CELLS

J. M. Hershman, A. Okunyan, S. Cannon, V. Hogen, Y. Rivina (Los Angeles, United States)

**14:24**

MONOCLONAL ANTIBODIES TO THYROID STIMULATING HORMONE RECEPTOR WITH POWERFUL AGONIST ACTIVITY TO THE RECEPTOR FOR THERAPY OF DIFFERENTIATED THYROID CANCER (DTC): STUDIES IN PRECLINICAL MODELS OF DTC AND PRIMARY HUMAN THYROID CELLS


**14:30**

ISOLATION AND CHARACTERIZATION OF CANCER THYROSPHERES

F. Frasca, F. Giuri, M. L. Nicolosi, S. Lotta, R. Masucci, M. Mamisia, R. Vigneri (Catania, Italy)
**POSTER DISCUSSIONS**

**Autoimmunity**

Chairperson: S. McLachlan (United States)

- **14:00** DEFINING ASSOCIATION OF THE FCRL GENE REGION WITH GRAVES’ DISEASE
  - By M. J. Simmonds, O. J. Brand, J. C. Barrett, P. R. Newby, J. A. Franklyn, S. C. L. Gough (Oxford, United Kingdom)

- **14:06** FIRST EVIDENCE OF A COMBINED CYTOTOXIC THYROGLOBULIN- AND THYROPEROXIDASE-SPECIFIC CELLULAR IMMUNE RESPONSE IN PATIENTS WITH HASHIMOTO’S THYROIDITIS

- **14:12** ENHANCED RESPONSE TO MOUSE THYROTROPIN (TSH) RECEPTOR IMMUNIZATION IN TSH RECEPTOR KNOCKOUT MICE
  - By M. Nakahata, N. Mitsuoka, H. Sakamoto, C. R. Chen, B. Rapoport, S. M. McLachlan, Y. Nagayama (Nagasaki, Japan)

- **14:18** ASSOCIATION OF FUNCTIONAL POLYMORPHISMS RELATED TO THE TRANSCRIPTIONAL LEVEL OF FOXP3 GENE WITH PROGNOSIS OF AUTOIMMUNE THYROID DISEASES
  - By M. Watanabe, N. Inoue, M. Monta, T. Tomizawa, T. Akamizu, K. Tsunekawa, Y. Hidaka, Y. Iwata (Saita, Japan)

- **14:24** ASSOCIATION ANALYSIS OF SIX NOVEL GRAVES’ DISEASE CANDIDATE GENES

- **14:30** T-CELL GENE EXPRESSION PATTERNS AFFECT QUANTITATIVE PHENOTYPIC CHARACTERISTICS OF HASHIMOTO’S THYROIDITIS
  - By M. Stefanic, S. Papic, L. Glavas-Obrovic, I. Mihalic (Osijek, Croatia)

**Deiodinases**

Chairperson: J. H. Bassett (United Kingdom)

- **14:00** CARDIAC UPTAKE AND METABOLISM OF 3-IODOTHYRONAMINE
  - By G. Chiellini, S. Ghelardoni, S. Frascarelli, M. Marchini, A. Saba, E. Galli, A. Raffaelli, T. Scanlan, R. Zucchi (Pisa, Italy)

- **14:06** RAPID ACTION OF THYROID HORMONE AND THE EXPRESSION OF IODOTHYRONINE DEIODINASE IN ENDOTHELIAL CELLS

- **14:12** THYROID HORMONE DEPENDENT DEREGULATION OF SPLICING FACTORS AND ALTERNATIVE SPLICING OF TYPE 1 IODOTHYRONINE DEIODINASE IN RENAL CANCER
  - By A. Piekielko-Witkowska, H. Wiszomirska, A. Wojcicka, P. Poplawski, J. Boguslawska, Z. Tanski, A. Nauman (Warsaw, Poland)

- **14:18** SPECIFIC DEIODINATION OF THE T3 METABOLITE TRIAC BY A NON-SELENODEIODINASE FROM AMPHIOXUS; FURTHER EVIDENCE THAT TRIAC IS THE PRIMORDIAL BIOACTIVE THYROID HORMONE
  - By W. Klootwijk, E. C. Friesema, T. J. Visser (Rotterdam, Netherlands)

- **14:24** DISTURBED EXPRESSION OF TYPE 2 AND TYPE 3 IODOTHYRONINE DEIODINASE IN PAPILLARY THYROID CARCINOMA

- **14:30** THE EFFECT OF VARIANTS IN THE IODOTHYRONINE DEIODINASE 2 GENE (DIO2) ON PSYCHOLOGICAL WELL-BEING IN 3 INDEPENDENT COHORTS
  - By V. Panicker, C. Dayan, O. Bjerkeset, J. Evans, P. Sariaan (Perth, Australia)
14:45 LONG TERM RESULTS IN PATIENTS (PTS) WITH MEDULLARY THYROID CANCER (MTC) ENROLLED IN A PHASE 1 STUDY OF XL184 (BMS 907351), AN ORAL INHIBITOR OF MET, VEGFR2 & RET.
(Houston, United States)

15:00 SUNITINIB IN PROGRESSIVE METASTATIC MEDULLARY THYROID CANCER

15:15 VANDETANIB IN LOCALLY ADVANCED OR METASTATIC MEDULLARY THYROID CANCER: A RANDOMIZED, DOUBLE-BLIND PHASE III TRIAL (ZETA)

15:30 EVIDENCE OF CLINICAL EFFICACY OF THE MULTI-TARGETED TYROSINE KINASE INHIBITOR PAZOPANIB IN RAPIDLY PROGRESSIVE RADIOIODINE-REFRACTARY METASTATIC DIFFERENTIATED THYROID CANCERS: RESULTS OF THE PHASE 2 CONSORTIUM STUDY MC057H

15:45 VANDETANIB IN LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (PAPILLARY OR FOLLICULAR; DTC): A RANDOMIZED, DOUBLE-BLIND PHASE II TRIAL

16:00 RANDOMIZED PHASE 2/3 TRIAL OF A TUMOR VASCULAR DISRUPTING AGENT FOSBRETABULIN TROMETHAMINE (CA4P) WITH CARBOPLATIN (C), AND PACLITAXEL (P) IN ANAPLASTIC THYROID CANCER (ATC): INTERIM SAFETY AND EFFICACY RESULTS OF THE FACT TRIAL
J. Balkissoon (Piedmont, United States)

14:45 THE THYROID EPIDEMIOLOGY, AUDIT, AND RESEARCH STUDY: THE NATURAL HISTORY OF ENDOGENOUS SUBCLINICAL HYPERTHYROIDISM
T. Vadiveloo, P. T. Donnan, L. Cochrane, G. P. Leese (Dundee, United Kingdom)

15:00 SUBCLINICAL HYPERTHYROIDISM (SCH): TO TREAT OR NOT TO TREAT? WHAT DO OUR PATIENTS PREFER IN THE CONTEXT OF A RANDOMIZED STUDY? DATA FROM THE PIRHATES STUDY
B. Goichot, S. Vinzio, J. M. Kuhn, M. Ladsous, E. Proust-Lemoine, J. L. Wemeau, P. Caron, J. Orgiazzi, F. Luca, O. Schenogrus, J. L. Schlenger (Strasbourg Cedex, France)

15:15 THYROID DYSFUNCTION ASSOCIATED WITH SYSTEMIC AL ALAMYLOIDOSIS
S. Gibbs, K. Vithian, N. Wassef, D. Hutt, P. Sattianayagam, J. Pinney, J. Gillmore, H. Lachmann, P. Hawkins, A. Wechalekar, M. Vanderpump (Chesit, Italy)

15:30 IODINE DEFICIENCY DURING GESTATION AND EARLY DEVELOPMENT IMPAIRS LUNG FUNCTION IN NEONATES

15:45 TREATMENT OF SUBCLINICAL HYPOTHYROIDISM AND CARDIOVASCULAR MORBIDITY AND MORTALITY – ANALYSIS OF THE UNITED KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE
S. S. Razvi, S. H. Pearce (Gateshead, United Kingdom)
### SUNDAY 12th SEPTEMBER

#### AFTERNOON

**Room 342AB**

**14:45 - 16:15**

**ORAL COMMUNICATIONS**

**Environmental factors**

Chairpersons: S. Andersen (Denmark), P. Smyth (Ireland)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45</td>
<td>ARCTIC RESIDENCE INFLUENCES THYROID HORMONES AND THYROID GLAND ACTIVITY</td>
<td>S. Andersen, B. Hvingel, K. Kleinschmidt, P. Laurberg (Aalborg, Denmark)</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>ENVIRONMENTAL TOXINS, BISPHENOL A (BPA) AND DICHLORODIPHENYLDICHLOROETHYLENE (DDE), DISRUPT THYROID HORMONE-MEDIATED EVENTS IN RAT PITUITARY GH3 CELLS</td>
<td>S. Andersen (Denmark), P. Smyth (Ireland)</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>LONG-TERM THYROID SEQUELAE OF CHILDHOOD CANCER</td>
<td>A. Spadaro, F. Branciforte, C. Scollo, M. Buscema, M. Tavarelli, D. Leonardi, S. D'Amico, M. La Spina, G. Pellegrini (Catania, Italy)</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>THYROID FUNCTION AND ENDOCRINE DISRUPTION FROM PERFLUOROCARbons IN DRINKING WATER: GENDER DIFFERENCES IN THE CS HEALTH PROJECT</td>
<td>S. Knox, T. Jackson, S. Freibee, B. Javins, A. Shankar, A. Ducatman (Morgantown, United States)</td>
<td></td>
</tr>
</tbody>
</table>

**Room 352AB**

**14:45 - 16:15**

**ORAL COMMUNICATIONS**

**Molecular aspects of the hypothalamus-pituitary-thyroid axis**

Chairpersons: A. Alkemade (The Netherlands), T. Ortiga-Carvalho (Brazil)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45</td>
<td>SUBUNIT INTERACTIONS INFLUENCE TSHR MULTIMERIZATION</td>
<td>R. Latif, K. Michalek, R. Ma, A. Baleam, T. F. Davies (New York, United States)</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>SLC5A8 EXPRESSION INDUCES A CHANNEL ACTIVITY ACTIVATED BY OXIDIZED ANIONS EXPLAINING ITS ROLE IN THE THYROID AND ITS ANTIPROLIFERATIVE EFFECT</td>
<td>S. Andersen (Denmark), P. Smyth (Ireland)</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>THE PRODUCTION OF A TTF-1 ANTAGONIST IN PCCL3 CELLS INDUCES A GLOBAL CELL DEDIFFERENTIATION AFFECTING THE EXPRESSION OF THOX-DUOXA GENES COUPLES 1 AND 2 OPPONENTLY, AND STRONGLY REDUCES CELL PROLIFERATION</td>
<td>S. Andersen (Denmark), P. Smyth (Ireland)</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>IODIDE: A NEW REGULATOR OF PITUITARY-THYROID AXIS?</td>
<td>C. Ferrero-Roberto, A. Letort, F. Libert, D. Christophe (Gosselies, Belgium)</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>IODIDE DEFICIENCY-INDUCED ANGIOGENESIS IS ASSOCIATED WITH SUPPRESSED TSHR MRNA EXPRESSION IN THE PITUITARY AND HYPOTHALAMUS</td>
<td>C. Ferrero-Roberto, A. Letort, F. Libert, D. Christophe (Gosselies, Belgium)</td>
<td></td>
</tr>
</tbody>
</table>

**Coffee break**

Exhibition Area 16:15 - 16:45

**Amphitheatre Bordeaux**

**16:45 - 18:15**

**SYMPOSIUM**

**Thyroid nodules**

Chairpersons: E. Alexander (United States), R. Y. A. de Camargo (Brazil)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45</td>
<td>ELASTOGRAPHY IN THE DIAGNOSIS OF THYROID NODULES</td>
<td>P. Vitti (Italy)</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Title</td>
<td>Speaker</td>
<td>Location</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>16:45</td>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>16:45</td>
<td>Nuclear accidents and thyroid blockade: are we ready?</td>
<td>Sponsored by Electricité de France</td>
<td>SY05</td>
</tr>
<tr>
<td>16:45</td>
<td>Chairpersons: J. Regaldo (France), M. Schlumberger (France)</td>
<td></td>
<td>SY05</td>
</tr>
<tr>
<td>16:45</td>
<td>CHERNOBYL CONSEQUENCES: THYROID DYSFUNCTION AND CANCER</td>
<td>Michael Tuttle (United States)</td>
<td>SY05</td>
</tr>
<tr>
<td>17:07</td>
<td>ARE THERE HEALTH CONSEQUENCES IN THE VICINITY OF NUCLEAR POWER PLANTS IN NORMAL FUNCTIONING CONDITIONS?</td>
<td>Jacques Esteve (France)</td>
<td>SY05</td>
</tr>
<tr>
<td>17:29</td>
<td>IODINE THYROID BLOCKING IN NUCLEAR AND RADILOGICAL EMERGENCIES</td>
<td>Shunichi Yamashita (Japan)</td>
<td>SY05</td>
</tr>
<tr>
<td>17:51</td>
<td>THE PRERedISTRIBUTION OF POTASSIUM IODINE TABLETS: THE FRENCH EXPERIENCE</td>
<td>Yves Garrier (France)</td>
<td>SY05</td>
</tr>
<tr>
<td>16:45</td>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
<td>Room 342AB</td>
</tr>
<tr>
<td>16:45</td>
<td>Allan-Herndon-Dudley syndrome and thyroid hormone transporters</td>
<td>Sponsored by Electricité de France</td>
<td>SY06</td>
</tr>
<tr>
<td>16:45</td>
<td>Chairpersons: L. Bergoglio (Argentina), F. A. R. Neves (Brazil)</td>
<td></td>
<td>SY06</td>
</tr>
<tr>
<td>16:45</td>
<td>GENETICS OF PLASMA MEMBRANE TRANSPORTERS</td>
<td>Edith Friesema (The Netherlands)</td>
<td>SY06</td>
</tr>
<tr>
<td>17:07</td>
<td>EARLY ATTEMPTS IN THE TREATMENT OF MCT8 GENE DEFECTS</td>
<td>Samuel Refetoff (United States)</td>
<td>SY06</td>
</tr>
<tr>
<td>17:29</td>
<td>MOLECULAR BASIS FOR DIFFERENCES IN HUMAN AND MOUSE BRAIN PHENOTYPES</td>
<td>Ulrich Schweizer (Germany)</td>
<td>SY06</td>
</tr>
<tr>
<td>17:51</td>
<td>THYROID HORMONE TRANSPORTERS IN THE BRAIN</td>
<td>Grant Andersen (United States)</td>
<td>SY06</td>
</tr>
<tr>
<td>16:45</td>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
<td>Room 352AB</td>
</tr>
<tr>
<td>16:45</td>
<td>Non-mammalian models in thyroid research</td>
<td>Sponsored by Electricité de France</td>
<td>SY07</td>
</tr>
<tr>
<td>16:45</td>
<td>Chairpersons: P. Banga (United Kingdom), B. Demeneix (France)</td>
<td></td>
<td>SY07</td>
</tr>
<tr>
<td>16:45</td>
<td>THE ZEBRAFISH</td>
<td>Robert Opitz (Belgium)</td>
<td>SY07</td>
</tr>
<tr>
<td>17:07</td>
<td>BIRDS (QUAIL)</td>
<td>Takashi Yoshimura (Japan)</td>
<td>SY07</td>
</tr>
<tr>
<td>17:29</td>
<td>CHICKEN</td>
<td>Vierle Darras (Belgium)</td>
<td>SY07</td>
</tr>
<tr>
<td>17:51</td>
<td>AMPHIBIA</td>
<td>Yun-Bi Shi (United States)</td>
<td>SY07</td>
</tr>
</tbody>
</table>
SUNDAY 12th SEPTEMBER  AFTERNOON

Amphitheatre Bordeaux  16:30 - 19:30

ASTRAZENECA SATELLITE SYMPOSIUM
Improving outcomes in thyroid cancer: has targeted therapy delivered?
Chairpersons: Martin Schlumberger (Paris, France), Samuel Wells (Bethesda, United States)

WELCOME AND INTRODUCTION
Martin Schlumberger (Paris, France)

DEFINING THE UNMET NEEDS IN ADVANCED MEDULLARY THYROID CANCER
Richard Kloos (Columbus, United States)

MEDULLARY THYROID CANCER - HAS TARGETED THERAPY DELIVERED?
Samuel Wells (Bethesda, United States)

BEYOND MEDULLARY THYROID CANCER – OVERVIEW AND INTRODUCTION
Martin Schlumberger (Paris, France)

BEYOND MEDULLARY THYROID CANCER – TARGETED THERAPY
FOR OTHER THYROID CANCERS
Lars Bastholt (Odense, Denmark)

CONCLUDING REMARKS
Samuel Wells (Bethesda, United States)

Amphitheatre Havane  16:30 - 19:30

MERCK SERONO SATELLITE SYMPOSIUM
The Thyroid and Diabetes
Chairperson: Jacques Orgiazzi (Lyon, France)

WELCOME AND INTRODUCTION
Jacques Orgiazzi (Lyon, France)

THYROID AND CARBOHYDRATE METABOLISM
Georg Brabant (Manchester, United Kingdom)

MANAGING PATIENTS WITH THYROID DISORDERS AND DIABETES
TYPE I AND II
Leonidas Duntas (Athens, Greece)

THYROID HORMONES AND ANALOGUES ON METABOLISM
REGULATION
Antonio Bianco (Miami, United States)
## Monday 13th September 2010

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Session Type</th>
<th>Time</th>
<th>Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>PL03</td>
<td>Satellite Symposium</td>
<td>07:30 - 08:30</td>
<td>Bayer Satellite Symposium</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>OC06</td>
<td>Oral communications</td>
<td>09:30 - 11:00</td>
<td>Topical Highlights 2</td>
<td>Grand Amphitheatre</td>
</tr>
<tr>
<td>OC09</td>
<td>Oral communications</td>
<td>09:30 - 11:00</td>
<td>Clinical Thyroidology - Nodules</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>OC10</td>
<td>Oral communications</td>
<td>09:30 - 11:00</td>
<td>Thyroid Hormone and the Brain</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>IG02</td>
<td>Implementing Guidelines</td>
<td>11:30 - 13:00</td>
<td>Implementing Guidelines for Thyroid Nodules</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>SY08</td>
<td>Symposium</td>
<td>11:30 - 13:00</td>
<td>Selenium and the Thyroid</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>SY09</td>
<td>Symposium</td>
<td>11:30 - 13:00</td>
<td>Molecular Mechanisms of Thyroid Cancer - Basic</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>SY10</td>
<td>Symposium</td>
<td>11:30 - 13:00</td>
<td>Hypothalamic Control of Energy Homoeostasis</td>
<td>Room 352AB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>13:00 - 14:00</td>
<td>Lunch Break</td>
<td></td>
</tr>
<tr>
<td>ME08</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>Targets of T4 Treatment in Hypothyroidism</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>ME09</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>Immuno-Modulators of Thyroid Functions</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>ME10</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>Radiation and the Thyroid Gland</td>
<td>Room 352AB</td>
</tr>
<tr>
<td>PD07</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>Clinical Thyroidology - Nodules</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>PD08</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>Graves Orbitopathy</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>PD09</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>Thyroid Cancer-Clinical II</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>PD10</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>Thyroid Cancer Translational</td>
<td>Room 352AB</td>
</tr>
<tr>
<td>PD11</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>Thyroid Hormone Transporters</td>
<td>Room 351</td>
</tr>
<tr>
<td>PD12</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>Thyroid Cell Biology</td>
<td>Room 341</td>
</tr>
<tr>
<td>OC11</td>
<td>Oral communications</td>
<td>14:45 - 16:15</td>
<td>Clinical Thyroidology - Hypothyroidism</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>OC12</td>
<td>Oral communications</td>
<td>14:45 - 16:15</td>
<td>Thyroid Cancer Clinical (Part I)</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>OC13</td>
<td>Oral communications</td>
<td>14:45 - 16:15</td>
<td>Graves Orbitopathy</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>OC14</td>
<td>Oral communications</td>
<td>14:45 - 16:15</td>
<td>Thyroid Hormone Transport and Action</td>
<td>Room 352AB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16:15 - 16:45</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>SY11</td>
<td>Symposium</td>
<td>16:45 - 18:15</td>
<td>Mechanism-Based Therapeutics for Advanced Thyroid Cancers</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>SY12</td>
<td>Symposium</td>
<td>16:45 - 18:15</td>
<td>Management of Graves' Orbitopathy</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>SY13</td>
<td>Symposium</td>
<td>16:45 - 18:15</td>
<td>Transporters in Thyroid Cell Biology</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>SY14</td>
<td>Symposium</td>
<td>16:45 - 18:15</td>
<td>Development and Applications of Novel Thyroid Hormone Analogues</td>
<td>Room 352AB</td>
</tr>
</tbody>
</table>
MONDAY 13th SEPTEMBER

**MORNING**

Amphitheatre Havane 07:30 - 08:30

**BAYER SATELLITE SYMPOSIUM**

Treatment of Differentiated Thyroid Cancer in the era of targeted therapy

- **07:00**  BREAKFAST AT BAR ARLEQUIN
- **07:30**  WELCOME AND INTRODUCTION
  - Martin Schlumberger (Villejuif, France)
- **07:35**  EPIDEMIOLOGY, DIAGNOSIS, AND UNMET NEED OF DTC
  - Yasuhiro Ito (Kobe, Japan)
- **07:50**  INHERENT BIOLOGY AND SIGNALING PATHWAYS IN DTC
  - Johannes Smit (Leiden, Netherlands)
- **08:05**  CLINICAL DEVELOPMENT OF TARGETED THERAPIES IN DTC
  - Marcia Brose (Philadelphia, United States)
- **08:20**  PANEL DISCUSSION
- **08:30**  CONCLUDING REMARKS
  - Martin Schlumberger (Villejuif, France)

Grand Amphitheatre 08:30 - 09:20

**ETA PRIZE LECTURE**

Chairpersons: Peter Laurberg (ETA President), Luigi Bartalena (ETA Secretary)

- **08:30**  ETA Merck-Serono Prize Lecture
  - THE RET GENE IN THYROID CANCER
  - Massimo Santoro (Naples, Italy)
- **08:55**  ETA Genzyme Prize for excellence in thyroid cancer research Lecture
  - TREATMENT OF METASTATIC DIFFERENTIATED THYROID CANCER: PITFALLS AND RECENT PROGRESS
  - Martin Schlumberger (Paris, France)
### Oral Communications - Grand Amphitheatre

**Monday 13th September**

**Morning**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30</td>
<td>Impact of Radioiodine Treatment on the Risk of Second Primary Cancer (SPC) Following Thyroid Cancer: A European Cohort Study</td>
<td>J.-P. Garsi, C. Rubino, S. Lönn, C. Corone, F. Hall, M. Ricard, F. de Vathaire (Villejuif, France)</td>
</tr>
<tr>
<td>09:45</td>
<td>IGF-1 Receptor Blockade Inhibits Akt Phosphorylation Induced by a Stimulatory Thyrotropin Receptor Antibody in Graves’ Orbital Preadipocyte Fibroblasts</td>
<td>S. Kumar, R. S. Babu, S. Demaray (Rochester, United States)</td>
</tr>
<tr>
<td>10:00</td>
<td>Genetic Immunization of C57Bl/6 Mice Against Human Δ33H TSHR Causes Specific Anti-TSH-Receptor Activity on a Cellular Level and Macrophage Infiltration of Orbital Tissues</td>
<td>B. Ziler, K. T. Johnson, A. Carpinteiro, M. Thanos, M. Schott, A. K. Eckstein (Essen, Germany)</td>
</tr>
<tr>
<td>10:15</td>
<td>Tissue-Specific Deletion of the Type 2 Deiodinase Gene Identifies a Role for Pituitary D2 in the TSH Feedback Mechanism</td>
<td>T. L. Fonseca, C. B. Ueta, M. P. O. Campos, M. C. Medina, A. C. Bianco (Miami, United States)</td>
</tr>
<tr>
<td>10:30</td>
<td>A Prospective Study on Impact of Subclinical Hypothyroidism During Pregnancy Receiving Left Thyroxine Treatment or Not on Neuropsychological Development of the Offspring</td>
<td>X. Yu, Z. Shao, W. Meng, H. Xue, Y.-B. Li, W. Wang, J. Li, Y. Chen, J. Li, M. Fan, H. Wang, H. Zhang, R. Gao (Shenyang, China)</td>
</tr>
<tr>
<td>10:45</td>
<td>The Oncogenic Actions of a Mutated Thyroid Hormone Receptor B in Transformed Human Thyroid Cells</td>
<td>S.-Y. Cheng, C. Lu, L. Zhao (Bethesda, United States)</td>
</tr>
</tbody>
</table>

### Oral Communications - Amphitheatre Bordeaux

**Monday 13th September**

**Morning**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30</td>
<td>Indirect Correlation of miRNAs and Cell Cycle Associated Genes Expression Suggests that miRNAs Affect Proliferation in Cold Thyroid Nodules</td>
<td>M. Eszlinger, R. Paschke (Leipzig, Germany)</td>
</tr>
<tr>
<td>09:45</td>
<td>Benign Thyroid Nodules Bearing the RET/PTC Oncogene Grow More Rapidly</td>
<td>V. Morotta, M. R. Sapio, A. Guerra, E. Campisano, M. Deandrea, M. Motta, P. P. Limone, G. Fenu, G. Rosset, M. Vitale (Napoli, Italy)</td>
</tr>
<tr>
<td>10:00</td>
<td>The Decision to Perform Thyroidectomy in Patients with Follicular Lesions of Undetermined Significance and Non-Diagnostic FNAs</td>
<td>J. Dy, L. Fogelfield, F. Kaddouch, S. Massarella (Chicago, United States)</td>
</tr>
<tr>
<td>10:15</td>
<td>Core-Needle Biopsy is More Useful than Repeated FNA in Thyroid Nodules with Previous Bethesda Category 1 or 3 FNA Result</td>
<td>D. G. Na, J. H. Kim, J. Y. Sung (Seoul, Republic of Korea)</td>
</tr>
</tbody>
</table>

---

Grand Amphitheatre 09:30 - 11:00

Amphitheatre Bordeaux 09:30 - 11:00
### Monday 13th September
#### Morning

**Implementing Guidelines**

**Implementing guidelines for thyroid nodules**

*Moderator: Ralf Paschke (Germany)*

*Case discussants: Susan Mandel (United States), Hirotoshi Nakamura (Japan), Fabian Pitoia (Argentina)*

*Voting machines available*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td>Selenium intake and thyroid hormone physiology</td>
<td>Lutz Schomburg (Germany)</td>
<td></td>
</tr>
<tr>
<td>11:52</td>
<td>Selenium and thyroid autoantibodies</td>
<td>Silvia Eskes (The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>12:14</td>
<td>Selenium in mild Graves' orbitopathy</td>
<td>Claudio Marcocci (Italy)</td>
<td></td>
</tr>
<tr>
<td>12:36</td>
<td>Maternal selenium status, thyroid function, and pregnancy outcome</td>
<td>Victor Pop (The Netherlands)</td>
<td></td>
</tr>
</tbody>
</table>

**Oral Communications**

**Thyroid hormone and the brain**

*Chairpersons: J. Rovet (Canada), J. Samarut (France)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30</td>
<td>Cerebellar abnormalities in mice lacking type 3 deiodinase and partial</td>
<td>R. P. Poets, D. S. Sharlin, L. Ng, A. Hernandez, D. L. St. Germain, D. Forrest (Bethesda, United States)</td>
<td></td>
</tr>
<tr>
<td>09:45</td>
<td>Thyroid hormone regulates BORG and SEPTIN4 expression in cerebellar</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>bergmann glia cells</td>
<td>S. Horn, C. Kaether, J. Mittag, M. K. Schäfer, H. Heuer (Iena, Germany)</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Children born to women with hypothyroidism in pregnancy show atypical</td>
<td>J. Rovet, M. P. McAndrew, J. Skocic, K. Willoughby, S. Woolner, E. Sheard (Toronto, Canada)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FMRI activation of the hippocampus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td>Expression pattern of thyroid hormone transporter and deiodinases in</td>
<td>S. Geysens, S. L. Van Henck, J. L. Ferrans, V. M. Darras (Leuven, Belgium)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>early chicken brain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Strategies to study the role of thyroid hormones in early chicken</td>
<td>S. Geysens, P. Tylzanowski, V. M. Darras (Leuven, Belgium)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>brain development by in vivo knockdown of type 2 and type 3 deiodinase</td>
<td>S. Geysens, P. Tylzanowski, V. M. Darras (Leuven, Belgium)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and OATP1C1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>Mutations in the thyroid hormone transporter MCT8 and the deiodinases</td>
<td>W. E. Visser, T. J. Visser (Rotterdam, Netherlands)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>D2 and D3 in a large cohort of subjects with unexplained mental</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>retardation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Symposium**

**Selenium and the thyroid**

*Chairpersons: L. Duntas (Greece), M. Zarkovic (Serbia)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td>Selenium intake and thyroid hormone physiology</td>
<td>Lutz Schomburg (Germany)</td>
<td></td>
</tr>
<tr>
<td>11:52</td>
<td>Selenium and thyroid autoantibodies</td>
<td>Silvia Eskes (The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>12:14</td>
<td>Selenium in mild Graves' orbitopathy</td>
<td>Claudio Marcocci (Italy)</td>
<td></td>
</tr>
<tr>
<td>12:36</td>
<td>Maternal selenium status, thyroid function, and pregnancy outcome</td>
<td>Victor Pop (The Netherlands)</td>
<td></td>
</tr>
</tbody>
</table>
MONDAY 13th SEPTEMBER MORNING

Room 342AB 11:30 - 13:00

SYMPOSIUM
Molecular mechanisms of thyroid cancer – Basic
Chairpersons: G. Brabant (United Kingdom), M. M. Xing (United States)

11:30 MICRO-RNA
Edna Teruko Kimura (Brazil)

11:52 TUMOR IMMUNOLOGY AND ASSOCIATED MACROPHAGES
James Fagin (United States)

12:14 THYROID CANCER STEM CELLS
Norisato Mitsutake (Japan)

Room 352AB 11:30 - 13:00

SYMPOSIUM
Hypothalamic control of energy homeostasis
Chairpersons: E. Fliers (The Netherlands), C. C. Pazos Moura (Brazil)

11:30 THYROID HORMONE SIGNALLING AND METABOLIC CONTROL
Anthony Hollenberg (United States)

11:52 MODULATION OF HEPATIC GLUCOSE PRODUCTION BY CENTRAL THYROID HORMONE ACTION
Lars Klieverik (The Netherlands)

12:14 THE ROLE OF THE THYROTROPIN-RELEASING HORMONE (TRH) NEURON AS A METABOLIC SENSOR IN HEALTH AND DISEASE
Csaba Fekete (Hungary)

12:36 LEPTIN SIGNALLING IN THE HYPOTHALAMO-PITUITARY-THYROID AXIS
Egberto G. Moura (Brazil)

Lunch break (Lunch bags distribution) Exhibition Area 13:00 - 14:00

Poster Zone 13:00 - 14:00

POSTER VIEWING SESSION
Group A2: P-0314-P-0572 (see page 72)
Authors will be present next to their poster in order to answer questions from delegates
MONDAY 13th SEPTEMBER

AFTERNOON

**ME07**
**MEET THE EXPERT**
Management of postpartum thyroiditis
Nobuyuki Amino (Japan)

**ME08**
**MEET THE EXPERT**
Targets of T4 treatment in hypothyroidism
Maria Alevizaki (Greece)

**ME09**
**MEET THE EXPERT**
Immu-no-modulators of thyroid functions
Luca Chiovato (Italy)

**ME10**
**MEET THE EXPERT**
Radiation and the thyroid gland
Shigenobu Nagataki (Japan)

**ME11**
**MEET THE EXPERT**
Imprinting epigenetic regulation of the deiodinase 3 gene
Arturo Hernandez (United States)

**ME12**
**MEET THE EXPERT**
New signalling pathways in the thyrocyte
Ana Maria Masini-Repiso (Argentina)
**MONDAY 13TH SEPTEMBER**

**AFTERNOON**

**Amphitheatre Bordeaux** 14:00 - 14:40

**POSTER DISCUSSIONS**

**Clinical thyroidology - Nodules**

Chairperson: E. Tomimori (Brazil)

- **14:00** ELASTIC SCATTERING SPECTROSCOPY (ESS) CAN BETTER DISCRIMINATE BENIGN FROM MALIGNANT THYROID LESIONS THAN CYTOTOLOGY IN PATIENTS WITH INDETERMINATE THYROID NODULES
  
  J. E. Rosen, H. Suh, S. Kim, S. Onazi, O. A’amar, I. Bigio, S. Lee (Boston, United States)

- **14:06** DIAGNOSIS OF THYROID CANCER BY QUANTITATIVE SONOGRAPHIC CALCIFICATION INDEX
  
  K.-Y. Chen, C.-N. Chen, M.-H. Wu, M.-H. Ho, H.-C. Tai, A. Chen, W.-C. Huang, K.-J. Chang (Taipei, Taiwan, China)

- **14:12** CHRONIC THYROTROPIN SUPPRESSION DOES NOT AFFECT GROWTH FACTOR RECEPTOR GENE EXPRESSION AND AKT PHOSPHORYLATION IN BENIGN HUMAN THYROID NODULES
  

- **14:18** THYROID MALIGNANCY AFTER FIST BENIGN FINE-NEEDLE ASPIRATION CYTOTOLOGY IN THYROID NODULE – A TEN YEAR EXPERIENCE
  
  F. F. R. Maia, P. S. Mattos, B. P. Silva, M. T. Pallone, E. Pavini, J. Vassallo, D. E. Zanutt-Wittmann (São Paulo, Brazil)

- **14:24** INTERSTITIAL LASER PHOTOCOAGULATION (ILP) OF BENIGN SOLITARY COLD THYROID NODULES – LONG-TERM EFFICACY
  
  H. Dissing, L. Hegedüs, F. N. Bennehbiø (Odense C, Denmark)

**Amphitheatre Havane** 14:00 - 14:40

**POSTER DISCUSSIONS**

**Graves’ orbitopathy**

Chairperson: L. Hegedüs (Denmark)

- **14:00** GENETIC VARIATIONS IN IMMEDIATE EARLY GENES WITH HIGH EXPRESSION IN GRAVES’ OPHTHALMOPATHY ARE ASSOCIATED WITH GRAVES’ DISEASE AND OPHTHALMOPATHY
  
  T. Planck, M. Sjögren, L. Groop, B. Hallengren, K. Szymanski, T. Bednarczuk, R. Ploski, M. Lantz (Malmö, Sweden)

- **14:06** TH1 (CXCL10) AND TH2 (CCL2) CHEMOKINES ARE DIFFERENTIALLY MODULATED BY IFN-GAMMA, TNF-ALPHA AND PPAR-GAMMA AGONISTS IN EXTRAOCULAR MUSCLE MYOBLASTS FROM PATIENTS WITH GRAVES’ OPHTHALMOPATHY
  
  A. Antonelli, S. M. Ferrari, S. Sellari Franceschini, E. Ferrareni, P. Fallahi (Fisa, Italy)

- **14:12** CHRONIC THYROTROPIN SUPPRESSION DOES NOT AFFECT GROWTH FACTOR RECEPTOR GENE EXPRESSION AND AKT PHOSPHORYLATION IN BENIGN HUMAN THYROID NODULES
  

- **14:18** THYROID MALIGNANCY AFTER FIST BENIGN FINE-NEEDLE ASPIRATION CYTOTOLOGY IN THYROID NODULE – A TEN YEAR EXPERIENCE
  
  F. F. R. Maia, P. S. Mattos, B. P. Silva, M. T. Pallone, E. Pavini, J. Vassallo, D. E. Zanutt-Wittmann (São Paulo, Brazil)

- **14:24** INTERSTITIAL LASER PHOTOCOAGULATION (ILP) OF BENIGN SOLITARY COLD THYROID NODULES – LONG-TERM EFFICACY
  
  H. Dissing, L. Hegedüs, F. N. Bennehbiø (Odense C, Denmark)
Monday 13th September

**Room 342AB**

**14:00 - 14:40**

**P-0518**

**Title:** Frequent Thyroid Cancer - Translational

**Chairperson:** G. Cote (United States)

- **14:00**
  - Preclinical assessment of therapeutic agents for thyroid cancer using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)

- **14:06**
  - Risk factors of differentiated thyroid cancer occurring in young patients aged from 0 to 35 years living in the Rhône-Alpes region of France: preliminary results of a population-based case-control study of thyroid disease history and anthropometry
  - G. M. Sassolas, M. Colonna, Z. Hadji-Nojiri, F. Borson-Chazot, F. de Vathaire (Boue, France)

- **14:12**
  - Prospective analysis of B-mode, power Doppler US and US-Elastography features in differential diagnosis of malignant thyroid nodules: comparison with cytological and histopathological diagnosis in a prospective study
  - M. Erologlu, E. Demir, O. Demir, S. Gulcu, N. Baykal (Ankara, Turkey)

- **14:18**
  - Role of FDG-PET/CT in the pre-surgical characterization of thyroid tumors with indeterminate cytology
  - D. Deandreis, A. Al Ghuzlan, P. Vielh, L. Chami, A. Auperin, J. Lumbroso, D. Hartl, E. Baudin, M. Schlumberger, S. Labbe (Villejuif, France)

- **14:24**
  - The characteristics of thyroid cancers showing no FDG uptake in PET/CT scan at diagnosis

**Room 352AB**

**14:00 - 14:40**

**P-0519**

**Title:** Thyroid cancer - Clinical II

**Chairperson:** J. Masjhur (Indonesia)

- **14:00**
  - Preclinical assessment of therapeutic agents for thyroid cancer using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)

- **14:06**
  - Risk factors of differentiated thyroid cancer occurring in young patients aged from 0 to 35 years living in the Rhône-Alpes region of France: preliminary results of a population-based case-control study of thyroid disease history and anthropometry
  - G. M. Sassolas, M. Colonna, Z. Hadji-Nojiri, F. Borson-Chazot, F. de Vathaire (Boue, France)

- **14:12**
  - Prospective analysis of B-mode, power Doppler US and US-Elastography features in differential diagnosis of malignant thyroid nodules: comparison with cytological and histopathological diagnosis in a prospective study
  - M. Erologlu, E. Demir, O. Demir, S. Gulcu, N. Baykal (Ankara, Turkey)

- **14:18**
  - Role of FDG-PET/CT in the pre-surgical characterization of thyroid tumors with indeterminate cytology
  - D. Deandreis, A. Al Ghuzlan, P. Vielh, L. Chami, A. Auperin, J. Lumbroso, D. Hartl, E. Baudin, M. Schlumberger, S. Labbe (Villejuif, France)

- **14:24**
  - The characteristics of thyroid cancers showing no FDG uptake in PET/CT scan at diagnosis
### MONDAY 13th SEPTEMBER

#### AFTERNOON

<table>
<thead>
<tr>
<th>Room 351</th>
<th>14:00 - 14:40</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>POSTER DISCUSSIONS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Thyroid hormone transporters</strong></td>
<td></td>
</tr>
<tr>
<td>Chairperson: H. Heuer (Germany)</td>
<td></td>
</tr>
<tr>
<td><strong>14:00</strong></td>
<td><strong>14:06</strong></td>
</tr>
<tr>
<td>THYROID HORMONE TRANSPORT AND ACTION IN THE FETAL RAT BRAIN</td>
<td>EXPRESSION AND FUNCTIONAL ACTIVITY OF THYROID HORMONE TRANSPORTERS IN MICRIVILLOUS PLASMA MEMBRANES FROM HUMAN TERM PLACENTAL SYNCTIOTROPHOCYTES</td>
</tr>
<tr>
<td><strong>14:12</strong></td>
<td><strong>14:18</strong></td>
</tr>
<tr>
<td>THE MECHANISMS INVOLVED IN TRANSHYRETIN-THYROXINE UPTAKE IN PLACENTA</td>
<td>PLACENTAL TRANSPORT OF THYROXINE BY TRANSHYRETIN IS REGULATED BY OXYGEN</td>
</tr>
<tr>
<td><strong>14:24</strong></td>
<td><strong>14:30</strong></td>
</tr>
<tr>
<td>ESSENTIAL MOLECULAR DETERMINANTS FOR THYROID HORMONE TRANSPORT AND FIRST STRUCTURAL IMPLICATIONS FOR MONOCARBOXYLATE TRANSPORTER 8</td>
<td>CORRELATION BETWEEN IN SILICO PREDICTED AND IN VITRO CONFIRMED THYROID-RELEVANT TRANSCRIPTION FACTOR BINDING SITES IN PROMOTERS OF HUMAN AND RABBIT GENES CONCERNING FOR PROTEINS PARTICIPATING IN THYROID HORMONE SYNTHESIS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Room 341</th>
<th>14:00 - 14:40</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>POSTER DISCUSSIONS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Thyroid cell biology</strong></td>
<td></td>
</tr>
<tr>
<td>Chairperson: M.T. Nunes (Brazil)</td>
<td></td>
</tr>
<tr>
<td><strong>14:00</strong></td>
<td><strong>14:06</strong></td>
</tr>
<tr>
<td>THE REGULATION OF THE OXIDATIVE STATUS IS INVOLVED IN THYROID CELL RESPONSES TO HIGH IODIDE DOSE</td>
<td>SLC5A8 PLAYS A KEY ROLE IN THE THYROID REGULATION BY IODIDE AND PROTECTS THYROCYTES AGAINST EXCESSIVE OXIDIZED IODINE PRODUCTION</td>
</tr>
<tr>
<td><strong>14:12</strong></td>
<td><strong>14:18</strong></td>
</tr>
<tr>
<td>NA+ / I- SYMPORTER (NIS) EXPRESSION AND LOCALIZATION DURING RAPID TRANSPORT INHIBITION BY IODIDE EXCESS</td>
<td>PLACENTAL TRANSPORT OF THYROXINE BY TRANSHYRETIN IS REGULATED BY OXYGEN</td>
</tr>
<tr>
<td><strong>14:24</strong></td>
<td><strong>14:30</strong></td>
</tr>
<tr>
<td>ESSENTIAL MOLECULAR DETERMINANTS FOR THYROID HORMONE TRANSPORT AND FIRST STRUCTURAL IMPLICATIONS FOR MONOCARBOXYLATE TRANSPORTER 8</td>
<td>COMPLETE THYROXINE-BINDING GLOBULIN DEFICIENCY, DUE TO A NOVEL p.A109T MUTATION, ASSOCIATED WITH INCREASED AFFINITY IN TRANSHYRETIN (p.A109T MUTATION) IN AN HYPOTHYROID PATIENT</td>
</tr>
</tbody>
</table>

---

**PD13**

**PD12**
MONDAY 13th SEPTEMBER

Amphitheatre Bordeaux 14:45 - 16:15

OC11 ORAL COMMUNICATIONS
Clinical thyroidology - Hypothyroidism
Chairpersons: A. Cappola (United States), A. Orlandi (Argentina)

14:45 COMPARISON OF FOUR STRATEGIES OF RADIOIODINE ABLATION IN PATIENTS WITH THYROID CANCER WITH LOW-RISK OF RECURRENCE: THE RANDOMIZED, PROSPECTIVE ESTIMABL STUDY ON 753 PATIENTS

15:00 HILO: MULTICENTRE RANDOMISED PHASE III CLINICAL TRIAL OF HIGH VS LOW DOSE RADIOIODINE, WITH OR WITHOUT RECOMBINANT HUMAN THYROID STIMULATING HORMONE (RHtSH), FOR REMNANT ABLATION FOR DIFFERENTIATED THYROID CANCER
U. Mallick (Newcastle upon Tyne, United Kingdom)

15:15 ABSENCE OF SURVIVAL BENEFIT OF RADIOACTIVE IODINE (RAI) AFTER THYROIDECTOMY IN LOW RISK DIFFERENTIATED THYROID CANCER (DTC) PATIENTS

15:30 THE ABSORBED DOSE TO THE BLOOD IS A BETTER PREDICTOR OF ABLATION SUCCESS THAN THE ADMINISTERED I-131 ACTIVITY IN THYROID CANCER PATIENTS

15:45 ROUTINE DIAGNOSTIC I-131 WHOLE BODY SCAN IN PATIENTS WITH “HIGH RISK” DIFFERENTIATED THYROID CANCER
S. De Meer, M. Vriens, P. Zelissen, I. Borel Rinkes, B. de Keizer (Utrecht, Netherlands)

16:00 ENDOCRINE EFFECTS OF VANDETANIB IN THYROID CANCER PATIENTS
M. Brassard, B. Nerudd, S. Trabado, S. Salenave, S. Brailly-Tabard, E. Baudin, S. Leboulleux, P. Chanson, M. Schlumberger, J. Young (Villaplai, France)

Amphitheatre Havane 14:45 - 16:15

OC12 ORAL COMMUNICATIONS
Thyroid cancer clinical (Part 1)
Chairpersons: R. Elisei (Italy), A. Gauna (Argentina)

14:45 COMPARISON OF FOUR STRATEGIES OF RADIOIODINE ABLATION IN PATIENTS WITH THYROID CANCER WITH LOW-RISK OF RECURRENCE: THE RANDOMIZED, PROSPECTIVE ESTIMABL STUDY ON 753 PATIENTS

15:00 HILO: MULTICENTRE RANDOMISED PHASE III CLINICAL TRIAL OF HIGH VS LOW DOSE RADIOIODINE, WITH OR WITHOUT RECOMBINANT HUMAN THYROID STIMULATING HORMONE (RHtSH), FOR REMNANT ABLATION FOR DIFFERENTIATED THYROID CANCER
U. Mallick (Newcastle upon Tyne, United Kingdom)

15:15 ABSENCE OF SURVIVAL BENEFIT OF RADIOACTIVE IODINE (RAI) AFTER THYROIDECTOMY IN LOW RISK DIFFERENTIATED THYROID CANCER (DTC) PATIENTS

15:30 THE ABSORBED DOSE TO THE BLOOD IS A BETTER PREDICTOR OF ABLATION SUCCESS THAN THE ADMINISTERED I-131 ACTIVITY IN THYROID CANCER PATIENTS

15:45 ROUTINE DIAGNOSTIC I-131 WHOLE BODY SCAN IN PATIENTS WITH “HIGH RISK” DIFFERENTIATED THYROID CANCER
S. De Meer, M. Vriens, P. Zelissen, I. Borel Rinkes, B. de Keizer (Utrecht, Netherlands)

16:00 ENDOCRINE EFFECTS OF VANDETANIB IN THYROID CANCER PATIENTS
M. Brassard, B. Nerudd, S. Trabado, S. Salenave, S. Brailly-Tabard, E. Baudin, S. Leboulleux, P. Chanson, M. Schlumberger, J. Young (Villaplai, France)
<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45</td>
<td>THYROID STIMULATING HORMONE RECEPTOR DEFINES THE CRITICAL ANTIGEN IN THE</td>
<td>S. Zhao, S. Tsui, A. Cheung, R. S. Douglas, T. J. Smith, J. P. Banga (London, United Kingdom)</td>
</tr>
<tr>
<td></td>
<td>DEVELOPMENT OF GRAVES’ ORBITOPATHY IN A NEW MURINE MODEL AND EXPLAINS THE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CLOSE ASSOCIATION WITH GRAVES’ DISEASE</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>DETECTION OF AUTOANTIBODIES AGAINST THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR</td>
<td>W. B. Minich, A. Eckstein, N. Dohnina, J. Köhrle, L. Schomburg (Berlin, Germany)</td>
</tr>
<tr>
<td></td>
<td>IN PATIENTS WITH GRAVES’ ORBITOPATHY BY LUMINESCENT IMMUNOPRECIPITATION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ANALYSIS</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>SEVERE ADVERSE EVENTS OF GLUCOCORTICOID TREATMENT OF GRAVES’ ORBITOPATHY:</td>
<td>C. Marcocci, T. Watt, Å. K. Rasmussen, U. Feltb-Rasmussen, M. A. Altea, J. Orpiaczi, L. Bartalena (Pisa, Italy)</td>
</tr>
<tr>
<td></td>
<td>RESULTS OF A SURVEY AMONG MEMBERS OF THE EUROPEAN THYROID ASSOCIATION</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>COMPARISON OF EARLY TOTAL THYROIDECTOMY WITH ANTITHYROID TREATMENT IN</td>
<td>C. Marcocci, T. Watt, Å. K. Rasmussen, U. Feltb-Rasmussen, M. A. Altea, J. Orpiaczi, L. Bartalena (Pisa, Italy)</td>
</tr>
<tr>
<td></td>
<td>PATIENTS WITH MODERATE TO SEVERELY ACTIVE GRAVES’ ORBITOPATHY: PRELIMINARY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RESULTS OF A RANDOMIZED PROSPECTIVE TRIAL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TREATED WITH ANTITHYROID DRUGS OR RADIOIODINE. A 4-YEAR RANDOMIZED STUDY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>EXPRESSIONS OF TWO THYROID HORMONE TRANSPORTERS (MCT8 AND OATP1A4) IN RAT</td>
<td>Y. N. Sun, L. Zhang, L. X. Lin, Y. M. Li, Y. Ye, Y. Q. Tan, Z. F. Chen (Tianjin, China)</td>
</tr>
<tr>
<td></td>
<td>PLACENTA TISSUE WITH THE STATUS OF IODINE SUFFICIENCY AND IODINE DEFICIENCY</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>IMMUINIZATION OF C57BL/6 AND BALB/C WITH ADENOVIRAL TSHR289 CAUSES SIGNIFICANT</td>
<td>K. T. Johnson, B. Ziler, M. Thanos, A. Carpinteiro, K. W. Schend, W. Minich, E. Galliers, Y. Nagayama, A. K. Eckstein (Essen, Germany)</td>
</tr>
<tr>
<td></td>
<td>INFILTRATION OF ORBITAL TISSUES WITH MACROPHAGES AND T-LYMPHOCYTES</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TOWARDS A THERAPY FOR MCT8 PATIENTS</td>
<td>J. Müller, M. Trajkovic-Anic, V. M. Darras, C. Groba, S. Lee, K. Bauer, T. J. Visser, H. Heuer (Jena, Germany)</td>
</tr>
<tr>
<td></td>
<td>PITUITARY-THYROID AXIS IN MICE</td>
<td></td>
</tr>
</tbody>
</table>
MONDAY 13th SEPTEMBER

Coffee break

Exhibition Area 16:45 - 16:45

SY11 SYMPOSIUM
Mechanism-based therapeutics for advanced thyroid cancers
Chairpersons: C. Durante (Italy), S. I. Sherman (United States)

16:45 \textbf{OVERVIEW OF THERAPEUTIC TARGETS}\nMassimo Santoro (Italy)

17:07 \textbf{SELECTION OF PATIENTS FOR TARGETED THERAPIES}\nLars Bastholt (Denmark)

17:29 \textbf{RESULTS OF CLINICAL TRIALS OF TARGETED THERAPIES}\nDave Pfister (United States)

17:51 \textbf{MANAGEMENT OF OFF-TARGET TOXICITY}\nManisha Shah (United States)

Amphitheatre Bordeaux 16:45 - 18:15

SY12 SYMPOSIUM
Management of Graves’ Ophthalmopathy (GO)
Chairpersons: G. M. E. S. Mazeto (Brazil), O. Torring (Sweden)

16:45 \textbf{IMMUNOPATHOGENESIS OF GO: WHERE DO WE STAND?}\nRebecca Bahn (United States)

17:07 \textbf{ETHNIC DIFFERENCES IN THE CLINICAL PRESENTATION OF GO}\nDaphne Khoo (Singapore)

17:29 \textbf{OPTIMAL USE OF STEROIDS IN GO AND THE ROLE OF HIGH DOSE IV METHYL-PREDNISOLONE}\nLuigi Bartalena (Italy)

17:51 \textbf{NOVEL TREATMENTS OF GO}\nMario Salvi (Italy)

Amphitheatre Havane 16:45 - 18:15

SY13 SYMPOSIUM
Transporters in thyroid cell biology
Chairpersons: J. Hershman (United States), F. Miot (Belgium)

16:45 \textbf{STRUCTURE-FUNCTION RELATIONSHIP OF THE SODIUM/IODIDE SYMPORTER (NIS)}\nNancy Carrasco (United States)

17:07 \textbf{MCT8 AS THYROID HORMONE EXPORTER IN THYROID CELLS}\nCaterina Di Cosmo (United States)

17:29 \textbf{PENDRIN AND APICAL IODIDE TRANSPORT}\nPeter Kopp (United States)

17:51 \textbf{ROLE OF CLC5 IN THE THYROID}\nMarie-France van den Hove (Belgium)

Room 342AB 16:45 - 18:15
MONDAY 13th SEPTEMBER  
AFTERNOON

Room 352AB  16:45 - 18:15

SYMPOSIUM
Development and applications of novel thyroid hormone analogues
Chairperson: M. T. Ackermans (The Netherlands), M. T. Barreto-Chaves (Brazil)

16:45  PHYSIOLOGICAL AND PHARMACOLOGICAL ACTIONS OF THYROID HORMONE ANALOGUES
Thomas Scanlan (United States)

17:07  CARDIAC EFFECTS OF THYRONAMINES
Ricardo Zucchi (Italy)

17:29  USE OF TR-BETA SELECTIVE AGONISTS IN METABOLIC SYNDROME
Miriam O. Ribeiro (Brazil)

17:51  NON-GENOMIC ACTION OF THYROID HORMONE ANALOGUES
Paul Davis (United States)
## MONDAY 13th SEPTEMBER

### IBSA INSTITUT BIOCHIMIQUE SATELLITE SYMPOSIUM

**Levothyroxine softgel capsules: an innovative formulation targeting thyroxine absorption and malabsorption**

Chairpersons: Aldo Pinchera (Pisa, Italy), Kenneth D. Burman (Washington, United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:30</td>
<td>WELCOME AND INTRODUCTION</td>
</tr>
<tr>
<td>18:35</td>
<td>THE NEW FDA QUALITY REQUIREMENTS AND THE BIOAVAILABILITY OF LEVOTHYROXINE SOFTGEL CAPSULES</td>
</tr>
<tr>
<td>18:45</td>
<td>NUTRITIONAL INTERFERENCES ON LEVOTHYROXINE ABSORPTION</td>
</tr>
<tr>
<td>19:00</td>
<td>GASTROINTESTINAL MALABSORPTION OF LEVOTHYROXINE</td>
</tr>
<tr>
<td>19:15</td>
<td>CONCLUSIONS</td>
</tr>
<tr>
<td>19:25</td>
<td>DISCUSSION</td>
</tr>
<tr>
<td>19:30</td>
<td>END OF SESSION</td>
</tr>
</tbody>
</table>

### DIAGNOSTIC HYBRIDS Inc. SATELLITE SYMPOSIUM

**Novel diagnostic tool for Graves' disease**

Chairpersons: George J. Kahaly (Mainz, Germany), Len D. Kohn (Ohio, United States)

- ROLE AND STRUCTURE OF THE TSH RECEPTOR IN GRAVES' DISEASE
  - Rebecca Bahn (Rochester, United States)

- DEVELOPMENT AND FDA CLEARANCE OF A NOVEL BIOASSAY FOR STIMULATING TSH RECEPTOR AUTOANTIBODIES (THYRETAIN®)
  - Paul D. Olivo (Athens, United States)

- THYRETAIN® IN PEDIATRIC GRAVES’ DISEASE
  - Rosaline Brown (Boston, United States)

- THYRETAIN® IS A FUNCTIONAL INDICATOR OF GRAVES’ THYROIDAL AND ORBITAL DISEASE
  - Katharina A. Ponto (Mainz, Germany)

ROUND-TABLE DISCUSSION
<table>
<thead>
<tr>
<th>Session Code</th>
<th>Session Type</th>
<th>Time</th>
<th>Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>PL04</td>
<td>Plenary Lecture</td>
<td>08:30 - 09:20</td>
<td>LATS PRIZE LECTURE</td>
<td>Grand Amphitheatre</td>
</tr>
<tr>
<td>OC15</td>
<td>Oral Communications</td>
<td>09:30 - 11:00</td>
<td>TYPIC HIGHLIGHTS 3</td>
<td>Grand Amphitheatre</td>
</tr>
<tr>
<td>OC16</td>
<td>Oral Communications</td>
<td>09:30 - 11:00</td>
<td>CLINICAL THYROIDOLOGY - HYPERTHYROIDISM</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>OC17</td>
<td>Oral Communications</td>
<td>09:30 - 11:00</td>
<td>THYROID CANCER BASIC (Part 2)</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11:00 - 11:30</td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
<tr>
<td>DR01</td>
<td>Debate</td>
<td>11:30 - 12:10</td>
<td>DO NOT TREAT SUB-CLINICAL HYPERTHYROIDISM</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>DR02</td>
<td>Debate</td>
<td>12:20 - 13:00</td>
<td>THYROID STEM CELLS DO NOT EXIST</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>SY15</td>
<td>Symposium</td>
<td>11:30 - 13:00</td>
<td>ADVANCES IN SURGICAL THERAPY OF THYROID CANCER</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>SY16</td>
<td>Symposium</td>
<td>11:30 - 13:00</td>
<td>IMMUNO MECHANISMS IN AUTOIMMUNE THYROID DISEASES (AITD): NEW DEVELOPMENTS AND FUTURE DIRECTIONS</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>SY17</td>
<td>Symposium</td>
<td>11:30 - 13:00</td>
<td>MOLECULAR MECHANISMS OF THYROID CANCER – TRANSLATIONAL</td>
<td>Room 352AB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>13:00 - 14:00</td>
<td>LUNCH BREAK</td>
<td></td>
</tr>
<tr>
<td>ME13</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>SUB CLINICAL HYPER THYROIDISM</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>ME15</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>MANAGEMENT OF PAEDIATRIC MEDULLARY THYROID CARCINOMA</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>ME16</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>A NEW SENSITIVE THYROGLOBULIN ASSAY</td>
<td>Room 352AB</td>
</tr>
<tr>
<td>ME17</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>CATHPSIN MEDIATED TG PROTEOLYSIS AND TH RELEASE</td>
<td>Room 351</td>
</tr>
<tr>
<td>ME18</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>CONTROL OF CEREBELLAR DEVELOPMENT BY THYROID HORMONE</td>
<td>Room 341</td>
</tr>
<tr>
<td>PD13</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>CLINICAL THYROIDOLOGY - CASE REPORTS</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>PD14</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>THYROID CANCER SURGERY</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>PD15</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>THYROID CANCER CLINICAL (Part 3)</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>PD16</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>IODINE AND THYROID</td>
<td>Room 352AB</td>
</tr>
<tr>
<td>PD17</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>THYROID HORMONE ACTIONS</td>
<td>Room 351</td>
</tr>
<tr>
<td>PD18</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>THE ROLE OF THYROID HORMONE IN BRAIN AND DEVELOPMENT</td>
<td>Room 341</td>
</tr>
<tr>
<td>PD19</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>THYROID AND ENERGY METABOLISM</td>
<td>Room 341</td>
</tr>
<tr>
<td>OC18</td>
<td>Oral Communications</td>
<td>14:45 - 16:15</td>
<td>THYROID CANCER CLINICAL (Part 2)</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>OC19</td>
<td>Oral Communications</td>
<td>14:45 - 16:15</td>
<td>EPIDEMIOLOGY OF THYROID DISEASES</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>OC20</td>
<td>Oral Communications</td>
<td>14:45 - 16:15</td>
<td>AUTOIMMUNITY</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>OC21</td>
<td>Oral Communications</td>
<td>14:45 - 16:15</td>
<td>IN VIVO AND IN VITRO MODELS OF THYROID DISEASES</td>
<td>Room 352AB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16:15 - 16:45</td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
<tr>
<td>Business Meeting</td>
<td></td>
<td>16:45 - 18:15</td>
<td>ATA BUSINESS MEETING</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>Business Meeting</td>
<td></td>
<td>16:45 - 18:15</td>
<td>ETA BUSINESS MEETING</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>Business Meeting</td>
<td></td>
<td>16:45 - 18:15</td>
<td>AOTA BUSINESS MEETING</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>Business Meeting</td>
<td></td>
<td>16:45 - 18:15</td>
<td>LATS BUSINESS MEETING</td>
<td>Room 352AB</td>
</tr>
</tbody>
</table>
TUESDAY 14th SEPTEMBER
MORNING

Grand Amphitheatre
08:30 - 09:20

LATS PRIZE LECTURE
Chairpersons: Hans Graf (LATS President), Anna Maria Masini Repiso (LATS Secretary)

Grand Amphitheatre
09:30 - 11:00

ORAL COMMUNICATIONS

Topic highlights 3
Chairpersons: Y. Toker (United States), S. Yamashita (Japan)

Amphitheatre Bordeaux
09:30 - 11:00

ORAL COMMUNICATIONS

Clinical thyrology - Hyperthyroidism
Chairpersons: E. Barrenchea (Philippines), U. Feldt-Rasmussen (Denmark)
OC17  ORAL COMMUNICATIONS

Thyroid cancer basic (Part 2)

Chairpersons: R. M. Melillo (Italy), M. Mitsutake (Japan)

09:30  TGFB HAS A PRO-APOPTOTIC ACTION IN HUMAN PRIMARY THYROID CELLS IN CULTURE THROUGH DIRECT DOWNREGULATION OF CDKN2B (p27KIP) PROMOTER AND INDUCTION OF CDK2 ACTIVITY


09:45  MODULATION OF SMAD4 BY MICRORNA miR-146b DISRUPTS TGF-β SIGNALING PATHWAY IN THYROID FOLLICULAR CELLS

M. V. Geraldo, A. S. Yamashita, E. T. Kimura (Sao Paulo, Brazil)

10:00  PAX8/PPARGAMMA FUSION PROTEIN MODULATES FOLLICULAR THYROID TUMORIGENESIS VIA PTEN-REGULATED UPREGULATION OF TUMOR SUPPRESSOR MIR-122

H. V. Reddi, P. Madde, D. Milosevic, J. H. Hackbarth, A. Algerciras-Schimnich, J. A. Copland, B. McIver, S. Grebe, N. Eberhardt (Rochester, United States)

10:15  IMPACT OF THE THYROID-TARGETED INACTIVATION OF THE THYROID HORMONE RECEPTOR β GENE ON E7 ONCOGENE-DRIVEN GROWTH AND NEOPLASTIC TRANSFORMATION OF THE THYROID GLAND

S. Selmi-Ruby, L. Bouazza, J. du Payrat, F. Bernier-Valentin, F. Flamand, F. Borson-Chazot, B. A. Rousset (Lyon, France)

10:30  DIRECT TARGETING OF FOCAL ADHESION KINASE (FAK) IN ANAPLASTIC THYROID CARCINOMA (ATC)

Y. Chen, M. Gale, Y. Henderson, S. Y. Lai (Houston, United States)

10:45  THE ROLE OF PBF IN NIS AND MCT8 CELLULAR TRAFFICKING


Coffee break

Amphitheatre Bordeaux 11:00 - 11:30

D3B1  DEBATE

Do not treat subclinical hypothyroidism

Chairperson: S. Pearce (United Kingdom)

Jean-Louis Wemeau (France) the “PRO” point of view.
Mario Vaisman (Brazil) the “CON” point of view.

Voting machines available

Amphitheatre Bordeaux 12:20 - 13:00

D3B2  DEBATE

Thyroid stem cells do not exist

Chairperson: K. M. Derwahl (Germany)

Terry Davies (United States) the “PRO” point of view.
Jacques Dumont (Belgium) the “CON” point of view.

Voting machines available
Tuesday, September 14

Amphitheatre Havane

11:30 - 13:00
SYMPOSIUM

Advances in surgical therapy of thyroid cancer
Chairpersons: R. Tufano (United States), Y. K. Youn (Korea)

11:30 MINIMIZING SURGICAL RISKS (NERVE MONITORING, CALCIUM MANAGEMENT)
Michele Minuto (Italy)

11:52 NEW METHODS (ROBOTICS, MINIMALLY INVASIVE SURGERY)
Woong Youn Chung (Korea)

12:14 CONTROVERSY ON CENTRAL NECK DISSECTION
Gerard Doherty (United States)

12:36 RE-OPERATION – WHEN AND HOW?
David Steward (United States)

Room 342AB

11:30 - 13:00
SYMPOSIUM

Molecular mechanisms of thyroid cancer – translational
Chairpersons: D. Ball (United States), F. Carlomagno (Italy)

11:30 DEFINING POORLY DIFFERENTIATED THYROID CANCER
Fulvio Basolo (Italy)

11:52 PI3K PATHWAY IN CANCER PROGRESSION
Matthew Ringel (United States)

12:14 SODIUM/IODIDE TRANSPORTER (NIS) DYSREGULATION
Christine Spitzweg (Germany)

12:36 BRAF MUTATION
Janele Cenetti (Brazil)

Room 352AB

11:30 - 13:00
SYMPOSIUM

Immuno mechanisms in Autoimmune Thyroid Diseases (AITD):
New developments and future directions
Chairpersons: R. Bahn (United States), L. J. de Groot (United States)

11:30 IMMUNOREGULATION IN A MOUSE MODEL OF GRAVES’ DISEASE
Basil Rapoport (United States)

11:52 CHEMOKINES AND THYROID AUTOIMMUNITY
Sergio Lira (United States)

12:14 THE ROLE OF DENDRITIC CELLS IN AITD
Claudia Pellizzas (Argentina)

12:36 VITAMIN D AND AITD
Klaus Badenhoop (Germany)

Exhibition Area

13:00 - 14:00
Lunch break (Lunch bags distribution)

Poster Zone

13:00 - 14:00

Poster Viewing Session
Display Group B1: P-0573 to P-0872 (see page 75)

Authors will be present next to their poster in order to answer questions from delegates
<table>
<thead>
<tr>
<th>Time</th>
<th>Location/Room</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 13:15 - 13:55 | Amphitheatre Bordeaux | **MEET THE EXPERT**  
Subclinical hyperthyroidism  
José Augusto Sgarbi (Brazil)                                                                                                                      |                                    |
| 13:15 - 13:55 | Amphitheatre Havane | **MEET THE EXPERT**  
The management of thyroid eye disease  
Anja Eckstein (Germany), Petros Perros (United Kingdom)                                                                                           |                                    |
| 13:15 - 13:55 | Room 342AB     | **MEET THE EXPERT**  
Management of paediatric medullary thyroid carcinoma  
Steven Waguespack (United States)                                                                                                              |                                    |
| 13:15 - 13:55 | Room 352AB     | **MEET THE EXPERT**  
A new sensitive thyroglobulin assay  
Rui Maciel (Brazil)                                                                                                                                |                                    |
| 13:15 - 13:55 | Room 351       | **MEET THE EXPERT**  
Cathepsin-mediated thyroglobulin proteolysis and thyroid hormone release  
Klaudia Brix (Germany)                                                                                                                             |                                    |
| 13:15 - 13:55 | Room 341       | **MEET THE EXPERT**  
Control of cerebellar development by thyroid hormones  
Frédéric Flamant (France)                                                                                                                          |                                    |
**TUESDAY 14TH SEPTEMBER**

**AFTERNOON**

<table>
<thead>
<tr>
<th>Amphitheatre Bordeaux</th>
<th>14:00 - 14:40</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PD13</strong> POSTER DISCUSSIONS</td>
<td><strong>Clinical thyroidology - Case reports</strong></td>
</tr>
<tr>
<td>Chairperson: L. Mercado-Asis (Philippines)</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>OUTCOMES OF CONSERVATIVE SURGERY FOR PAPILLARY THYROID CARCINOMAS PRESENTING WITH LARYNGOTRACHEAL INVASION</td>
</tr>
<tr>
<td>N. Wada, S. Hirakawa, K. Masudo, N. Yuka, Y. Rino, M. Masuda (Yokohama, Japan)</td>
<td>P-0573</td>
</tr>
<tr>
<td>14:06</td>
<td>PREDICTIVE FACTORS FOR CENTRAL LYMPH NODE METASTASIS IN PAPILLARY THYROID MICROCARCINOMA</td>
</tr>
<tr>
<td>14:12</td>
<td>A FAMILY WITH CONGENITAL HYPOTHYROIDISM DUE TO A COMBINATION OF LOSS-OF-FUNCTION MUTATIONS IN THE TSH RECEPTOR AND ADENYLYL CYCLASE-HEMAGGLUTININ GENES</td>
</tr>
<tr>
<td>J. Lado-Abeal, I. Castro-Piedras, F. Palos-Paz, I. J. Labarta-Aizpun, R. Alvero-Gambrio (Lubbock, United States)</td>
<td>P-0576</td>
</tr>
<tr>
<td>14:24</td>
<td>DISTRACTIVE THYROIDITIS IN STEM CELL TRANSPLANT RECIPIENTS</td>
</tr>
<tr>
<td>E. M. Alfaro, M. A. Habra, A. K. Ying (Houston, United States)</td>
<td>P-0577</td>
</tr>
<tr>
<td>14:30</td>
<td>A CASE OF SUCCINATE DEHYDROGENASE D MUTATION PRESENTING WITH HEAD AND NECK PARAGANGLIOMAS AND INVASIVE FOLLICULAR THYROID CARCINOMA</td>
</tr>
<tr>
<td>L. Paumen, E. Heyns, V. Vander Poorten, B. Decallos (Leuven, Belgium)</td>
<td>P-0578</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Amphitheatre Havane</th>
<th>14:00 - 14:40</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PD14</strong> POSTER DISCUSSIONS</td>
<td><strong>Thyroid cancer surgery</strong></td>
</tr>
<tr>
<td>Chairperson: H. Takami (Japan)</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>OUTCOMES OF CONSERVATIVE SURGERY FOR PAPILLARY THYROID CARCINOMAS PRESENTING WITH LARYNGOTRACHEAL INVASION</td>
</tr>
<tr>
<td>N. Wada, S. Hirakawa, K. Masudo, N. Yuka, Y. Rino, M. Masuda (Yokohama, Japan)</td>
<td>P-0573</td>
</tr>
<tr>
<td>14:06</td>
<td>PREDICTIVE FACTORS FOR CENTRAL LYMPH NODE METASTASIS IN PAPILLARY THYROID MICROCARCINOMA</td>
</tr>
<tr>
<td>14:12</td>
<td>A CASE OF SUCCINATE DEHYDROGENASE D MUTATION PRESENTING WITH HEAD AND NECK PARAGANGLIOMAS AND INVASIVE FOLLICULAR THYROID CARCINOMA</td>
</tr>
<tr>
<td>L. Paumen, E. Heyns, V. Vander Poorten, B. Decallos (Leuven, Belgium)</td>
<td>P-0578</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Amphitheatre Bordeaux</strong></th>
<th>14:00 - 14:40</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PD13</strong> POSTER DISCUSSIONS</td>
<td><strong>Clinical thyroidology - Case reports</strong></td>
</tr>
<tr>
<td>Chairperson: L. Mercado-Asis (Philippines)</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>OUTCOMES OF CONSERVATIVE SURGERY FOR PAPILLARY THYROID CARCINOMAS PRESENTING WITH LARYNGOTRACHEAL INVASION</td>
</tr>
<tr>
<td>N. Wada, S. Hirakawa, K. Masudo, N. Yuka, Y. Rino, M. Masuda (Yokohama, Japan)</td>
<td>P-0573</td>
</tr>
<tr>
<td>14:06</td>
<td>PREDICTIVE FACTORS FOR CENTRAL LYMPH NODE METASTASIS IN PAPILLARY THYROID MICROCARCINOMA</td>
</tr>
<tr>
<td>14:12</td>
<td>A FAMILY WITH CONGENITAL HYPOTHYROIDISM DUE TO A COMBINATION OF LOSS-OF-FUNCTION MUTATIONS IN THE TSH RECEPTOR AND ADENYLYL CYCLASE-HEMAGGLUTININ GENES</td>
</tr>
<tr>
<td>J. Lado-Abeal, I. Castro-Piedras, F. Palos-Paz, I. J. Labarta-Aizpun, R. Alvero-Gambrio (Lubbock, United States)</td>
<td>P-0576</td>
</tr>
<tr>
<td>14:24</td>
<td>DISTRACTIVE THYROIDITIS IN STEM CELL TRANSPLANT RECIPIENTS</td>
</tr>
<tr>
<td>E. M. Alfaro, M. A. Habra, A. K. Ying (Houston, United States)</td>
<td>P-0577</td>
</tr>
<tr>
<td>14:30</td>
<td>A CASE OF SUCCINATE DEHYDROGENASE D MUTATION PRESENTING WITH HEAD AND NECK PARAGANGLIOMAS AND INVASIVE FOLLICULAR THYROID CARCINOMA</td>
</tr>
<tr>
<td>L. Paumen, E. Heyns, V. Vander Poorten, B. Decallos (Leuven, Belgium)</td>
<td>P-0578</td>
</tr>
</tbody>
</table>
TUESDAY 14th SEPTEMBER

Room 342AB 14:00 - 14:40

PD35  POSTER DISCUSSIONS
Thyroid cancer clinical (Part 3)
Chairperson: B. McIver (United States)

14:00 USEFULNESS OF ULTRA-SENSITIVE THYROGLOBULIN (TG) ASSAY IN THE FOLLOW-UP OF
DIFFERENTIATED THYROID CARCINOMA (DTC) PATIENTS
(Catania, Italy)

14:06 CLINICAL UTILITY OF THE STIMULATED THYROGLOBULIN DETERMINATION IN FOLLOW UP
OF PATIENTS WITH WELL DIFFERENTIATED THYROID CARCINOMAS
M. Skogor, C. Nase, M. Milas, C. McQuade, N. Nazir, V. Grover (Cleveland, United States)

14:12 RECOMBINANT HUMAN THYROGLOBULIN (rHST) STIMULATED THYROGLOBULIN OF
<1NG/ML: NEED FOR CONTINUED SURVEILLANCE?
G. Smolarz, S. J. Mendel (Philadelphia, United States)

14:18 LONG-TERM FOLLOW-UP OF PATIENTS WITH PAPILLARY AND FOLLICULAR THYROID
CANCER: A PROSPECTIVE STUDY ON 968 PATIENTS
M. Brassard, J. Bougat, A. Eged-Sonsense, C. Corriveau, M. Munnier, M. Toulemonde, F. Bonhomme-Chabot,
M. Schlumberger (Villupur, France)

14:24 SUPPRESSIVE DOSES OF LENTHYROXINE AND LEVELS OF FSH DURING PREGNANCY IN
PATIENTS WITH THYROID CARCINOMA PREVIOUSLY TREATED BY TOTAL THYROIDECTOMY
AND RADIOIODINE ABLATION OF THYROID REMNANT
N. Besic, M. Pavlova, M. Jurca, A. Zupan (Ljubljana, Slovenia)

14:30 THYROID HORMONE LEVELS HAVE A PROGNOSTIC RELEVANCE IN PATIENTS WITH
METASTASIZED DIFFERENTIATED THYROID CARCINOMA

Room 352AB 14:00 - 14:40

PD36  POSTER DISCUSSIONS
Iodine and thyroid
Chairperson: L. M. Zanini Maciel (Brazil)

14:00 HORMONAL REGULATION OF IODIDE UPTAKE IN PLACENTAL PRIMARY CULTURES
B. Burns, C. O’Herlihy, P. Smyth (Dublin, Ireland)

14:06 EXPRESSION OF A THYROGLOBULIN (TG) VARIANT IN MOUSE KIDNEY GLOMERULUS
I. Hisatome, N. L. Koles, K. Suzuki (Hagashkimurayama-shi, Japan)

14:12 A SURVEY ON IODINE NUTRITIONAL STATUS OF RESIDENTS IN COASTAL AREA OF
SOUTHEAST CHINA
Z.-H. Chen (Puchau, China)

14:18 WHAT IS THE IODIDE CONCENTRATION REQUIRED FOR OPTIMAL EFFICIENCY OF HORMONE
PRODUCTION BY THYROID GLAND ?
F. Bernier-Valentin, B. A. Roussel (Lyon, France)

14:24 REGULATION OF THE RAT INTRATHYROIDAL DEHALOGENASES AND ITS IMPLICATIONS FOR
THE WOLF-CHAIKOFF EFFECT
J. C. Solis-S., P. Villalobos, A. Orozco, G. Delgado, A. Quintanar-Stephano, P. Garcia-Solis, M. C. Garcia-G,
H. L. Hernandez-Montiel, M. L. Robles-Ovejero, C. Valverde-R (Queretaro, Mexico)

14:30 A NOVEL ROLE FOR AMP-ACTIVATED PROTEIN KINASE IN THE REGULATION OF IODIDE AND
GLUCOSE UPTAKE IN THYROCYES
B. M. Andrade, R. Araujo, R. Perry, E. Souza, D. Carvalho, R. Celdid (Rio de Janeiro, Brazil)
TUESDAY 14TH SEPTEMBER

POSTER DISCUSSIONS
Thyroid hormone actions
Chairperson: A. Aranda (Spain)

14:00
ROLE OF THE THYROID HORMONE RECEPTOR IN DNA DAMAGE AND CELLULAR SENESCENCE
A. Zambrano, V. Garcia-Carpizo, M. Gomez-Ferreria, A. Aranda (Madrid, Spain)

14:06
TR ALFA ACTIVATION FULLY RESTORES THE IMPAIRED BAT ADAPTATIVE THERMOGENESIS
INDUCED BY HYPOTHYROIDISM
L. X. S. Farah, F. Brito, R. J. Nassif, T. Scanlan, M. O. Ribeiro (Sao Paulo, Brazil)

14:12
THE Δ337 MUTATION ON THE TR-BETA CAUSES ALTERATIONS ON GLUCOSE HEPATIC
METABOLISM
L. A. Santiago, D. A. Santiago, R. D. S. Fraga, A. Cordeiro, F. E. Wondisford, C. C. Panso-Moura,
T. M. Origa-Carvalho (Rio de Janeiro, Brazil)

14:18
ACTIVATION OF AMPK SIGNALING INDUCED BY 3,5-T2 AND T3 ATTENUATES ADIPOGENESIS
BY ENHANCING NITRIC OXIDE PRODUCTION IN L1/T3 CELLS
A. Del Visco, A. Secondo, A. Esposito, C. Franco, E. Silvestri, F. Goglia, M. Moreno,
L. M. T. Caranzone (Benevento, Italy)

14:24
EFFECTS OF THYROID HORMONE RECEPTOR A1 ON GLUCOSE METABOLISM
M. Vujovic, B. Vennstrom, J. Mittag (Stockholm, Sweden)

14:30
NCOR AFFECTS TSHβ MRNA EXPRESSION IN TAT1 CELLS INDEPENDENT OF LIGAND
L. A. Santiago, S. Matsumoto, M. I. Chiamolera, T. M. Origa-Carvalho, F. E. Wondisford (Baltimore,
United States)

POSTER DISCUSSIONS
The role of thyroid hormone in brain and development
Chairperson: J. Bernal (Spain)

14:00
THE EFFECT OF MATERNAL HYPOTHYROIDISM ON MICRORNA EXPRESSION PROFILES IN
BRAIN OF OFFSPRINGS
Q. Xing, Z. Shan, Y. Gao, W. Teng (Shenyang, China)

14:06
EFFECTS OF LEVOTHYROXINE TREATMENT ON OFFSPRING BRAIN DEVELOPMENT IN
PREGNANT RATS WITH SUBCLINICAL HYPOTHYROIDISM
H. M. Zhang (Shenyang, China)

14:12
THYROID HORMONE (T3) INCREASES NEUROGLOBIN AND CYTOGLOBIN GENE EXPRESSION
ON RAT CORTEX, HIPPOCAMPUS AND CEREBELLUM
K. O. Carneiro, M. A. Sato, R. M. B. Masciel, G. Giannocco (Santo Andre, Brazil)

14:18
EXPRESSION OF THYROID HORMONE TRANSPORTERS IN THE HUMAN HYPOTHALAMUS
A. Alkemade, E. C. Friesema, D. F. Swaab, T. J. Visser, E. Fliers (Amsterdam, Netherlands)

14:24
ALTERED FUNCTIONING OF THE HUMAN HIPPOCAMPUS IN CONGENITAL HYPOTHYROIDISM
AT ADOLESCENCE
J. F. Rovet, S. M. Wheeler, M. P. McAndrews, E. Sheard (Toronto, Canada)

14:30
GREY MATTER ALTERATIONS IN CHILDREN WITH THYROID HORMONE INSUFFICIENCIES
DURING PREGNANCY
J. F. Rovet, J. Skocic (Toronto, Canada)
TUESDAY 14th SEPTEMBER  AFTERNOON

**Amphitheatre Bordeaux**  14:45 - 16:15

**ORAL COMMUNICATIONS**

*Thyroid cancer clinical (Part 2)*

Chairperson: D. Hartl (France), M. Torlontano (Italy)

**OC18**

**14:45**

**BRAF MUTATION-SELECTIVE INHIBITION OF THYROID CANCER CELLS BY THE NOVEL MEK INHIBITOR RDEA119 AND GENETIC-POTENTIATED SYNERGISM WITH THE MTOR INHIBITOR TEMSIROLIMUS**

D. Liu, J. Xing, B. Trink, M. Xing (Baltimore, United States)

**P-0796**

**15:00**

**MICROSCOPIC AND MACROSCOPIC CENTRAL NODE METASTASES SHOW DIFFERENT CLINICAL SIGNIFICANCE**

Y. S. Lee, B. W. Kim, K.-J. Kim, H.-S. Chang, C. S. Park (Seoul, Korea, Republic Of)

**P-0792**

**15:15**

**THE THYROID HORMONE METABOLITE 3,5-DIOIDO-L-TYROSINE PREVENTS HEPATIC FAT ACCUMULATION AND SYSTEMIC INSULIN RESISTANCE THROUGH DIRECT ACTIVATION OF SIRTUIN 1 (SIRT1)**

F. de Lange, F. Cioffi, R. Senese, V. Valli, M. Moreno, A. Lombardi, E. Silvestri, F. Cegola, A. Lanni (Caserta, Italy)

**P-0793**

**15:30**

**SIRTUIN PROTEIN EXPRESSION AND ACTIVITY ARE NEGATIVELY REGULATED BY THYROID HORMONE**


**P-0792**

**14:00**

**3,5-T2 ACTIVATES AN ISOFORM OF THE THYROID HORMONE RECEPTOR B1 WHICH IS DIFFERENT FROM THAT ACTIVATED BY T3 IN FUNDULUS HETEROCCLITUS**

A. M. Cisneros, P. Villalobos, J. C. Solis-S, C. Valverde-K, A. Orozco (Querétaro, Mexico)

**P-0799**

**14:06**

**ABSENCE OF TRH-R1 IN MICE AFFECTS THE GHIRELIN SYSTEM BY DIFFERENT PATHWAYS**

S. Mayerl, C. Groba, T. J. Visser, H. Heuer (Jena, Germany)

**P-0790**

**14:12**

**REGULATION OF THE THERMOGENIC FUNCTION BY THE NUCLEAR T3 RECEPTOR ISOFORMS, TRB1 AND TRB3 IN BROWN ADIPOSE TISSUE**

R. Martinez de Serna, T. S. Scanlan, M.-J. Obregon (Madrid, Spain)

**P-0791**

**14:18**

**VASCULAR INVASION: A SIMPLE FACTOR FOR TAILORING RADIOIODINE ADJUNCTIVE TREATMENT AND FOLLOW-UP OF DIFFERENTIATED THYROID CARCINOMAS BIGGER THAN 1 CM. LONG-TERM ANALYSIS OF A SERIES OF 698 CASES**

F. Bonichon, I. Soubeyran, X. Carrat, H. Trouette, G. Belléannée, P. Lagarde, B. Henriquès, A.-L. Cazeau, J. Palussière (Bordeaux, France)

**P-0793**

**14:24**

**THE CLINICAL IMPACT OF AN “ONGOING RISK STRATIFICATION” IN PATIENTS WITH DIFFERENTIATED THYROID CANCER**

M. G. Castagna, V. Belardi, C. Capri, A. Theohdouropoulos, F. Pacini (Siena, Italy)

**P-0794**

**14:30**

**3,5-DIIODO-L-THYRONINE PREVENTS HEPATIC FAT ACCUMULATION AND SYSTEMIC INSULIN RESISTANCE THROUGH DIRECT ACTIVATION OF SIRTUIN 1 (SIRT1)**

F. Bonichon, I. Soubeyran, X. Carrat, H. Trouette, G. Belléannée, P. Lagarde, B. Henriquès, A.-L. Cazeau, J. Palussière (Bordeaux, France)

**P-0795**

**14:44**

**BRAF MUTATION-SELECTIVE INHIBITION OF THYROID CANCER CELLS BY THE NOVEL MEK INHIBITOR RDEA119 AND GENETIC-POTENTIATED SYNERGISM WITH THE MTOR INHIBITOR TEMSIROLIMUS**

D. Liu, J. Xing, B. Trink, M. Xing (Baltimore, United States)

**P-0796**

**15:07**

**MICROSCOPIC AND MACROSCOPIC CENTRAL NODE METASTASES SHOW DIFFERENT CLINICAL SIGNIFICANCE**

Y. S. Lee, B. W. Kim, K.-J. Kim, H.-S. Chang, C. S. Park (Seoul, Korea, Republic Of)

**P-0792**

**15:21**

**REGULATION OF THE THERMOGENIC FUNCTION BY THE NUCLEAR T3 RECEPTOR ISOFORMS, TRB1 AND TRB3 IN BROWN ADIPOSE TISSUE**

R. Martinez de Serna, T. S. Scanlan, M.-J. Obregon (Madrid, Spain)

**P-0790**

**15:27**

**THE CLINICAL IMPACT OF AN “ONGOING RISK STRATIFICATION” IN PATIENTS WITH DIFFERENTIATED THYROID CANCER**

M. G. Castagna, V. Belardi, C. Capri, A. Theohdouropoulos, F. Pacini (Siena, Italy)

**P-0794**

**15:33**

**3,5-DIIODO-L-THYRONINE PREVENTS HEPATIC FAT ACCUMULATION AND SYSTEMIC INSULIN RESISTANCE THROUGH DIRECT ACTIVATION OF SIRTUIN 1 (SIRT1)**

F. Bonichon, I. Soubeyran, X. Carrat, H. Trouette, G. Belléannée, P. Lagarde, B. Henriquès, A.-L. Cazeau, J. Palussière (Bordeaux, France)

**P-0795**

**15:39**

**SIRTUIN PROTEIN EXPRESSION AND ACTIVITY ARE NEGATIVELY REGULATED BY THYROID HORMONE**


**P-0793**

**15:45**

**BRAF MUTATION-SELECTIVE INHIBITION OF THYROID CANCER CELLS BY THE NOVEL MEK INHIBITOR RDEA119 AND GENETIC-POTENTIATED SYNERGISM WITH THE MTOR INHIBITOR TEMSIROLIMUS**

D. Liu, J. Xing, B. Trink, M. Xing (Baltimore, United States)

**P-0796**
TUESDAY 14th SEPTEMBER  AFTERNOON

Amphitheatre Havane  14:45 - 16:15

**ORAL COMMUNICATIONS**

**Epidemiology of thyroid diseases**

Chairpersons: H. Gharib (United States), H. Völzke (Germany)

**OC19**

14:45 INCREASED SERUM TRIGLYCERIDE LEVELS IN CHEST walls PERIODIC AUTOMONAL sibling WITH THYROIDitis: ARE THERE DRUG EFFECTS?  

15:00 THE SPECTRUM OF THYROID CANCER IN INDIA: A REVIEW  
A. P. Mondal, U. Chakrabarty, A. Dasgupta, S. Banerjee, S. Ghosh (Kolkata, India)

15:15 OLD SALT, NEW DISEASE: THE EPIDEMIOLOGY OF TSH RECEPTOR Anti-bodies IN THE UNITED STATES  

15:30 ASSESSMENT OF THE EFFECTS OF IODINE INGESTION ON THYROID FUNCTION IN A POPULATION IN PUNJAB, INDIA  

15:45 THE ROLE OF IODINE IN THE CONTROL OF THYROID FUNCTION IN PREGNANCY IN A UNITED STATES POPULATION  

16:00 PARITY IS NOT RELATED TO AUTOIMMUNE THYROID DISEASE IN A POPULATION-BASED STUDY OF JAPANESE-BRAZILIANS  
J. A. Sgarbi, L. K. Matsumura, T. S. Kasamatsu, R. M. B. Maciel (Sao Paulo, Brazil)

---

**OC20**

**Autoimmunity**

Chairpersons: W. B. Kim (Korea), B. Yoshiyuki (Japan)

**OC-115**

14:45 NEUTRAL ANTIBODIES TO THE TSH RECEPTOR ARE PRESENT IN GRAVES’ DISEASE AND REGULATE SELECTIVE SIGNALING CASCADES  
B. S. Prabhu, A. Banerjee, P. Bhattacharya, A. Gopisetty, C. Yu (Chicago, United States)

15:00 RECOGNIZING T CELL EPITOPES OF hTSHR-ECD  
L. J. De Groot (Providence, United States)

15:15 INDUCTION OF REGULATORY T CELLS TO TREAT AUTOIMMUNE THYROID DISEASES  
J. H. Gunz (Munich, Germany)

15:30 MONOZYGOUS TWIN PAIRS DISCORDANT FOR HASHIMOTO’S THYROIDITIS DEMONSTRATE A MUTE PROFILE OF GENES CARDINAL TO THYROID ANATOMY IN THE DEVELOPMENT OF AUTOIMMUNE THYROIDITIS  
S. T. Loukas, A. Nett, S. Haidounis, E. Patsouli, D. G. Kontadakis, A. Mantzouras (Athens, Greece)

15:45 EFFECTS OF LEVOTHYROXINE ADMINISTRATION ON THE COURSE OF GRAVES’ DISEASE AFTER DISCONTINUATION OF ANTITHYROID DRUG THERAPY  
E. H. Duntas (Athens, Greece)

16:00 PARITY IS NOT RELATED TO AUTOIMMUNE THYROID DISEASE IN A POPULATION-BASED STUDY OF JAPANESE-BRAZILIANS  
J. A. Sgarbi, L. K. Matsumura, T. S. Kasamatsu, R. M. B. Maciel (Sao Paulo, Brazil)
**TUESDAY 14th SEPTEMBER**

**AFTERNOON**

**Room 352AB** 14:45 - 16:15

**OC21  ORAL COMMUNICATIONS**

*In vivo and in vitro models of thyroid diseases*

Chairpersons: C. Alvarez (Spain), Y. C. Kong (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45</td>
<td>NEW HOPE: IMMUNE-TOLERANCE AGAINST GRAVES’ DISEASE</td>
<td>B. Shi (Xi’an, China)</td>
</tr>
<tr>
<td>15:00</td>
<td>AUTONOMOUS DIFFERENTIATION OF MURINE EMBRYONIC FOLLICULAR CELLS AND C-CELLS EX VIVO: CHARACTERIZATION OF A NEW THYROID ORGAN CULTURE MODEL</td>
<td>G. Szinnai, A. Carré, S. Dortchning, M. Castanet, K. Hafen, R. Scharffmann, M. Polak (Basel, Switzerland)</td>
</tr>
<tr>
<td>15:15</td>
<td>ENHANCED IMMUNE RESPONSE IN TRANSGENIC MICE EXPRESSING PRO-APOPTOTIC BID IN THE THYROID</td>
<td>S. H. Wang, Y. Fan, J. R. Baker, Jr (Ann Arbor, United States)</td>
</tr>
<tr>
<td>15:45</td>
<td>SWINE FOLLICLES IN THREE-DIMENSIONAL MORPHO-FUNCTIONAL CULTURE ARE HOMOLOGOUS TO THE THYROID IN VIVO AND BY MORPHOMETRIC ANALYSIS CAN DETERMINE THE FUNCTIONAL STATUS</td>
<td>M. Herrera, C. Spinel, J. Rivero (Bogota, Colombia)</td>
</tr>
<tr>
<td>16:00</td>
<td>TSH AND TSH RECEPTOR AUTOANTIBODIES INHIBIT OSTEOCLASTOGENESIS EARLY IN DEVELOPMENT</td>
<td>T. F. Davies, R. Ma, S. Maeshed, R. Latif, M. Zaidi (New York, United States)</td>
</tr>
</tbody>
</table>

**Coffee break** 16:15 - 16:45

**Exhibition Area**

**BUSINESS MEETINGS**

**ATA BUSINESS MEETING**

Amphitheatre Bordeaux 16:45 - 18:15

**ETA BUSINESS MEETING**

Amphitheatre Havane 16:45 - 18:15

**AOTA BUSINESS MEETING**

Room 342AB 16:45 - 18:15

**LATS BUSINESS MEETING**

Room 352AB 16:45 - 18:15
SCIENTIFIC PROGRAM

Role and structure of the TSH receptor in Graves’ disease
Rebecca S. BAHN, M.D. (Mayo Clinic, Rochester, MN, USA)

Development and FDA clearance of a novel bioassay for stimulating TSH receptor autoantibodies (Thyretain®)
Paul D. OLIVO, M.D., Ph.D. (DHI, Athens, OH, USA)

Thyretain in pediatric Graves’ disease
Rosalind S. BROWN, M.D. (Harvard Children Hospital, Boston, MA, USA)

Thyretain is a functional indicator of Graves’ thyroidal and orbital disease
Katharina A. PONTO, M.D. (Gutenberg University, Mainz, Germany)

ROUND-TABLE DISCUSSION

Dinner and Refreshments will be provided immediately following symposium
## WEDNESDAY 15th SEPTEMBER 2010

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Session Type</th>
<th>Session Time</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>PL05</td>
<td>Plenary Lecture</td>
<td>08:30 - 09:20</td>
<td>AGDA VAN METER-AWARD LECTURE</td>
<td>Grand Amphitheatre</td>
</tr>
<tr>
<td>OC22</td>
<td>Oral communications</td>
<td>09:30 - 11:00</td>
<td>TUSSC HIGHLIGHTS SESSION 4</td>
<td>Grand Amphitheatre</td>
</tr>
<tr>
<td>OC23</td>
<td>Oral communications</td>
<td>09:00 - 11:00</td>
<td>MEDULLARY THYROID CANCER</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>OC24</td>
<td>Oral communications</td>
<td>09:30 - 11:00</td>
<td>DEIODINASES AND ENERGY HOMEOSTASIS</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11:00 - 11:30</td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
<tr>
<td>IG02</td>
<td>Implementing Guidelines</td>
<td>11:30 - 13:00</td>
<td>IMPLEMENTING GUIDELINES FOR MEDULLARY THYROID CANCER</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>SY18</td>
<td>Symposium</td>
<td>11:30 - 13:00</td>
<td>PREGNANCY AND THYROID DISEASES</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>SY19</td>
<td>Symposium</td>
<td>11:30 - 13:00</td>
<td>MOLECULAR EPIDEMIOLOGY OF THYROID CANCER</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>SY20</td>
<td>Symposium</td>
<td>11:30 - 13:00</td>
<td>DEVELOPMENTAL ROLE OF DEIODINASES</td>
<td>Room 352AB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>13:00 - 14:00</td>
<td>LUNCH BREAK</td>
<td></td>
</tr>
<tr>
<td>Posters</td>
<td></td>
<td>13:00 - 14:00</td>
<td>POSTER VIEWING SESSION</td>
<td>Poster Zone</td>
</tr>
<tr>
<td>ME19</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>RISK OF 131I</td>
<td>Posters Zone</td>
</tr>
<tr>
<td>ME21</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>IODINE IN PREGNANCY</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>ME22</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>SCREENING OF CONGENITAL HYPOTHYROIDISM</td>
<td>Room 352AB</td>
</tr>
<tr>
<td>ME23</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>CROSS TALKS IN SIGNALLING PATHWAYS IN THYROID CANCER</td>
<td>Room 351</td>
</tr>
<tr>
<td>ME24</td>
<td>Meet the Expert</td>
<td>13:15 - 13:55</td>
<td>DISRUPTORS OF THYROID HORMONE ACTION</td>
<td>Room 341</td>
</tr>
<tr>
<td>PD20</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>CLINICAL THYROIDOLOGY - HYPOTHYROIDISM</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>PD21</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>CLINICAL THYROIDOLOGY - NONTOXIC GOITER</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>PD22</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>THYROID CANCER CLINICAL (Part 4)</td>
<td>Room 352AB</td>
</tr>
<tr>
<td>PD23</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>THYROID CANCER CLINICAL (Part 5)</td>
<td>Room 352AB</td>
</tr>
<tr>
<td>PD24</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>THYROID HORMONE METABOLITES AND ACTION</td>
<td>Room 331</td>
</tr>
<tr>
<td>PD25</td>
<td>Poster discussions</td>
<td>14:00 - 14:40</td>
<td>DEVELOPMENT AND FUNCTION OF THYROID CELLS</td>
<td>Room 341</td>
</tr>
<tr>
<td>OC25</td>
<td>Oral communications</td>
<td>14:45 - 16:15</td>
<td>THYROID CANCER CLINICAL (Part 3)</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>OC26</td>
<td>Oral communications</td>
<td>14:45 - 16:15</td>
<td>THYROID GLAND DEVELOPMENT</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>OC27</td>
<td>Oral communications</td>
<td>14:45 - 16:15</td>
<td>LATE BREAKING COMMUNICATIONS</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>OC28</td>
<td>Oral communications</td>
<td>14:45 - 16:15</td>
<td>LATE BREAKING COMMUNICATIONS</td>
<td>Room 352AB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>16:15 - 16:45</td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
<tr>
<td>SY21</td>
<td>Symposium</td>
<td>16:45 - 18:15</td>
<td>ISSUES IN THE MANAGEMENT OF LOW-RISK THYROID CANCER</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>SY22</td>
<td>Symposium</td>
<td>16:45 - 18:15</td>
<td>GENETICS OF AUTOIMMUNE THYROID DISEASES (AITD)</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>SY23</td>
<td>Symposium</td>
<td>16:45 - 18:15</td>
<td>ROLE OF REACTIVE OXYGEN SPECIES IN THYROID CELL BIOLOGY</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>SY24</td>
<td>Symposium</td>
<td>16:45 - 18:15</td>
<td>THYROID HORMONE ACTION AND LIPID/ENERGY METABOLISM</td>
<td>Room 352AB</td>
</tr>
</tbody>
</table>
14th INTERNATIONAL THYROID CONGRESS • Paris, Palais des congrès • 11-16 September 2010

Wednesday 15th September

MORNING

Grand Amphitheatre 08:30 - 09:20

PL08
ATA VAN METER AWARD LECTURE
Chairpersons: Terry F. Davies (ATA President), Richard T. Kloos (ATA Secretary)

Van Meter Lectureship Award
Supported by Mary Ann Liebert, Inc., Publishers.

The Van Meter Lectureship Award established in 1930, recognizes outstanding contributions to research on the thyroid gland or related subjects. The award is given each year to an investigator who is not older than the age of 45 in the year of the award.

Grand Amphitheatre 09:30 - 11:00

OC22
ORAL COMMUNICATIONS

Topic highlights 4
Chairpersons: M. Abalovich (Argentina), A. Bianco (United States)

09:30
RECOMBINANT HUMAN THYROTROPIN STIMULATED RADIOIODINE THERAPY OF NODULAR
GOITER ALLOWS MAJOR REDUCTION OF THE RADIATION BURDEN WITH RETAINED EFFICACY
S. Fast, L. Hegedüs, P. Grupe, V. E. Nielsen, C. Bluhme, L. Bastholt, S. J. Bonnema (Odense, Denmark)  
09:45
GLOBAL MICRO RNA EXPRESSION IN PAPILLARY THYROID CARCINOMAS OF YOUNG
PATIENTS EXPOSED TO RADIATION
K. Unger, A. Elmahjoub, T. Bogdanova, G. Thomas (London, United Kingdom)  
10:00
NOVEL LOCUS ON CHROMOSOME 1P36 ASSOCIATED WITH TSH AND THYROID FUNCTION
IDENTIFIED BY GENOME WIDE ASSOCIATION STUDY
V. Panicker, S. G. Wilson, J. P. Walsh, S. J. Brown, J. P. Beilby, N. Suranau, B. S. Kato, R. Richards,  
E. M. Lim, S. J. Fletcher, T. D. Spector (Perth, Australia)  
10:15
TYPE 3 DEIODINASE IN PANCREATIC β-CELL IS CRITICAL FOR GLUCOSE HOMEOSTASIS
A. C. Bianco (Miami, United States)  
10:30
THE SWISS IODIZED SALT PROGRAM PROVIDES ADEQUATE IODINE FOR SCHOOL CHILDREN
AND PREGNANT WOMEN BUT WEANING INFANTS NOT RECEIVING IODINE-CONTAINING
COMPLEMENTARY FOODS ARE IODINE DEFICIENT
M. Andersson, I. Aeberli, N. Wüst, A. M. Piacenza, T. Bucher, I. Henschen, M. Haldemann,  
M. B. Zimmermann (Zürich, Switzerland)  
10:45
ZEBAFISH AS A MODEL TO STUDY THYROID MORPHOGENESIS: A CINEMATIC VIEW OF
THYROID BUDDING, MIGRATION AND FOLLICULOGENESIS
E. Maquet, R. Opitz, S. Costagliola (Brussels, Belgium)

Amphitheatre Bordeaux 09:30 - 11:00

OC23
ORAL COMMUNICATIONS

Medullary thyroid cancer
Chairpersons: B. Jarzab (Poland), A. Sakurai (Japan)

09:30
IDENTIFICATION OF POTENTIAL BIOMARKERS OF RESPONSE TO VANDETANIB TREATMENT
USING A PRECLINICAL MODEL OF HUMAN MEDULLARY THYROID CARCINOMA
S. Broustin, B. Petit, T. Robert, C. Dupuy, A. J. Ryan, M. Schlumberger, J.-M. Bidart (Villésquier, France)

09:45
SORAFENIB AND THE MEK INHIBITOR AZD 6244 SYNERGISTICALLY REDUCE CELL VIABILITY
OF MEDULLARY THYROID CANCER CELLS

10:00
META-ANALYSIS OF CHILDREN WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A FROM
1995-2009: IMPACT OF RET MUTATION ANALYSIS AND CONSENSUS GUIDELINES ON AGE AT
THYROIDECTOMY OVER THE LAST 15 YEARS
G. Szirmai, S. Sarmacki, J.-P. Traviaggi, M. Schlumberger, M. Polak (Basel, Switzerland)
**WEDNESDAY 15th SEPTEMBER**

**MORNING**

10:15  **PHENOTYPIC ASSOCIATION AMONG RET, GSTP1, CYP1A1M1 AND TP53 GENES POLYMORPHISMS IN PATIENTS WITH MEDULLARY THYROID CARCINOMAS**


10:30  **PROGNOSTIC FACTORS OF DISEASE-FREE SURVIVAL AFTER THYROIDECTOMY IN 170 YOUNG PATIENTS WITH A RET GERMILINE MUTATION**


10:45  **PROGNOSTIC SIGNIFICANCE OF PROCALCITONIN/CALCITONIN RATIO IN MEDULLARY THYROID CANCERS AT THE TIME OF DIAGNOSIS, DURING FOLLOW-UP AND UNDER TREATMENT**

C. Do Cao, C. Bauters, L. Leclerc, M.-C. Vantyghem, A. Berdelou, S. Aubert, E. Leteurtre, B. Carnaille, F. Patton, J.-L. Wémeau, M. d’Herbomez (Lille, France)

**OC-139**

**OC24  ORAL COMMUNICATIONS**

**Deiodinases and energy homeostasis**

**Chairpersons:** B. W. Kim (United States), R. Peeters (The Netherlands)

09:30  **TYPE-2 IODOTHYRONINE DEIODINASE (D2) IN SKELETAL MUSCLE OF C57BL MICE: AUTHENTICITY AND INCREASED RESPONSES TO ADRENERGIC STIMULATION IN THYROID HORMONE RECEPTOR-α NULL MICE (THRA-0/0)**

J. E. Silva, W. Ramadan, A. Marsili, P. R. Larsen (Springfield, United States)

09:45  **ENDOPLASMIC RETICULUM-STRESS AND CHEMICAL CHAPERONES REGULATE TYPE 2 DEIODINASE AND THYROID HORMONE SIGNALING**

R. Arrojo E Drigo, W. S. da Silva, M. Castillo, T. Fonseca, S. Ribich, G. Simovic, A. C. Bianco (Miami, United States)

10:00  **3-IODOTHYRONAMINE (T1AM) CAUSES WEIGHT LOSS IN MICE VIA REDUCTION IN FOOD CONSUMPTION**

B. D. Hettinger, K. Schuff, D. Marks, T. Scanlan (Portland, United States)

10:15  **ACCLIMATIZATION AT THERMONEUTRALITY UNCOVERS MARKED METABOLIC PHENOTYPE IN MICE WITH TARGETED INACTIVATION OF THE TYPE 2 DEIODINASE**

M. Castillo, J. A. Hall, D. E. Cohen, A. C. Bianco (Miami, United States)

10:30  **ALTERATIONS IN LEPTIN SIGNALING IN THE CENTRAL HYPOTHYROID TRH-R1 KNOCKOUT MOUSE**

C. Groba, S. Mayerl, T. Visser, K. Bauer, H. Hoar (Jena, Germany)

10:45  **THE END-ORGAN EFFECTS OF LIOTHYRONINE FOR LEVOTHYROXINE SUBSTITUTION THERAPY IN PRIMARY HYPOTHYROIDISM: A RANDOMIZED, DOUBLE-BLIND, CROSS-OVER STUDY**

F. S. Cali, J. D. Linderman, M. Zemskova, S. Smith, M. C. Skandies, P. W. Butler, G. Csako, R. Costello, F. Pucino (Bethesda, United States)

**Coffee break**

11:00 - 11:30

**Amphitheatre Bordeaux**

11:30 - 13:00

**IG03  IMPLEMENTING GUIDELINES**

**Implementing guidelines for medullary thyroid cancer**

Moderator: Richard Kloos (United States)

Case discussants: Henning Dralle (Germany), Ana Luisa Maia (Brazil), Akira Miyachi (Japan)

Voting machines available
WEDNESDAY 15TH SEPTEMBER

MORNING

Amphitheatre Havane  11:30 - 13:00

SYMPOSIUM

Pregnancy and thyroid diseases
Chairpersons: M. Abalovich (Argentina), A. Stagnaro-Green (United States)

11:30         T4 TRANSPORT ACROSS THE PLACENTA
Shiao Chan (United Kingdom)

11:52         TREATMENT OF HYPOTHYROIDISM IN PREGNANCY
Greg Brent (United States)

12:14         TREATMENT OF HYPERTHYROIDISM IN PREGNANCY
Graciela Alcaraz (Argentina)

12:36         OUTCOME OF THE CATS STUDY IN PREGNANT WOMEN
John Lazarus (United Kingdom)

Room 342AB  11:30 - 13:00

SYMPOSIUM

Developmental role of deiodinases
Chairpersons: G. Balazs (Hungary), M. Murakami (Japan)

11:30         ROLE OF DEIODINASES IN ADIPOGENESIS
Renata Araujo (Brazil)

11:52         SUSCEPTIBILITY TO DIFFERENTIATED THYROID CANCER
Erich Sturgis (United States)

12:14         MOLECULAR SIGNATURE OF RADIATION INDUCED THYROID TUMORS
Vladimir Saenko (Japan)

12:36         MOLECULAR SIGNATURE OF SPONTANEOUS THYROID TUMORS
Adel El-Naggar (United States)

Room 352AB  11:30 - 13:00

SYMPOSIUM

Molecular epidemiology of thyroid cancer
Chairpersons: B. Rousset (France), L. Ward (Brazil)

11:30         POPULATION STUDIES OF GENETIC RISK FOR THYROID CANCER
Krystian Jazdzewski (United States)

11:52         SUSCEPTIBILITY TO DIFFERENTIATED THYROID CANCER
Erich Sturgis (United States)

12:14         MOLECULAR SIGNATURE OF RADIATION INDUCED THYROID TUMORS
Vladimir Saenko (Japan)

12:36         MOLECULAR SIGNATURE OF SPONTANEOUS THYROID TUMORS
Adel El-Naggar (United States)

Lunch break (Lunch bags distribution)  Exhibition Area  13:00 - 14:00

Poster Zone  13:00 - 14:00

POSTER VIEWING SESSION

Group B2: P-0873-P-1148 (see page 75)
Authors will be present next to their poster in order to answer questions from delegates
<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Session</th>
<th>Topic</th>
<th>Presenter</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15 - 13:55</td>
<td>Amphitheatre Bordeaux</td>
<td>ME19</td>
<td>Meet the Expert: Risk of 131I</td>
<td>Florent de Vathaire (France)</td>
<td>France</td>
</tr>
<tr>
<td>13:15 - 13:55</td>
<td>Room 342AB</td>
<td>ME21</td>
<td>Meet the Expert: Iodine in pregnancy</td>
<td>Sumihisa Kubota (Japan)</td>
<td>Japan</td>
</tr>
<tr>
<td>13:15 - 13:55</td>
<td>Room 352AB</td>
<td>ME22</td>
<td>Meet the Expert: Screening of congenital hypothyroidism</td>
<td>Suzana Nesi França (Brazil)</td>
<td>Brazil</td>
</tr>
<tr>
<td>13:15 - 13:55</td>
<td>Room 351</td>
<td>ME23</td>
<td>Meet the Expert: Cross talks in signalling pathways in thyroid cancer cells</td>
<td>Minho Shong (Korea)</td>
<td>Korea</td>
</tr>
<tr>
<td>13:15 - 13:55</td>
<td>Room 341</td>
<td>ME24</td>
<td>Meet the Expert: Disruptors of thyroid hormone action</td>
<td>Noriyuki Koibuchi (Japan)</td>
<td>Japan</td>
</tr>
</tbody>
</table>
WEDNESDAY 15th SEPTEMBER AFTERNOON

Amphitheatre Bordeaux 14:00 - 14:40

POSTER DISCUSSIONS
Clinical thyroidology - Hypothyroidism
Chairperson: L. Hegedus (Denmark)

14:00 DETECTION OF INCREASED FREQUENCY OF THYROID HYPOPLASIA IN SUBJECTS IRRADIATED IN UTERO AS THE RESULT OF CHERNOBYL CATASTROPHE
V. Drozd, L. Danilova, M. Lushchik, T. Leonova, T. Platonova, A. Grigorovich, V. Sivuda, I. Branovan, I. Biko, C. Reiners (Minsk, Belarus) P-0873

14:06 NEW INSIGHTS INTO THYROIDGLUCAGON PATHOPHYSIOLOGY REVEALED BY THE STUDY OF A FAMILY WITH CONGENTIAL GOITER

14:12 IMPAIRED NEURODEVELOPMENT BY THYROXINE DEFICIENCY IN EARLY PREGNANCY CAN BE REVERSED BY RESTORATION OF THYROID STATUS AND/OR BY THYROXINE PRODUCED BY THE CHILD
N. Momotani, S. Iwama (Tokyo, Japan) P-0875

14:18 CLINICAL COURSE OF FOUR PEDIATRIC PATIENTS WITH CONGENTIAL HYPOTHYROIDISM HARBORING NOVEL MUTATIONS IN THE TSHR GENE

14:24 LOW-NORMAL OR HIGH-NORMAL TSH TARGET LEVELS DURING TREATMENT OF HYPOTHYROIDISM - A PROSPECTIVE COMPARATIVE STUDY
G. A. Carvalho, A. Boeving, R. B. Radominski, S. Pac-Filho, H. Grau (Cantuiba, Brazil) P-0877

14:30 PSYCHOMOTOR DELAY IN PATIENTS WITH CONGENTIAL HYPOTHYROIDISM: INADEQUATE TREATMENT OR GENETIC SYNDROMES?
M. Morandini, J. Léger, M. Polak, M. Castanet (Paris, France) P-0878

Amphitheatre Havane 14:00 - 14:40

POSTER DISCUSSIONS
Clinical thyroidology - Nontoxic goiter
Chairperson: M. Schnitman (Argentina)

14:00 LONG-TERM OUTCOME OF RHTSH STIMULATED RADIOIODINE (131I) THERAPY FOR BENIGN NONTOXIC NODULAR GOITER
S. Fast, V. E. Nielsen, F. Gruse, H. Bøe-Jørgensen, L. Bastholt, S. J. Bonnema, L. Hegedüs (Odense, Denmark) P-0909

14:06 PROSPECTIVE RANDOMIZED DOUBLE-BLINDED CONTROLLED STUDY OF LOCAL ANESTHETIC WOUND INFILTRATION IN TOTAL THYROIDECTOMY

14:12 IODINE STATUS, SELENIUM DEFICIENCY AND THYROID AUTOIMMUNITY IN THE ETIOLOGY OF ENDEMIC GOITER IN SCHOOLCHILDREN OF ISFAHAN, IRAN
A. Hassanzadeh Keshteli, A. Abdi, M. Hashemipour, M. Amini (Isfahan, Republic Islamic of Iran) P-0911

14:18 THYROID-SPECIFIC AND GENERIC QUALITY OF LIFE IN PATIENTS WITH NON-TOXIC GOITER, COMPARED TO THE GENERAL POPULATION
N. Momotani, S. Iwama (Tokyo, Japan) P-0912

14:24 EFFECTIVENESS OF ADMINISTRATION OF LITHIUM AND RECOMBINANT HUMAN TSH IN THE TREATMENT OF MULTINODULAR NONTOXIC GOITER WITH RADIOACTIVE IODINE

14:30 PREFERABLE STRATEGY IN TREATMENT OF THE MULTINODULAR GOITER
M. Vaiman (Ramat Yim, Israel) P-0914
**WEDNESDAY 15th SEPTEMBER**

**AFTERNOON**

**Room 242AB 14:00 - 14:40**

**POSTER DISCUSSIONS**

**Thyroid cancer clinical (Part 4)**

*Chairperson: D. Topliss (Australia)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Paper ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>HIGH PREVALENCE OF RAS MUTATIONS IN RET NEGATIVE SPORADIC MEDULLARY THYROID CARCINOMA</td>
<td>M. M. Moura, B. M. Cavaca, M. J. Bugalho, V. Lurie (Lisboa, Portugal)</td>
<td>P-0921</td>
</tr>
</tbody>
</table>

**Room 252AB 14:00 - 14:40**

**POSTER DISCUSSIONS**

**Thyroid cancer clinical (Part 5)**

*Chairperson: G. Carvalho (Brazil)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Paper ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>18F-FDG-PET AND 18F-OHH-PET IN DETECTION OF BIOCHEMICALLY PROGRESSIVE MEDULLARY THYROID CARCINOMA</td>
<td>H. H. G. Verbeek, K. P. Knoo, J. W. B. de Groot, J. T. M. Plukker, A. H. Brouwer, T. P. Links (Groningen, Netherlands)</td>
<td>P-0922</td>
</tr>
</tbody>
</table>
### POSTER DISCUSSIONS

#### Thyroid hormone metabolites and action

**Chairperson:** P. de Lange (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Poster Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>QUANTITATIVE ASSAY OF 3-IODOTHYRONAMINE CONCENTRATIONS IN HUMAN BLOOD</td>
<td>E. Galli, M. Marchini, A. Sabo, G. Chellini, S. Storti, S. Berit, G. Jevase, R. Zucchi (Pisa, Italy)</td>
</tr>
<tr>
<td>14:06</td>
<td>LOW DOSE POLYMEROMINATED DIPHENYLETHERS (PDEs) SUPPRESSES THYROID HORMONE RECEPTOR (TR)-MEDIATED TRANSCRIPTION, INHIBITS CEREBELLAR FURIN/KE CELL DENDRITIGENESIS, SYNAPTOGENESIS AND IMPAIRS GRANULE CELL NEURITOGENESIS</td>
<td>K. Bibaszhimieb, T. Iwasaki, J. Kuma-Raizuda, T. Okuma-Usushi, Y. Ishizaki, N. Kodushi (Maibashi, Japan)</td>
</tr>
<tr>
<td>14:12</td>
<td>IN VITRO EFFECTS OF SELECTED ENDOCRINE DISRUPTING CHEMICALS ON EXPRESSION OF NUCLEAR THYROID HORMONE RECEPTOR SUBTYPES AND NUCLEAR RECEPTOR COACTIVATORS IN HUMAN PRIMARY HEPATOCELES AND MCF-7 CELLS</td>
<td>J. Breko, D. Maciejova, S. Ondelkova, M. Firkova, R. Vural, Z. Dvorak (Bratislava, Slovakia)</td>
</tr>
<tr>
<td>14:18</td>
<td>OVERLAP AND DIFFERENCES IN GENES REGULATED BY T3 AND T3A</td>
<td>P. Mol-Van Mullem, E. Visser, T. Visser, R. Posters (Rotterdam, Netherlands)</td>
</tr>
<tr>
<td>14:24</td>
<td>GLUTATHIONE S-TRANSFERASE IS DOWNREGULATED BY T3 IN LIVER BUT NOT IN KIDNEY – ANOTHER GENDER ISSUE</td>
<td>L. Faustino, A. Pinto, A. Cordovino, L. Lopez, N. Almida, T. Ortiga-Carvalho (Rio de Janeiro, Brazil)</td>
</tr>
<tr>
<td>14:30</td>
<td>THE IMPACT OF A UNIQUE NONSENSE MUTATION IN THE THRB GENE, E457X, ON RESISTANCE TO THYROID HORMONE COMPLEXITIES</td>
<td>N. Akulevich, V. Sanenko, T. Rogoznovitch, V. Drozd, T. Leonova, T. Mytyukova, M. Matouse, S. Yamashita (Minsk, Belarus)</td>
</tr>
</tbody>
</table>

### POSTER DISCUSSIONS

#### Development and function of thyroid cells

**Chairperson:** M. Nilsson (Sweden)

<table>
<thead>
<tr>
<th>Time</th>
<th>Poster Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>MICRORNA AND THYROID DEVELOPMENT</td>
<td>W. Rodriguez Gonzalez, R. K. Dadhich, L. Jin, S. Costagliola (Brussels, Belgium)</td>
</tr>
<tr>
<td>14:06</td>
<td>EVALUATION OF Basal THYROTROPIN IN RESPONSE TO THYROTROPIN-RELEASING HORMONE STIMULATION</td>
<td>L. Lukinac, D. Krulic, J. Jukić, Z. Labar, Z. Kusić (Zagreb, Croatia)</td>
</tr>
<tr>
<td>14:12</td>
<td>ROLE OF FOXO1 TRANSCRIPTION FACTOR IN THE THYROID CELL PROLIFERATION INDUCED BY TSH AND IGF-1</td>
<td>M. A. Zaballos, P. Santisteban (Madrid, Spain)</td>
</tr>
<tr>
<td>14:18</td>
<td>CAVOLIN-1 IS REQUIRED FOR PROPER APICAL HORMONE SYNTHESIS IN THYROID FOLLICLES</td>
<td>A. Zitouni, C. Khalida, V. Van Reugemont, A. Wéron, J. Van Sande, J. Dumont, M. Senou, A.-C. Gérard, M.-C. Many (Brussels, Belgium)</td>
</tr>
<tr>
<td>14:30</td>
<td>DETECTING TRANSMEMBRANE INTERFACES OF TSH RECEPTOR OLIGOMERS</td>
<td>R. Latif, M. R. Ali, S. A. Moosibed, M. Meusr, T. F. Davies (New York, United States)</td>
</tr>
</tbody>
</table>
WEDNESDAY 15th SEPTEMBER

AFTERNOON

POSTER DISCUSSIONS

Genetics and Genomics of thyroid diseases

Chairperson: D. Fuhrer (Germany)

14:00  ASSOCIATION STUDY OF THE IL22/IL22RA1 GENE POLYMORPHISM AND PAPILLARY THYROID CANCER IN KOREAN POPULATION
I. H. Shin, Y. G. Eun, S. W. Kim, S. Y. Song, K. H. Kwon (Seoul, Republic of Korea)

14:06  V600E MUTATION DETECTION IN FINE NEEDLE ASPIRATION FROM INDETERMINED OR SUSPECTIVE TO MALIGNANCY THYROID NODULE USING REAL TIME PCR GENOTYPING

14:12  PAPILLOMAVIRUS IN GENES OF THE STEROID HORMONE BIOSYNTHESIS AND METABOLISM PATHWAYS, SMOKING AND GRAVES’ DISEASE RISK
N. E. Butala, R. B. Barbieri, M. B. Martino, R. B. Santos, J. H. Romaldini, L. S. Ward (Campinas, Brazil)

14:18  IS PENDRED’S SYNDROME A GENETICALLY HETEROGENEOUS DISEASE? MOLECULAR ANALYSIS OF 4 CANDIDATE GENES AND GENOTYPE PHENOTYPE CORRELATIONS
V. Cirello, M. Muzza, P. Castorina, A. Mattini, P. Beck-Peccoz, L. Fugazzola (Milan, Italy)

14:24  COMPARATIVE ANALYSIS OF GENE EXPRESSION PROFILES OF PAPILLARY THYROID MICROCARCINOMA AND PAPILLARY THYROID CARCINOMA

14:30  THE USE OF A SET OF GENETIC MARKERS HELP TO DISCRIMINATE BENIGN AND MALIGNANT THYROID NODULES WITH A FINE NEEDLE ASPIRATION PATTERN OF FOLLICULAR PROLIFERATION IN AN AREA OF BORDERLINE IODINE DEFICIENCY

ORAL COMMUNICATIONS

Thyroid cancer clinical (Part 3)

Chairpersons: T. Links (The Netherlands), K. Suzuki (Japan)

14:45  THE IMPACT OF SPECT/CT HYBRID IMAGING IN DETECTING REGIONAL LYMPH NODE INVOLVEMENT IN TI PAPILLARY THYROID CARCINOMA: PRESENTING AN UPDATE ON A BICENTRIC STUDY INCLUDING 202 PATIENTS

15:00  HISTOLOGICALLY AGGRESSIVE TYPES OF FOLLICULAR CELL-DERIVED THYROID CANCER OFTEN HAVE RADIOACTIVE AVID DISTANT METASTASES: A STUDY OF 314 PATIENTS WITH DISTANT METASTASES AT A SINGLE INSTITUTION

15:15  LOW RADIATION DOSE TO RELATIVES AFTER DISCHARGE OF THYROID CANCER PATIENTS TREATED WITH I-131
H. Remy, E. Camps, M. Ricard, J. Borget, J. Lavielle, J. Coulot, M. Schlumberger (Villejuif, France)

15:30  IN VIVO FUNCTION OF SODIUM-IODIDE SYMPORTER (NIS) IN MOUSE MODELS OF PAPILLARY AND FOLLICULAR THYROID CANCER STUDIED WITH A NOVEL NIS-TARGETING RADIOPHARMACEUTICAL AND POSITRON-EMISSION TOMOGRAPHY IMAGING

15:45  WHAT ARE YOUR PATIENTS USING AND ARE THEY TELLING YOU ABOUT IT? COMPLEMENTARY AND ALTERNATIVE MEDICINE USE AMONG PATIENTS WITH THYROID CANCER: 2010
J. E. Rosen, R. B. Saper, P. Gardiner, G. Bloom, E. N. Pearce, S. Lee (Boston, United States)

16:00  DETERMINATION OF URINARY IODINE IN PATIENTS UNDERGOING CONTRAST MEDIA IMAGING STUDIES: IDENTIFICATION OF THE REQUIRED PERIOD FOR THE URINARY IODINE RETURNS TO BASELINE
WEDNESDAY 15th SEPTEMBER

Amphitheatre Havane 14:45 - 16:15

**ORAL COMMUNICATIONS**

**Thyroid gland development**

Chairpersons: S. Zannini (Italy), J. Deladoey (Canada)

**OC26**

14:45 Knockout of DICER disrupts thyroid function

D. Frezzetti, G. Calì, L. Nitsch, H. Fagman, G. De Vita, R. Di Lauro (Napoli, Italy)

15:00 Jagged/serrate notch ligands regulate early thyroid morphogenesis in zebrafish

P. Porazzi, T. de Filippis, F. Manetti, D. Calebri, N. Tiso, L. Persani (Milan, Italy)

15:15 CDH16 is a novel target of the transcription factor PAX8

T. de Cristofaro, I. Fichiera, T. Di Palma, S. Zannini (Napoli, Italy)

15:30 Loss of function mutations in NKO2.5 transcriptional factor are associated with thyroid ectopy: a study of 107 patients with thyroid dysgenesis

H. E. Ramos, S. Novi-Franca, B. C. Freitas, V. T. Boldarini, I. Kurni, C. P. Camacho, M. R. Dias da Silva, R. M. R. Maciel (Curitiba, Brazil)

15:45 First foxE1 activating mutation in syndromic congenital hypothyroidism

A. Carre, M. Castanet, R. T. Hamza, E. Tren, M. ElKholy, M. Polak (Paris, France)

16:00 Claudin-1 expression in solid cell nests of the thyroid: further evidence for a stem/basal cell phenotype of papillary carcinoma.

C. Colato, A. Fierabracci, A. Dandano, F. Monzani, M. Chilosi, G. Martignoni, F. Menestrina, M. Fendelghini (Verona, Italy)

**Room 342AB 14:45 - 16:15**

**OC27**

**ORAL COMMUNICATIONS**

**Late breaking communications (Part 1)**

Chairpersons: A. Piekielko-Witkowska (Poland), J. L. Wemeau (France)

14:45 A novel role of the NF-kappa-B transcription factor in the thyrotropin-regulated thyroid differentiation gene expression

J. P. Nicola, M. Nazaee, A. M. Masimo-Riposo (Córdoba, Argentina)

15:00 Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC)

K. Jazdzewski, J. Boguslawska, J. Jendrzejewski, S. Liyanarachchi, J. Pachucki, K. A. Wardyn, A. Nauman, A. de la Chapelle (Warsaw, Poland)

15:15 Development of a novel molecular classifier to accurately identify benign thyroid nodules in patients with indeterminate FNA cytology


15:30 Transforming potential of novel dual Ret mutation found in Slovak family

M. Poturnajova, S. Fekocseva, M. Benej, V. Altemanova (Bratislava, Slovakia)

15:45 In patients with nodular Hashimoto's thyroiditis the frequency of papillary thyroid carcinoma on cytology is closely related to serum TSH and is reduced by treatment with l-thyroxine


16:00 Epidemiological and clinico-morphological features of thyroid cancer detected as a result of four consecutive cycles of screening in the framework of the Ukraine-U.S.A. Thyroid Project

M. Tronko (Ukraine)
WEDNESDAY 15th SEPTEMBER  
AFTERNOON

SY21  
Issues in the management of low-risk thyroid cancer  
Chairpersons: C. Liberman (Chile), A. M. Sawka (Canada)

16:45  HOW TO DEFINE LOW-RISK PATIENTS FOR INITIAL AND LONG-TERM MANAGEMENT ?  
Ian Hay (United States)

17:15  ROLES OF SURGERY AND RA (EMPHASIS ON MINIMALLY INVASIVE FTC)  
Paul Ladenson (United States)

17:45  FOLLOW-UP OF THE PATIENTS “LESS THAN TOTAL THYROIDECTOMY-NO RADIOACTIVE IODINE”  
Koichi Ito (Japan)
WEDNESDAY 15th SEPTEMBER

SY22 SYMPOSIUM
Genetics of Autoimmune Thyroid Diseases (AITD)
Chairpersons: A. Allahabadia (United Kingdom), Y. Tomer (United States)

16:45 APPROACHES TO IDENTIFYING AITD SUSCEPTIBILITY GENES
Simon Pearce (United Kingdom)

17:07 ETHNIC DIFFERENCES IN THE GENETICS OF AITD
Takashi Akamizu (Japan)

17:29 THE ROLE OF DETOXIFYING GENES IN AITD
Joao Romaldini (Brazil)

17:51 POLYGLANDULAR SYNDROMES AND AITD: IMMUNOGENETIC MECHANISMS
George Kahaly (Germany)

SY23 SYMPOSIUM
Role of reactive oxygen species in thyroid cell biology
Chairpersons: G. Juvenal (Argentina), L. Persani (Italy)

16:45 IDENTIFICATION OF THE DUOX MATURATION FACTOR AND ITS DEFECTS
Samuel Refetoff (United States)

17:07 DUOX 1 AND THYROID H2O2 GENERATION
Xavier De Deken (Belgium)

17:29 ROLE OF DUOX 2 AND OTHER NOX EXPRESSION IN THE THYROID
Corinne Dupuy (France)

17:51 HYDROGEN PEROXIDE, DNA DAMAGE AND MUTAGENESIS IN THE DEVELOPMENT OF THYROID TUMORS
Knut Krohn (Germany)

SY24 SYMPOSIUM
Thyroid hormone action and lipid/energy metabolism
Chairpersons: A. Bianco (United States), M. A. Pisarev (Argentina)

16:45 THE ROLE OF TR-ALPHA IN THE REGULATION OF ENERGY METABOLISM
Jens Mittag (Sweden)

17:07 BILE ACIDS AND THYROID HORMONE ACTIVATION
Georg Brahmbutz (United Kingdom)

17:29 CELLULAR ASPECTS OF THYROID HORMONE EFFECTS ON ENERGY EXPENDITURE
Brian Kim (United States)

17:51 THYROID HORMONE ACTION IN STATES OF INSULIN-RESISTANCE AND STEATOSIS
Mary Elizabeth Patti (United States)
### THURSDAY 16\textsuperscript{th} SEPTEMBER 2010

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Session Type</th>
<th>Session Time</th>
<th>Session Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>PL06</td>
<td>Plenary Lecture</td>
<td>08:30 - 09:20</td>
<td>AOTA PRIZE LECTURE</td>
<td>Grand Amphitheatre</td>
</tr>
<tr>
<td>SY25</td>
<td>Symposium</td>
<td>09:30 - 11:00</td>
<td>METASTATIC AND RECURRENT THYROID CANCER MANAGEMENT Supported by an unrestricted educational grant by Genzyme</td>
<td>Grand Amphitheatre</td>
</tr>
<tr>
<td>SY26</td>
<td>Symposium</td>
<td>09:30 - 11:00</td>
<td>THYROID DISEASES AND THE METABOLIC SYNDROME</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>SY27</td>
<td>Symposium</td>
<td>09:30 - 11:00</td>
<td>CLINICALLY RELEVANT ALTERATIONS IN NON-THYROIDAL DISEASES ?</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>SY28</td>
<td>Symposium</td>
<td>09:30 - 11:00</td>
<td>THYROID DEVELOPMENT</td>
<td>Room 352AB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11:00 - 11:15</td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>11:15 - 12:00</td>
<td>CLOSING CEREMONY</td>
<td>Grand Amphitheatre</td>
</tr>
</tbody>
</table>
THURSDAY 16TH SEPTEMBER  MORNING

PLENARY LECTURE
AOTA Prize Lecture
Chairpersons: Junji Konishi (AOTA President), Yoshiharu Murata (AOTA Secretary)
Nagataki-FUJIFILM prize

SYMPOSIUM
Metastatic and recurrent thyroid cancer management
Supported by an unrestricted educational grant by Genzyme
Chairpersons:  F. Borson-Chazot (France), R. Smallridge (United States)

SYMPOSIUM
Thyroid diseases and the metabolic syndrome
Chairpersons:  A. Lewinski (Poland), A. Pinchera (Italy)

SYMPOSIUM
Clinically relevant alterations in non-thyroidal diseases
Chairpersons:  M. Erdogan (Turkey), K. Poppe (Belgium)
THURSDAY 16th SEPTEMBER

MORNING

Room 352AB  09:30 - 11:00

SYMPOSIUM

Thyroid development
Chairpersons: P. Macchia (Italy), C. R. Nogueira (Brazil)

09:30  USING MICE MODEL OF THYROID FOLLICULAR CELL DEVELOPMENT
Roberto di Lauro (Italy)

09:52  THYROID GENE EXPRESSION DURING HUMAN FETAL DEVELOPMENT
Michel Polak (France)

10:14  C CELL DEVELOPMENT
Mikael Nilsson (Sweden)

10:36  MENDELIAN AND NON-MENDELIAN MECHANISMS OF THYROID DYSGENESIS
Guy Van Vliet (Canada)

Coffee break  Exhibition Area  11:00 - 11:15

CLOSING CEREMONY
Grand Amphitheatre  11:15 - 12:00

Chairperson: J. Orgiazzi (France)

Presentation of the Young Investigator Awards

Invitation to the 15th International Thyroid Congress
September 17-23, 2015
Orlando, FL, United States
**POSTERS**

1134 posters will be presented during the congress. Because of this large number of posters, posters will not be displayed for the entire congress but will be organised in 2 different groups (A & B), corresponding to the following display / presentation schedule:

<table>
<thead>
<tr>
<th>GROUP</th>
<th>Display period</th>
<th>Poster Viewing session</th>
<th>Poster Viewing Time</th>
<th>First Poster</th>
<th>Last Poster</th>
</tr>
</thead>
<tbody>
<tr>
<td>A2</td>
<td></td>
<td></td>
<td></td>
<td>P0314</td>
<td>P0572</td>
</tr>
<tr>
<td>B2</td>
<td></td>
<td></td>
<td></td>
<td>P0873</td>
<td>P1148</td>
</tr>
</tbody>
</table>

Poster viewing sessions will take place from 13:00 to 14:00 on September 12th, 13th, 14th and 15th, 2010. Authors will be present next to their poster in order to answer questions from delegates and session chairs.

**Poster discussion sessions**

156 posters will be presented as brief oral presentations during the following Poster Discussion Sessions from 14:00 to 14:40:

<table>
<thead>
<tr>
<th>First Poster</th>
<th>Last Poster</th>
<th>Display Group</th>
<th>Session Title</th>
<th>Session Date</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>F0001</td>
<td>F0006</td>
<td>A</td>
<td>Clinical thyroidology - Hyperthyroidism</td>
<td>Sunday September 12</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>F0032</td>
<td>F0037</td>
<td>A</td>
<td>Environmental factors - Iodine</td>
<td>Sunday September 12</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>F0093</td>
<td>F0098</td>
<td>A</td>
<td>Thyroid cancer clinical I</td>
<td>Sunday September 12</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>F0114</td>
<td>F0115</td>
<td>A</td>
<td>Thyroid cancer basic</td>
<td>Sunday September 12</td>
<td>Room 302AB</td>
</tr>
<tr>
<td>F0227</td>
<td>F0232</td>
<td>A</td>
<td>Autoimmunity</td>
<td>Sunday September 12</td>
<td>Room 301</td>
</tr>
<tr>
<td>F0285</td>
<td>F0290</td>
<td>A</td>
<td>Oxidases</td>
<td>Sunday September 12</td>
<td>Room 341</td>
</tr>
<tr>
<td>F0314</td>
<td>F0319</td>
<td>A</td>
<td>Clinical thyroidology - Nodules</td>
<td>Monday September 13</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>F0398</td>
<td>F0403</td>
<td>A</td>
<td>Graves' ophthalmopathy</td>
<td>Monday September 13</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>F0423</td>
<td>F0428</td>
<td>A</td>
<td>Thyroid cancer clinical II</td>
<td>Monday September 13</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>F0518</td>
<td>F0523</td>
<td>A</td>
<td>Thyroid cancer translational</td>
<td>Monday September 13</td>
<td>Room 302AB</td>
</tr>
<tr>
<td>F0524</td>
<td>F0529</td>
<td>A</td>
<td>Thyroid hormone transporters</td>
<td>Monday September 13</td>
<td>Room 301</td>
</tr>
<tr>
<td>F0534</td>
<td>F0539</td>
<td>A</td>
<td>Thyroid cell biology</td>
<td>Monday September 13</td>
<td>Room 341</td>
</tr>
<tr>
<td>F0573</td>
<td>F0578</td>
<td>B</td>
<td>Clinical thyroidology - Case reports</td>
<td>Tuesday September 14</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>F0608</td>
<td>F0613</td>
<td>B</td>
<td>Thyroid cancer surgery</td>
<td>Tuesday September 14</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>F0614</td>
<td>F0619</td>
<td>B</td>
<td>Thyroid cancer clinical III</td>
<td>Tuesday September 14</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>F0695</td>
<td>F0700</td>
<td>B</td>
<td>Iodine and thyroid</td>
<td>Tuesday September 14</td>
<td>Room 302AB</td>
</tr>
<tr>
<td>F0701</td>
<td>F0706</td>
<td>B</td>
<td>Thyroid hormone actions</td>
<td>Tuesday September 14</td>
<td>Room 301</td>
</tr>
<tr>
<td>F0778</td>
<td>F0783</td>
<td>B</td>
<td>The role of thyroid hormone in brain and development</td>
<td>Tuesday September 14</td>
<td>Room 341</td>
</tr>
<tr>
<td>F0786</td>
<td>F0793</td>
<td>B</td>
<td>Thyroid and energy metabolism</td>
<td>Tuesday September 14</td>
<td>Room 341</td>
</tr>
<tr>
<td>F0873</td>
<td>F0878</td>
<td>B</td>
<td>Clinical thyroidology - Hypothyroidism</td>
<td>Wednesday September 15</td>
<td>Amphitheatre Bordeaux</td>
</tr>
<tr>
<td>F0899</td>
<td>F0914</td>
<td>B</td>
<td>Clinical thyroidology - Nontoxic goiter</td>
<td>Wednesday September 15</td>
<td>Amphitheatre Havane</td>
</tr>
<tr>
<td>F0921</td>
<td>F0926</td>
<td>B</td>
<td>Thyroid cancer clinical IV</td>
<td>Wednesday September 15</td>
<td>Room 342AB</td>
</tr>
<tr>
<td>F1002</td>
<td>F1007</td>
<td>B</td>
<td>Thyroid cancer clinical V</td>
<td>Wednesday September 15</td>
<td>Room 302AB</td>
</tr>
<tr>
<td>F1008</td>
<td>F1013</td>
<td>B</td>
<td>Thyroid hormone metabolism and action</td>
<td>Wednesday September 15</td>
<td>Room 301</td>
</tr>
<tr>
<td>F1011</td>
<td>F1016</td>
<td>B</td>
<td>Development and function of thyroid cells</td>
<td>Wednesday September 15</td>
<td>Room 341</td>
</tr>
<tr>
<td>F1080</td>
<td>F1085</td>
<td>B</td>
<td>Genetics and Genomics of thyroid diseases</td>
<td>Wednesday September 15</td>
<td>Room 341</td>
</tr>
</tbody>
</table>
POSTER ZONES

HALL HAVANE

FOYER BORDEAUX

AMPHITHEATRE BORDEAUX

REGISTRATION AREA

EXHIBITION

TO CONFERENCE ROOMS

HALL BORDEAUX

EXHIBITION

TO CONFERENCE ROOMS

POSTER ZONE
### POSTERS – GROUP A

Display Period: Sunday 12th and Monday 13th September 2010

<table>
<thead>
<tr>
<th>POSTER</th>
<th>FIRST POSTER</th>
<th>LAST POSTER</th>
<th>DISPLAY ZONE</th>
<th>POSTER VIEWING*</th>
<th>DISCUSSED POSTERS**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autoimmunity</td>
<td>P-0007</td>
<td>P-0042</td>
<td>Hall Havane</td>
<td>Sunday September 12th, 2010</td>
<td>PD03 (page 24)</td>
</tr>
<tr>
<td>Autoimmunity</td>
<td>P-0217</td>
<td>P-0242</td>
<td>Foyer Bordeaux</td>
<td>Sunday September 12th, 2010</td>
<td>PD03 (page 24)</td>
</tr>
<tr>
<td>Clinical thyroidology – Case reports</td>
<td>P-0543</td>
<td>P-0672</td>
<td>Hall Bordeaux</td>
<td>Monday September 13th, 2010</td>
<td></td>
</tr>
<tr>
<td>Clinical thyroidology – Hyperthyroidism</td>
<td>P-0001</td>
<td>P-0006</td>
<td>Hall Havane</td>
<td>Sunday September 12th, 2010</td>
<td>PD01 (page 22)</td>
</tr>
<tr>
<td>Clinical thyroidology – Hyperthyroidism</td>
<td>P-0243</td>
<td>P-0284</td>
<td>Foyer Bordeaux</td>
<td>Sunday September 12th, 2010</td>
<td></td>
</tr>
<tr>
<td>Clinical thyroidology – Nodule</td>
<td>P-0314</td>
<td>P-0319</td>
<td>Hall Bordeaux</td>
<td>Monday September 13th, 2010</td>
<td>PD07 (page 35)</td>
</tr>
<tr>
<td>Clinical thyroidology – Nodule</td>
<td>P-0521</td>
<td>P-0587</td>
<td>Hall Bordeaux</td>
<td>Monday September 13th, 2010</td>
<td></td>
</tr>
<tr>
<td>Deiodinases</td>
<td>P-0285</td>
<td>P-0290</td>
<td>Foyer Bordeaux / Hall Bordeaux</td>
<td>Sunday September 12th, 2010</td>
<td>PD06 (page 24)</td>
</tr>
<tr>
<td>Environmental factors – Drug-induced thyroid abnormalities</td>
<td>P-0284</td>
<td>P-0303</td>
<td>Hall Bordeaux</td>
<td>Sunday September 12th, 2010</td>
<td></td>
</tr>
<tr>
<td>Environmental factors – Iodine</td>
<td>P-0042</td>
<td>P-0047</td>
<td>Hall Havane</td>
<td>Sunday September 12th, 2010</td>
<td>PD02 (page 22)</td>
</tr>
<tr>
<td>Environmental factors – Others</td>
<td>P-0288</td>
<td>P-0292</td>
<td>Hall Havane</td>
<td>Sunday September 12th, 2010</td>
<td></td>
</tr>
<tr>
<td>Graves’ orbitopathy</td>
<td>P-0398</td>
<td>P-0403</td>
<td>Hall Bordeaux</td>
<td>Monday September 13th, 2010</td>
<td>PD08 (page 35)</td>
</tr>
<tr>
<td>Graves’ orbitopathy</td>
<td>P-0404</td>
<td>P-0422</td>
<td>Hall Bordeaux</td>
<td>Monday September 13th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid cancer – Basic</td>
<td>P-0398</td>
<td>P-0403</td>
<td>Hall Havane</td>
<td>Sunday September 12th, 2010</td>
<td>PD04 (page 23)</td>
</tr>
<tr>
<td>Thyroid cancer – Basic</td>
<td>P-0284</td>
<td>P-0286</td>
<td>Hall Havane / Foyer Bordeaux</td>
<td>Sunday September 12th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid cancer – Clinical I</td>
<td>P-0093</td>
<td>P-0098</td>
<td>Hall Havane</td>
<td>Sunday September 12th, 2010</td>
<td>PD03 (page 23)</td>
</tr>
<tr>
<td>Thyroid cancer – Clinical I</td>
<td>P-0299</td>
<td>P-0308</td>
<td>Hall Havane</td>
<td>Sunday September 12th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid cancer – Clinical II</td>
<td>P-0423</td>
<td>P-0428</td>
<td>Hall Bordeaux</td>
<td>Monday September 13th, 2010</td>
<td>PD09 (page 36)</td>
</tr>
<tr>
<td>Thyroid cancer – Clinical II</td>
<td>P-0429</td>
<td>P-0517</td>
<td>Hall Bordeaux</td>
<td>Monday September 13th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid cancer translational</td>
<td>P-0518</td>
<td>P-0623</td>
<td>Hall Bordeaux</td>
<td>Monday September 13th, 2010</td>
<td>PD10 (page 36)</td>
</tr>
<tr>
<td>Thyroid cell biology</td>
<td>P-0534</td>
<td>P-0539</td>
<td>Hall Bordeaux</td>
<td>Monday September 13th, 2010</td>
<td>PD12 (page 37)</td>
</tr>
<tr>
<td>Thyroid hormone metabolism</td>
<td>P-0291</td>
<td>P-0293</td>
<td>Hall Bordeaux</td>
<td>Sunday September 12th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid hormone synthesis</td>
<td>P-0440</td>
<td>P-0442</td>
<td>Hall Bordeaux</td>
<td>Monday September 13th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid hormone transport</td>
<td>P-0530</td>
<td>P-0533</td>
<td>Hall Bordeaux</td>
<td>Monday September 13th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid hormone transporters</td>
<td>P-0524</td>
<td>P-0529</td>
<td>Hall Bordeaux</td>
<td>Monday September 13th, 2010</td>
<td>PD01 (page 37)</td>
</tr>
</tbody>
</table>

*Poster Viewing sessions will take place from 13:00 to 14:00 on the mentioned date.
Authors will be present next to their poster in order to answer potential questions from delegates.

**Posters presented as a brief oral presentations.
POSTERS – GROUP A
Display Period: Sunday 12th and Monday 13th September 2010
P-0001 → P-0219
POSTERS – GROUP A
Display Period: Sunday 12th and Monday 13th September 2010
P-0220 → P-0572
# POSTERS – GROUP B

**Display Period:** Tuesday 14th and Wednesday 15th September 2010

P-0573 → P-1148

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>FIRST POSTER</th>
<th>LAST POSTER</th>
<th>DISPLAY ZONE</th>
<th>POSTER VIEWING*</th>
<th>DISCUSSED POSTERS**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical thyroidology – Case reports</td>
<td>P-0573</td>
<td>P-0578</td>
<td>Hall Havane</td>
<td>Tuesday September 14th, 2010</td>
<td>P13 (page 48)</td>
</tr>
<tr>
<td>Clinical thyroidology – Case reports</td>
<td>P-0579</td>
<td>P-0607</td>
<td>Hall Havane</td>
<td>Tuesday September 14th, 2010</td>
<td></td>
</tr>
<tr>
<td>Clinical thyroidology – Hypothyroidism</td>
<td>P-0573</td>
<td>P-0578</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td>P20 (page 60)</td>
</tr>
<tr>
<td>Clinical thyroidology – Hypothyroidism</td>
<td>P-0579</td>
<td>P-0598</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td></td>
</tr>
<tr>
<td>Clinical thyroidology – Nontoxic goiter</td>
<td>P-0899</td>
<td>P-0914</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td>P21 (page 60)</td>
</tr>
<tr>
<td>Clinical thyroidology – Nontoxic goiter</td>
<td>P-0815</td>
<td>P-0820</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td></td>
</tr>
<tr>
<td>Clinical thyroidology – Subclinical thyroid diseases</td>
<td>P-0830</td>
<td>P-0835</td>
<td>Foyer Bordeaux</td>
<td>Tuesday September 14th, 2010</td>
<td></td>
</tr>
<tr>
<td>Development and function of thyroid cells</td>
<td>P-1051</td>
<td>P-1056</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td>P32 (page 62)</td>
</tr>
<tr>
<td>Epidemiology of thyroid diseases</td>
<td>P-1094</td>
<td>P-1123</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td></td>
</tr>
<tr>
<td>Experimental / animal models</td>
<td>P-1033</td>
<td>P-1044</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td></td>
</tr>
<tr>
<td>Genetics and Genomics of thyroid diseases</td>
<td>P-1080</td>
<td>P-1085</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td>P26 (page 63)</td>
</tr>
<tr>
<td>Genetics and Genomics of thyroid diseases</td>
<td>P-1086</td>
<td>P-1090</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td></td>
</tr>
<tr>
<td>Iodine and thyroid</td>
<td>P-0995</td>
<td>P-1000</td>
<td>Hall Havane</td>
<td>Tuesday September 14th, 2010</td>
<td>P316 (page 49)</td>
</tr>
<tr>
<td>Medullary thyroid carcinoma</td>
<td>P-1124</td>
<td>P-1148</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td></td>
</tr>
<tr>
<td>New drugs</td>
<td>P-1045</td>
<td>P-1050</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td></td>
</tr>
<tr>
<td>Non-Thyroidal Illnesses</td>
<td>P-1018</td>
<td>P-1022</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td></td>
</tr>
<tr>
<td>The role of thyroid hormone in brain and development</td>
<td>P-0778</td>
<td>P-0783</td>
<td>Hall Havane</td>
<td>Tuesday September 14th, 2010</td>
<td>P158 (page 50)</td>
</tr>
<tr>
<td>Thyroid and energy metabolism</td>
<td>P-0798</td>
<td>P-0793</td>
<td>Foyer Bordeaux</td>
<td>Tuesday September 14th, 2010</td>
<td>P319 (page 53)</td>
</tr>
<tr>
<td>Thyroid cancer – Basic</td>
<td>P-0829</td>
<td>P-0872</td>
<td>Foyer Bordeaux / Hall Bordeaux</td>
<td>Tuesday September 14th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid cancer – Clinical I</td>
<td>P-0829</td>
<td>P-0844</td>
<td>Hall Havane</td>
<td>Tuesday September 14th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid cancer – Clinical II</td>
<td>P-0829</td>
<td>P-1000</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid cancer – Clinical III</td>
<td>P-0814</td>
<td>P-0839</td>
<td>Hall Havane</td>
<td>Tuesday September 14th, 2010</td>
<td>P315 (page 49)</td>
</tr>
<tr>
<td>Thyroid cancer – Clinical IV</td>
<td>P-0821</td>
<td>P-0826</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td>P322 (page 63)</td>
</tr>
<tr>
<td>Thyroid cancer – Clinical V</td>
<td>P-1002</td>
<td>P-1007</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td>P323 (page 63)</td>
</tr>
<tr>
<td>Thyroid cancer surgery</td>
<td>P-0808</td>
<td>P-0813</td>
<td>Hall Havane</td>
<td>Tuesday September 14th, 2010</td>
<td>P314 (page 48)</td>
</tr>
<tr>
<td>Thyroid function regulation / TSH / TRH</td>
<td>P-0794</td>
<td>P-0809</td>
<td>Foyer Bordeaux</td>
<td>Tuesday September 14th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid gland development</td>
<td>P-1057</td>
<td>P-1058</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid hormone actions/effects – Other</td>
<td>P-0791</td>
<td>P-0796</td>
<td>Hall Bordeaux</td>
<td>Tuesday September 14th, 2010</td>
<td>P217 (page 50)</td>
</tr>
<tr>
<td>Thyroid hormone actions/effects – Other</td>
<td>P-0795</td>
<td>P-0777</td>
<td>Hall Havane</td>
<td>Tuesday September 14th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid hormone actions/effects – Thyroid hormone and metabolism</td>
<td>P-0797</td>
<td>P-0792</td>
<td>Hall Havane</td>
<td>Tuesday September 14th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid hormone actions/effects – Thyroid hormone and metabolism</td>
<td>P-0743</td>
<td>P-0744</td>
<td>Hall Havane</td>
<td>Tuesday September 14th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid hormone actions/effects – Thyroid hormone and the immune system</td>
<td>P-0784</td>
<td>P-0787</td>
<td>Hall Havane / Foyer Bordeaux</td>
<td>Tuesday September 14th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid hormone actions/effects – Thyroid hormone and the immune system</td>
<td>P-0728</td>
<td>P-0742</td>
<td>Hall Havane</td>
<td>Tuesday September 14th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid hormone analogues</td>
<td>P-1017</td>
<td>P-1019</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td></td>
</tr>
<tr>
<td>Thyroid hormone metabolites and action</td>
<td>P-1088</td>
<td>P-1093</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td>P324 (page 62)</td>
</tr>
<tr>
<td>Thyroid hormone issues</td>
<td>P-1014</td>
<td>P-1016</td>
<td>Hall Bordeaux</td>
<td>Wednesday September 15th, 2010</td>
<td></td>
</tr>
</tbody>
</table>

*Poster Viewing sessions will take place from 13:00 to 14:00 on the mentioned date.

Authors will be present next to their poster in order to answer potential questions from delegates.

**Posters presented as brief oral presentations.
POSTERS – GROUP B
Display Period: Tuesday 14th and Wednesday 15th September 2010
P-0573 → P-0786
POSTERS – GROUP B
Display Period: Tuesday 14th and Wednesday 15th September 2010
P-0787 – P-1148

FOYER BORDEAUX

AMPHITHEATRE BORDEAUX

BUFFET

EXHIBITION

HALL BORDEAUX
# POSTERS LIST

## GROUP A

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>P0001 – P0572</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster View</th>
<th>Poster Viewing Time</th>
<th>First Poster</th>
<th>Last Poster</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sun. Sept. 12th</td>
<td>13:00 – 14:00</td>
<td>P0001</td>
<td>P0313</td>
</tr>
<tr>
<td>Mon. Sept. 13th</td>
<td></td>
<td>P0314</td>
<td>P0572</td>
</tr>
</tbody>
</table>

## DISCUSSED POSTERS (PD01) (see page 22)

### Clinical thyroidology – Hyperthyroidism

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-0001</td>
<td>LACK OF IN VITRO CONSTITUTIVE ACTIVITY FOR FOUR PREVIOUSLY REPORTED TSH RECEPTOR MUTATIONS IDENTIFIED IN PATIENTS WITH NONAUTOIMMUNE HYPERTHYROIDISM AND HOT THYROID CARCINOMAS</td>
<td>H. Jaeschke, S. Mueller, M. Eszlinger, R. Paschke (Leipzig, Germany)</td>
</tr>
<tr>
<td>P-0003</td>
<td>LEVELS OF NEONATAL THYROID HORMONE IN PRETERM INFANTS AND NEURODEVELOPMENTAL OUTCOME AT 39 YEARS</td>
<td>F. L. R. Williams, R. Hume (Dundee, United Kingdom)</td>
</tr>
<tr>
<td>P-0004</td>
<td>INHIBITION OF THE NUCLEAR RECEPTOR CAR AND ITS DOWNSTREAM TARGET GENES BY PROLONGED, BUT NOT ACUTE, CRITICAL ILLNESS IRRITATIVE OF FEEDING STATUS</td>
<td>L. Mebiu, S. Derde, E.-J. Ververs, G. Van den Berghe (Leuven, Belgium)</td>
</tr>
<tr>
<td>P-0005</td>
<td>THYROID HORMONE RECEPTORS ARE DOWN-REGULATED IN SKELETAL MUSCLE OF PATIENTS WITH NON-THYROIDAL ILLNESS SYNDROME SECONDARY TO NON-SEPTIC SHOCK, BY A MECHANISM INDEPENDENT OF THE NF-KB PATHWAY</td>
<td>J. Lado-Abeal, A. Romero, I. Castells-Podar, A. Rodriguez-Perez, J. Alvarez-Escudero (Lubbock, United States)</td>
</tr>
<tr>
<td>P-0006</td>
<td>STUDIES ON REARRANGED, GERMLINE ANTIBODY GENES THAT PREDILECT POTENTIALLY AUTOREACTIVE B CELLS TO PRODUCE THYROID STIMULATING ANTIBODIES IN GRAVES DISEASE: EXPRESSION AS RECOMBINANT FAB ANTIBODY FOR EVALUATION OF ANTIGEN BINDING SPECIFICITY</td>
<td>C. Hargreaves, D. Dunn-Walters, J. P. Banga (London, United Kingdom)</td>
</tr>
<tr>
<td>P-0007</td>
<td>THE EVALUATION OF CD4+CD25+HIGH, CD4+CD25+CD127LOW AND CD4+FOXP3+ T CELLS IN THE PERIPHERAL BLOOD OF CHILDREN WITH AUTOIMMUNE THYROID DISEASES</td>
<td>A. Bossowski, M. Mostowaski, M. Dziewonska, M. Murega, B. Sawicka, A. Bodzenta-Lukaszyk (Bialystok, Poland)</td>
</tr>
<tr>
<td>P-0008</td>
<td>LEVELS OF THYROID AUTOANTIBODIES IN PATIENTS WITH GRAVES DISEASE WITH AND WITHOUT GRAVES OPHTALMOPATHY</td>
<td>M. A. Boyanov, D. J. Bakalov, G. S. Shentikova (Sofia, Bulgaria)</td>
</tr>
<tr>
<td>P-0009</td>
<td>HERPES VIRUS TYPE 7 AND GSTP1 GENE VARIANTS ROLE IN THE SUSCEPTIBILITY TO AUTOIMMUNE THYROID DISEASES IN TWO DIFFERENT POPULATIONS: A GENE-ENVIRONMENT INTERACTION</td>
<td>N. E. Bufalo, G. Effraimidis, X. G. Vos, C. F. Reis, A. C. N. Silva, J. L. Leite, R. B. Santos, J. H. Romaldini, W. M. Wierenga, L. S. Ward (Campinas, Brazil)</td>
</tr>
<tr>
<td>P-0010</td>
<td>THYROID DISORDERS IN PATIENTS WITH CELIAC DISEASE</td>
<td>E. Akın, A. Ögür, A. Ucler, A. B. Demirezer, R. Ersoy, O. Ersoy, B. Cakir (Ankara, Turkey)</td>
</tr>
<tr>
<td>P-0011</td>
<td>AUTOIMMUNITY ON THE PERIPHERAL BLOOD OF CHILDREN WITH AUTOIMMUNE THYROID DISEASES ASSOCIATED WITH AUTOIMMUNE GASTRITIS</td>
<td>M. Centanni, M. G. Santaguida, S. C. Del Duca, S. M. Ferrari, P. Fallahi, A. Antonelli (Lamia, Italy)</td>
</tr>
<tr>
<td>P-0012</td>
<td>ELEVATED CALCITONIN LEVELS CAN BE DUE TO THYROID AUTOIMMUNITY?</td>
<td>P. Caron, L. Leclerc, C. Bantier, C. Do Cao, M. d'Herbomez (France)</td>
</tr>
<tr>
<td>P-0013</td>
<td>EPITOPES RECOGNITION PATTERNS OF THYROGLOBULIN ANTIBODY IN SERA FROM PATIENTS WITH HASHIMOTO’S THYROIDITIS AND GRAVES DISEASE</td>
<td>C. Anil, O. Aydemir, M. Kilic, A. Gurey (Ankara, Turkey)</td>
</tr>
</tbody>
</table>

## Autoimmunity

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-0013</td>
<td>STUDIES ON REARRANGED, GERMLINE ANTIBODY GENES THAT PREDILECT POTENTIALLY AUTOREACTIVE B CELLS TO PRODUCE THYROID STIMULATING ANTIBODIES IN GRAVES DISEASE: EXPRESSION AS RECOMBINANT FAB ANTIBODY FOR EVALUATION OF ANTIGEN BINDING SPECIFICITY</td>
<td>C. Hargreaves, D. Dunn-Walters, J. P. Banga (London, United Kingdom)</td>
</tr>
<tr>
<td>P-0014</td>
<td>THE EVALUATION OF CD4+CD25+HIGH, CD4+CD25+CD127LOW AND CD4+FOXP3+ T CELLS IN THE PERIPHERAL BLOOD OF CHILDREN WITH AUTOIMMUNE THYROID DISEASES</td>
<td>A. Bossowski, M. Mostowaski, M. Dziewonska, M. Murega, B. Sawicka, A. Bodzenta-Lukaszyk (Bialystok, Poland)</td>
</tr>
<tr>
<td>P-0015</td>
<td>LEVELS OF THYROID AUTOANTIBODIES IN PATIENTS WITH GRAVES DISEASE WITH AND WITHOUT GRAVES OPHTALMOPATHY</td>
<td>M. A. Boyanov, D. J. Bakalov, G. S. Shentikova (Sofia, Bulgaria)</td>
</tr>
<tr>
<td>P-0016</td>
<td>HERPES VIRUS TYPE 7 AND GSTP1 GENE VARIANTS ROLE IN THE SUSCEPTIBILITY TO AUTOIMMUNE THYROID DISEASES IN TWO DIFFERENT POPULATIONS: A GENE-ENVIRONMENT INTERACTION</td>
<td>N. E. Bufalo, G. Effraimidis, X. G. Vos, C. F. Reis, A. C. N. Silva, J. L. Leite, R. B. Santos, J. H. Romaldini, W. M. Wierenga, L. S. Ward (Campinas, Brazil)</td>
</tr>
<tr>
<td>P-0017</td>
<td>THYROID DISORDERS IN PATIENTS WITH CELIAC DISEASE</td>
<td>E. Akın, A. Ögür, A. Ucler, A. B. Demirezer, R. Ersoy, O. Ersoy, B. Cakir (Ankara, Turkey)</td>
</tr>
<tr>
<td>P-0018</td>
<td>AUTOIMMUNITY ON THE PERIPHERAL BLOOD OF CHILDREN WITH AUTOIMMUNE THYROID DISEASES ASSOCIATED WITH AUTOIMMUNE GASTRITIS</td>
<td>M. Centanni, M. G. Santaguida, S. C. Del Duca, S. M. Ferrari, P. Fallahi, A. Antonelli (Lamia, Italy)</td>
</tr>
<tr>
<td>P-0019</td>
<td>ELEVATED CALCITONIN LEVELS CAN BE DUE TO THYROID AUTOIMMUNITY?</td>
<td>P. Caron, L. Leclerc, C. Bantier, C. Do Cao, M. d'Herbomez (France)</td>
</tr>
<tr>
<td>P-0020</td>
<td>EPITOPES RECOGNITION PATTERNS OF THYROGLOBULIN ANTIBODY IN SERA FROM PATIENTS WITH HASHIMOTO’S THYROIDITIS AND GRAVES DISEASE</td>
<td>C. Anil, O. Aydemir, M. Kilic, A. Gurey (Ankara, Turkey)</td>
</tr>
</tbody>
</table>
IS THERE ANY ASSOCIATION BETWEEN CLINICAL RELEVANCE OF A NOVEL TSI BIOASSAY FOR INCREASED FREQUENCY OF BclI AND A3669G

REGULATORY AND HELPER T CELLS IN UNTREATED BREAST CANCER CELLS ARE ABLE TO EXPRESS SJÖGREN’S SYNDROME AND POLYGLANDULAR PREVALENCE OF AUTOANTIBODIES TO THYROID ANTI-PENDRIN ANTIBODY, A NOVEL AUTOANTIBODY, ASSOCIATIONS BETWEEN SUBCLINICAL THE TSI TITRE OF A NOVEL BIOASSAY SHOWS GREATER DEVELOPMENT OF A NOVEL BIOASSAY FOR THE G. Mendeluk (Buenos Aires, Argentina) S. Curi, P. Chenlo, L. Palaoro, V. Mesch, M. Rosales ANTI-THYROID ANTIBODIES AND ANTI-SPERM DISEASE THE EXTRATHYROIDAL MANIFESTATIONS OF GRAVES’ DISEASE WITH AUTOIMMUNE THYROID DISEASE GLUCOCORTICOID GENE POLYMORPHISMS IN PATIENTS GIRLS WITH TURNER’S SYNDROME FAILURE JAPANESE-BRAZILIAN THYROID STUDY TRADITIONAL CARDIOVASCULAR RISK FACTORS: THE HYPOTHYROIDISM AND TRADITIONAL AND NON- TRADITIONAL IMMUNE-RELATED MOLECULES IN GRAVES’ DISEASE THYROID DISEASES IN SUBJECTS NEWLY DIAGNOSED WITH GRAVES’ Autoimmune thyroid disease severity

ASSOCIATIONS OF PLASMA INTERLEUKIN LEVELS WITH CRYSTAL STRUCTURE OF THE TSH RECEPTOR BOUND TO A BLOCKING TYPE TSHR AUTOANTIBODY HANDLING STEPS AND HIGH STABILITY OF CAMP BINDING AUTOANTIBODIES IN GRAVES’ DISEASE (Nimes, France)


FIRST AUTOMATED HUMAN TRAK IMMUNOASSAY ON KRYPTOR® FOR TSH RECEPTOR AUTOANTIBODIES G. Sarkissian, M. Gautier, N. G. M. Mongenthaler, B. Darboux (Nimes, France)


FIRST AUTOMATED HUMAN TRAK IMMUNOASSAY ON KRYPTOR® FOR TSH RECEPTOR AUTOANTIBODIES G. Sarkissian, M. Gautier, N. G. M. Mongenthaler, B. Darboux (Nimes, France)


FIRST AUTOMATED HUMAN TRAK IMMUNOASSAY ON KRYPTOR® FOR TSH RECEPTOR AUTOANTIBODIES G. Sarkissian, M. Gautier, N. G. M. Mongenthaler, B. Darboux (Nimes, France)


FIRST AUTOMATED HUMAN TRAK IMMUNOASSAY ON KRYPTOR® FOR TSH RECEPTOR AUTOANTIBODIES G. Sarkissian, M. Gautier, N. G. M. Mongenthaler, B. Darboux (Nimes, France)


FIRST AUTOMATED HUMAN TRAK IMMUNOASSAY ON KRYPTOR® FOR TSH RECEPTOR AUTOANTIBODIES G. Sarkissian, M. Gautier, N. G. M. Mongenthaler, B. Darboux (Nimes, France)


FIRST AUTOMATED HUMAN TRAK IMMUNOASSAY ON KRYPTOR® FOR TSH RECEPTOR AUTOANTIBODIES G. Sarkissian, M. Gautier, N. G. M. Mongenthaler, B. Darboux (Nimes, France)


FIRST AUTOMATED HUMAN TRAK IMMUNOASSAY ON KRYPTOR® FOR TSH RECEPTOR AUTOANTIBODIES G. Sarkissian, M. Gautier, N. G. M. Mongenthaler, B. Darboux (Nimes, France)


FIRST AUTOMATED HUMAN TRAK IMMUNOASSAY ON KRYPTOR® FOR TSH RECEPTOR AUTOANTIBODIES G. Sarkissian, M. Gautier, N. G. M. Mongenthaler, B. Darboux (Nimes, France)
Environmental factors - Iodine

P-0046 PREVALENCE OF IODINE DEFICIENCY AMONG HYPOHYROID PATIENTS: A PILOT STUDY
K. Z. Alishahi, E. M. Ahwai (Jeddah, Saudi Arabia)

P-0048 IODINE DEFICIENCY WITHIN IODINE SUFFICIENCY
P. Minamitani, P. Nazon, Y. Melibah, H. Delhold, M. Hedayati, F. Arini (Tehran, Islamic Republic of Iran)

P-0050 NEONATAL THYROID STATUS IN AN AREA OF IODINE SUFFICIENCY
F. Arini, M. S. Hosseini, A. Amourengar, M. Tolibi, E. Arini (Tehran, Islamic Republic of Iran)

P-0051 THERAPEUTIC EFFECT OF IODINE ON BENIGN HUMAN PROSTATIC HYPERPLASIA
R. E. Nafisi-Ashtiani, M. Navab-Vilalba, C. Acers (Jerquilla, Mexico)

P-0052 DISPERSION OF AREA-TERMIMENTER-SPECIFIC TSH REFERENCE INTERVAL IN PREGNANT WOMEN WITH SAME IODINE INTAKE
A. Bozorgzad, M. Aghani, R. Rostami, J. Nousrouxarakhd (Rubia, Islamic Republic of Iran)

P-0053 SWINE AND MICE CLOSED FOLLICULAR THYROID CELLS IN A THREE-DIMENSIONAL CULTURE REPRODUCE THE WOLF-ChAiroFF EFFECT
J. Rivera, M. Herrera, C. Ochoa, C. Spinel (Bogota, Colombia)

P-0054 IODINE MODULATES DOMERCUBIN AND SODIUM BUTYRATE-INDUCED APOPTOSIS IN THYROID CANCER CELLS THROUGH ERK/P38-RELATED BCL-XL EXPRESSION
G. G. Chen, X. H. Liu, A. C. Vlantes, G. M. Teo, C. A. van Hasselt (Hong Kong, China)

P-0055 CLUSTER OF THYROID DYSFUNCTION SECONDARY TO IODINE TOXICITY FROM A SOY MILK PRODUCT
E. Chua, C. Corwell, R. McQuilty, B. Crawford (Camperdown, Australia)

P-0056 SPECTRUM OF THYROID DISEASES IN GERICATRIC POPULATION 10 YEARS AFTER MANDATORY IODINATION IN ANKARA
B. Yılmaz, Ö. Demir, F. Atıcı, M. Erdogdu (Ankara, Turkey)

P-0057 IODINE STATUS OF JAPANESE PREGNANT WOMEN: REFERENCE VALUES FOR SPOT URINE IODINE CONCENTRATIONS IN IODINE-SUFFICIENT REGION
Y. Fuse, T. Okabe, S. Yamaguchi, M. Yamaguchi, N. Ariza, S. Harada, Y. Shishiba, M. Irie (Tokyo, Japan)

P-0058 IODINE EXCRETION IN PREGNANT WOMEN IN QUECTRATO, MEXICO

P-0059 ESTABLISHMENT AND ON-GOING OPERATION OF NATIONAL QUALITY
J. Yu (Beijing, China)

P-0060 THE STATUS OF IODINE NUTRITION OF EXOTIC WORKERS IN CHANGPING DISTRICT OF BEIJING, CHINA
J. Yu (Beijing, China)

P-0061 ASSOCIATION BETWEEN BODY MASS INDEX AND GLOTTIC INJURY IN SCHOOL CHILDREN IN BIFAHAN, IRAN
K. Hoshmat-Ghalandari, N. Khali, M. Hashemipour, S. A. Shoebestian (Bifahan, Islamic Republic of Iran)

P-0062 INVESTIGATION AND STUDY OF WATER IODINE LEVELS DIFFERENT AREA ON CHILDREN’S INTELLIGENCE AND THYROID FUNCTION
Q. Z. Jia, X. D. Zhang, X. P. Wen (Lanzhou, China)

P-0063 IODINE INTAKE AND THYROID CANCER IN CROATIA

P-0064 IODINE INTAKE IN CROATIA – THE RESULTS OF A NATIONWIDE SURVEY 2009
Z. Kurtić, T. Jukić, N. Rajek, D. Mrčić, H. Čupić, Z. Sonicki (Zagreb, Croatia)

P-0065 IODINE SATURATION OF SENIORS IN THE CZECH REPUBLIC
J. Kvicala (Prague 1, Czech Republic)

P-0066 EFFECTS OF IODIDE EXCESS ON MITOCHONDRIAL SUPEROXIDE PRODUCTION AND MITOCHONDRIAL MEMBRANE POTENTIAL IN FRTL CELLS
L. Y. Li, M. Li, X. M. Yao, Z. P. Chen (Tianjin, China)

P-0067 COMPARATIVE STUDY ON THYROID MORPHOLOGY AND FUNCTION IN RATS AND MICE WITH DIFFERENT LEVELS OF POTASSIUM IODIDE INTAKE
L. X. Lin, Y. N. Sun, Y. Ye, M. M. Li, Y. Q. Yan, Z. P. Chen (Tianjin, China)

P-0068 DOSIS-DEPENDENT APOPTOTIC EFFECT OF MOLECULAR IODINE IN TWO NEUROBLASTOMA CELL LINES: POSSIBLE PARTICIPATION OF RETINOID ACID RECEPTOR
R. E. Nafisi-Ashtiani, M. Navab-Vilalba, C. Acers (Jerquilla, Mexico)

P-0069 GONADAL IMPACT OF TREATMENT WITH IODINE 131 IN WOMEN WITH DIFFERENTIATED THYROID CANCERNA
M. M. Pavlove, M. J. Benavente, J. M. Khizer-Rohmanto, A. M. Fadel, S. Gutierrez, G. Chebel (Barros Arros, Argentina)

P-0070 THE IMPACT OF IODINE, IBON DEFICIENCY ON THE THYROID FUNCTION AMONG PREGNANT WOMEN
M. Qian, Y. Li, M. Di, A. Raheman, X. Wang, Y. Yun, M. Gabe-Medlin, Z. Chen (Tianjin, China)

P-0071 STUDY OF FREQUENCY OF GLOTTIS IN OAXACA (MEXICO): ANALYSIS OF ETIOLOGICAL FACTORS
E. Ramirez-Vargas (Oaxaca, Mexico)

P-0072 CYTOSKELETON DISRUPTION AS A POSSIBLE CAUSE OF THE IMPAIRED STABILITY AND TRANSLATION EFFICIENCY OF SODIUM-IODIDE SYMPORTER (NIS) TRANSCRIPT IN PCCl3 CELLS TREATED WITH EXCESS OF IODIDE
E. Ramirez-Vargas (Oaxaca, Mexico)

P-0073 STUDY ON THE EFFECTS OF IODINE ON THE EXPRESSION OF SODIUM-IODIDE SYMPORTER IN THE MAMMARY EPITHELIUM
M. H. Shen, J. Yu, N. S. Wang, X. L. Liu, X. Yu (Harbin, China)

P-0074 CHANGES IN DIABETIC IODINE INTAKE IN THE ABSENCE OF KONISEI SALT AVAILABILITY
P. Smyth, R. Burns, C. O’Herlihy (Dublin 4, Ireland)

P-0075 ATMOSPHERIC IODINE INGESTION COMPENSATING FOR INADEQUATE DIETARY INTAKE

P-0076 GLOTTIS AND BODY MASS INDEX: IS THERE ANY RELATION BETWEEN THEM IN SCHOOLCHILDREN?
S. A. Shoebestian, N. Khali, M. Hashemipour, K. Hoshmat (Bifahan, Islamic Republic of Iran)

P-0077 IODINE DEFICIENCY IN PREGNANCY AND GESTATION DIABETES – PREVENTIVE MEASURES
Z. Szybinski (Koitos, Poland)
The role of the frozen biopsy for the central thyroid cancer in kidney transplant patients; P-0116

Papillary thyroid carcinoma with and association of low ablation-thyroglobulin; P-0115

Risk factors for recurrence and mortality due to differentiated thyroid carcinoma in Navarra (Spain); P-0114

Fixed positron emission tomography with computed tomography (PET CT) scans in the evaluation of persistent/recurrent differentiated thyroid cancer; A. Al-Khalili, M. Alhassani, A. Al-Sugair

Risk factors for recurrence and mortality due to differentiated thyroid carcinoma in Navarra (Spain); E. Anda, P. Salvador, J. P. Martinez de Estaban, A. Furras, E. Layana, E. Mendizabal (Pamplona, Spain)

Unilateral thyroid lobectomy for differentiated thyroid carcinoma; G. Andry, M. Paesmans, M. Delmelle, E. Willemse, A. Digonnet, C. De Keyser, L. Vandevelde, G. Andry, J. Hoang (Sydney, Australia)

Role of 18F-FDG-PET in radioiodine negative thyroid carcinoma; S. Angelines, I. Hoang (Sydney, Australia)

Papillary thyroid carcinoma (PTC) with and without nodal metastases at time of surgery demonstrate divergent patterns of post-operative serum thyroglobulin (Tg) values; T. Angiolillo, J. LoPresti (Los Angeles, United States)


Day and 25-hour stay thyroid surgery: our experiences at the Royal Melbourne Hospital; A. Ashrafti, J. Miller (Melbourne, Australia)


Role of the frozen biopsy for the central lymph node during surgery in thyroid papillary carcinoma; J. S. Bar, C. K. Jung, D. J. Lim, W. C. Park, K. Y. Sung, J. S. Kim, B. J. Song, N. S. Kim, J. K. Nam (Seoul, Republic of Korea)


Case of a patient with acromegaly and a dischondroma follicular thyroid carcinoma; A. Balázs-Waligorska, F. Fulkowska, A. Krzynowek, G. Sokolowski, A. Storange, A. Hulakesowska-Dydzyczak (Krakow, Poland)

A comparison of two groups of patients with differentiated thyroid carcinoma treated with radioiodine 131I following endogenous and exogenous stimulation of TSH; A. Balázs-Waligorska, F. Fulkowska, A. Krzynowek-Koski, G. Sokolowski, A. Hulakesowska-Dydzyczak (Krakow, Poland)

The importance of tail cell histology on the clinical behavior of papillary thyroid carcinoma; Z. W. Balogh, K. Shalique, K. Mottone, V. A. Livolsi (Philadelphia, United States)

Proteomic profiling of papillary thyroid carcinoma; Y. Ben, G. Yamamoto, M. Takada, Y. Ban, K. Shimizu, H. Aka, T. Igarashi, T. Tsukahara, T. Hirano (Tokyo, Japan)

Radioiodo lymphoscintigraphy and intraoperative gamma probe detection for sentinel lymph node biopsy in papillary thyroid carcinoma; I. Baner, J. Martinez-Rodriguez, R. Quirre, J. Jimenez-Bonilla, M. de Arzolla, F. Portilla-Quintosocuch, P. Molina-Quintero, A. Bahia-Yaxali, R. del Castillo, J. M. Cancel (Santiago, Spain)

BRAS VAMSE and RET/PTC rearrangements in a Brazilian cohort of sporadic papillary carcinomas and correlation with clinical-pathological features: identification of tumors subgroups; A. U. Bastos, G. Gher, J. P. Hamelry, J. M. Geretti (Sao Paulo, Brazil)

Synchronous bone metastases in papillary microcarcinoma; H. Razaeeb, G. G. Froma, S. S. Prabh, N. L. Busady (Houston, United States)

A case of papillary thyroid cancer with sarcomatoid reaction; B. Bendale, C. Darwin, C. Li, K. Blackwell, I. Chopra (Los Angeles, United States)

Prognostic factors of metastatic follicular thyroid carcinoma: value of radioiodine uptake; D. Bentovii, E. Chumony, J. Benoliel, B. Raymond, X. Fontara, J. Durcqwrt, F. Buserwe (Nice, France)

Lymph node persistence of differentiated thyroid cancer in the central compartment of the neck: consequence of inadequate therapeutic surgery or absence of prophylactic lymph node dissection? E. Frennstrom, D. Tarah, J. Vaillant, E. Sotema, F. Sebät, J.-P. Henni (Marseille, France)

Multimodal imaging for recurrent differentiated thyroid cancer: ultrasonography, 131I-spect-scintigraphy, fine-needle biopsy; M. Biermann, B. Johnsen, A. Naum, L. Helgeland, L. Alden, J. E. Varhaug, M. Brauckhoff (Bergen, Norway)

Monocentric retrospective study from pathologic fine needle aspiration to decision: the real life; A. Mensah, H. Bihan, M. Psowski, A. Lakdar, M.-L. Dumont, T. Bui, B. Cazabat, J. Vaillant, E. Sotema, F. Sebaàt, J.-P. Henni (Marseille, France)
P-0146 MIND THE STATIN BEFORE RADIOACTIVE IOHENE THERAPY
H. Rihan, V. Herba, I. Kollan-Pottel, G. Bauch, R. Döste, R. Coban (Bolagny, France)

P-0157 SIZE OF THYROID CANCER AND THYROIDECTOMY INDICATION
A. Ben Lakhdar, M. F. Yusekale, A. Mena, H. Rihan, Y. Guillem, M. Oustra, B. Frachet, M. L. Dumont, B. Costeberelace, L. Ouadi, A. Martin, G. Bauch, A. Neuman, R. Coban (Bolagny, France)

P-0168 CA125 CLAUDIN-5 IMMUNOSTAINING AS A USEFUL PROGNOSTIC MARKER IN THE ASSESSMENT OF PAPILLARY THYROID CARCINOMA
C. Calato, A. Darzanto, P. Brazaunda, F. Mantsari, M. Chiosi, F. Menestrina, M. Perdriglioni (Verona, Italy)

P-0169 A PRELIMINARY DATA ON STUDY OF DIFFERENTIATED THYROID CANCER IN GRANADA
M. Cortes-Berdonces, A. García-Martín, M. A. Moreno de Fuentes, I. Luque-Fernández, M. Vay-Vey, E. Tormo-Vela (Granada, Spain)

P-0170 DIFFERENTIATED THYROID CANCER: AN ANALYSIS OF HISTOLOGICAL SUBTYPES
M. Cortes-Berdonces, A. García-Martín, E. Tormo-Vela, M. Romano-Matíoz, M. A. Moreno de Fuentes (Granada, Spain)

P-0171 SIMULTANEOUS OCCURRENCE OF PAPILLARY AND MEDULLARY CARCINOMA: CASE REPORT

P-0172 PAPILLARY THYROID MICROCARCINOMA: SIZE DOES MATTER
N. Coutinot, L. G. de Minto, H. Menzies, B. Dilagert, R. Garnier, J.-C. Tabet, E. Naiss, L. Gaultier, R. Charrond, A. Beucher (Montreal, Canada)

P-0173 STUDY OF THE HISTOLOGICAL PROFILE OF PAPILLARY THYROID CARCINOMA ASSOCIATED TO HASHIMOTO THYROIDITIS

P-0174 PAPILLARY THYROID CANCER: DIFFERENT BEHAVIOR OF MICROCARCINOMAS COMPARED WITH TUMORS OF 11-20 MM IN DIAMETER
L. A. Darde, E. Monte, E. N. Cohen, P. D. Fragoso (Córdoba, Argentina)

P-0175 THYROIDCORTY WITH ULTRASOUND DISSECTOR: A MULTICENTRE EXPERIENCE
F. P. ijella (Perugia, Italy)

P-0177 CLINICAL CHARACTERISTICS OF POORLY DIFFERENTIATED THYROID CARCINOMAS IN A FRENCH ANTICANCER CENTER
C. De La Fouchardiere, O. Papi, L. Semen, L. Benoist, J. C. Lfant, M. Deceuninck, J. L. Per, C. De Greepen, F. Benoist-Chaude, J.-P. Devé (Lyon, France)

P-0178 CLINICAL EXPERIENCE WITH ANAPLASTIC THYROID CARCINOMA (ATC)
C. De La Fouchardiere, O. Papi, L. Semen, L. Benoist, J. C. Lfant, M. Deceuninck, C. Carre, L. Per, P. Borel-Chaude, J.-P. Devé (Lyon, France)

P-0179 VALUE OF ULTRASONOGRAPHY IN PRE- AND POSTOPERATIVE MONITORING OF LARYNGEAL NERVES FUNCTION IN PATIENTS UNDERGOING THYROIDECTOMY
M. Dedecjus, Z. Adamczewski, J. Brzezinski, A. Lewinski, M. Hershman (Washington, United States)

P-0180 PROGNOSTIC VALUE OF SERUM PRE-ABLATIVE THYROSITES IN DIFFERENTIATED THYROID CANCER

P-0181 ELEVATED PROLIFERATION AND CELL DEATH IN POST-CHROMIC PAPILLARY THYROID CARCINOMA WITH CONSIDING THYROTROPIN
A. Dinata, M. Hudhby, H. Hägg, C. Larsson, J. Zedamius (Stockholm, Sweden)

P-0182 SHOULD SUBTOTAL THYROIDECTOMY BE INCLUDED AS APPROPRIATE FOR WELL-DIFFERENTIATED THYROID CANCER?
S. R. Downing, O. Bolundardou, D. C. Chang, W. A. Frederick (Washington, United States)

P-0183 A PILOT ROLE FOR NECK ULTRASONOGRAPHY IN THE FOLLOW-UP MANAGEMENT OF CLINICALLY SELECTED VERY LOW-RISK PAPILLARY THYROID CARCINOMA PATIENTS

P-0184 SENTINEL LYPY NODE BIOPSY WITH METHYLTHION BLUE DYE IN DIFFERENTIATED THYROID CARCINOMA AND DECISION FOR SELECTIVE MODIFIED RADICAL NECK DISTECTION
R. Duda, I. Markovsz, I. Dzabic, M. Buta, G. Papic, Z. Milovanovic (Belgrade, Serbia)

P-0185 THYROGLOBULIN DUCT CYST THYROID TUMORS – SURGICAL STRATEGY AFTER TWELVE CASES
R. Duda, I. Markovsz, M. Buta, I. Dzabic, M. Jevric, G. Papic (Belgrade, Serbia)

P-0186 SURGERY OF DIFFERENTIATED THYROID CANCER IN CHILDREN AND ADOLESCENTS
R. Duda, I. Markovsz, I. Dzabic, M. Buta, M. Orui, M. Jerze, Z. Milovanovic (Belgrade, Serbia)

P-0187 RECURRENT LARYNGEAL NERVE DELIBERATION AND RECONSTRUCTION DURING THE REOPERATION DUE TO THYROID CANCER AND RECURRENT GOITER

DISCUSSED POSTERS (PD04) (see page 23)

Thyroid cancer - Basic

P-0188 DIFFERENCES IN THE EXPRESSION PROFILES OF NORMAL CONTRALATERAL TISSUES OF PAPILLARY THYROID CANCER PATIENTS EXPOSED TO THE CHERNOBYL FALLOUT
G. Doms, M. Taratula, B. Jaraz, J. Dumont, K. Unger, G. Thomas, N. Otsuki, M. Marchant (Brussels, Belgium)

P-0189 IN-VITRO STUDY OF TYROSINE KINASE INHIBITORS, HISTOKINASE DEACTIVATION INHIBITORS AND THEIR COMBINATION ON PRIMARY THYROID CANCER CELL LINES CHARACTERISED BY THEIR MUTATIONS
D. Chan, H. P. Kottke, L. -Y. Tsung, D. G. Braunstein (Singapore, Singapore)

P-0190 REARRANGED ANAPLASTIC LYMPHOMA KINASE (ALK) GENE FOUND FOR THE FIRST TIME IN ADULT-ONSET PAPILLARY THYROID CANCER CASES AMONG ATOMIC BOMB SURVIVORS
K. Habatama, M. Mokazi, H. Yoshih, K. Inakaichi, K. Nakachi, Y. Kusunoki (Hiroshima, Japan)

P-0191 PROTECTION AGAINST 131I-INDUCED DOUBLE STRAND DNA BREAKS IN THYROID CELLS
J. M. Herschman, A. Skym, S. Cannon, Y. Hoyer, Y. Rivnaya (Los Angeles, United States)

P-0192 MONOCLOAL ANTIBODIES TO THYROID STIMULATING HORMONE RECEPTOR WITH POULAR ACTIVITY AS THERAPY FOR DIFFERENTIATED THYROID CANCER (DTC): STUDIES IN PRECLINICAL MODELS OF DTC AND PRIMARY HUMAN THYROID CELLS

P-0193 ISOLATION AND CHARACTERIZATION OF CANCER THYROID SPHERES
F. Faiza, P. Giant, M. L. Nicolson, S. Lotta, R. Maasert, M. Mamou, R. Vigneri (Catania, Italy)

Thyroid cancer - Basic

P-0194 GENETIC VARIANTS OF THE THYROGLOBULIN GENE (TG) ARE ASSOCIATED WITH THYROID CANCER RISK
A. Aki, S. Pastor, W.-A. Garcia-Quiroz, I. Barrios, J. Castell, R. Martos, A. Valdivieso (Barcelona, Spain)
DUOX1 IS INDUCED IN HUMAN THYROID CELLS SUBJECTED TO KRYO-BLADDER AND IS RESPONSIBLE FOR THE BYSTANDER EFFECT

M. Schlumberger, C. Dupuy (Villejuif, France)

BRAFV600E ANALYSIS ON FINE NEEDLE ASPIRATION CASES

M. C. Zatelli

RECTIONAL GENOME-WIDE TRANSCRIPTIONAL FUNCTIONAL RELEVANCE OF PARTICULAR RESIDUES

P-0207 INFLUENCE OF DIFFERENTIAL PROTEIN EXPRESSION TO LYMPH NODE METASTASIS OF PAPILLARY THYROID CARCINOMAS HARBORING BRAF V600E MUTATION: PRELIMINARY RESULTS OF PROTEOMIC ANALYSIS


ANTIPROLIFERATIVE EFFECT OF 1,25-DIHYDOXYVITAMIN D3 ON ANAPLASTIC THYROID CANCER AS A SINGLE AGENT AND IN COMBINATION WITH PACLITAXEL AND SUBEROYLANILIDE HYDROXYACID

I. Cinkutsev, L. Verlinden, L. Overbeek, R. Rouillon, C. Mathieu, A. Veronckx, B. Decaluwe (Leuven, Belgium)

DIFFERENCE IN EFFICACY AND MODE OF ACTION OF MICRORNA AND MRNA EXPRESSION IN AUTONOMOUS THYROID CANCERS HARBORING BRAF V600E MUTATION: LYMPH NODE METASTASIS OF PAPILLARY THYROID CANCER AS A SINGLE AGENT AND IN COMBINATION WITH PACLITAXEL AND SUBEROYLANILIDE HYDROXYACID

A. C. Bianco (Miami, United States)

THE SCALE OF GENOME-WIDE TRANSCRIPTIONAL REGULATION EFFECTS IN HEALTHY HUMAN CELLS COMPARED OF CELL TYPE, DONOR BACKGROUND AND GENOTIC TREATMENT

P-0212 IN VITRO STUDIES OF RADIOTHERMOLOGICAL EFFECTS OF BORON NEUTRON CAPTURE THERAPY (BNT) ON DIFFERENTIATED THYROID CANCER

O. Pontiggia, M. Carpano, M. Pugliese, M. C. Zatelli, G. Trasforini, S. Leoni, M. Rossi, G. Boccuzzi (Torino, Italy)

THE LIGHT OF GENOME-WIDE TRANSCRIPTIONAL REGULATION EFFECTS IN HEALTHY HUMAN CELLS COMPARED OF CELL TYPE, DONOR BACKGROUND AND GENOTIC TREATMENT

N. Palestini, F. Mainini, N. Fortunati, G. Boccuzzi (Torino, Italy)

A CYTOTOXIC DRUG AND UNDECER OF IODINE PROTECTS THYROID CELLS FROM BRAF1799A MUTATION


INFLUENCE OF DIFFERENTIAL PROTEIN EXPRESSION TO LYMPH NODE METASTASIS OF PAPILLARY THYROID CARCINOMAS HARBORING BRAF V600E MUTATION: PRELIMINARY RESULTS OF PROTEOMIC ANALYSIS


ANTIPROLIFERATIVE EFFECT OF 1,25-DIHYDOXYVITAMIN D3 ON ANAPLASTIC THYROID CANCER AS A SINGLE AGENT AND IN COMBINATION WITH PACLITAXEL AND SUBEROYLANILIDE HYDROXYACID

I. Cinkutsev, L. Verlinden, L. Overbeek, R. Rouillon, C. Mathieu, A. Veronckx, B. Decaluwe (Leuven, Belgium)

DIFFERENCE IN EFFICACY AND MODE OF ACTION OF MICRORNA AND MRNA EXPRESSION IN AUTONOMOUS THYROID CANCERS HARBORING BRAF V600E MUTATION: LYMPH NODE METASTASIS OF PAPILLARY THYROID CANCER AS A SINGLE AGENT AND IN COMBINATION WITH PACLITAXEL AND SUBEROYLANILIDE HYDROXYACID

A. C. Bianco (Miami, United States)

THE SCALE OF GENOME-WIDE TRANSCRIPTIONAL REGULATION EFFECTS IN HEALTHY HUMAN CELLS COMPARED OF CELL TYPE, DONOR BACKGROUND AND GENOTIC TREATMENT

N. Palestini, F. Mainini, N. Fortunati, G. Boccuzzi (Torino, Italy)

A CYTOTOXIC DRUG AND UNDECER OF IODINE PROTECTS THYROID CELLS FROM BRAF1799A MUTATION


INFLUENCE OF DIFFERENTIAL PROTEIN EXPRESSION TO LYMPH NODE METASTASIS OF PAPILLARY THYROID CARCINOMAS HARBORING BRAF V600E MUTATION: PRELIMINARY RESULTS OF PROTEOMIC ANALYSIS

P-0221 ASSOCIATION OF OGG1, XRCC1, XRCC2 AND XRCC3 POLYMORPHISMS WITH DIFFERENTIATED THYROID CANCER: A CASE-CONTROL STUDY
W. A. García Quispes, A. Akdi, G. Pérez-Machado, S. Pastor, P. Galetu, J. Burián, J. Castell, A. Velázquez, R. Marcos (Barcelona, Spain)

P-0222 ABBERRANT EXPRESSION OF PYRUVATE KINASE M2 IS IMPORTANT FOR THYROID CANCER METABOLISM, GROWTH AND INVASION
H. Guan, W. Zhang, Y. Gao, Z. Shan, W. Tang (Shenyang, China)

P-0223 EXPRESSION OF THE MEMBERS OF TGF-β PATHWAY IN THYROID CANCER
M. Galulova, J. Garonec, J. Anamato, I. Makslova, I. Barchikov (Stara Zagora, Bulgaria)

P-0224 MOLECULAR SIGNATURES OF ANAPLASTIC Carcinomas
A. Holmström, G. Dom, G. Andry, C. Trésallet, B. Franc, E. Latière, C. Mambrault (Brussels, Belgium)

P-0225 ANCHOR IN THYROID CANCER CELLS
K. Jensen, A. Patel, J. Costelloe, A. Bauer, V. Vasko (Bethesda, United States)

P-0226 ADMS, TFF3 AND LGA3 ARE DISCRIMINATIVE MOLECULAR MARKERS IN FINE-NEEDLE ASPIRATION BIOPSY OF BENIGN AND MALIGNANT THYROID TUMOURS

P-0227 GENETIC ALTERATIONS OF FOS-LIKE ANTIGEN-2 IN PAPILLARY THYROID CARCINOMA
S. W. Kim, K. H. Kwon, J. H. Jung (Seoul, Republic of Korea)

P-0228 ENHANCED APOTOPSIS IN COMBINATION THERAPY OF DEMETHYLATING AGENT AND HDAC INHIBITOR IN THYROID CANCER CELL LINE
J. S. Kim, J. S. Bae, N. C. Park, Y. A. Kim, K. Y. Seung (Ulsan, Republic of Korea)

P-0229 TOTAL THYROIDECTOMY AND ESTABLISHMENT OF THYROID CANCER MODEL IN THE MOUSE
S.-K. Kim, H.-K. Shin, H. W. Kwon, T.-S. Kim (Goyang-si, South Korean)

P-0230 BRAF V600E MUTATION IS ASSOCIATED WITH TUMOR AGGRESSIVENESS IN PAPILLARY THYROID CANCER

P-0231 RELEVANCE OF SERUM CYTOKINES AND ADHESION MOLECULES IN THYROID CANCER

P-0232 DISSECTING MOLECULAR EVENTS IN THYROID NEOPLASIA PROVIDES EVIDENCE FOR DISTINCT EVOLUTION OF FOLLICULAR ADENOMA AND CARCINOMA

P-0233 EXTRACELLULAR MATRIX 1 (ECM1) EXPRESSION IN ANAPLASTIC THYROID CANCERS AND IDENTIFICATION OF ITS 5’ REGULATORY SEQUENCES – POTENTIAL IMPLICATIONS FOR THYROID CANCER MANAGEMENT?
G. Lal, P. Gomez Contreras, R. Askalden, R. J. Westph (Iowa City, United States)

P-0234 ENDONUCLEOL REGULATORS OF MITOCHONDRIAL BIogenesis IN TWO CELLULAR MODELS OF FOLLICULAR THYROID CARCINOMA
S. Le Pennec, D. Minhos-Ferri, N. Boutou-Bozamundo, C. Jacques, D. Guillotin, R. Houglatte, Y. Mithieux, F. Navarrot (Angers, France)

P-0235 HUMAN MELOD SUPPRESSOR CELLS ARE INDUCED BY MEDULLARY AND ANAPLASTIC THYROID CARCINOMA CELLS IN ASSOCIATION WITH COX2 OVER-EXPRESSION
M. G. Lechner, D. J. LaBette, A. L. Epstein (Los Angeles, United States)

P-0236 PTGS PROMOTES MITOGENIC MECHANISMS IN THYROID CELLS THROUGH AUTOCRINE PATHWAYS OF INTERACTION WITH GROWTH FACTORS
G. D. Lewy, G. Ryan, M. Read, V. Smith, J. Feng, A. Warfield, M. Egg, R. Swel, N. Sharmin, P. Kiran, K. Franklin, C. McClos, K. Baarst (Birmingham, United Kingdom)

DISCUSSED POSTERS (PD05) (see page 24)

Autoimmun

P-0237 DEFINING ASSOCIATION OF THE FCRL GENE REGION WITH GRAVES’ DISEASE
M. J. Summundo, O. J. Brand, P. R. Newby, J. A. Franklin, S. C. L. Gough (Oxford, United Kingdom)

P-0238 FIRST EVIDENCE OF A COMBINED CYTOTOXIC T-HYPOCRITIC- AND THYROPHOBID-SPECIFIC CELLULAR IMMUNE RESPONSE IN PATIENTS WITH HASHIMOTO’S THYROIDITIS
C. Papakonoulou, D. Foroulis, M. Elid, A. Theil, C. Bernecker, H. S. Willenberg, F. Schütte, M. Mansmann, T. Nguyen, W. A. Scherb, M. Schott (Dusseldorf, Germany)

P-0239 ENHANCED RESPONSE TO MOUSE THYROTROPIN (TSH) RECEPTOR IMMUNIZATION IN TSH RECEPTOR KNOCKOUT MICE
M. Nakahara, N. Mitakotake, H. Sakamoto, C. R. Chen, B. Rappeport, S. M. McLaughlin, Y. Noguska (Japan, Japan)

P-0240 ASSOCIATION OF FUNCTIONAL POLYMORPHISMS RELATED TO THE TRANSCRIPTIONAL LEVEL OF F03’ GENE WITH PROGNOSIS OF AUTOIMMUNE THYROID DISEASES
M. Watanabe, N. Ikusa, M. Motta, R. Tomizawa, T. Akaiwa, A. Takumi, Y. Hidaka, Y. Isayama (Nara, Japan)

P-0241 ANALYSIS AND TREATMENT OF SIX NOVEL GRAVES’ DISEASE CANDIDATE GENES

P-0242 T-CELL GENE EXPRESSION PATTERNS AFFECT QUANTITATIVE PHENOTYPIC CHARACTERISTICS OF HASHIMOTO’S THYROIDITIS
M. Stefani, S. Papic, L. Glavas-Borovac, I. Mihaljevi (Orahovica, Croatia)

Clinical thyroidology - Hyperthyroidism

P-0243 HYPERTHYROIDISM AND PREGNANCY: IT IS ADVISABLE TO GET TSH IN THE UPPER NORMAL LIMIT IN ALL PATIENTS TREATED WITH ANTITHYROID DRUGS?
G. N. Alzama, M. S. Alvachov, O. Levall, M. S. Stivel, M. P. Maritine, S. Vazquez, S. Gutierrez (Ciudad Autonoma de Buenos Aires, Argentina)

P-0244 GRAVES’ THYROTOXICOSIS-INDUCED TRANSIENT CARDIOIMPATI
N. Aljohani, S. ElKanee (Riyadh, Saudi Arabia)

P-0245 RADIOACTIVE IODINE FOR GRAVES’ DISEASE: 120 CASES
N. Ben Abdallah (Tunis, Tunisia)

P-0246 A CONTINUOUS BLOCK-REPLACEMENT REGIMEN BETWEEN RADIODINE THERAPY OF HYPERTHYROIDISM: A RANDOMIZED TRIAL SHOWING DISTINCT SIMILARITIES BETWEEN GRAVES’ DISEASE AND TOXIC NODULAR GOITERS
S. J. Bonnema, G. G. Pou, T. Askeland, R. M. Weigel (Iowa City, United States)

P-0247 ASSESSMENT OF CLINICAL AND LABORATORY LIMITS BETWEEN HASHIMOTO’S DISEASE
M. F. Borges, J. D. Reis, B. F. Ferreira, M. A. Lima (Uberaba, Brazil)
A CASE REPORT: HYPERCALCEMIA DUE TO GRAVES’ DISEASE

INTRODUCTION
Hypercalcaemia due to Graves’ disease is an uncommon complication of the disease. The presentation of hypercalcaemia can be variable, ranging from asymptomatic to life-threatening. We report a case of hypercalcaemia in a patient with Graves’ disease who was managed successfully with medical therapy.

CASE REPORT
A 67-year-old woman presented to our endocrinology clinic with a 6-month history of fatigue, weight loss, and dyspnea. She had a history of hyperthyroidism treated with antithyroid medications for the past year. On physical examination, she was afebrile, with a blood pressure of 120/80 mm Hg, a heart rate of 100 beats per minute, and a respiratory rate of 16 breaths per minute. Her height was 160 cm, and her weight was 50 kg. She had a goiter and was noted to have exophthalmos.

LAB RESULTS
On biochemical testing, her serum calcium was 12.5 mg/dL (normal range: 8.8-10.2 mg/dL), and her thyroid function tests showed elevated triiodothyronine (T3) and thyroxine (T4) levels with suppressed thyroid-stimulating hormone (TSH). Her vitamin D level was normal. Other laboratory investigations, including renal, hepatic, and bone function tests, were within normal limits.

MANAGEMENT
The patient was treated with beta-blockers and antithyroid medications to control her hyperthyroidism. A bone density scan was performed, which showed a T-score of -3.5 at the lumbar spine, indicating severe osteoporosis. The patient was prescribed teriparatide and alendronate, and calcium supplements were added to her routine therapy.

DISCUSSION
Hypercalcaemia due to Graves’ disease occurs in approximately 1-2% of patients. It can be treated effectively with medical therapy, but in severe cases, total thyroidectomy may be required. Early recognition and prompt treatment are essential to prevent complications such as cardiac arrhythmias, nephrocalcinosis, and psychiatric disturbances.

CONCLUSION
In conclusion, hypercalcaemia due to Graves’ disease is a rare but treatable complication. Early recognition and appropriate management can prevent serious sequelae.

REFERENCES

M. Cesur
Department of Endocrinology and Metabolism, Hacettepe University Hospital, Ankara, Turkey
4-posters_posters 01/09/10 17:09 Page88

THE EFFECT OF VARIANTS IN THE IODOTHYRONINE DISTURBED EXPRESSION OF TYPE 2 AND TYPE 3 SPECIFIC DEIODINATION OF THE T3 METABOLITE TRIAC SPECIFIC DEIODINATION

THE EFFECT OF SUNITINIB ON GROWTH AND PROLIFERATION OF NORMAL-RAT THYROID CELL LINE, HUT-4

INTERFERON-ALPHA-INDUCED THYROID DISEASES IN CHRONIC HEPATITIS C PATIENTS

THYROID FUNCTION AND SUNITINIB TREATMENT

THYROID FUNCTION DURING INTERFERON ALPHA TREATMENT, IN HEPATITIS C PATIENTS AND CO INFECTED WITH HIV

CARDIAC UPTAKE AND METABOLISM OF 3-IODOTHYRONAMINE

RAPID ACTION OF THYROID HORMONE AND THE EXPRESSION OF IODOTHYRONINE DEIODINASE IN ENDOThelial CELLS

THYROID HORMONE DEPENDENT DEREGULATION OF SPlicing FACTORS AND ALTERNATIVE SPLICING OF TYPE 1 IODOTHYRONINE DEIODINASE IN RENAL CANCER

SPECIFIC DEIODINATION OF THE TS METABOLITE TRIC By A NON-SELENODEIODINASE FROM AMPHIOXUS; BY A NON-SELENODEIODINASE FROM AMPHIOXUS; BY A NON-SELENODEIODINASE FROM AMPHIOXUS; BY A NON-SELENODEIODINASE FROM AMPHIOXUS; BY A NON-SELENODEIODINASE FROM AMPHIOXUS; BY A NON-SELENODEIODINASE FROM AMPHIOXUS; BY A NON-SELENODEIODINASE FROM AMPHIOXUS; BY A NON-SELENODEIODINASE FROM AMPHIOXUS; BY A NON-SELENODEIODINASE FROM AMPHIOXUS; BY A NON-SELENODEIODINASE FROM AMPHIOXUS; BY A NON-SELENODEIODINASE FROM AMPHIOXUS;
Clinical thyroidology - Nodules

DISCUSSED POSTERS (PD07) (see page 35)

Clinical thyroidology - Nodules

P-0314 ELASTIC SCATTERING SPECTROSCOPY (ESS) CAN BETTER DISCRIMINATE BENIGN FROM MALIGNANT THYROID LESIONS THAN CYTOLGY IN PATIENTS WITH INDETERMINATE THYROID NODULES

J. E. Roson, H. Sud, S. Kim, S. Ohri, O. A’amar, I. Bigio, S. Lux (Boston, United States)

P-0315 DIAGNOSIS OF THYROID CANCER BY QUANTITATIVE SONOGRAPHIC CALCIFICATION INDEX

K. Y. Chen, W. Xue, L. Qian, W. H. Hu, H. C. Tai, A. Chen, W.-C. Huang, K.-J. Chang (Taipei, Taiwan, China)

P-0316 CHRONIC THYROID SUPPRESSION DOES NOT INFLUENCE THE RATE OF BENIGN, INDETERMINATE AND MALIGNANT BIOPSY (FNAB) OF THYROID NODULES AFFECT THE PATIENTS HAVE NON-BENIGN THYROID NODULES WHO REFER TO TEHRAN’S HOSPITAL FROM 2001 UNTIL 2008

H. S. Heidari

P-0317 EFFECTS OF SENSITIVE ON SPONTANEOUS AUTOMMUNE THYROIDITIS IN NONHDH2-MICE

W. Wang, X. Xie, Z. Sha, W. Teng (Shenyang, China)

P-0318 EFFECTS OF ZINC LEVEL ALTERATIONS IN ADOLESCENTS AND THYROID DISEASE

S. Takahashi, R. Krassakhalin, N. Bojotgadhavil (Thiblis, Georgia)

P-0319 SCORING OF THYROID NODULES?

S. Mariotti (Cagliari, Italy)

P-0320 CLINICAL USEFULNESS OF CONTRAST-ENHANCED ULTRASOUND AND ELASTOGRAPHY FOR THE DIAGNOSIS OF THYROID TUMORS ASSOCIATED WITH RECURRENT THYROID CANCER


P-0321 IMPORTANCE OF NODULE LOCALIZATION IN ELASTOGRAPHIC EVALUATION OF THYROID NODULES


P-0322 WHICH AXIOMS SHOULD BE PERFORMED FOR ELASTOGRAPHIC SCORING IN THYROID NODULE?


P-0323 ELASTOGRAPHIC EVALUATION OF THYROID NODULES – THYROID PEI AND RFA-

D. S. Ozdemir, D. Tuzun, A. Oguz, G. Guler (Ankara, Turkey)

P-0324 Califorin and RFA APPLIED IN CYTOLGY ASPECTS OF THYROIDITIS

P-0325 ELASTOGRAPHIC EVALUATION OF THYROID NODULES – THYROID PEI AND RFA-

D. S. Ozdemir, D. Tuzun, A. Oguz, G. Guler (Ankara, Turkey)
Clinical thyroidology - Nodules

P-0347 MANAGEMENT OF THYROID NODULES ABOUT 180 TUNISIAN PATIENTS
I. Khiatni, A. Baha, S. Hadj Mitt, R. Salem, H. Hakimi, H. Marmouch, M. Golid, S. Mahjoub (Mostar, Tunisia)

P-0348 CLINICAL APPLICATION OF THREE-DIMENSIONAL CONTRAST ULTRASONOGRAPHY IN THYROID GLAND
M. Kimata, N. Nakashima, Y. Kijima, H. Yoshinaka, S. Natsugoe (Kagoshima, Japan)

P-0350 TOTAL VERSUS SUB-TOTAL THYROIDECTOMY IN THE TREATMENT OF NON-MALIGNANT THYROID DISEASES
T. Y. Koraitim (Alexandria, Egypt)

P-0352 TOTAL THYROIDECTOMY: IS IDENTIFICATION OF RECURRENT LARYNGEAL NERVE MANDATORY?
T. Y. Koraitim (Alexandria, Egypt)

P-0355 IS THE SUPPRESSION THERAPY OF THE THYROID NODULES JUSTIFIED?
A. Knif, L. E. Boumezzine, T. Boukhatem, M. B. Khaled (Sidi Bel-Abbes, Algeria)

P-0356 THYROID NODULES: ULTRASOUND FEATURES, FINE NEEDLE ASPIRATION CYTOLOGY (FNAC) AND FINAL PATHOLOGY: A RETROSPECTIVE AND CORRELATIVE STUDY IN A HOSPITAL TERTIARY HOSPITAL
S. Y. Kua, R. Dabbabi, A. Baba, N. Bhouri, I. Khochtali, S. Mahjoub (Mostar, Tunisia)

P-0357 FACTORS AFFECTING INADEQUATE SAMPLING OF ULTRASOUND FEATURES: OUTCOMES AFTER FINE NEEDLE ASPIRATION CYTOLOGY (FNAC) AND FINAL PATHOLOGY.
S. Y. Kua, R. Dabbabi, A. Baba, N. Bhouri, I. Khochtali, S. Mahjoub (Mostar, Tunisia)

P-0359 RECURRENCE AFTER TOTAL THYROIDECTOMY: IS IDENTIFICATION OF RECURRENT LARYNGEAL NERVE MANDATORY?
T. Y. Koraitim (Alexandria, Egypt)

P-0364 CAN VASCULARITY ON POWER DOPPLER ULTRASOUND PREDICT THYROID MALIGNANCY?
H. J. Moon, Y. K. Koak, E. K. Kim (Seoul, Republic of Korea)

P-0367 INCLUSION OF ULTRASOUND FEATURES IN THE EVALUATION AND FOLLOW-UP OF THYROID NODULES: ADVANTAGES AND LIMITATIONS
A. M. Orlando, A. C. Pinas, C. G. Frascaroli, H. L. Flahaut (Buenos Aires, Argentina)

P-0370 CHANGES IN THE THYROID NODULES, RESULTS OF A THREE YEAR FOLLOW-UP OF THE MARSHALL ISLANDS RESIDENTS

P-0371 INCLUSION OF ULTRASOUND FEATURES IN THE EVALUATION AND FOLLOW-UP OF THYROID NODULES: ADVANTAGES AND LIMITATIONS
A. M. Orlando, A. G. Pons, C. G. Frascaroli, H. L. Flahaut (Buenos Aires, Argentina)

P-0372 THYROIDECTOMY USING THE THERMAL WELDING SYSTEM: INITIAL FINDINGS
Z. T. Olszewski, C. Palat, H. Uyar, Y. Arikain (Antalyakasimpasa, Turkey)
DISCUSSED POSTERS (P068) (see page 35)

Graves’ orbitopathy

P-0396 SOCIAL VARIATIONS IN IMMEDIATE EARLY GENES
P-0395 ASSOCIATION OF TRAIL GENE POLYMORPHISM WITH
P-0394 CLINICAL VALUE OF SONOGRAPHIC CALCIFICATION
P-0393 PATTERN OF EXPERIENCE IN CHILDREN WITH GRAVES’
P-0392 RETROSPECTIVE ANALYSIS OF 728 CASES OF THYROID
P-0391 THE RETROSPECTIVE ANALYSIS OF PATIENTS AFTER
P-0390 ASSOCIATION OF TGF-β1 GENE +869T/C POLYMORPHISM
P-0389 HYALINIZING TRABECULAR TUMOR OF THE THYROID:
P-0388 STUDY OF REAL TIME TISSUE ELASTOGRAPHY (RTE) IN
P-0387 CLINICAL AND IMAGING FEATURES OF PANCREATIC
P-0386 DIAGNOSIS OF PATIENTS WITH GRAVES’ OPTHALMOPATHY
P-0385 GENETIC VARIATIONS IN IMMEDIATE EARLY GENES
P-0384 DESCRIPTIVE STATISTICS FOR THYROIDECTOMY OF CHILDREN WITH GRAVES’ DISEASE AND OPTHALMOPATHY
P-0383 THE RETROSPECTIVE ANALYSIS OF PATIENTS AFTER THYROID NODULAR OPERATION IN CHINA
P-0382 CLINICAL VALUE OF SONOGRAPHIC CALCIFICATION PATTERNS IN THYROID NODULES
P-0381 MINIMALLY INVASIVE APPROACH TO THE TREATMENT OF HYPERTHYROIDISM AND THYROID DISORDERS
P-0380 ACCIDENTAL EXPOSURE TO RADIATION IN FINE NEEDLE ASPIRATION OF THYROID NODULES: A LEARNING CURVE
P-0379 EVALUATION OF USEFULNESS OF VIDEO-ASSISTED MINIMALLY INVASIVE APPROACH TO THE TREATMENT OF THYROID NODULES
P-0378 WHAT IS THE IMPACT OF NEW ULTRASONOGRAPHY ON THE IDENTIFICATION OF THYROID NODULES? A LEARNING CURVE
P-0377 REAL-TIME QUANTITATIVE ULTRASOUND DOPPLER FLOW FOR DIFFERENTIAL DIAGNOSIS OF BENIGN AND MALIGNANT THYROID NODULES
P-0376 DETECTION OF HOOK EFFECT IN THE MEASUREMENT OF THYROGLOBULIN IN FINE NEEDLE ASPIRATES IN BENIGN NODULES AND NORMAL THYROID
P-0375 INTERFERENCE FROM A NEW ULTRASOUND DETECTION OF HOOK EFFECT IN THE MEASUREMENT OF THYROGLOBULIN IN FINE NEEDLE ASPIRATES IN BENIGN NODULES AND NORMAL THYROID
P-0374 SIMULTANEOUS STUDY OF IMMUNE AND PROTEOMIC CHARACTERISTICS OF FINE-NEEDLE ASPIRATES
P-0373 CLINICAL UTILTY OF A MULTIDISCIPLINARY THYROID PATHOLOGY CONFERENCE IN AN ACADEMIC INSTITUTION: A FOURTEEN YEAR PROSPECTIVE STUDY
P-0372 LONG-TERM FOLLOW-UP OF CHILDREN WITH GRAVES’ DISEASE AND OPHTALMOPATHY: ASSOCIATION WITH GENETIC FACTORS
P-0371 THE ASSOCIATION OF TRAIL, BAX AND BCL-2 GENES WITH THE RISK OF DEVELOPING GRAVES’ ORBITOPATHY IN CHILDREN
P-0370 GENETIC VARIATIONS IN IMMEDIATE EARLY GENES WITH HIGH EXPRESSION IN GRAVES’ OPHTALMOPATHY: ASSOCIATED WITH GRAVES’ DISEASE AND OPHTALMOPATHY
P-0369 TH1 (CXCL10) AND TH2 (CCL2) CHEMOKINES ARE ASSOCIATED WITH GRAVES’ DISEASE AND OPHTALMOPATHY ARE ASSOCIATED WITH GRAVES’ DISEASE AND OPHTALMOPATHY
P-0368 SURFACE LANCE AND INTERVENTION FOLLOWING THYROID LORECTOMY
P-0367 CORRELATION BETWEEN SONOGRAPHIC FEATURES PREDICTIVE OF MALEKANZY AND FNAB CYTOLOGY RESULTS OF THYROID NODULES
P-0366 ECHOCARDIOGRAM OF DIAGNOSIS OF THYROID CANCER
P-0365 L. R. Middleton
P-0364 DISCRIPTIVE STATISTICS FOR HEMITHYROIDECTOMY IN THE UNITED STATES OF AMERICA BASED ON THE UHC DISCHARGE DATABASE
P-0363 DESCRIPTIVE STATISTICS FOR HEMITHYROIDECTOMY IN THE UNITED STATES OF AMERICA BASED ON THE UHC DISCHARGE DATABASE
P-0362 D. Covelli
P-0361 MANDINLIAIN-INS UP TO THE TREATMENT OF HYPERTHYROIDISM AND THYROID DISORDERS
P-0360 WHAT IS THE IMPACT OF NEW ULTRASONOGRAPHY ON THE IDENTIFICATION OF THYROID NODULES? A LEARNING CURVE
P-0359 ASSOCIATION OF TRAIL GENE POLYMORPHISM WITH THYROID NODULE DISEASE IN BAOXTOU
P-0358 EVALUATION OF USEFULNESS OF VIDEO-ASSISTED MINIMALLY INVASIVE APPROACH TO THE TREATMENT OF THYROID NODULES
P-0357 REAL-TIME QUANTITATIVE ULTRASOUND DOPPLER FLOW FOR DIFFERENTIAL DIAGNOSIS OF BENIGN NODULES AND NORMAL THYROID
P-0356 DETECTION OF HOOK EFFECT IN THE MEASUREMENT OF THYROGLOBULIN IN FINE NEEDLE ASPIRATES IN BENIGN NODULES AND NORMAL THYROID
P-0355 SIMULTANEOUS STUDY OF IMMUNE AND PROTEOMIC CHARACTERISTICS OF FINE-NEEDLE ASPIRATES
P-0354 CLINICAL UTILTY OF A MULTIDISCIPLINARY THYROID PATHOLOGY CONFERENCE IN AN ACADEMIC INSTITUTION: A FOURTEEN YEAR PROSPECTIVE STUDY
P-0353 GENETIC VARIATIONS IN IMMEDIATE EARLY GENES WITH HIGH EXPRESSION IN GRAVES’ OPHTALMOPATHY: ASSOCIATED WITH GRAVES’ DISEASE AND OPHTALMOPATHY
P-0352 RETROSPECTIVE ANALYSIS OF 728 CASES OF THYROID NODULES
P-0351 ASSOCIATION OF TGF-β1 GENE +869T/C POLYMORPHISM WITH THYROID NODULE DISEASE IN BAOXTOU
P-0350 WHAT IS THE IMPACT OF NEW ULTRASONOGRAPHY ON THE IDENTIFICATION OF THYROID NODULES? A LEARNING CURVE
P-0349 GENETIC VARIATIONS IN IMMEDIATE EARLY GENES WITH HIGH EXPRESSION IN GRAVES’ OPHTALMOPATHY: ASSOCIATED WITH GRAVES’ DISEASE AND OPHTALMOPATHY
P-0348 MANDINLIAIN-INS UP TO THE TREATMENT OF HYPERTHYROIDISM AND THYROID DISORDERS
P-0347 DIAGNOSTIC ACCURACY OF FINE-NEEDLE ASPIRATION VERSUS CORE-NEEDLE BIOPSY IN THYROID NODULES
P-0346 OFFICE BASED ULTRASOUND GUIDED FINE NEEDLE ASPIRATION (FNA) OF THYROID NODULES
P-0345 LONG-TERM FOLLOW-UP OF CHILDREN WITH GRAVES’ DISEASE: TREATMENT OUTCOME AND RISK OF GRAVES’ ORBITOPATHY
P-0344 DESCRIPTIVE STATISTICS FOR THYROID SURGERY FOR BENIGN THYROID DISORDER IN THE UNITED STATES OF AMERICA BASED ON THE UHC DISCHARGE DATABASE
P-0343 THE RETROSPECTIVE ANALYSIS OF PATIENTS AFTER THYROID NODULAR OPERATION IN CHINA
P-0342 MACROPHAGE-INDUCED PHAGOCYTOSIS AS A POSSIBLE MECHANISM OF ACTION OF RITUXIMAB (RTX) IN GRAVES’ ORBITOPATHY (GO)
P-0341 CLINICAL USEFULNESS OF RETINAL BLOOD FLOW MEASUREMENT IN THE ASSESSMENT OF GRAVES’ OPHTALMOPATHY ACTIVITY
P-0340 ACCIDENTAL EXPOSURE TO RADIATION IN FINE NEEDLE ASPIRATION OF THYROID NODULES: A LEARNING CURVE
P-0339 THE ASSOCIATION OF TRAIL, BAX AND BCL-2 GENES WITH THE RISK OF DEVELOPING GRAVES’ ORBITOPATHY IN CHILDREN
P-0338 STUDY OF REAL TIME TISSUE ELASTOGRAPHY (RTE) IN PATIENTS WITH THYROID AND PARATHYROID DISEASE – A NEW ATTEMPT TO ESTABLISH QUANTITATIVE AND QUALITATIVE METHODS
P-0337 INTERFERENCE FROM A NEW ULTRASOUND CONDUCTING GEL LEADS TO ARTIFACT AND AFFECTS BOTH INTERPRETATION AND DIAGNOSIS: ACCURACY IN FINE NEEDLE ASPIRATION
P-0336 DIAGNOSTIC ACCURACY OF FINE-NEEDLE ASPIRATION OFFICE BASED ULTRASOUND GUIDED FINE NEEDLE
14th INTERNATIONAL THYROID CONGRESS • Paris, Palais des congrès • 11-16 September 2010

Graves' orbitopathy

P-0404 HOW LONG COULD THE DELAY BETWEEN A RTU THYROID GRAVES' OPHTHALMOPATHY AND THE VENTUAL DEVELOPMENT OF OVER HYPERTHYROIDISM? D. Bellabarba (Sherbrooke, Canada)

P-0405 PROSALA PPAR - GENE POLYMORPHISMS IS ASSOCIATED WITH GRAVES' OPHTHALMOPATHY J. Dresnowe, India

P-0406 THYROID ULTRASONOGRAPHIC EVALUATION IN PATIENTS WITH GRAVES' OPHTHALMOPATHY I. Dia Panapits Fedorovskiy, M. Berche, M. Tzarzur, F. Mann, E. Héron, L. Leenhardt (Paris, France)

P-0407 ORBITAL LYMPHOMA IN GRAVES' OPHTHALMOPATHY - A CASE REPORT Z. Hajdukowska, D. Bahna (Belgrade, Serbia)


P-0410 INTRAORBITAL DEDONASIS TYPE 2 IS DOWNREGULATED IN CHRONIC PHASE OF OPHTHALMOPATHY T. Planck, R. Dzodic, I. Komerdus, I. Chikh, T. Mamedova, G. Stashuk (Moscow, Russian Federation)

P-0411 EVALUATION OF EXTRA OCULAR MUSCLES/TOTAL ORBIT AREA RATIO BY A SIMPLE MANUAL COMPUTER AIDED HISTOCALC (CAD) TECHNIQUE R. Le Moli, A. Pluchino, V. Maseria, A. Latomu, C. Regalbuto, A. Latina, Italy

P-0412 EVALUATION AND COMPARISON OF THE EFFECTS OF PENTOXIFYLLINE, NICOTINAMIDE/ALLOPURINOL AND METHYL PREDNISOLONE IN THE PROPTOSIS, PENTOXIFYLLINE, NICOTINAMIDE/ALLOPURINOL AND PREDICTION OF THERAPEUTIC EFFECT OF ORBITAL RADIOTHERAPY J. Shon, V. Fan, Y. Ge, J. Li, S. Liu, Y. Xue, C. Xie (Guangzhou, China)

P-0413 EVALUATION OF B-MODE, POWER DOPPLER US AND US-ELASTOGRAPHY FEATURES IN DIFFERENTIAL DIAGNOSIS OF MALIGNANT THYROID NODULES: COMPARISON WITH CYTOLOGICAL AND HISTOPATHOLOGICAL DIAGNOSIS IN A PROSPECTIVE STUDY M. F. Erdoğan, Ö. Demir, S. Güllü, N. Başkal, Turkey

P-0414 EVOLVING ROLE OF FDG-PET/CT IN THE PRE-SURGICAL CHARACTERIZATION OF THYROID TUMORS WITH INDETERMINATE CYTOLOGY D. L. Schwartz, J. A. Bankson (Houston, United States)

P-0415 DISCUSSION POSTERS (PD09) (see page 36)

Thyroid cancer - Clinical II

P-0417 TRIPTIDOLINE INHIBITS CYTOKINE-INDUCED ACTIVATION OF RETRO-OCULAR FIBROBLASTS FROM PATIENTS WITH GRAVES' OPHTHALMOPATHY Y. Shu-Xun, W. Ying, P. Guiran, L. Xin-ping Lu (Zhengzhou city, China)

P-0418 THE IMPACT OF HYPOTHYROIDISM ON GRAVES' OPHTHALMOPATHY OUTCOME POST RADIOTHERAPY: A RETROSPECTIVE COHORT M. Stein, I. Barson, P. Thurs, R. Bahar (Bournemouth, United States)

P-0419 A PROSPECTIVE STUDY ON THE EFFECTS OF RADIOTHERAPY TREATMENTS ON HYPERPLASIA IN PATIENTS WITH GRAVES' OPHTHALMOPATHY (GO) N. Y. Szendrono, M. Shernoson, V. Lalikavazova, I. Belova (Moscow, Russian Federation)

P-0420 PREDICTION OF THERAPEUTIC EFFECT OF ORBITAL RADIOACTIVITY ON THYROID ASSOCIATED OPHTALMOPATHY: OUTCOME POST RADIOACTIVE IODINE THERAPY (RIT) FOR HYPERTHYROIDISM Y. Shu-Xun, W. Ying, P. Guiran, L. Xin-ping Lu (Zhengzhou city, China)

P-0421 THYROID ASSOCIATED OPHTHALMOPATHY OUTCOME POST RADIOACTIVE IODINE THERAPY - A RETROSPECTIVE COHORT STUDY I. Bancos, J. Durski, P. Thapa, R. Bahn (Rochester, United States)

P-0422 DEPOT SPECIFIC DIFFERENCES BETWEEN ORBITAL AND SUBCUTANEOUS PREADIPOCYTES CONTRIBUTE TO THE PATHOGENESIS OF GRAVES' OPHTALMOPATHY L. Zhang, F. Genneman-Jones, C. Lane, D. A. Rees, M. Ludgate (Cardiff, United Kingdom)

P-0423 PROCLINICAL ASSESSMENT OF THERAPEUTIC AGENTS FOR THYROID CANCER USING DYNAMIC CONTRAST- ENHANCED MAGNETIC RESONANCE IMAGING (DCE-MRI) S. Y. Lai, Y. Chen, M. Gule, R. Lemos, J. N. Myers, D. L. Schwartz, J. A. Bankson (Houston, United States)

P-0424 RISK FACTORS OF DIFFERENTIATED THYROID CANCER OCCURRING IN YOUNG PATIENTS AGED FROM 5 TO 35 YEARS LIVING IN THE RHÔNE ALPES REGION OF FRANCE: PRELIMINARY RESULTS OF A POPULATION- BASED CASE-CONTROL STUDY OF THYROID DISEASE HISTORY, AND ANTHROPOMETRY G. M. Saslawska, M. Colonna, Z. Haddad-Nerjiti, P. Chauvel, G. B. Dall'Antonia, K. E. Russell (Lyon, France)

P-0425 PROSPECTIVE ANALYSIS OF B-MODE, POWER Doppler Uppermg Of Us And Us-Elastography Features In Differential Diagnosis Of Malignant Thyroid Nodules: Comparison With CytoLOGical And HistopAtHological Diagnosis In A Prospective Study M. F. Erdoğan, Ö. Demir, S. Güllü, N. Başkal (Ankara, Turkey)

P-0426 ROLE OF FDG-PET/CT IN THE PRE-SURGICAL CHARACTERIZATION OF THYROID TUMORS WITH INDETERMINATE CYTOLOGY D. L. Schwartz, J. A. Bankson (Houston, United States)

P-0427 DISCUSSION POSTERS (PD09) (see page 36)

Thyroid cancer - Clinical II

P-0428 ROLE OF FDG-PET/CT IN THE PRE-SURGICAL CHARACTERIZATION OF THYROID TUMORS WITH INDETERMINATE CYTOLOGY D. L. Schwartz, J. A. Bankson (Houston, United States)

P-0429 VIDEO PRESENTATION OF SURGICAL TECHNIQUE OF SENTINEL LYMPH NODE BIOPSY IN DIFFERENTIATED THYROID CARCINOMA USING METHYLEN BLUE DYE R. Dushal, I. Markevits, I. Djuric, M. Buta, M. Ivic (Belgrade, Serbia)
P-0430 CLINICOPATHOLOGICAL FEATURES AND PROGNOSIS OF PATIENTS WITH FOLLICULAR THYROID CARCINOMA IN CHILDREN
Y. Emran, S. Udono, K. Emranoto, S. Watanabe, H. Shihara, M. Yoshida, H. Nozuchi, Y. Nagoshi, S. Naguchi (Beppe, Japan)

P-0431 TREATMENT AND LONG-TERM OUTCOME IN PATIENTS WITH LARYNGOTRACHEAL INVASION DIFFERENTIATED THYROID CANCER

P-0432 CCXCL2 EXPRESSION IN PAPILLARY THYROID CARCINOMA: A POTENTIAL ROLE IN THE METASTASIS PROCESS
M. R. Evangelinellis, R. Delolio, J. M. Corvelli (Sao Paulo, Brazil)

P-0433 CELL CYCLE MEASURERS IN ANAPLASTIC THYROID CANCER
J. Evans, H. Cram, S. Durrah, B. Bruggeman, P. McLaughlin, D. Goldenberg (Hershey, United States)

P-0434 SUPPORTING TREATMENT DECISIONS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER (DTC) UNDER RADIODOSE-311 THERAPY: ROLE OF BIOLOGICAL DOSIMETRY ASSESSMENT

P-0435 INTERNATIONAL THYROID CANCER PATIENT SURVEY
K. Farneth, B. Barten, J. Shyu, G. Bloom, H. Rimmulle, R. Barath, S. Lefli (Rowlands Gill, United Kingdom)

P-0436 THE CLINICAL SIGNIFICANCE OF A DE NOVO APPEARANCE OF T3bN IN A PREVIOUSLY T3bLb-NEGATIVE PATIENT DURING POST-OPERATIVE MONITORING FOR DIFFERENTIATED THYROID CANCER (DTC)
J. Farhat, I. Pottuce, J. LoPresti, C. Spencer (Panorama City, United States)

P-0437 SERUM THYROGLOBULIN AS PREDICTION TOOL IN THE CLINICAL SIGNIFICANCE OF A DE NOVO APPEARANCE OF T3bN IN A PREVIOUSLY T3bLb-NEGATIVE PATIENT DURING POST-OPERATIVE MONITORING FOR DIFFERENTIATED THYROID CANCER (DTC)
E. N. Faure, K. Farneth, P. McLaughlin, D. Goldenberg, J. Evans, R. Wernert, J. Flament, C. Schvartz (Reims, France)

P-0438 PREDICTIVE FACTORS OF RECURRENCES AND PERSISTENCE/RECURRENCE RATE TO THYROID CANCER AFTER ABLATION IS AS EFFECTIVE AND HAS A SIMILAR INFLUENCE OF THE DECISION TO PERFORM IN HYPOTHYROID STATE IN PATIENTS WITH DIFFERENTIATED THYROID CANCER: A POTENTIAL ROLE IN THE METASTASIS PROCESS
A. Heilo, C. Saif, J. Puchot, E. Brabencova, M. Patey, D. Kere (Buenos Aires, Argentina)

P-0439 LIPOPENIC ACID IN COMPLEX TREATMENT OF DYSPHONIA INOCULATION AS TREATMENT STRATEGIES IN PAPILLARY THYROID CANCER (PTC) METASTASIS
J. J. Gorgojo, S. Donay, F. Almodovar, E. Lopez, H. Requejo, P. Pinado (Alcorcon, Spain)

P-0440 CASE REPORT: THYROID LYMPHOMA… A DIAGNOSTIC DILEMMA
M. R. Finozzi, P. D. Orellano (Montevideo, Uruguay)

P-0441 IS THE DIFFERENCE IN THYROID CANCER INCIDENCE BETWEEN THE BELGIAN REGIONS ASSOCIATED WITH VARIATIONS IN SURGICAL PRACTICE?
J. Francart, R. G. van den Bruel, A. Cuif-Job, J. Pochart, E. Brabencova, M. Patey, D. Kere (Reims, France)

P-0442 COMPARISON OF THE RESULTS OF THYROID NODULES CYTOLGICAL AND HISTOLOGICAL INVESTIGATION
A. F. Rashkovich, S. V. Zaitseva, A. V. Gantarskiy (Saint Petersburg, Russian Federation)

P-0443 COMPARISON OF THE RESULTS OF THYROID NODULES CYTOLGICAL AND HISTOLOGICAL INVESTIGATION
E. G. Gasparyan (Saint Petersburg, Russian Federation)

P-0444 COMPARISON OF THE RESULTS OF THYROID NODULES CYTOLGICAL AND HISTOLOGICAL INVESTIGATION
A. F. Rashkovich, S. V. Zaitseva, A. V. Gantarskiy (Saint Petersburg, Russian Federation)

P-0445 COMPARISON OF THE RESULTS OF THYROID NODULES CYTOLGICAL AND HISTOLOGICAL INVESTIGATION
E. G. Gasparyan (Saint Petersburg, Russian Federation)

P-0446 SUCCESSFUL RADIOIODINE ABLATION OF BONE METASTASES FROM THYROID FOLLICULAR CARCINOMAS
I. Geran, N. Ravivancheli, A. Geran, R. Miftari, B. Geran (Tirana, Albania)

P-0447 ELEVATED STIMULATED THYROGLOBULIN LEVELS AND A POSITIVE RADIO-IMMUNOELECTROPHORETIC SCAN CAUSED BY THYMIC HYPERPLASIA IN A PATIENT WITH A HISTORY OF THYROID CARCINOMA – A CASE STUDY
R. A. Goranova, E. Mallick (Newcastle upon Tyne, United Kingdom)

P-0448 COMPARISON OF HEBICAL THYROTROPIN PLAN WITH CONVENTIONAL THYROID GLUTAMINE THYREORADIOGRAPHY PLAN IN A PATIENT WITH KNOWN PAPILLARY THYROID CANCER AND RECURRENT DISEASE FOLLOWING COMPLETION THYROIDECTOMY: A CASE STUDY
R. A. Goranova, N. Willins, J. Mott, E. Mallick (Newcastle upon Tyne, United Kingdom)

P-0449 FIRST REPORT OF ESTABLISHMENT OF EFFECTIVENESS OF A- LIPOPENIC ACID IN COMPLEX TREATMENT OF DYSPHONIA AFTER THYROID OPERATION
M. Gamboshka, O. Larea, O. Palamarchuk (Kiev, Ukraine)

P-0450 IMMUNOBLOK AND PERCUTANEOUS ETHANOL INJECTION AS TREATMENT STRATEGIES IN PAPILLARY THYROID CANCER (PTC) METASTASIS

P-0451 WILL THE REVISED ATA 2009 MANAGEMENT GUIDELINES ON THYROID NODULES AND DIFFERENTIATED THYROID CANCER (DTC) CHANGE THE EXTENT OF SURGERY AND BENEFIT THE SHORT TERM OUTCOME OF DTC PATIENTS IN A TOTAL THYROIDECTOMY SETTING?

P-0452 A HIGHLY ADVANCED METASTATIC TALL CELL PAPILLARY THYROID CARCINOMA: THE ROLE OF SURGERY AND A MULTIDISCIPLINARY WORK TEAM. A CASE REPORT
J. L. Guerra, A. Cavalli, D. Cragnolino, C. Silva, F Galas, J. Cayoz, P. Tsuro, M. Negumara (Plato, Argentina)

P-0453 THYROID CARCINOMA. THE EXPERIENCE IN OUR UNIVERSITY HOSPITAL FOR THESE FIRST TEN YEARS OF EXISTENCE
J. L. Guerra, A. Cavalli, E. Fucheguyon, J. Sahabi, A. Woold, P. Saco, M. Negumara (Plato, Argentina)

P-0454 CYLINDRICAL LYMPH NODE METASTASES FROM PTC: TREATMENT WITH ULTRASOUND-GUIDED PERCUTANEOUS ETHANOL INJECTION
A. Heda (Oslo, Norway)

P-0455 USEFULNESS OF THYROGLOBULIN MEASUREMENT IN FINE-NEEDLE ASPIRATION FOR DIAGNOSING METASTATIC CERVICAL LYMPH NODES FROM PAPILLARY THYROID CANCER: EMBLISH THE FINE-NEEDLE ASPIRATION THYROGLOBULIN CUT-OFF VALUES

P-0456 NEW ENDOSCOPIC THYROIDECTOMY TECHNIQUE THE BLATIAL AERIAL-HAACK APPROACH (BA)

P-0457 USEFULNESS OF THYROGLOBULIN MEASUREMENT IN FINE-NEEDLE ASPIRATION FOR DIAGNOSING METASTATIC CERVICAL LYMPH NODES FROM PAPILLARY THYROID CANCER: EMBLISH THE FINE-NEEDLE ASPIRATION THYROGLOBULIN CUT-OFF VALUES
P-0458 | THE PREVALENCE AND CLINICAL CHARACTERISTICS OF THYROID CANCER PATIENTS PRESENTING WITH COEXISTING BREAST CANCER


P-0459 | ELASTOGRAPHY IN THYROID LESIONS: A PROSPECTIVE STUDY IN AN ENDEMIC REGION

G. Ilomel, F. Cosset (Cagliari, Italy)

P-0460 | ELASTOGRAPHY IN THYROID LESIONS: A PROSPECTIVE STUDY IN SARDINIA REGION

G. Ilomel (Cagliari, Italy)

P-0461 | ELASTOGRAPHY OF THE THYROID GLAND IN DEMENTIATING MALIGNANT NODES

G. Ilomel (Cagliari, Italy)

P-0462 | A NOVEL CELL LINES DERIVED FROM PAPILLARY THYROIDCARCINOMA


J. Y. Mok, I. J. Kim (Busan, Republic of Korea)

S. U. Woo, G. S. Son, E. S. Lee, J. B. Lee, J. W. Bae, Y. S. Kim (Ulsan, Republic of Korea)

H. Y. Kim (Ulsan, Republic of Korea)

M. S. Kim (Busan, Republic of Korea)


Y. -.-M. Kim (Inchon, Republic of Korea)

P-0463 | CLINICAL AND HISTOPATHOLOGICAL FEATURES OF INCIDENTAL AND NONINCIDENTAL PAPILLARY THYROIDMICROCARCINOMA


P-0464 | PREVALENCIA OF MALIGNANCE IN THYROID NODULES WITH INDETERMINATE CYTOLOGY AND ULTRASONOGRAPHIC FEATURES OF MALIGNANT NODES


P-0465 | INCIDENCE AND SIGNIFICANCE OF DELPHIAN NODE METASTASIS IN PAPILLARY THYROIDCANCER


P-0466 | SERUM BIOCHEMICAL DUAL ASSAY OF ANTI-WDR4 ANTI-BODY AND HYPER VMETA-R: A NOVEL STRATEGY FOR THE EARLY DIAGNOSIS OF THYROID NEOPLASM

S. K. Hasegawa, G. Shiota, C. Shigemasa (Yonago, Japan)

P-0467 | EVALUATING THE THYROID AFTER CARDIAC CATHETERIZATION FOR CONGENITAL CARDIOPATHY

F. Jégoux, M. Corsten (Ottawa, Canada)

P-0468 | HAS THE INCIDENCE OF POST-OPEERATIVE HEMATOMA FOLLOWING THYROID SURGERY CHANGED? A SYSTEMATIC REVIEW OF LITERATURE

H. Javandia, M. Covington (Ottawa, Canada)

P-0469 | PREDICTIVE FACTORS OF THYROID PAPILLARYMICROCARCINOMA RECURRANCE

J. Iglesias, A. Mitrana, V. Patrou, C. Bledert, G. Le Cloch (Rennes, France)

P-0470 | COMPARISON OF OUTCOME BETWEEN HIGH DOSE RADIOTHERAPIC IODINE ABLATION AND LOW Dose RADIOTHERAPIC IODINE ABLATION IN PATIENTS WITH PAPILLARY THYROIDMICROCARCINOMA


P-0471 | RADIATION-INDUCED THYROID CANCER AFTER RADIOTHERAPY FOR CHILDHOOD CANCER

M. Irajová (Prag, Czech Republic)

P-0472 | CLINICAL FEATURES OF PAPILLARY THYROID CARCINOMA IN ELDERLY PATIENTS OVER 60 YEARS

T. Jakl, N. Dabelic, R. Gracan, M. Boric, J. Stančić, Z. Kraus (Zagreb, Croatia)

P-0473 | SCREENING THYROID ULTRASOUND REVEALS HIGH FREQUENCY OF THYROID PAPILLARY CARCINOMA IN KOREAN ACRHEEMALIC PATIENTS

H.-C. Kang, H. K. Kim (Goyang, Republic of Korea)

P-0474 | DOES PROGRESSIVE IPTH LEVEL HAVE ANY IMPACT ON POST-TSHYROIDECTOMY HYPOCALCEMIA?


P-0475 | THYROID CARCINOMAS IN AN UNITED ARAB EMIRATE REFERRAL HOSPITAL

A. B. Khalid, A. Hammoud, N. Nawaz, J. Raja (Abu Dhabi, United Arab Emirates)

P-0476 | ROLE OF IMMUNOHISTOCHEMICAL PANEL INCLUDING GALECTIC, CK18, HBME1, CITED1 AND CITED2 IN THE CLASSIFICATION OF FOLLICULAR PATTERNED THYROID TUMORS

A. Khan, E. F. Courae, A. Fischer, M. S. Terme, S. Arun, M. Sattan, R. M. Qureshi, G. F. Whelan (Wexford, United States)

P-0477 | CLINICAL SIGNIFICANCE OF SERIAL MEASUREMENTS OF SERUM THYRSEDOXIN IN THYROID CANCER MANAGEMENT

M. A. Khan, S. Fatima, J. Ibrahim (Islamabad, Pakistan)

P-0478 | TREATMENT OF RADIOIODINE INDUCED HAEMODIAPYSIS AFTER THYROIDECTOMY BY MALIGNOSONOGRAPHY

Y. -.-M. Kim, J. Y. Lim (Seoul, Republic of Korea)

P-0479 | PAPILLARY THYROIDCARCINOMA WITH THYROIDITIS: LYMPH NODE METASTASIS AND COMPLICATIONS

Y. S. Kim, C. R. Kowen (Ulsan, Republic of Korea)

P-0480 | THE PREDICTIVE FACTORS AND PATTERN OF LYMHPHATIC METASTASIS IN PAPILLARY THYROID CANCER: PROSPECTIVE STUDY


P-0481 | LARYNGEAL PRESERVATION BY VERTICAL HEMILARYNGECTOMY IN LOCALLY ADVANCED THYROID CANCER


P-0482 | PATTERNS AND PREDICTIVE FACTORS OF LATERAL LYMPH NODE METASTASIS IN PAPILLARY THYROIDMICROCARCINOMA

Y. S. Kim, C. R. Kowen, B. K. Ko (Ulsan, Republic of Korea)

P-0483 | CONSIDERANCE OF HEMANGIOENDOTHELITIS WITH PAPILLARY THYROIDCARCINOMA: THE INFLUENCE OF LYMPH NODE METASTASIS


P-0484 | ULTRASOUND-GUIDED FINE-NEEDLE ASPIRATION BIOPSY OF THYROID NODES AND NICK MASSES WITH AN EMPHASIS ON TECHNIQUE

D. W. Kim (Busan, Republic of Korea)

P-0485 | FOLLICULAR AND HEMILARYNGEAL CARCINOMA OF THE THYROID IN IODINE SUFFICIENT AREA: RETROSPECTIVE ANALYSIS OF KOREAN MULTICENTER DATA


P-0486 | NADPDQ-QUINONE OXIDOREDUCTASE 1 AND NRH QUINONE OXIDOREDUCTASE 2 INHOMORPHISMS IN PAPILLARY THYROIDMICROCARCINOMA: CORRELATION WITH PHENOTYPE


P-0487 | HEMODYNAMIC CHANGES DURING ENDOSCOPIC THYROID SURGERY USING BILATERAL AXILLO-BREAST APPROACH WITH CARBON DIOXIDE INFLATION


P-0488 | EFFECTS OF THE DIFFERENT DOSE OF RADIOACTIVE IODINE FOR REMNANT ABLATION ON THE SUCCESSFUL ABLATION AND LONG-TERM RECURRENCE

DISCUSSED POSTERS (PD10) (see page 36)

Thyroid cancer translational

P-0516 FREQUENCY OF GERMINE PTEN MUTATIONS IN DIFFERENTIATED THYROID CANCER
R. Nagy, S. Ganapathy, I. Comencic, P. Molnár, M. Orkell, K. Plasma, C. Eng, M. Ringel, R. Klaus (Columbus, United States)

P-0519 OVEREXPRESSION OF THE IGFBP3 RECEPTOR AND OF INSULIN RECEPTOR IN PROLIFERA TION OF PROGENITOR/STEM CELLS FROM HUMAN THYROID CANCER
R. Malagnap, U. Sand, R. Vignieri, A. Bellows (Catania, Italy)

P-0521 CAN BAX/PROTECT MUTATION PREDICT LYMPH NODE METASTASIS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER
J. K. Nand (Dublin, Republic of Korea)

P-0522 LARGE SCALE TRANSCRIPTOME ANALYSES DEVOTED TO THE IDENTIFICATION OF MOLECULAR MARKERS OF THE INVASIVE FORMS OF PAPILLARY THYROID CANCER
B. A. Rousset, L. Zanhini, N. Bolk, F. Brandt, Chazot (Birmingham, United Kingdom)

P-0523 MOLECULAR CHARACTERIZATION OF 80 CASES OF FOLLICULAR ADENOMAS AND CARCINOMAS OF THE THYROID
A. C. F. Ferreira, B. S. Fortunato, K. Richard (Brisbane, Australia)

P-0524 TRANSPLANTATION OF THYROID BY TRANSHYDRENTHYRONINE UPTAKE IN PATIENT
L. Carvalho, R. Araujo (Rio de Janeiro, Brazil)

P-0525 ESSENTIAL MOLECULAR DETERMINANTS FOR THYROID HORMONE TRANSPORT AND FIRST STRUCTURAL IMPLICATIONS FOR MONOCARBOXYLATE TRANSPORTERS
A. Kinne, G. Kliment, C. S. Hrohig, A. Grütter, J. Kohle, G. Krause, U. Schneu (Berlin, Germany)

DISCUSSED POSTERS (PD12) (see page 37)

Thyroid cell biology

P-0534 THE REGULATION OF THE OXIDATIVE STATUS IS INVOLVED IN THYROID CELL RESPONSES TO HIGH IODIDE DIO E
G. L. Leoni, P. Santinelli, A. De La Viria (Madrid, Spain)

P-0535 SLC5A8 PLAYS A KEY ROLE IN THE THYROID REGULATION BY IODIDE AND PROTECTS THYROC TYES AGAINST EXCESSIVE IODIZED IODINE PRODUCTION
S. Lindenhal, V. Flachon, F. Berenguer, P. Franken, J. Gülfalps, A. Onda-Mendes, M. Gérard, C. Vidal, J. Ducrè, T. Parvash (Nice, France)

P-0536 N.A.: I-SYMPOTOM (IN) EXPRESSION AND LOCALIZATION DURING RAPID TRANSPORT INHIBITION BY IODIDE EXCESS
A. A. Arrigada, E. Alborero, S. Baur, N. Carvare, A. Kaleris, C. Rodel (Buenos Aires, Cuba)

P-0537 HIPERLEPTINEMIA DIRECTLY INHIBITS THYROID RISE UP TAK E AND TYPE I (D1) ACTIVITY IN LEAN AD LIBITUM FED RATS
R. Arruza, A. C. F. Ferreira, F. Reiche, B. Andrade, E. Souza, D. Carvalho (Rio de Janeiro, Brazil)

P-0538 THE CARBOXY-TERMINAL OF APC IS INVOLVED IN THYROID MORPHOLOGY AND FUNCTION
A. Yokozuna, N. Oda, R. Numan, M. Iinaka (Okayama, Japan)

P-0539 CORRELATION BETWEEN IN SILICO PREDICTED AND IN VITRO CONFIRMED THYROID-RELEVANT TRANSCRIPTION FACTOR BINDING SITES IN PROMOTERS OF HUMAN AND RAT GY D/transcribing PROTEINS PARTICIPATING IN THYROID HORMONE SYNTHESIS

Thyroid hormone synthesis

P-0541 THYROID CALCIUM AND NA/P/H-DEPENDENT HCO3 GENERATING ACTIVITY IS INCREASED IN DIABETIC RATS
A. C. P. Ferreira, M. C. S. Santos, W. M. Braga, J. Schroder, G. Cali., E. Móved, D. P. Carvalho (Rio de Janeiro, Brazil)

P-0542 FUNCTIONAL CONSEQUENCES OF DUAL OXIDASE-TYRPHOREDOXIN PLASMA MEMBRANE INTERACTION

P-0543 DO WE NEED TO MEASURE THE SALIVA/SERUM RADIOACTIVE IODIDE RATIO TO DIAGNOSE IODIDE TRANSPORT DEFECTS?
S. Fukuda, A. Hishinuma, N. Nakatake, C. Tomida, T. Tanaka (Kumamoto, Japan)

Thyroid hormone transport

P-0530 TRANSPORT OF T4 AND T3 IN INTESTINAL (Caco2) CELLS
N. Soldr, W. S. Voss, T. J. Voss (Rotterdam, Netherlands)
Clinical thyroidology - Case reports

P-0543 METHIMAZOLE-INDUCED HEPATIC STEATOSIS: CASE REPORT AND LITERATURE REVIEW
B. Alcón, P. M. Reddy, A. Salahy (New York, United States)

P-0544 AN UNUSUAL PRESENTATION: SUBACUTE THYROIDITIS DEVELOPING IN A PATIENT WITH HASHIMOTO’S THYROIDITIS
U. Musa, C. Antl, A. Geczyw (Ankara, Turkey)

P-0545 MINIMALLY INVASIVE FOLLICULAR CARCINOMA WITHOUT VASCULAR INVASION PRESENTING AS INITIALLY BONE METASTASIS

P-0546 THYROID STIMULATING HORMONE (TSH) AND FREE THYRoxINE LEVELS (FT4) IN PREGNANT FEMALES >25 WEEKS GESTATION AND NON-PREGNANT FEMALES WHO HAVE CLINICAL PROBLEMS AND HYPOTHYROID SYMPTOMS: EVIDENCE SUPPORTING POOR CORRELATION BETWEEN TSH AND FT4
T. Bilal MD, DAROG (Del Mar, United States)

P-0547 PARANEOPLASTIC SECRETION OF ACTH BY PRIMARY ANGIOSARCOMA OF THYROID, A RARE ENTITY
M. Cakir, S. Ipekci, K. Ozturk (Konya, Turkey)

P-0548 GRAVES’ DISEASE WITH UNILATERAL INVOLVEMENT: A RARE ENTITY
M. Cakir, C. Gedikbasi, Z. ERFAANI ( Mashhad, Iran)

P-0549 A DIFFICULT DECISION – HASHIMOTO’S THYROIDITIS OR SUBACUTE THYROIDITIS?
M. Cakir, S. Ipekci, K. Ozturk (Konya, Turkey)

P-0550 SYNCHRONOUS METASTATIC UTERINE LEIOMYOMA AND PAPILLARY CARCINOMA OF THE THYROID GLAND

P-0551 FULMINANT BACTERIAL THYROIDITIS IN PATIENTS WITH GRAVES’ DISEASE AND PAPILLARY THYROID CARCINOMA
M. Dąbrowska, M. Mierzejewska, J. Skołod, A. Pawlak, L. Piotrowska, S. Wnuk, R. Slman (Warsaw, Poland)

P-0552 RIEDEL’S THYROIDITIS – A CASE FOR LOW DOSE COMBINATION THERAPY WITH TAMSULOSIN AND DEXAMETHASONE LONG TERM

P-0553 PARATHYRITIS COINCIDENTLY ASSOCIATED WITH PATILLARY THYROID MICROCARCINOMA
M. E. Diayoune, M. Godl, C. Casta, S. Diaconescu (Larri, Romania)

P-0554 UNG METASTASES OF A THYROID-TYPE CARCINOMA ARISING IN STRUMA OVARII: A CASE REPORT
S. M. Diez, J. M. Tenforde, M. Shihong, S. Ipekci, K. Ozturk (Konya, Turkey)

P-0555 ROUTINE BIOLOGICAL THYROID INVESTIGATION USING THE AUTOMATED ANALYZER UNICEL Dxi 800 BECKMAN COULTER
A. Georges, S. Mond, J.-B. Corelli (Pouzac, France)

P-0556 THYROID PROTECTION GONE AWRY: A RARE CASE OF IODODERMA
A. F. Guerrero, K. M. Shaikh, K. T. Guerrero (Washington, DC, United States)

P-0557 AN UNUSUAL CASE OF RIEDEL’S THYROIDITIS ASSOCIATED WITH HYPOTHYROIDISM AND SCLEIRODERMIC CHLORANGIITIS WITH OBJECTIVE RESPONSE TO L-THYROXINE
S. Hyer, A. Tran (Wallington, United Kingdom)

P-0558 TWO NONSECRETIVE NERVES ENCRUCHE BY THE RIEDEL’S THYROIDITIS: REPORT OF 2 CASES AND COMPLETE HEART BLOCK
M. I. Tan, H. Maamari, C. Guerra, J. Sauvage, A. Azoulay, L. Lambert (Paris, France)

P-0559 GRAVES DISEASE ASSOCIATED TO CLINICAL MANIFESTATIONS OF MEN I-A-RABITY: A CASE REPORT
C. S. Martin, C. Constanzi, S. V. Ficu (Bucharest, Romania)

P-0560 PRIMARY ANGIOCARCINOMA OF THYROID: A RARE PRIMARY THYROID MALIGNANCY – TWO CHINESE CASE REPORTS AND A BRIEF REVIEW OF THE CURRENT LITERATURE
M. Shihung, Z. You Cheng (Lanzhou, China)

P-0561 A CASE OF IDIOPATHIC MYXOEDEMA WITH THE REMISSION OF IDIOPATHIC THROMBOCYTOPENIC PURPURA
Y.-Q. Xiang (Wenzhou, China)

P-0562 TSH PROMOTED ESTROGENIC PROPERTIES IN ENDOMETRIOSIS: A CASE REPORT
Y.-L. Yang, K. Yoshioka, E. Morio, K. Hasunuma, H. Ohashi (Narita, Japan)

P-0563 CENTRAL HYPERTHYROIDISM IN AN INFANT WITH PRECOCIOUS PUBERTY: A CASE REPORT
I. M. Taha, C. K. Gharagheghei, Z. Effanian (Mashhad, Iran)

P-0564 Dyspariaphlogistic NEUROEPITHELIAL TUMOR (NET): POSSIBLE LINK TO MATERNAL HYPOTHYROIDISM?
J. F. Rovet, J. Nogueira, E. Wilkja (Toronto, Canada)

P-0565 PREOCIOUS PUBERTY: A CASE REPORT

P-0566 PRIMARY ANGIOCARCINOMA OF THYROID: A RARE CASE OF RECURRENT SILENT THYROIDITIS
M. K. Tran, A. Tran (Wallington, United Kingdom)

P-0567 TWO NONRECURRENT NERVES ENCRUCHE BY THE RIEDEL’S THYROIDITIS: REPORT OF 2 CASES AND COMPLETE HEART BLOCK
M. I. Tan, H. Maamri, C. Guerra, J. Sauvage, A. Azoulay, L. Lambert (Paris, France)

P-0568 ULTRASOUND, ELASTOGRAPHY AND FDG-PET/CT IMAGING IN RIEDEL’S THYROIDITIS: REPORT OF 2 CASES
S. Bendre, H. Monpeyssen, S. Desarnaud, J. Haroche, M. Asselah, A. Aouda, H. Lamberts (Paris, France)

P-0569 AN UNUSUAL CASE OF RIEDEL’S THYROIDITIS
M. Dąbrowska, M. Mierzejewska, J. Skołod, A. Pawlak, L. Piotrowska, S. Wnuk, R. Slman (Warsaw, Poland)

P-0570 A RARE CASE OF CHRONIC LYMHPHOCYTIC LEUKEMIA / SMALL LYMHPHOCYTIC LYMPHOMA PRESENTING IN THE THYROID GLAND
J. J. Shin, D. Choe, M. Milan, J. Mitchell, A. Siperstein, E. Berber (Cleveland, United States)

P-0571 A CASE OF IODODEMA IN A PATIENT WITH PRIMARY ANGIOCARCINOMA OF THE THYROID GLAND
J. J. Shin, D. Choe, M. Milan, J. Mitchell, A. Siperstein, E. Berber (Cleveland, United States)

P-0572 COEXISTENCE OF TWO RARE TUMORS OF THE THYROID IN 49 YEARS OLD MEN
S. R. Solo (Bisho, Spain)

P-0573 MEDULLARY CARCINOMA OF THYROID DEVELOPING IN A PATIENT WITH HASHIMOTO’S DISEASE ASSOCIATED TO CLINICAL MANIFESTATIONS OF MEN I-A-RABITY: A CASE REPORT
C. S. Martin, C. Constanzi, S. V. Ficu (Bucharest, Romania)

P-0574 AN UNUSUAL PRESENTATION: SUBACUTE THYROIDITIS ASSOCIATED WITH HYPOTHYROIDISM AND SCLEIRODERMIC CHLORANGIITIS WITH OBJECTIVE RESPONSE TO L-THYROXINE
S. Hyer, A. Tran (Wallington, United Kingdom)

P-0575 SYMPTOMS: EVIDENCE SUPPORTING POOR CORRELATION BETWEEN TSH AND FT4 IN PATIENTS WITH CLINICAL PROBLEMS AND HYPOTHYROID SYMPTOMS
J. S. Kim, B. J. Song, S. S. Jung, J. S. Bae (Seoul, Republic of Korea)

P-0576 AN UNUSUAL CASE OF RIEDEL’S THYROIDITIS
M. Dąbrowska, M. Mierzejewska, J. Skołod, A. Pawlak, L. Piotrowska, S. Wnuk, R. Slman (Warsaw, Poland)

P-0577 THYROID PROTECTION GONE AWRY: A RARE CASE OF IODODERMA
A. F. Guerrero, K. M. Shaikh, K. T. Guerrero (Washington, DC, United States)
**GROUP B**

**Display period:** Tues. Sept. 14th – Wed. Sept. 15th

<table>
<thead>
<tr>
<th>P0573 - P1148</th>
</tr>
</thead>
</table>

### DISCUSSED POSTERS (PD13) (see page 48)

**Clinical thyroidology - Case reports**

<table>
<thead>
<tr>
<th>Posters Viewing session</th>
<th>Poster Viewing Time</th>
<th>First Poster</th>
<th>Last Poster</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tues. Sept. 14th</td>
<td>13:00 – 14:00</td>
<td>P0573</td>
<td>P0872</td>
</tr>
<tr>
<td>Wed. Sept. 15th</td>
<td></td>
<td>P0873</td>
<td>P1148</td>
</tr>
</tbody>
</table>

**Clinical thyroidology - Case reports**

- **P-0594**
  - **ESOPHAGEAL SQUAMOUS CELL CARCINOMA METASTASIS TO THE THYROID GLAND: CASE REPORT**
  - S. S. Staniec, F. Balkan, A. Lusliogullari, F. Saglam, R. Ersoy, B. Cakir
  - (Ankara, Turkey)

- **P-0585**
  - **THYROID ABSCESSES IN A PATIENT WITH DIABETES MELLITUS**
  - S. S. Staniec, F. Balkan, C. I. Niiroma, A. Yağan, R. Ersoy
  - (Ankara, Turkey)

- **P-0586**
  - **A CASE OF MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A WITH MULTIPLE METASTASES**
  - (Tokyo, Japan)

- **P-0587**
  - **AN UNCOMMON CASE OF MIXED EMIA MEGACOLON**
  - M. K. Huszta, M. A. Guillon, J. Faustor, J. E. Villena
  - (Lima, Peru)

- **P-0588**
  - **THYROID DISEASES AMONG WOMEN PATIENTS WITH PSYCHOMOTORIC DISORDER OR IRREGULAR MENSTRUATION: ANALYSIS AT WOMEN'S HEALTH CARE CLINIC IN JAPAN**
  - M. Kato, N. Ot, T. Kato, M. Kuroyama, R. Yamada, M. Kavamura, A. Sakurati, R. Otsuka
  - (Tokyo, Japan)

- **P-0589**
  - **PERICARDIAL EFFUSION ASSOCIATED WITH GRAVES' DISEASE**
  - N. Lima
  - (Sao Paulo, Brazil)

- **P-0590**
  - **SEVERE HYPOCALCEMIA COMPLICATING TOTAL THYROXINE REDUCTIONS AFTER MALABSORPTIVE ENTPAS: PROCEDURE FOR OBESITY**
  - D. Desgaste, M. Skala, P. Paulus, A. Aubert, P. Lothaime
  - (Montigny-Le-Tilleul, Belgium)

- **P-0591**
  - **THYROTIC CARDIOMYOPATHY RESEMBLING ACUTE CORONARY SYNDROME**
  - B. S. Lonzar (Sofia, Bulgaria)

- **P-0592**
  - **TWO NOVEL MUTATIONS OF THYROID HORMONE RECEPTOR beta INDUCES THYROID HORMONE RESISTANCE SYNDROME IN BRAZILIAN FAMILIES**
  - (Sao Paulo, Brazil)

- **P-0593**
  - **DEVELOPMENT OF SARCOIDOSIS IN A PATIENT WITH FAMILIAL THYROID CANCER AND SARCoid REACTION**
  - A. Makave, K. Lukkoutsa, A. Ireviktione, E. Makareva
  - (Takrist, Russian Federation)

- **P-0594**
  - **HYPERTHYROIDISM AFTER LITHIUM THERAPY FOR BIPOLAR DISORDER**
  - H. Marmouch, M. A. Habra, A. K. Ying
  - (Sofia, Bulgaria)

- **P-0595**
  - **THYROID METASTASIS FROM RECTAL CARCINOMA: CASE REPORT AND LITERATURE REVIEW**
  - S. S. Inancli, F. Balkan, A. Usluogullari, F. Saglam, R. Ersoy, B. Cakir
  - (Ankara, Turkey)

- **P-0596**
  - **MYASTHENIC SYNDROME OR JUST A MANIFESTATION OF HYPOFUNCTIONALITY?**
  - B. Cakir
  - (Ankara, Turkey)

- **P-0597**
  - **THYROID ECTOPIC TUMORS WITH MULTIPLE METASTASES TO THE THYROID Gland: CASE REPORT**
  - T. Moin, D. Lu, N. Moatamed, C. Darwin
  - (Los Angeles, United States)

- **P-0598**
  - **MULTIMORPHIC SYNDROME OR JUST A MANIFESTATION OF HYPOFUNCTIONALITY?**
  - M. A. GUILLEN, J. FAUSTOR, J. E. VILLENA
  - (Lima, Peru)

- **P-0599**
  - **DEVELOPMENT OF SARCOIDOSIS IN A PATIENT WITH FAMILIAL THYROID CANCER AND SARCoid REACTION**
  - A. Makave, K. Lukkoutsa, A. Ireviktione, E. Makareva
  - (Takrist, Russian Federation)

- **P-0600**
  - **HYPERTHYROIDISM AFTER LITHIUM THERAPY FOR BIPOLAR DISORDER**
  - H. Marmouch, M. A. Habra, A. K. Ying
  - (Sofia, Bulgaria)

- **P-0601**
  - **THYROID TUMOURS: REPORT OF 11 CASES**
  - T. Moin, D. Lu, N. Moatamed, C. Darwin
  - (Los Angeles, United States)
DISCUSSED POSTERS (PD15) (see page 49)
Thyroid cancer - Clinical III

P-0614 UNISENSITIVITY OF ULTRA-SENSITIVE THYROGLOBULIN (TG) ASSAY IN THE FOLLOW-UP OF DIFFERENTIATED THYROID CANCER (DTC) PATIENTS
P. Malandrim, A. Lima, I. Martinanes, G. Fernimello, S. Massoccoli, R. A. Falco, M. Ruse, G. Pellegrini (Udine, Italy)

P-0615 CLINICAL UTILITY OF THE STIMULATED THYROGLOBULIN DETERMINATION IN FOLLOW UP OF PATIENTS WITH WELL DIFFERENTIATED THYROID CARCINOMAS
D. M. Hartl, S. Lehurec, R. Bandi, A. Al Ghuwair, M. Schlimmerber, J.-F. Travaqil (Villeneuve, France)

DISCUSSED POSTERS (PD14) (see page 48)
Thyroid cancer surgery

P-0616 RECOMMUN ANTI HUMAN THYROTROPHIN (RTH) STIMULATED THYROGLOBULIN OF <1NG/ML: NEED FOR CONTINUED SURVEILLANCE?
G. Smolare, S. J. Mandel (Philadelphia, United States)

P-0617 LONG-TERM FOLLOW-UP PATIENTS WITH PAPILLARY AND FOLLICULAR CANCER: A PROSPECTIVE STUDY ON 968 PATIENTS
M. Basar, J. Bengt, A. Edet, C. Cunnee, O. Mundler, M. Toubeau, F. Bonichon, M. Pellegrini (Evreux, France)

P-0618 SUPPRESSIVE DOSES OF LEVOTHYROXINE AND LEVELS OF TSH DURING PREGNANCY IN PATIENTS WITH THYROID CARCINOMA PREVIOUSLY TREATED BY TOTAL THYROIDECTOMY AND RADIODEThYRE ABLATION OF THYROID REMNANT
N. Besic, M. Pavlovic, M. Isur, A. Zupan (Slajkvar, Slovenia)

P-0619 THYROID HORMONE LEVELS HAVE A PROGNOSTIC RELEVANCE IN PATIENTS WITH METASTASES DIFFERENTIATED THYROID CARCINOMA

P-0611 ROUTINE CENTRAL NECK DISSECTION FOR PAPILLARY THYROID CANCER IS SAFE AND RESULTS IN LOWER INCIDENCE OF OCCULT SOLID METASTASES
D. M. Hartl, S. Lehurec, R. Bandi, A. Al Ghuwair, M. Schlimmerber, J.-F. Travaqil (Villeneuve, France)

P-0610 THE PRESENCE OF INTRAOPERATIVE MONITORING OF PARATHYROID HORMONE (IOPTH) IN PATIENT WITH PARATHYROID ADENOMA
J. C. Ribeiro (Faro, Portugal)

P-0609 ROUTINE CENTRAL NECK DISSECTION FOR PAPILLARY THYROID CANCER IS SAFE AND RESULTS IN LOWER INCIDENCE OF OCCULT SOLID METASTASES
D. M. Hartl, S. Lehurec, R. Bandi, A. Al Ghuwair, M. Schlimmerber, J.-F. Travaqil (Villeneuve, France)

P-0608 THE USEFULNESS OF RECOMBINANT HUMAN TSH IN THE MANAGEMENT OF PATIENTS WITH WELL DIFFERENTIATED THYROID CARCINOMAS
M. Skugor, C. Na, M. Milas, M. Kaz, V. Greer (Cleveland, United States)

P-0607 AMIODARONE-INDUCED THYROIDITIS – TWO CASE REPORTS

P-0606 UNUSUAL SITES OF METASTASES FROM DIFFERENTIATED THYROID CANCER
M. G. Chiofalo, S. Losito, F. Fulciniti, A. Tommaselli, M. Gallo, M. F. L. Cecilia, L. Pezzola (Naples, Italy)

P-0605 ANCA - POSITIVE VASCULITIS IN A PATIENT WITH GRAYES' DISEASE
Z. Semanov, D. Telepykova, M. Takcikov (Kolmar, Slovakia)

P-0604 HYPOCALCEMIA AND ITS MANAGEMENT
J. C. Ribeiro (Faro, Portugal)

P-0603 THYROIDectomy FOLLOWING-GASTRIC BYPASS: SEVERE HYPOCALCEMIA AND ITS MANAGEMENT
L. A. Orloff (San Francisco, United States)

P-0602 CARCINOMA AND GROWTH-HORMONE-SECRETING MACROADENOMA OF THE PINEAL GLAND: A PROOF OF CONCEPT STUDY OF IMMUNOTHERAPY IN A PATIENT WITH ACTH-DEFICIENT CUSHING’S SYNDROME
M. G. Chiofalo, S. Losito, F. Fulciniti, A. Tommaselli, M. Gallo, M. F. L. Cecilia, L. Pezzola (Naples, Italy)

P-0601 ANCA - POSITIVE VASCULITIS IN A PATIENT WITH GRAVES' DISEASE
Z. Semanov, D. Telepykova, M. Takcikov (Kolmar, Slovakia)

P-0600 PRIMARY HYPERPARATHYROIDISM REMISSION AFTER P-0597
THYROIDECTOMY FOLLOWING GASTRIC BYPASS: SEVERE HYPOCALCEMIA AND ITS MANAGEMENT
L. A. Orloff (San Francisco, United States)

P-0599 ANCA - POSITIVE VASCULITIS IN A PATIENT WITH GRAVES' DISEASE
Z. Semanov, D. Telepykova, M. Takcikov (Kolmar, Slovakia)

P-0598 HYPOCALCEMIA AND ITS MANAGEMENT
J. C. Ribeiro (Faro, Portugal)

P-0597 PRIMARY HYPERPARATHYROIDISM REMISSION AFTER VIDEO-ASSISTED PARATHYROIDECTOMY (MIVAP) WITH INTRAOPERATIVE MONITORING OF PARATHYROID HORMONE (IOPTH) IN PATIENT WITH PARATHYROID ADENOMA
R. O. C. Oliveira, V. S. Preat, A. N. Couto, M. H. Carneiro, J. C. Ribeiro (Faro, Portugal)

P-0596 ANATOMICAL CYTOLAPAS POST-OP ASSOCIATED RELAPSING POLYCHONDRIITIS FOLLOWING TREATMENT FOR GRAVES' DISEASE
K. Sato, Y. Arai, K. Ishimura, K. Kusumoto, Y. Iwado, K. Okamura (Kitakyusyu, Japan)

P-0595 ANTINEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE VASCULITIS IN A PATIENT WITH ANCA POSITIVE VASCULITIS

P-0594 INTRAOPERATIVE MONITORING OF PARATHYROID HORMONE (IOPTH) IN PATIENT WITH PARATHYROID ADENOMA
J. C. Ribeiro (Faro, Portugal)

P-0593 THYROIDectomy FOLLOWING-GASTRIC BYPASS: SEVERE HYPOCALCEMIA AND ITS MANAGEMENT
L. A. Orloff (San Francisco, United States)

P-0592 ROUTINE CENTRAL NECK DISSECTION FOR PAPILLARY THYROID CANCER IS SAFE AND RESULTS IN LOWER INCIDENCE OF OCCULT SOLID METASTASES
D. M. Hartl, S. Lehurec, R. Bandi, A. Al Ghuwair, M. Schlimmerber, J.-F. Travaqil (Villeneuve, France)

P-0591 PRIMARY HYPERPARATHYROIDISM REMISSION AFTER THYROIDECTOMY FOLLOWING GASTRIC BYPASS: SEVERE HYPOCALCEMIA AND ITS MANAGEMENT
L. A. Orloff (San Francisco, United States)

P-0590 THYROIDectomy FOLLOWING-GASTRIC BYPASS: SEVERE HYPOCALCEMIA AND ITS MANAGEMENT
L. A. Orloff (San Francisco, United States)
P-0625
UTILITY OF GALECTINS TESTING ON THYROID FINE-NEEDLE ASPIRATION CYTOTOLOGY FOR PRODROPHETIC RISK STRATIFICATION IN PAPILLARY THYROID CARCINOMA

P-0626
EVALUATION OF THE PROGNOSIS OF THE RECURRENT PAPILLARY THYROID CANCER AND ITS RISK FACTOR AFTER REOPERATION

P-0627
DISTURBING CHARACTERISTICS OF THE INCIDENCE OF MULTIPLE PRIMARY CANCERS IN THYROID CANCER PATIENTS
K.-J. Lim, T.-C. Cho, C. Hheeb, N.-M. Tounge, J.-D. Lin (Taoyuan Shian, Taiwan)

P-0628
RADIOACTIVE IODINE (131I-RAI)-RESISTANT ADVANCED DIFFERENTIATED THYROID CANCER (DTC): A NATURAL HISTORY OF A MONO-INSTITUTIONAL SERIES
I. Leseci, L. Pucioo, F. Soremi, E. Crana, F. Rognoni, E. Berrettini, A. Minuesta, V. Tora, L. Llosta (Milan, Italy)

P-0629
METASTASIS OF A PAPILLARY CARCINOMA OF THE THYROID GLAND IN A BRANCHIAL CYST
P. Paulus, D. Dequanter, M. Shahla, N. Nagy, P. Lothaire (Montigny-Le-Tilleul, Belgium)

P-0630
THE PROBLEM OF THYROGLOBULIN, CALCITONIN, AND PARATHORMON DETERMINATION IN FINE NEEDLE ASPIRATES

P-0631
PECULIARITIES OF METABOLIC STATUS IN PATIENTS, OPERATED ON THYROID CARCINOMA AND HAVING, TREATED WITH RADIIOODINE
T. A. Mityukova, V. M. Drozd, T. A. Leonova, Z. Kusic (Zagreb, Croatia)

P-0632
ADIPOCYTOKYNES AND INSULIN RESISTANCE
F. Santos, D. Costa (Porto, Portugal)

P-0633
ANY DIFFERENCE BETWEEN CLINICALLY OVERT AND BILATERAL NECK DISSECTION WITH ULTRASCISION FOR PATIENTS TREATED WITH RADIOIODINE TREATMENT?
S. Janosevic, M. Mitrovic (Belgrade, Serbia)

P-0634
PAPILLARY THYROID CARCINOMA – A MULTIVARIATE PROGNOSTIC IMPACT IN 20 YEARS FOLLOW-UP

P-0635
SPINAL METASTASIS IN PAPILLARY THYROID CARCINOMA-A RETROSPECTIVE ANALYSIS
A. C. Martins, R.Sansom, I. Lambert, V. Luce (Lisbon, Portugal)

P-0636
BLEE: MUTATION AND EXPRESSION OF HLA-DR and HLA-DP in DIFFERENTIATED THYROID CARCINOMA

P-0637
RATE OF SOPHISTICATED MARGINS IN PAPILLARY THYROID CANCER IS ASSOCIATED WITH INCREASING INCIDENCE OF PAPILLARY THYROID CANCER
A. Mathur, S. Bhat, A. Gethin, M. Klima, W. Moss, D. W. Duk, O. Clark, E. Kehelev (Bolthuda, United States)

P-0638
PROGNOSTIC FACTORS IN PAPILLARY THYROID CANCER—LONG TERM FOLLOW-UP STUDY OF 2007 PTc PATIENTS

P-0639
DIFFERENTIATED THYROID CANCER IN ELDERLY PATIENTS— A RETROSPECTIVE REVIEW OF CHARACTERISTICS AND CLINICAL BEHAVIOR

P-0640
UTILITY OF GALECTIN-3 TESTING ON THYROID FINE-NEEDLE ASPIRATION CYTOTOLOGY FOR THE DIAGNOSTIC VALUE OF THYROGLOBULIN, CALCITONIN, AND PARATHORMON DETERMINATION IN FINE NEEDLE ASPIRATES
L. Assumpção, J. Vassallo, D. E. Zantut-Wittmann (Curitiba, Brazil)

P-0641
DIFFERENTIATED THYROID CANCER: FOLLOW-UP OF 542 PATIENTS IN A BRASILIAN ESPESSLED CENTER FOR UP TO 35 YEARS
T. G. Melo, L. Assumpção, D. Wittmann, E. Fischer (Campinas, Brazil)

P-0642
CLINICAL FEATURES AND LONG TERM OUTCOME OF METASTATIC DIFFERENTIATED THYROID CARCINOMA
R. M. Hinozawa, M. Mattro, J. V. Taglant, E. C. Castilli, M. A. Mampers, Y. Kyo, M. S. M. Marone, G. M. S. Maurits (Bertacchi, Brazil)

P-0643
THYROID CARCINOMA FOLLOW-UP OF 542 PATIENTS IN A BRAZILIAN ESPERLIZED CENTER FOR UP TO 35 YEARS
R. M. Menezes, C. trovisan, M. Indolfo, F. C. Ferreria (Brazili, Brazil)

P-0644
WHAT DOES IT CHAGE IF WE ADOPT THE NOW REVISED AYA GUIDELINES FOR THYROID CANCER?
F. Y. Masaki (Canberra, Australia)

P-0645
THE DIAGNOSTIC VALUE OF THYROGLOBULIN CONCENTRATION IN THE FINE-NEEDLE BIOPSY HISTOPATHOLOGICAL FINDINGS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER - 10 YEARS EXPERIENCE
S. J. Mikosinski, J. Makarevicz, L. Osenkowka, P. Janek, S. Sporny, L. Panienski (Gdansk, Poland)

P-0646
MEASURING THE hMAA IN PERIPHERAL BLOOD AS A MARKER OF THYROID CANCER RECURRENCE IN PATIENTS WITH THYROID CARCINOMA AFTER TREATMENT WITH RADIIOODINE THERAPY
F. B. Nader, R. M. D. B. Maciel (Sao Paulo, Brazil)

P-0647
PAPILLARY CANCER IN A THYROGLOSSAL DUCT CYST
J. Weng, Q.-Y. Duh, O. Clark, E. Kebebew (Bethesda, United States)

P-0648
DIFFERENTIATED THYROID CANCER IS ASSOCIATED WITH INCREASING INCIDENCE OF SPINAL METASTASES IN PAPILLARY THYROID CANCER

P-0649
SYNCRONIC WITH THYROID CANCER. CASE REPORT AND LITERATURE REVIEW
R. M. Menezes, C. trovisan, P. M. Indolfo, F. C. Ferreria (Brazili, Brazil)

P-0650
ASYMPTOMATIC UVEAL MELANOMA IN PERIPHERAL BLOOD AS A MARKER OF THYROID CANCER RECURRENCE IN PATIENTS WITH THYROID CARCINOMA AFTER TREATMENT WITH RADIIOODINE THERAPY
F. B. Nader, R. M. D. B. Maciel (Sao Paulo, Brazil)

P-0651
RADIOIODINE REMNANT ABATION OF DIFFERENTIATED THYROID CANCER DOES NOT FURTHER INCREASE ARBITRARY DAMAGE TO MEMBRANE LIPIDS
I. Makarevicz, A. Lewinski, M. Krawick-Lewinska (Gdansk, Poland)

P-0652
IMMUNE RESPONSE TO PAPILLARY THYROID CARCINOMA: A RETROSPECTIVE ANALYSIS
M. Milas, J. Shin, M. Gupta, C. Nael, M. Skaporn, J. Mitchell, E. Berta, A. Spenceon (Cleveland, United States)

P-0653
DIFFERENTIATED THYROID CANCER PATIENTS- A RETROSPECTIVE REVIEW OF CHARACTERISTICS AND CLINICAL BEHAVIOUR
ULTRASOUND-GUIDED LASER ABLATION OF THYROID MICROCARCINOMA IN A PATIENT AT HIGH SURGICAL RISK: A NOVEL THERAPEUTIC ALTERNATIVE


A CLINICAL STUDY OF THYROID CARCINOMA: CASES OF DIFFERENTIATED CARCINOMA CONSENTIENT WITH CHRONIC THYROIDITIS (SHAMSTROM'S THYROIDITIS)

T. Miuchi, T. Shimomura, K. Hironaka, K. Oishi, R. Watanabe, T. Arai (Tokyo, Japan)

INHIBITORS OF TYR Kinases: A NEW THERAPEUTIC OPTION FOR CEREBELLAR METASTASES OF THYROID CARCINOMA

M. M. Khan, B. Toussaint, G. Weryha, M. Klein (Vandoeuvre-les-Nancy, France)

TREATMENT WITH INHIBITORS OF TYR Kinases IN REFRACTORY THYROID CANCER: THE GAME WORTH THE CANDLE

M. M. Khan, B. Toussaint, G. Weryha, M. Klein (Vandoeuvre-les-Nancy, France)

THE VARIABLE PRESENTATIONS OF ANAPLASTIC THYROID CANCER TREATED WITH INHIBITORS OF TYROSINE KINASES IN P-0656


ALTERATION OF PROTEINS S100A10 AND TRANSGELIN-2 DISCRIMINATES BETWEEN METASTASIZED AND NON-METASTASIZED PAPILLARY THYROID CARCINOMAS AS DETECTED BY MALDI DIAGNOSTIC MASS SPECTROMETRY AND IMMUNO histoCHEMISTRY


FOCAL THYROID INCIDENTALOMA DETECTED BY FDG-PET/CT

I. L. Y. Nilsson, P. Anthberg, J. E. Jonsson, A. Sundin (Stockholm, Sweden)

SYMPTOMATIC RECURRENT THYROID CANCERS IN THE POSTOPERATIVE QUALITY OF LIFE AMONG PATIENTS TREATED WITH TOTAL THYROIDECTOMY FOR THYROID CANCER – A CLINICAL DILEMMA WITH CYTOLOGICAL EVIDENCE FOR PAPILLARY CARCINOMA


SPECIALIZED QUIP IN THE FOLLOW-UP OF TG – ANTIBODY MEASUREMENT IN THE FOLLOW-UP OF THYROID CANCER: A CLINICAL DILEMMA

R. N. Nenkov, R. Radev (Varna, Bulgaria)

THE IMPORTANCE OF AN IODINE-RESTRICTED DIET PERIPHERAL BLOOD AND IODINE URINARY EXCRETION: THE CORRELATION BETWEEN MRNA NIS EXPRESSION IN THE THYROID AND STIMULATED TG IN LOW RISK PATIENTS, BUT NOT IN INTERMEDIATE OR HIGH RISK PATIENTS WITH DIFFERENTIATED THYROID CANCER

A. Handberg, C. Rytter, J. Faber (Herlev, Denmark)

USE OF HDAC INHIBITOR VALPROIC ACID AND PPAR-5 ALTERNATION OF PROTEINS S100A10 AND TRANSGELIN-2 DISCRIMINATES BETWEEN METASTASIZED AND NON- DELETED PROTEIN S100A10 CONTRIBUTES TO THE ADAPTATION OF DIFFERENTIATED THYROID CANCER – A CLINICAL DILEMMA


RECOMBINANT HUMAN THYROTROPIN IN THE MANAGEMENT OF METASTASES TO THE LUNG IN PATIENTS WITH THYROID CANCER: RESULTS FROM AN OPEN-LABEL STUDY


RECOMBINANT HUMAN THYROTROPIN IN THE MANAGEMENT OF METASTASES TO THE LUNG IN PATIENTS WITH THYROID CANCER: RESULTS FROM AN OPEN-LABEL STUDY


THE CANDLE?

T. Arai (Tokyo, Japan)

THE CANDLE?

T. Mitsuhashi

REFRACTORY THYROID CANCER: THE GAME WORTH THE CANDLE

M. M. Khan, B. Toussaint, G. Weryha, M. Klein (Vandoeuvre-les-Nancy, France)
EXPRESSION OF A THYROGLOBULIN (TG) VARIANT IN WHICH IS THE NECESSITY OF REPEAT A STIMULATED THYROGLOBULIN MEASUREMENT IN FINE-NEEDLE ASPIRATE WASHOUTS FOR DETECTING LOCAL TUMOR RECURRENCE OF THE CENTRAL NECK IN PATIENTS WITH A HISTORY OF DIFFERENTIATED THYROID CANCER

J. W. Park, J. M. Lee, J. H. Bae, H. M. Yoon, W. B. Kim, S. J. Hong, Y. K. Shong (Seoul, Republic of Korea)

THE CLINICO-PATHOLOGICAL CHARACTERISTICS AND PROGNOSTIC VALUE OF PAPILLARY THYROID MICROCARCINOMA AND THE MALIGNANCY RATES OF ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION CYTOLOGY IN THYROID NODULES SMALLER THAN 1CM


PATTERN OF LATERAL NECK METASTASIS IN NO PAPILLARY THYROID CARCINOMA

F. Juglar, V. Patton, C. Beddert, G. Le Cloch (Rennes, France)

OCCULT LYMPH NODE METASTASIS IN DIFFERENTIATED THYROID CARCINOMA INCREASE LOCOREGIONAL RECURRENCE

F. Juglar, V. Patton, C. Beddert, G. Le Cloch (Rennes, France)

IS 0.225 MG INJECTED TWICE, THE CORRECT DOSE OF RECOMBINANT HUMAN TSH (RHTSH) DOSE IN PATIENTS CONFIRMED FREE OF DISEASE STATUS, IN PATIENTS WITH RECURRENT DIFFERENTIATED THYROID CANCER? A NOVEL ROLE FOR AMP-ACTIVATED PROTEIN KINASE IN THE REGULATION OF IODIDE AND GLUCOSE UPTAKE IN THYROID TUMORS

F. Jégoux, A. Noike, T. Minnich, H. Kierdorf, S. Meins (Bremen, Germany)

THE ASSOCIATION OF INSULIN RESISTANCE WITH SUBCLINICAL HYPOTHYROIDISM

J. Rezzonick, H. Niepomniszcze, M. Rezzonick, E. Pusiol, M. Alberto, J. Rezzonico, H. Niepomniszcze, M. Rezzonico, E. Pusiol (Buenos Aires, Argentina)

GLUCOSE METABOLISM AND T3 ATTENUATES ADIPOGENESIS BY ENHANCING BAT ADAPTATIVE THERMOGENESIS IN VITRO IN HUMAN LIPOTROPHIC CELLS

F. E. Wondisford, C. C. Pazos-Moura, T. M. Ortiga-Carvalho (São Paulo, Brazil)

THE CLINICOPATHOLOGICAL CHARACTERISTICS AND MANAGEMENT OF THYROID NODULES SMALLER THAN 1CM IN UKEK KIDNEY GLUCOSURIA


THYROID HORMONE ACTIONS/ Effects - Thyroid hormone and metabolism

A SURVEY ON RICE DIET NUTRITIONAL STATUS OF RESIDENTS IN COASTAL AREA OF SOUTHEAST CHINA

Z.-H. Chen (Fuzhou, China)

WHAT IS THE IODINE CONCENTRATION REQUIRED FOR OPTIMAL EFFICIENCY OF HORMONE PRODUCTION BY THYROID GLAND?

E. Bernas-Valentin, B. A. Reaupey (Lyon, France)

REGULATION OF THE RAT INTRATHYROIDAL DEIODINASES AND ITS IMPLICATION FOR THE WOLFF-CHAKOFF EFFECT


A NOVEL ROLE FOR AMP-ACTIVATED PROTEIN KINASE IN THE REGULATION OF IOIDE AND GLUCOSE UPTAKE IN THYROCYTES

B. M. Anda2, A. Arazno, P. Perry, E. Souza, D. Carvalho, R. Cordell (Rio de Janeiro, Brazil)

DISCUSSED POSTERS (PD17) (see page 50)

Thyroid hormone actions

ROLE OF THE THYROID HORMONE RECEPTOR IN DNA DAMAGE AND CELLULAR SENSITIVITY

A. Zambrano, V. Garcia-Carrión, M. Gómez-Serrao, A. Arias (Madrid, Spain)

TR ALFA ACTIVATION FULLY RESTORES THE IMPAIRED BAT ADAPTATIVE THERMOGENESIS INDUCED BY HYPOTHYROIDISM

L. X. Sun, F. Brits, R. J. Nasroll, J. Scanlan, M. O. Ribotno (Rio Paulo, Brazil)

THE 5MT MUTATION ON THE TR CYTOSOL ALTERATIONS ON GLUCOSE HEPATIC METABOLISM

L. A. Santiago, D. A. Santiago, R. D. S. Freja, A. Cordone, F. E. Wondisford, C. C. Pazos-Moura, T. M. Ortiga-Carvalho (São Paulo, Brazil)

ACTIVATION OF AMPK SIGNALING INDUCED BY 5MT-2 AND 5MT ATTENUATES ADIPOGENESIS BY Enhancing NITRIC OXIDE PRODUCTION IN LI-21 CELLS

A. Del Villano, A. Secundoa, A. Espoaa, C. Franco, E. Silviott, F. Foglia, M. Mootoa, E. M. S. Carneiros (Santos, Brazil)

EFFECTS OF THYROID HORMONE RECEPTOR A1 ON GLUCOSE METABOLISM

M. Vujovic, B. Vennstrom, J. Mittig (Stockholm, Sweden)

NCOX AFFECTS TSH MIRNA EXPRESSION IN T1I CELLS INDEPENDENTLY OF LIGAND

L. A. Santiago, S. Maitamotno, M. I. Chiamelara, T. M. Ortiga-Carvalho, F. E. Wondisford (Baltimore, United States)

Thyroid hormone actions/effects - Thyroid hormone and metabolism

THE ASSOCIATION OF INSULIN RESISTANCE WITH SUBCLINICAL HYPOTHYROIDISM

J. Rezzonick, H. Niepomniszcze, M. Rezzonick, E. Pusiol, M. Alberto, G. Bonta (Munster, Germany)

THE POTENTIAL ROLE OF THE THYROID HORMONES IN THE DNA DAMAGE OF THE HEART TISSUES, IN DIABETIC RATS

A. Cazar, F. Kowara, A. Sepulveda, A. Engin, N. Allan (Ankara, Turkey)

IN VITRO INHIBITION OF TYPE 2 IODOTHYRONINE DEIODINASE ACTIVITY IN CULTIVATED STIMULATED RAT BROWN ADIPOSE TISSUE BY THIMEROSAL


INDICATE CITROMETRY IS AN EXCELLENT INDICATOR OF OVERT THYROID DYSFUNCTION

R. Prinselo, S. Lageano, J. Quintanar, G. Frithbeek, J. Salvador, J. C. Gallo (Pamplona, Spain)
P-0711 EXPRESSION OF GHRELIN AND OBESITATIN IN THYROID GLAND
M. Zachalska, E. Gargul, J. Kasprzak, M. Bczykowski, J. Sudyb-Zanala, A. Koperszak, A. Lukaszewy, J. Swinski (Poznan, Poland)

P-0712 WEIGHT LOSS AFTER THERAPY OF HYPOTHYROIDISM IS MAINLY CAUSED BY EXCRETION OF EXCESS BODY WATER ASSOCIATED WITH MYXODEMA J. Karmisholt, S. Anderson, P. Leurtzb (Aalborg, Denmark)


P-0714 EFFECTS OF VARYING THYROID HORMONE LEVELS ON BONE TURNOVER AND BONE SITES SYSTEM IN MEN WITH DIFFERENTIATED THYROID CARCINOMA A. K. Uzun, S. Salinan, P. Atal, H. Buzigno, N. C. Obey, B. Onuf R. Szolaki, F. Angel (Bari, Italy)

P-0715 IMPAIRED THYROID HORMONE EFFECT ON MITOCHONDRIAL FUNCTION IN OBSESE ADOLESCENTS SUBJECTED TO OBSESE ADULTS J. Kovetsy, L. K. Wilme, P. Pedersen, J. Larsen (Naestved, Denmark)

P-0716 DIFFERENTIAL CHANGES IN PERIPHERAL MCT1 AND MCT9 EXPRESSION DURING ILLNESS J. Kozikul, E. Flens, A. Baxten (Amsterdam, Netherlands)


P-0718 RESPONSE OF RAT GASTROCRNIM SKELETAL MUSCLE LIPID METABOLISM TO T3 ADMINISTRATION: FOCUS ON FAT (CON A. Lombardi, L. Napoletti, R. A. Bousell, M. Mormo, P. De Lange, E. Skooten, A. Lamt, F. Goglia (Napoli, Italy)

P-0719 INFLUENCE OF REFERENCE PHYSIOLOGICAL DOSES OF TRIIODOTHYRONINE ON GENE EXPRESSION AND SERUM ADIPOKINE CONCENTRATION IN OBSESE RATS AND OBSESE RABS SUBMITTED TO FOOD RESTRICTION C. R. Nogueira, R. Luccinato, A. Nascimento, M. T. Silve, R. Olomp, M. Chovira, D. Campos, C. R. Padovan, A. C. Ciogna (Botucatu, Brazil)

P-0720 SUPRAPHYSIOLOGICAL DOSES OF TRIODOTHYRONINE (T3) PROVOKE DEOXYRIBONUCLEIC ACID (DNA) DAMAGE AND CRITICATIVE STRESS IN OBSESE ANIMALS SUBMITTED TO CALORIE RESTRICTION (CR) C. R. Nogueira, M. T. Silve, R. Luccinato, R. Olomp, J. Martinez, M. Chovira, C. Citon, S. C. A. Ciogna (Botucatu, Brazil)

P-0721 TSH REGULATES ICI ENZ DNA AND T3 DIOXIDONE ACTIVITY AND EXPRESSION IN BROWN ADOCYCIES R. Martinez de Mena, M. J. Omord (Madrid, Spain)


P-0723 INFLUENCE OF TIME OF ADMINISTRATION LEVOTHYROXINE ON SERUM TSH CONCENTRATION D. Popkova, E. Grineva, A. Babenko (Sant-Petersburg, Russian Federation)

P-0724 THYROID HORMONES IN THE EUTHYROID RANGE PRODUCE SUBCLINICAL BODY MASS COMPOSITION IN WOMEN: THE OPLS STUDY P. Rao, G. R. Williams, E. Murphy, D. M. Reid, C. Rous, D. Peterson, A. C. Gasor, B. Eastland, S. Roesl (Gatton, United Kingdom)

P-0725 THYROID DYSFUNCTION AND THYROID AUTODAIDROIES IN TYPE DIABETIC PATIENTS H. B. Shabbaz, M. Moshina, M. Samini (Alvray, Islamic Republic of Iran)

P-0726 HYPOTHYROIDISM ABOLISHES SPECIFIC EFFECTS OF NO- POLYUNSATURATED FATTY ACIDS ON LIPID METABOLISM: EVIDENCE OF SIGNALLING PATHWAY INTERACTIONS L. L. Souza, A. C. Carles, G. S. P. Maia, K. J. Oliveira, C. C. Paes-Moura (Rio de Janeiro, Brazil)


P-0728 REDUCTION OF LIPID LEVELS IN SUBCLINICAL HYPOTHYROIDISM TREATED WITH LEVOTHYRONINE M. L. D. Alves, T. R. C. Pereira, H. H. S. Medeiros, M. D. B. Oliveira, M. H. Gahara (Bertbeiro, Pretto, Brazil)

---

**Thyroid hormone actions/effects - Thyroid hormone and metabolism**

P-0731 ASSESSMENT OF BAROREFLEX ACTIVITY IN RATS WITH HYPOTHYROIDISM J. M. M. Angleron, W. G. Marccio, E. Colombo, M. A. Sato (Rio de Janeiro, Brazil)

P-0732 CARDIAC EFFECTS OF GLYPHOSAR RETAIL-DERIVED RECEPTOR POLYMORPHISM IN PATIENTS WITH THYROTOXICOSIS A. Babenko, A. A. Popkova, A. V. Kostareva (Saint Petersburg, Russian Federation)

P-0733 ACUTE EFFECT OF T3 ON GENES RELATED TO CARDIAC METABOLISM AND CONTRACTILTY IN RATS WITH AORTIC TENDOSIS E. L. Bronner, D. Camps, P. R. Souza, A. Ciogna, M. T. Nunes (Rio de Janeiro, Brazil)

P-0734 THYROID HORMONE INCREASES RAPIDLY THE POL-A TAIL LENGTH OF THE ANGIOGENIN II TYPE 1 RECEPTOR MRNA IN CARDIOMYOCYTES G. Dim, E. Bronner, F. G. Silva, M. T. Nunes, M. L. Barreto-Chaves (Rio de Janeiro, Brazil)

P-0735 ARE SERUM TSH LEVELS ASSOCIATED WITH OXIDIZED LOW DENSITY LIPOPROTEIN? T. Herrmann, S. E. Baunmester, R. Wölcke, C. Wann, U. Schmitz, H. Wallachobisch, M. Nauck, J. Liebmann (Giessen, Germany)

P-0736 ARE CHANGES OF SERUM TSH LEVELS ASSOCIATED WITH ALTERATION OF CARDIAC ELECTRICAL ACTIVITY? RESULTS FROM A LARGE POPULATION-BASED COHORT STUDY T. Herrmann, S. E. Baunmester, T. Rethlmann, J. Iker, N. Söds, M. Nauck, H. Wölcke, M. Dower (Gießen, Germany)

P-0737 REVERSIBLE DIALER CAROTIDOPATHY WITH HYPOTHYROIDISM TREATMENT I. Khochtali, N. Hamza, A. Baba, W. Dabbabi, O. Harzallah, S. Mahjoub (Jiddles, Tunisia)

P-0738 THE THYROID HORMONE LEVELS AND LIPID CONCENTRATIONS FROM A HEALTH EXAMINATION-BASED STUDY IN TAIWAN F.-H. Liu, J.-D. Lin, I.-N. Lin (Taipei, Taiwan, China)


P-0740 GRAVES DISEASE, AUTODEOGENE IMMUNE THYROIDITIS, INSULIN RESISTANCE AND CARDIOVASCULAR RISK FACTORS C. Nunez, M. Alves, M. Pereira, F. Rebelo, E. Carvalho, I. Panente, C. Palmeiro, O. Soula, J. Behrle, R. Ramalho, C. Bazumol, D. Carvalho, L. Delgado, J. L. Medina (Porto, Portugal)
P-0740 • IMPACT OF TOBACCO ON MATERNAL AND FETAL OUTCOME IN TERTIARY CARE HOSPITAL IN A RURAL AREA OF POLAND
A. Janjua, D. A. Sawaya, A. Malmberg, M. Dajani (Toronto, Canada)

P-0741 • COMPLETE REGRESSION IN UTERO OF A LARGE FETAL HYPOPLASIA ASSOCIATED WITH INTRAUTERINE GROWTH RETARDATION
E. Leveque, N. Fischlinger, F. Brucker-Davis (Nice, France)

P-0742 • POSTTRANSCRIPTIONAL PROTEIN MODIFICATIONS AS A POSSIBLE CONTRIBUTOR TO THE PATHOGENESIS OF HYPOTHYROIDISM IN ADULTS WITH MODERATE IODINE DEFICIENCY
U. F. Machado, M. T. Nunes (São Paulo, Brazil)

P-0743 • TRANSPLANTATION OF TRANSPLANTATION-REHABILITATED HYPOTHYROID HUMAN THYROID CELLS INTO RATS WITH EXPERIMENTAL HYPOTHYROIDISM: FUNCTIONAL AND IMMUNOLOGICAL ASPECTS
R. M. Romano, M. T. Nunes, J. M. Ferreira, M. T. Nunes (São Paulo, Brazil)

P-0744 • OXYURIS VERmIS: AN ALTERNATIVE Model FOR STUDYING THE IMMUNE RESPONSE TO PARASITIC INFECTION
S. N. Aslam, S. H. Khan, S. Qayum, M. M. Ansari (Pakistan)

P-0745 • DEFICIENT THYROID FUNCTION IN AN AREA OF MILD IODINE DEFICIENCY
F. Michas, N. Zakopoulos, M. Alevizaki (Athens, Greece)

P-0746 • IMPROVEMENT IN THYROID AND ESTROGENIC HORMONE METABOLISM IN MURINE HYPOTHYROID Models
S. N. Aslam, S. H. Khan, S. Qayum, M. M. Ansari (Pakistan)

P-0747 • IMPLICATIONS OF MATERNAL THYROID FUNCTION ON FETAL GROWTH: A PROSPECTIVE FOLLOW-UP STUDY IN SOUTHERN ITALY
R. Tempesta, M. Elia, G. Giorgianni, M. M. Montesinos, V. A. Alamino, I. D. Mascanfroni (Córdoba, Argentina), A. Bongain, P. Fenichel, S. Hieronimus (Nice, France)

P-0748 • CAN POSTTRANSFUSION THYROIDITIS AFFECT BLOOD PRESSURE IN SUBJECTS UNDERGOING AUTOIMMUNE HYPERTHYROIDISM TREATMENT WITH PTU FOR THE MANAGEMENT OF GRAVES’ DISEASE
J. Gil, A. Basta, I. Kaim, A. Hubalewska-Dydejczyk (Krakow, Poland), U. Feldt-Rasmussen (Copenhagen, Denmark)

P-0749 • THE HUMAN HYPOTHALAMIC-PITUITARY-ENDOCRINE AXIS (HPG) IN MALE RATS IMPAIRMENT ON HYPOTHALAMUS-PITUITARY-GONADS (HPG) AXIS FUNCTION IN EXPERIMENTAL HYPOTHYROIDISM
T. M. T. Zorn, M. T. Nunes (São Paulo, Brazil)

P-0750 • CAN POSTTRANSFUSION THYROIDITIS AFFECT BLOOD PRESSURE IN SUBJECTS UNDERGOING AUTOIMMUNE HYPERTHYROIDISM TREATMENT WITH PTU FOR THE MANAGEMENT OF GRAVES’ DISEASE
J. Gil, A. Basta, I. Kaim, A. Hubalewska-Dydejczyk (Krakow, Poland), U. Feldt-Rasmussen (Copenhagen, Denmark)

P-0751 • THE HUMAN HYPOTHALAMIC-PITUITARY-ENDOCRINE AXIS (HPG) IN MALE RATS IMPAIRMENT ON HYPOTHALAMUS-PITUITARY-GONADS (HPG) AXIS FUNCTION IN EXPERIMENTAL HYPOTHYROIDISM
T. M. T. Zorn, M. T. Nunes (São Paulo, Brazil)

P-0752 • IMPLICATIONS OF MATERNAL THYROID FUNCTION ON FETAL GROWTH: A PROSPECTIVE FOLLOW-UP STUDY IN SOUTHERN ITALY
R. Tempesta, M. Elia, G. Giorgianni, M. M. Montesinos, V. A. Alamino, I. D. Mascanfroni (Córdoba, Argentina), A. Bongain, P. Fenichel, S. Hieronimus (Nice, France)

P-0753 • NEWBORN BABIES TEND TO BECOME SUBCLINICAL HYPOTHYROID WHEN USING PTU FOR THE MANAGEMENT OF GRAVES’ DISEASE IN COMPARISON WITH USING MMI
Y. Kamis, H. Yoshimura, K. Makusa, M. Matsuno, M. Suzuki, K. Ik, K. (Tokyo, Japan)

P-0754 • HYPOPHYSEAL-STIMULATING EFFECT OF EXTRAXTRACT OF TRANSPLANTATION-REHABILITATED HUMAN THYROID CELLS IN RAT HYPOTHALAMUS
R. M. Romano, M. T. Nunes, J. M. Ferreira, M. T. Nunes (São Paulo, Brazil)

P-0755 • DEFICIENT THYROID FUNCTION IN AN AREA OF MILD IODINE DEFICIENCY
F. Michas, N. Zakopoulos, M. Alevizaki (Athens, Greece)

P-0756 • IMPLICATIONS OF MATERNAL THYROID FUNCTION ON FETAL GROWTH: A PROSPECTIVE FOLLOW-UP STUDY IN SOUTHERN ITALY
R. Tempesta, M. Elia, G. Giorgianni, M. M. Montesinos, V. A. Alamino, I. D. Mascanfroni (Córdoba, Argentina), A. Bongain, P. Fenichel, S. Hieronimus (Nice, France)

P-0757 • IMPLICATIONS OF MATERNAL THYROID FUNCTION ON FETAL GROWTH: A PROSPECTIVE FOLLOW-UP STUDY IN SOUTHERN ITALY
R. Tempesta, M. Elia, G. Giorgianni, M. M. Montesinos, V. A. Alamino, I. D. Mascanfroni (Córdoba, Argentina), A. Bongain, P. Fenichel, S. Hieronimus (Nice, France)

P-0758 • THE HUMAN HYPOTHALAMIC-PITUITARY-ENDOCRINE AXIS (HPG) IN MALE RATS IMPAIRMENT ON HYPOTHALAMUS-PITUITARY-GONADS (HPG) AXIS FUNCTION IN EXPERIMENTAL HYPOTHYROIDISM
T. M. T. Zorn, M. T. Nunes (São Paulo, Brazil)

P-0759 • HYPOPHYSEAL-STIMULATING EFFECT OF EXTRAXTRACT OF TRANSPLANTATION-REHABILITATED HUMAN THYROID CELLS IN RAT HYPOTHALAMUS
R. M. Romano, M. T. Nunes, J. M. Ferreira, M. T. Nunes (São Paulo, Brazil)

P-0760 • DEFICIENT THYROID FUNCTION IN AN AREA OF MILD IODINE DEFICIENCY
F. Michas, N. Zakopoulos, M. Alevizaki (Athens, Greece)

P-0761 • THE HUMAN HYPOTHALAMIC-PITUITARY-ENDOCRINE AXIS (HPG) IN MALE RATS IMPAIRMENT ON HYPOTHALAMUS-PITUITARY-GONADS (HPG) AXIS FUNCTION IN EXPERIMENTAL HYPOTHYROIDISM
T. M. T. Zorn, M. T. Nunes (São Paulo, Brazil)

P-0762 • CAN POSTTRANSFUSION THYROIDITIS AFFECT BLOOD PRESSURE IN SUBJECTS UNDERGOING AUTOIMMUNE HYPERTHYROIDISM TREATMENT WITH PTU FOR THE MANAGEMENT OF GRAVES’ DISEASE
J. Gil, A. Basta, I. Kaim, A. Hubalewska-Dydejczyk (Krakow, Poland), U. Feldt-Rasmussen (Copenhagen, Denmark)

P-0763 • DEFICIENT THYROID FUNCTION IN AN AREA OF MILD IODINE DEFICIENCY
F. Michas, N. Zakopoulos, M. Alevizaki (Athens, Greece)

P-0764 • THE HUMAN HYPOTHALAMIC-PITUITARY-ENDOCRINE AXIS (HPG) IN MALE RATS IMPAIRMENT ON HYPOTHALAMUS-PITUITARY-GONADS (HPG) AXIS FUNCTION IN EXPERIMENTAL HYPOTHYROIDISM
T. M. T. Zorn, M. T. Nunes (São Paulo, Brazil)

P-0765 • DEFICIENT THYROID FUNCTION IN AN AREA OF MILD IODINE DEFICIENCY
F. Michas, N. Zakopoulos, M. Alevizaki (Athens, Greece)

P-0766 • THE HUMAN HYPOTHALAMIC-PITUITARY-ENDOCRINE AXIS (HPG) IN MALE RATS IMPAIRMENT ON HYPOTHALAMUS-PITUITARY-GONADS (HPG) AXIS FUNCTION IN EXPERIMENTAL HYPOTHYROIDISM
T. M. T. Zorn, M. T. Nunes (São Paulo, Brazil)

P-0767 • DEFICIENT THYROID FUNCTION IN AN AREA OF MILD IODINE DEFICIENCY
F. Michas, N. Zakopoulos, M. Alevizaki (Athens, Greece)

P-0768 • THE HUMAN HYPOTHALAMIC-PITUITARY-ENDOCRINE AXIS (HPG) IN MALE RATS IMPAIRMENT ON HYPOTHALAMUS-PITUITARY-GONADS (HPG) AXIS FUNCTION IN EXPERIMENTAL HYPOTHYROIDISM
T. M. T. Zorn, M. T. Nunes (São Paulo, Brazil)

P-0769 • DEFICIENT THYROID FUNCTION IN AN AREA OF MILD IODINE DEFICIENCY
F. Michas, N. Zakopoulos, M. Alevizaki (Athens, Greece)

P-0770 • DEFICIENT THYROID FUNCTION IN AN AREA OF MILD IODINE DEFICIENCY
F. Michas, N. Zakopoulos, M. Alevizaki (Athens, Greece)
DISCUSSION POSTERS (PD19) (see page 50)
The role of thyroid hormone in brain and development

P-0788 THE EFFECT OF MATERNAI HYPOTHYROIDISM ON MICRONEMA EXPRESSION PROFILES IN BRAIN OF OFFSPRINGS
Q. Xing, Z. Huang, Y. Gao, W. Teng (Shenyang, China)
P-0789 EFFECTS OF LEVOTHYROID TREATMENT ON OFFSPRING BRAIN DEVELOPMENT IN PREGNANT RATS WITH SUBCLINICAL HYPOTHYROIDISM
P-0790 THYROID HORMONE (T3) INCREASES NEUROGLOBIN EFFECTS OF LEVOTHYROXINE TREATMENT ON THE HUMAN HYPOTHALAMUS AND CYTOGLOBIN GENE EXPRESSION ON RAT CORTEX,
S. Wang, Y. Gao, J.-Y. Mao, C.-L. Fan, H. Wang, H.-M. Zhang (Shenyang, China)
P-0791 THE HYPOTHALAMUS AND CYTOGLOBIN GENE EXPRESSION ON RAT CORTEX,
S. Wang, Y. Gao, J.-Y. Mao, C.-L. Fan, H. Wang, H.-M. Zhang (Shenyang, China)
P-0792 THYROID HORMONE METABOLITE 3,5-DIIODO-L-THYRONINE PREVENTS HIGH FAT DIET-INDUCED INSULIN RESISTANCE: FOCUS ON MUSCLE MITOCHONDRIAL PROTEOME AND FUNCTION
M. Moreno, F. Silvestro, D. Gliner, R. de Lange, A. Lombardi, A. Lami, F. Goglia (Benevento, Italy)
P-0793 SIRTUIN1 PROTEIN EXPRESSION AND ACTIVITY ARE NEGATIVELY REGULATED BY THYROID HORMONE

Thyroid function regulation / TSH / TRH

P-0794 ANALYTICAL PERFORMANCES AND REFERENCE RANGES OF NEW ULTRASENSITIVE TSH AND FREE THYROXINE ASSAYS ON THE ADVANTAGE CENTRAL RADIUS/ RADIUS SYSTEMS
A. Agin, F. Gavos, M. H. H. H. Hecmance, F. Massart (Strasbourg, France)
P-0795 TSH AND THYROIDGLITOBULINE MODULATE MICRONEMA EXPRESSION THAT REGULATE THYROID CELL GROWTH
P-0796 FAMILIAL GLUCOCORTICOID DEFICIENCY (FGD) AS A NEW CAUSE OF NON-AUTO IMMUNE HYPERTHYROTROPINEMIA (HyperTSH)
M. Butteri, D. V. Libo, D. Figini Kasparyk, G. Radetti, L. Persani (Milan, Italy)
P-0797 THE EFFECT OF THE MENSURAL CYCLE, A SAMPLE OF IMPRANIS RHYTHM, ON THYROID VOLUME AND PITUITARY FUNCTION
P-0798 DIMINISHED CIRCADIAN RHYTHMS IN EXTREME INFRAHIST RHYTHM, ON THYROID VOLUME AND PITUITARY FUNCTION
P-0799 EXPERIMENTAL HYPOTHYROIDISM REDUCES LEPTIN REGULATION OF THE THERMOGENIC FUNCTION BY THE THYROID HORMONE METABOLITE 3,5-DIIODO-L-THYRONINE: AN INTESTINAL RESPONSE TO DIFFERENT KIETERIOPOIESIS
P-0800 SYSTEMS OF NEW ULTRASENSITIVE TSH AND FREE THYROXINE ASSAYS ON THE ADVANTAGE CENTRAL RADIUS/ RADIUS SYSTEMS
A. Agin, F. Gavos, M. H. H. H. Hecmance, F. Massart (Strasbourg, France)
P-0801 DEMENTED CIRCADIAN RHYTHM, IN EXTREME INFRAHIST RHYTHM, ON THYROID VOLUME AND PITUITARY FUNCTION
P-0842 TSH BIOACTIVITY IN CHILDREN WITH ISOLATED CENTRAL HYPOTHYROIDISM ASSOCIATED WITH MACROCRINOMA

P-0833 THE PITUITARY-THYROID AXIS SET POINT IS UNINFLUENCED BY 5'-CHROMOSOME IN ACTIVATION PATTERN: A TWINS STUDY
P. S. Harner, T. H. Blu, K. O. Kyvik, L. Høgdal (Odense C, Denmark)

P-0834 ACUTE TD ADMINISTRATION REDUCES THE TSH LABELING AT THE PERIPHERY OF HYPOTHYROID RAT THYRIOTOPS INDEPENDENTLY OF THE ACTIN CYTOPLASM: A POSSIBLE NON GENOMIC ACTION OF THYROID HORMONE ON TSH SECRETION

P-0835 ROLE OF 2-iodo-hexadecanal in the Thyroid Autoregulatory Mechanism

P-0836 INTERLAY BETWEEN PHOSPHOINOSITIDE-3-KINASE, MAXIMALIST TARGET OF RAPAMYCIN (PI3K/mTOR) AND 5'-AMP-ACTIVATED PROTEIN KINASE (AMPK) PATHWAYS IN THE REGULATION OF IO UPTAKE IN THYROCYTES
E. C. D. Souza, R. M. Andrade, E. N. Naccetti, A. C. F. Ferrone, D. P. D. Cardoso (Rio de Janeiro, Brazil)

P-0837 THYROGLUBLIN (TG) ACTIVATES MAPK PATHWAYS TO NORMALIZE WITH A THYROID-STIMULATING DIET
E. C. L. D. Souza, P. Miśkiewicz, K. Knypl, E. Bar-Andziak (Warsaw, Poland)

P-0838 EFFECTS OF IOXIDE SUPPLEMENTATION ON THYROID HORMONE CONCENTRATIONS IN PRETERM INFANTS BORN BEFORE 28 WEEKS' GESTATIONAL AGE

P-0839 TSH CONCENTRATION IN A POPULATION WITH NO EVIDENCE OF TSHUPTAKE: A POSSIBLE NON GENOMIC ACTION OF THYROID HORMONE ON TSH SECRETION
E. C. L. D. Souza, R. M. Andrade, E. N. Naccetti, A. C. F. Ferrone, D. P. D. Cardoso (Rio de Janeiro, Brazil)

P-0840 SYMPTOMS OF SUBCLINICAL HYPOTHYROIDISM ARE CLINICALLY AND PATHOLOGICALLY REDUCED AFTER IOXIDE SUPPLEMENTATION IN A POPULATION WITH NO EVIDENCE OF TSHUPTAKE: A POSSIBLE NON GENOMIC ACTION OF THYROID HORMONE ON TSH SECRETION
E. C. L. D. Souza, P. Miśkiewicz, K. Knypl, E. Bar-Andziak (Warsaw, Poland)

P-0841 ASSOCIATION BETWEEN SUBCLINICAL HYPOTHYROIDISM AND PREVALENCE OF RENAL/METABOLIC MARKERS IN NORMAL CHILDREN FROM RURAL AREAS WITH SUBCLINICAL HYPOTHYROIDISM PATIENT AND EUTHYROID SUBJECTS
S. A. Sonbolestan, S. A. Mohamadi, N. Khalili Boroujeni (Tehran, Islamic Republic of Iran)

P-0842 ASSOCIATION BETWEEN SUBCLINICAL HYPOTHYROIDISM AND PREVALENCE OF RENAL/METABOLIC MARKERS IN NORMAL CHILDREN FROM RURAL AREAS WITH SUBCLINICAL HYPOTHYROIDISM PATIENT AND EUTHYROID SUBJECTS
S. A. Sonbolestan, S. A. Mohamadi, N. Khalili Boroujeni (Tehran, Islamic Republic of Iran)
INTERACTION OF CYSTEINE CATHEPSINS WITH DNA-
ASSOCIATED PROTEINS – A NEW MECHANISM FOR
MALIGNANT DEVELOPMENT IN THE THYROID?

P-0862
CHARACTERIZATIONS OF A HUMAN THYROID CANCER
CELL LINE, DHH-4, ESTABLISHED FROM A POORLY
DIFFERENTIATED THYROID CARCINOMA EXHIBITING
MULTIPLE BONE METASTASES
J. Tsuchiya (Sendai, Japan)

P-0863
SURVIVORSHIP PHRASE OF THYROID CANCER
P-0865
CHARACTERIZATIONS OF A HUMAN THYROID CANCER
COMPARISON OF MRNA AND MICRORNA EXPRESSION
DETECTION OF INCREASED FREQUENCY OF THYROID
P-0873
THE INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN
P-0871
METHYLATION OF PEBP1, A METASTASIS SUPPRESSOR
BRAF IN PRIMARY AND RECURRENT PAPILLARY
P-0868
GENOME-WIDE GENE EXPRESSION INDUCED BY
A NEW SENSITIVE AUTOMATED THYROGLOBULIN ASSAY
P-0866
COPY NUMBER ABERRATIONS IN PAPILLARY THYROID
P-0865
PSYCHOMOTOR DELAY IN PATIENTS WITH CONGENITAL
HYPOTHYROIDISM AND ADJUSTMENT OF
THYROID SUBSTITUTION AND OPEN-ANGLE GLAUCOMA
P-0887
PREVALENCE OF OBESITY IN OVERT HYPOTHYROIDISM
P-0885
PREVALENCE OF ARTERIAL HYPERTENSION IN PATIENTS
FINAL HEIGHT IN PATIENTS AFFECTED BY CONGENITAL
THYROID DYSFUNCTION AND AGE: TEHRAN LIPID AND
P-0882
ULTRASONOGRAPHIC EVALUATION OF THE THYROID,
RELATIONSHIP BETWEEN SUBOPTIMAL SELENIUM
DEFICIENCY IN EARLY PREGNANCY CAN BE REVERSED
BY RESTORATION OF THYROID STATUS AND/OR BY
THYROIDINE PRODUCED BY THE CHILD
N. Momotani, S. Inama (Tokyo, Japan)

P-0876
CLINICAL COURSE OF FOUR PEDIATRIC PATIENTS WITH
CONGENITAL HYPOTHYROIDISM HARBOURING NOVEL
MUTATIONS IN THE TSHR GENE
A. Kiyaro, N. Akilevich, V. Surushe, N. Nikitina,
M. Sumina, E. Chermova, A. Shkaratov, E. Parshkova,
E. Chumakhtina, O. Malevsky, M. Smirnova, V. Aranovich,
J. Gerh, Y. Skorodok (Ekaterinburg, Russian Federation)

P-0877
PSYCHOMOTOR DELAY IN PATIENTS WITH CONGENITAL
HYPOTHYROIDISM: INADEQUATE TREATMENT OR
GENETIC SYNDROMES?
M. Muzandiyi, J. Liger, M. Polak, M. Carastan (Paris, France)

P-0878
LOW NORMAL OR HIGH NORMAL TSH TARGET LEVELS
DURING TREATMENT OF HYPOTHYROIDISM – A
PROSPECTIVE COMPARATIVE STUDY
G. A. Carvalho, A. Borring, B. R. Radimkeri, G. Paz-Filho,
H. Graf (Curitiba, Brazil)

Clinical thyroidology - Hypothyroidism

P-0879
HYPOTHYROIDISM AND ADJUSTMENT OF
LEVOTHYROXINE SUBSTITUTION THERAPY IN PREGNANT
WOMEN
T. Sekhri, S. Nan, J. Sethi, J. Agarwal (Delhi, India)

P-0880
RELATIONSHIP BETWEEN SUBOPTIMAL SELENIUM
STATUS AND SUBCLINICAL HYPOTHYROIDISM IN SAUDI
MALES WITHOUT CORONARY HEART DISEASE
E. Alsaleh, G. Serra (Jeddah, Saudi Arabia)

P-0881
ULTRASONOGRAPHIC EVALUATION OF THE THYROID,
DETERMINATION OF IODINA AND IODINE
CONCENTRATION IN KITCHEN SALT USED BY
SCHOOLCHILDREN IN RIBEIRAO PRETO, SÃO PAULO,
BRASIL
M. L. D. Alves, G. Duarte, A. M. Naveira, E. K. Tommori
(Ribeirão Preto, Brazil)

P-0882
THERODIPONTICATION AND AGE: TEHRAN LIPID AND
GLUCOSE STUDY (TLGS)
A. Amousaug, H. Delibah, F. Aziz (Tehran, Islamic Republic
of Iran)

P-0883
HIGHER RISK OF LEVOTHYROXINE REPLACEMENT THERAPY IN ADULT PATIENTS WITH CONGENITAL HYPOTHYROIDISM AND THYROID AGENESIS WITH RESPECT TO ADULT PATIENTS WITH POST-SURGICAL HYPOTHYROIDISM
B. Bagattini, L. Montanelli, A. Pinchera, P. Vitti, M. Tonacchera (Pisa, Italy)

P-0884
FINAL HEIGHT IN PATIENTS AFFECTED BY CONGENITAL
HYPOTHYROIDISM DIAGNOSED AT NEONATAL
SCREENING
B. Bagattini, L. Montanelli, M. De Servo, M. Campi, P. Agostì,
G. De Marco, C. Di Cosmo, A. Perri, L. Chiovato, P. Vitti,
A. Pinchera, M. Tonacchera (Pisa, Italy)

Clinical thyroidology - Hypothyroidism

P-0885
PREVALENCE OF ARTERIAL HYPERTENSION IN PATIENTS
WITH OVERT HYPOTHYROIDISM
N. Ben Abdallah (Tunis, Tunisia)

P-0886
PREVALENCE OF OBESITY IN OVERT HYPOTHYROIDISM
N. Ben Abdallah (Tunis, Tunisia)

P-0887
THYROID SUBSTITUTION AND OPEN-ANGLE GLAUCOMA
-A POPULATION BASED REGISTRI VIEW OF
PRESCRIPTIONS-
J. Calissendorf, R. Ljung (Stockholm, Sweden)
THYROID DYSFUNCTION AND ANEMIA DURING P-0896
MORE THAN MYXEDEMA COMA, SHE HAS SHEEHAN'S! A P-0895
THYROID HYPOFUNCTION A POSSIBLE IMPORTANT P-0894
OUTCOME OF TREATMENT IN CONGENITAL P-0893
THE EFFECT OF MILD L-THYROXIN DOSE INCREMENT ON P-0892
LEVOTHYROXINE TREATMENT IN HYPOTHYROIDISM P-0891
THE STUDY OF GASTRIC MOTILITY AND HELICOBACTER P-0890
COLESEVELAM HCL: A MODALITY TO ADDRESS THE P-0889
DIFFERENCES BASED ON GENDER AND AGE IN P-0888
LEVOTHYROXINE DOSE REQUIREMENT IN P-0887
HYPOTHYROID PATIENTS COMPARED TO P-0886
VERY LARGE NUMBER OF THYROIDECTOMIZED PERIPHERAL TISSUES: ANALYSIS OF FT3/FT4 RATIO IN A P-0885
DOES NOT PROVIDE A BALANCED T3 AND T4 SUPPLY TO P-0884
PATIENTS WHO HAVE RECEIVED RADIOIODINE THERAPY FOR BENIGN NONTOXIC MULTINODULAR RETROSTERNAL GOITER: DATA FROM A CASE SERIES. J. I. Chang, T. C. Baird, J. S. LoPresti (Los Angeles, United States)

DISCUSSED POSTERS (PD21) (see page 60)
Clinical thyroidology - Nontoxic goiter

P-0897 BILATERAL ANTEROLATERAL COMPARTMENT SYNDROME IN A PATIENT WITH NEVOID DIAGNOSED HYPOPHYDROIDISM: A LOCAL CASE REPORT K. Kilajaparnol, C. Lim, T. Sullivan (Singapore, Singapore)
P-0898 OBSERVATIONAL STUDY OF THE INITIAL MANAGEMENT OF HYPOPHYDROIDISM IN FRANCE: THE ORCHIDEE STUDY B. Delamer, J.-P. Aubert, R. Landon, S. Roux (Rennes, France)
P-0899 EVALUATION OF THE PSYCHOMETRICAL STATUS OF THE PATIENTS WHO HAVE RECEIVED RADIODOXINE TREATMENT FOR GRAVES DISEASE BY CATAMNESIS DATA D. Ripangade, A. Deshpande, I. Koteswara, J. Kodad, T. Maredona (Mosceo, Russian Federation)
P-0900 THE USEFULNESS OF ULTRASONIC IN FOLLOW-UP OF THE PATIENT WITH DYSHORMONOGENETIC CONGENITAL HYPOPHYDROIDISM M. Nandita (Poznan, Poland)
P-0901 CAN LEVOTHYROXINE BE TAKEN AS EVENING DOSE?: A PROSPECTIVE RANDOMISED CONTROLLED TRIAL COMPARING EFFICACY OF MORNING VS EVENING DOSE OF LEVOTHYROXINE R. Rajput, S. Chatterjee, M. Rajput (Rohtak, India)
P-0902 PRIMARY HYPOPHYDROIDISM PRESENTING AS PITUITARY MASS CAUSING COMPREHENSIBLE SYMPTOMS: A CASE REPORT S. Galoiu, A. Latina, F. Frasca, P. Malandrino, I. Marturano, E. Lagoudianakis, H. Markogiannakis, A. Latina (Bat Yam, Israel)
P-0904 TRACING FAMILY HISTORY OF HYPOPHYDROID DISEASE AND GENDER: PREDICTIVE FACTORS OF EARLY HYPOPHYDROIDISM IN EARLY HYPOPHYDROID TREATMENT OF GRAVES DISEASE Y. C. Sun, N. Y. Jiang, Y. F. Sun, X. Xiong (Guangzhou, China)
P-0905 THE INTERPLAY BETWEEN ENVIRONMENTAL AND GENETIC FACTORS IN A GROUP OF PATIENTS WITH AUTOIMMUNE THYROIDITIS H. I. Ura, S. Galain, C. Podia-Igna, M. Purtos, D. Iucchin, B. Stanescu, D. Hortopan, D. Alexandrescu (Bucharest, Romania)
P-0906 ANALYSIS OF DNA SINGLE NUCLEOTIDE POLYMORPHISMS BY PERIODQUANTITATING V. Marotta, M. R. Sapio, A. Guerra, G. Camponio, R. Formisano, G. Rossi, G. Pares, M. Vitale (Napoli, Italy)
P-0907 HYPOPHYDROIDISM IN PATIENTS WITH PITUITARY ADENOMA: ANALYSIS OF 34 PATIENTS PRE- AND POST-OPERATION M. Yamada, K. Hotta, H. Hashimoto, T. Satoh, S. Yamada, M. Mori (Matsubara, Japan)
P-0908 PERICARDIAL EFFUSION IN HYPOPHYDROID PATIENTS N. B. Zelnikova, V. Parukh (Kyiv, Ukraine)

Clinical thyroidology - Nontoxic Goiter

P-0909 LONG-TERM OUTCOME OF BRITISH SIMULATED RADIODOXINE (IUS) THERAPY FOR BENIGN NONTOMIC NODULAR GOITER S. Fast, V. E. Naidoo, P. Grange, H. Balshaw, L. Burallit, J. R. J. Romana, L. Nagy (Oslo, Denmark)
P-0911 IODINE STATUS, SELENIUM DEFICIENCY AND THYROID AUTOIMMUNITY IN THE ETIOLOGY OF ENDEMIC GOITER IN SCHOOL CHILDREN OF ISFAHAN, IRAN A. Hassanzadeh Keshteli, A. Abdi, M. Hashemipour, M. Amiri (Isfahan, Islamic Republic of Iran)
P-0912 THYROID-SPECIFIC AND GENERIC QUALITY OF LIFE IN PATIENTS WITH NON-TOXIC GOITRE, COMPARED TO THE GENERAL POPULATION P. Cramon, T. Watt, L. Hegedus, S. Venus, M. Grønvold, P. K. R. Magalhaes, L. M. Z. Maracal (Rio de Janeiro, Brazil)
P-0913 EFFECTIVENESS OF ADMINISTRATION OF LITHIUM AND RADIOACTIVE IODINE (131I) THERAPY FOR BENIGN NONTOXIC MULTINODULAR NONTOMIC GOITER WITH RADIOACTIVE IODINE D. S. Alvanzo, P. E. Aspayo, W. M. Araiza, V. F. Mejila, P. R. K. Magalhaes, L. M. Z. Maracal (Rio de Janeiro, Brazil)
P-0914 PREFERENCES STRATEGIES IN TREATMENT OF THE MULTINODULAR GOITER M. Vazian (Bab Yarm, Israel)

Clinical thyroidology - Nontoxic Goiter

P-0916 RESULTS FROM AN OBSERVATIONAL STUDY ON GENERAL PRACTITIONERS’ AND ENDOCRINOLOGISTS’ MEDICAL PRACTICE FOR THE MANAGEMENT OF SIMPLE GOITER IN FRANCE: THE DIAGONALE STUDY P. Canu, P. Lebert, R. Landson (Toulouse, France)
POSTERS B

14th INTERNATIONAL THYROID CONGRESS • Paris, Palais des congrès • 11-16 September 2010

DISCUSSED POSTERS (PD23) (see page 61)

1023 CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS AND OUTCOME OF T3A VS T3B THYROID CARCINOMAS

1024 MEASURING TFF3/LGALS3 MRNA RATIO IN FNABS FROM THYROID NODE WITH METASTATIC AND RECURRENT FOLLICULAR THYROID CANCER
H. Tokuuye (Tokyo, Japan)

1025 THE CLINICOPATHOLOGICAL DIFFERENCES IN PAPILLARY THYROID CANCER WITH OR WITHOUT CONSTITUTIVE CHRONIC LYMPHOCYTIC THYROIDITIS
Y.-H. Yoon, B.-S. Koo (Daegu, Republic of Korea)

1026 CLINICAL SIGNIFICANCE OF RAS MUTATIONS IN FOLLICULAR CARCINOMA OF THE THYROID
M. Webber (Bridgend, United Kingdom)

1027 THYROID REMNANT ABLATION IN OUTPATIENTS WITH 131I-0.1 GBq OF I-131
K. Tokuuye (Tokyo, Japan)

1028 STRONG IMPLICATIONS FOR IODINE ABLATION: NO TIE, NO DRAIN TECHNIQUE USING HARMONIC SCALPEL IN THYROID SURGERY
D. Vidalgin, D. Viola, M. Martinho, T. Azevedo, T. Martins, N. Cunha (Guangzhou, China)

1029 COMPARISON OF PEDIATRIC THYROID CANCER WITH ADULT THYROID CANCER IN A SINGLE THYROID CANCER CLINIC

1030 THE SELECTION OF THE INITIAL SURGERY EXTENT FOR DIFFERENTIATED THYROID CANCER WITHOUT METASTASIS
S. Wang (Guangzhou, China)

1031 THE VALUE OF DETECTABLE THYROID-LIBERATED TSH IN THE FOLLOW-UP AND TREATMENT OF DIFFERENTIATED THYROID CARCINOMA
E. Hindié, E. Vassilatou, N. Klonaris, A. Vrionidou, D. Ioannidis, A. Koletti, G. Thomas (London, United Kingdom)

1032 THE CLINICAL USE OF F-18 FDG PET IN PATIENTS WITH THYROID CANCER
M. Ruan, A. Maré, A. Alver, S. Mandel (Istanbul, Turkey)

1033 THE SELECTION OF THE INITIAL SURGERY EXTENT FOR DIFFERENTIATED THYROID CANCER USING SELECTIVE RADIOIODINE ABLATION
Y. Loui, I. Alyomar, H. Kaito (Sakai, Japan)

1034 THE CLINICAL SIGNIFICANCE OF BRAF MUTATION STATUS IN PAPILLARY THYROID CARCINOMAS WITH BRAF MUTATION STATUS IN PAPILLARY THYROID CARCINOMAS
G. Thomas (London, United Kingdom)

1035 SHORT-TERM QUALITY OF LIFE RELATED TO DYSPHAGIA IN PATIENTS SUBMITTED TO THYROIDECTOMY FOR LOCALIZED THYROID CARCINOMA: IS THERE ANY DIFFERENCE BETWEEN T1A AND T1B?

1036 MEASURING TFF3/LGALS3 MRNA RATIO IN FNABS FROM THYROID NODE WITH METASTATIC AND RECURRENT FOLLICULAR THYROID CANCER
H. Tokuuye (Tokyo, Japan)

1037 THE BENEFIT OF A NURSE-LED VOCAL CORD FUNCTION CLINIC IN THE MANAGEMENT OF THYROID CANCER
M. Webber (Bridgend, United Kingdom)

1038 LONG-TERM STABILISATION OF A HUGE INOPERABLE THYROID CARCINOMA WITH RADIOIODINE THERAPY UNDER RECOMMEND 70 MEASUREMENT OF EFFECTIVE DOSE TO CAREGIVERS AND ESTABLISHMENT OF SAFETY PRECAUTIONS
S. Y. Pae, S. R. Zakavi, M. Watanabe, Y. Hidaka, Y. Iwatani, A. Miyauchi (Osaka, Japan)

1039 TWO CASES OF THYROID METASTASIS OF CLEAR CELL RENAL CARCINOMA
T. Inoue, T. Mitsuhashi, R. Watanabe, K. Hiruma, K. Ono (Tokyo, Japan)

1040 IN SPY 2009 GUIDELINES ON MULTICOX-TI PAPILLARY CANCER: IS THIS APPROPRIATE? LONG-TERM RETROSPECTIVE ANALYSIS IN A NUCLEAR MEDICINE CENTER
A. T. Triantafoulou (Bucharest, Romania)

1041 DISCUSSION ON RISK FACTORS FOR LOCAL RECURRENT OF THYROID CANCER
F. J. Rodrigues, A. Neves, C. O. Santos, F. Araujo, J. Romaldini (Campinas, Brazil)

1042 INSTRUMENTAL SWALLOWING EVALUATION IN PATIENTS SUBMITTED TO THYROID SURGERY FOR PRIMARY THYROID CANCER: IS THERE ANY DIFFERENCE BETWEEN T1A AND T1B?

1043 INSTRUMENTAL SWALLOWING EVALUATION IN PATIENTS SUBMITTED TO THYROIDECTOMY FOR LOCATED THYROID CANCER USING SELECTIVE RADIOIODINE ABLATION
Y. Loui, I. Alyomar, H. Kaito (Okayama, Japan)

1044 THE CLINICAL USE OF F-18 FDG PET IN PATIENTS WITH THYROID CANCER
M. Ruan, A. Maré, A. Alver, S. Mandel (Istanbul, Turkey)

1045 DISCUSSION ON RISK FACTORS FOR LOCAL RECURRENT OF THYROID CANCER
F. J. Rodrigues, A. Neves, C. O. Santos, F. Araujo, J. Romaldini (Campinas, Brazil)

1046 DISCUSSION ON RISK FACTORS FOR LOCAL RECURRENT OF THYROID CANCER
F. J. Rodrigues, A. Neves, C. O. Santos, F. Araujo, J. Romaldini (Campinas, Brazil)

1047 SHORT-TERM FOLLOW-UP OUTCOME OF STAGE I THYROID CANCER PATIENTS IN 2000: IS THERE ANY DIFFERENCE BETWEEN BRAF/RTK4 MUTATION IN PRESENT IN THE PRIMARY TUMOUR?

1048 LONG-TERM FOLLOW-UP OUTCOME OF THYROID PAPILLARY MICROCARCINOMA
A. Vrionidou, D. Ioannidis, A. Koletti, N. Klonaris, K. Katsoedes, C. Vaskopopoulos, I. Travrac (Athens, Greece)

1049 THE SELECTION OF THE INITIAL SURGERY EXTENT FOR DIFFERENTIATED THYROID CANCER WITHOUT METASTASIS
S. Wang (Guangzhou, China)

1050 CLINICAL OUTCOMES OF RE-OPERATION FOR LOCO-REGIONAL RECURRENCE OF PAPILLARY THYROID CANCER
J. H. Yoon, S. J. Hong, N. B. Kim, Y. K. Shong (Seoul, Republic of Korea)

1051 THE VALUE OF DETECTABLE THYROID-LIBERATED TSH IN THE FOLLOW-UP AND TREATMENT OF DIFFERENTIATED THYROID CANCER
E. Hindié, E. Vassilatou, N. Klonaris, A. Vrionidou, D. Ioannidis, A. Koletti, G. Thomas (London, United Kingdom)

1052 DISCUSSION ON RISK FACTORS FOR LOCAL RECURRENT OF THYROID CANCER
F. J. Rodrigues, A. Neves, C. O. Santos, F. Araujo, J. Romaldini (Campinas, Brazil)

1053 THE CLINICOPATHOLOGICAL DIFFERENCES IN PAPILLARY THYROID CANCER WITH OR WITHOUT CONSTITUTIVE CHRONIC LYMPHOCYTIC THYROIDITIS
Y.-H. Yoon, B.-S. Koo (Daegu, Republic of Korea)

1054 THE CLINICOPATHOLOGICAL DIFFERENCES IN PAPILLARY THYROID CANCER WITH OR WITHOUT CONSTITUTIVE CHRONIC LYMPHOCYTIC THYROIDITIS
Y.-H. Yoon, B.-S. Koo (Daegu, Republic of Korea)

1055 CLINICAL SIGNIFICANCE OF RAS MUTATIONS IN FOLLICULAR CARCINOMA OF THE THYROID
M. Webber (Bridgend, United Kingdom)

1056 COMPARISON OF PEDIATRIC THYROID CANCER WITH ADULT THYROID CANCER IN A SINGLE THYROID CANCER CLINIC
S. R. Zakavi, M. Watanabe, Y. Hidaka, Y. Iwatani, A. Miyauchi (Osaka, Japan)

1057 COMPARISON OF PEDIATRIC THYROID CANCER WITH ADULT THYROID CANCER IN A SINGLE THYROID CANCER CLINIC
S. R. Zakavi, M. Watanabe, Y. Hidaka, Y. Iwatani, A. Miyauchi (Osaka, Japan)

1058 THE VALUE OF DETECTABLE THYROID-LIBERATED TSH IN THE FOLLOW-UP AND TREATMENT OF DIFFERENTIATED THYROID CANCER
E. Hindié, E. Vassilatou, N. Klonaris, A. Vrionidou, D. Ioannidis, A. Koletti, G. Thomas (London, United Kingdom)

1059 THE SELECTION OF THE INITIAL SURGERY EXTENT FOR DIFFERENTIATED THYROID CANCER WITHOUT METASTASIS
S. Wang (Guangzhou, China)

1060 THE CLINICOPATHOLOGICAL DIFFERENCES IN PAPILLARY THYROID CANCER WITH OR WITHOUT CONSTITUTIVE CHRONIC LYMPHOCYTIC THYROIDITIS
Y.-H. Yoon, B.-S. Koo (Daegu, Republic of Korea)
**DISCUSSED POSTERS (PD24) (see page 62)**

**Thyroid metabolism and action**

**P-1027**
ORDINATE AND OVERWEIGHT ARE MAJOR RISK FACTORS OF RECURRENCE AFTER THYROIDECTOMY FOR MACROCRINE PAPILLARY THYROID CARCINOMA
C. Trottier, S. Naddev, G. Gudomain-Pint, H. Salapagata, C. Haung, L. Leenhardt, F. Monnoye (Paris, France)

**P-1028**
DISCUSSION OF THYROID METABOLISM AND ACTION

**P-1029**
LONG-TERM FOLLOW UP OF ELDERLY PATIENTS WITH SURGICAL MANAGEMENT OF PRIMARY HYPERPARATHYROIDISM (PHPT)
M. Fysekidis, B. Frachet, G. Reach, B. Rousseau, A. Martin, R. Cohen (Bobigny, France)

**P-1030**
NEW PTEN GENE ALTERATIONS IN A BRAZILIAN PATIENT WITH CONDENS SYNDROME
E. F. Lima, G. A. Augusto, S. Marci (São Paulo, Brazil)

**P-1031**
PARATHYRITIS PRESENTING AS THYROID AND PARATHYROID GYNS IN HIV-INFECTED PATIENTS
K. E. Neves (Brasilia, Brazil)

**P-1032**
INFLUENCE OF PROTEINURIA ON THYROID HORMONE PARAMETERS IN PATIENTS WITH CHRONIC RENAL FAILURE
W. Reinhardt, M. Bnuecker, S. Dohll, S. Behrendt, K. Mann, O. Wiltke (Fremes, Germany)

**P-1033**
RESPONSE TO IODIDE INCREASING DOSES IN ACINI OF MOUSE PAROTID GLAND
Y. López Plasencia AND TREATMENT DILEMMA

**P-1034**
LONG-TERM FOLLOW UP OF ELDERLY PATIENTS WITH SURGICAL MANAGEMENT OF PRIMARY HYPERPARATHYROIDISM (PHPT)
M. Fysekidis, B. Frachet, G. Reach, B. Rousseau, A. Martin, R. Cohen (Bobigny, France)

**P-1035**
NEW PTEN GENE ALTERATIONS IN A BRAZILIAN PATIENT WITH CONDENS SYNDROME
E. F. Lima, G. A. Augusto, S. Marci (São Paulo, Brazil)

**P-1036**
PARATHYRITIS PRESENTING AS THYROID AND PARATHYROID GYNS IN HIV-INFECTED PATIENTS
K. E. Neves (Brasilia, Brazil)

**P-1037**
INFLUENCE OF PROTEINURIA ON THYROID HORMONE PARAMETERS IN PATIENTS WITH CHRONIC RENAL FAILURE
W. Reinhardt, M. Bnuecker, S. Dohll, S. Behrendt, K. Mann, O. Wiltke (Fremes, Germany)

**P-1038**
RESPONSE TO IODIDE INCREASING DOSES IN ACINI OF MOUSE PAROTID GLAND
Y. López Plasencia AND TREATMENT DILEMMA
**THYROID gland development**

**P-1057** EFFECTS OF DIOSGENIN ON CELL PROLIFERATION INDUCED BY IGF-1 IN PRIMARY HUMAN NORMAL THYROID CYTES
D. Bian, H. Ma, X. Tian, L. Gao, J. Zhao (Jinan, China)

**P-1058** DUOX 2 PROMOTER ACTIVITY REGULATED BY TTF-1, PAX 8, NIK 2,5 AND TAZ IN THYROID CELLS
L. D. C. Cardoso, R. C. C. Penha, A. C. F. Ferreira, D. P. De Carvalho, M. W. Costa (Niterói, Brazil)

**P-1059** ASSOCIATION STUDIES OF THE SLC22A4 GENE WITH GRAVES’ DISEASE IN CHINESE HAN POPULATION
X. Hou, W. Song, Z. Shao, Y. Li, J. Mao (Shenyang, China)

**DIscussed POSTERS (PD26) (see page 63)**

Genetics and Genomics of thyroid diseases

**P-1060** ASSOCIATION STUDY OF THE IL2/IL2RA GENE POLYMORPHISM AND PAPILLARY THYROID CANCER IN KOREAN POPULATION
I. H. Shin, Y. C. Kim, S. W. Kim, S. Y. Sung, K. H. Kwon (Seoul, Republic of Korea)

**P-1061** VARIATION MUTATION DETECTION IN FINE-NEEDLE ASPIRATION FROM INDENTIFIED OR SUSPICIOUS TO MALIGANCY THYROID NODULE USING REAL TIME PCR GENOTYPING

**P-1062** POLYMORPHISMS IN GENES OF THE THYROID HORMONE BIOSYNTHESIS AND METABOLISM PATHWAYS, SMOKING AND GRAVES’ DISEASE RISK

**P-1063** IN PENDECREF SYNDROME A GENETICALLY HETEROGENEOUS DISEASE? MOLECULAR ANALYSIS OF 4 CANDIDATE GENES AND GENOTYPE PHENOTYPE CORRELATIONS
V. Cinellis, M. Mistura, P. Castorina, A. Maffini, P. Beck-Peccoz, L. Fugazzola (Milan, Italy)

**P-1064** COMPARATIVE ANALYSIS OF GENE EXPRESSION PROFILES OF PAPILLARY THYROID MICROCARCINOMA AND PAPILLARY THYROID CARCINOMA

**P-1065** THE USE OF A SET OF GENETIC MARKERS TO HELP TO DISCRIMINATE BENIGN AND MALIGNANT THYROID NODULES WITH FINE-NEEDLE ASPIRATION PATTERN OF FOULARCULAR PROLIFERATION IN AN AREA OF BORDERSIDE IOINE DEFICIENCY

**DISCUSSSED POSTERS (PD25) (see page 62)**

Development and function of thyroid cells

**P-1038** PARATHYROIDECTOMY PREVENTS BONE FROM DETERIORATING AFTER MENOPAUSE WITHOUT CALCIUM AND VITAMIN D SUPPLEMENTATION
K. Fukada, H. Dait, K. Fujimoto, N. Oussi, S. Satomi (Sendai, Japan)

**P-1039** A NEW METHOD FOR EARLY THYROID NODULE DETECTION
G. V. Garelianu, M. Gheorghe, A. M. Ghengigean, M.P. Gariuzilu (Bucharest, Romania)

**P-1040** EPIDERMAL GROWTH FACTOR STIMULATION IMPAIRS THYROID IODIDE TRANSPORT BY BOTH MAP KINASE-DEPENDENT AND -INDEPENDENT MECHANISMS
C. Ingeson, T. Carlson, M. Nilsson (Göteborg, Sweden)

**P-1041** THYROID HORMONE MODULATION AFTER ACUTE AND CHRONIC SLEEP LOSS
N. C. Rodrigues, D. Lusitano, N. S. Cruz, C. P. Nascimento, P. A. V. Megiddo, J. Pimentel, M. L. Andersen, D. P. Carvalho, M. P. Marques (São Paulo, Brazil)

**P-1042** HUMAN THYROID PRIMARY CULTURE
A. P. Santi, A. Pozzobon, G. V. Abreu, S. B. R. M. F. Pasini (Porto Alegre, Brazil)

**P-1043** RADIOFREQUENCY ABLATION WITH AND WITHOUT EPIDERMAL GROWTH FACTOR STIMULATION IMPAIRS PARATHYROIDECTOMY PREVENTS BONE FROM DETERIORATING AFTER MENOPAUSE WITHOUT CALCIUM AND VITAMIN D SUPPLEMENTATION
L. Fugazzola (Milan, Italy)

**P-1044** EXPRESSION OF THE TYPE I DEOXYGENASE (iD) IN NEUROENDOCRINE TUMORS
R. E. A. Van Hoozen, M. Koek, E. F. Kemming, T. Visser (Rotterdam, Netherlands)

**P-1045** SCHIZOPHRENIA: OUR EXPERIENCE IN ADVANCED THYROID CANCER
I. Brilli, S. Marchisotta, A. Montanese, C. Formichii, F. Pancì (Napoli, Italy)

**P-1046** ANTI-PROLIFERATIVE EFFECT OF THE PHYTO-CHEMICAL PLUMBAGIN ON HUMAN THYROID CANCER CELL LINES WITH BRAF MUTATIONS
A. Chakraborty, S. K. K. Sundar, M. Ray, A. A. Narkar (Mumbai, India)

**P-1047** CORNEA VERTICILLATA INDUCED BY VANDENAN THERAPY

**P-1048** MOLECULAR AND STRUCTURAL INSIGHTS INTO SWITCHING SMALL MOLECULE – THYROIDSTIMULATING RECEPTOR COMPLEXES BETWEEN ACTIVE AND INACTIVE STATES
A.-K. Haas, G. Klimas, I. Hoyser, I. Parkert, B. Schulein, S. Neumann, M. Gershengorn, G. Krause (Berlin, Germany)

**P-1049** A THYROID STIMULATING HORMONE RECEPTOR (TSH-R) TARGETED APPROACH FOR THERAPEUTIC INTERFERENCE IN THYROID CANCER: CREATING AN IMMUNOMARKER BY FUSING TSH-BINDING ANTIBODIES AND PSUEDOMUNAS EXOTOXIN

**P-1050** DIOSGENIN INDUCES APOPTOSIS IN PRIMARY HUMAN THYROID CELLS
S. M. Ma, Y. W. Yuan, Z. W. Li, L. Gao, J. J. Zhao (Jinan, China)

**P-1051** EVALUATION OF BASAL THYROIDSTIMULATING HORMONE STIMULATION IN RESPONSE TO THYROIDSTIMULATING HORMONE IN RELATION TO THE TSH AND IGF-1 receptors
M. A. Zaazalle, P. Santinibehar, M. A. Zaazalle, E. Luqan, E. Aladina, M. A. Zaazalle (Madrid, Spain)

**P-1052** ROLE OF FOCSI TRANSCRIPTION FACTOR IN THE THYROID CELL PROLIFERATION INDUCED BY TSH AND IGF-1
C. V. Gavrilci, M. D. Guzau, M. D. Guzau, R. C. C. Penha, A. C. F. Ferreira, D. P. Carvalho, M. W. Costa (Niterói, Brazil)

**P-1053** TRANSMEMBRANE HELIX 5 OF THE THYROIDSTIMULATING RECEPTOR LICKS EXHIBITS DIFFERENT CONFORMATIONS THAN IN OTHER GPCR STRUCTURES AND FUNCTION AS ASSEMBLING COMPONENT FOR THE ACTIVE STATE
I. Hoyser, G. Klimas, A.-K. Haas, A. Kreuschew, C. Worth, R. Schulein, G. Krause (Berlin, Germany)

**P-1054** CORNEA VERTICILLATA INDUCED BY VANDETANIB
A. Chakraborty, R. M. K. Saha, M. Mead, T. F. Davies (New York, United States)

**P-1055** DIOSGENIN INDUCES APOPTOSIS IN PRIMARY HUMAN NORMAL THYROID CELLS INDUCED BY IGF-1 IN PRIMARY HUMAN NORMAL THYROID CELLS
L. Marique, C. Khidiha, V. Van Regemorter, A. Wretlind, I. Van Sickle, J. Diamant, M. Senoo, A.-C. Girard, M.-L. Mary (Brussels, Belgium)

**P-1056** DETECTING TRANSMEMBRANE INTERFACES OF TSH RECEPTOR DIOGENIC
R. Latif, M. R. Ak, S. A. Mohmedhid, M. Meant, T. F. Davies (New York, United States)
Genetics and proteomics of thyroid diseases

P-1066 MRNA BRAF EXPRESSION ANALYSIS – DIAGNOSTIC FINDINGS FOR FAMILIAL DIFFERENTIATED THYROID CARCINOMA PATIENTS IN A BRAZILIAN COHORT
A. J. Tincani, L. S. Ward, F. P. Araujo (Campinas, Brazil)

P-1067 MULTIPLE BRAF-BASED LUMINESCENCE ASSAYS FOR THE RAPID AND SIMULTANEOUS DETECTION OF THE MOST COMMON MUTATIONS AND TRANSLOCATIONS IN THYROID CANCER

P-1068 ABSENCE OF PAX8, TSH RECEPTOR AND NOXI-2.5 GENES MUTATIONS IN PATIENTS WITH THYROID DYSGENESIS
E. S. Brau, C. B. Bertelli, S. Mariu (São Paulo, Brazil)

P-1069 LOW FREQUENCY OF TPO GENE MUTATIONS IN PATIENTS WITH THYROID DYSGENESIS
E. S. Brau, C. B. Bertelli, I. S. S. Rubio, S. Mariu (São Paulo, Brazil)

P-1070 EFFICACY OF HIGH RESOLUTION MELTING IN THE DETECTION OF REASOMATIC MUTATIONS IN THYROID FINE-NEEDLE ASPIRATION BIOPSY
M. Buratto, F. Tagliati, G. Traversini, D. Bertan, R. Rossi, E. C. degli Uberti, M. C. Zatelli (Ferrara, Italy)

P-1071 ALLELIC DISCRIMINATION IS MORE SENSITIVE THAN DIRECT SEQUENCING IN THE DIAGNOSIS OF SOMATIC BRAF V600E MUTATION IN THYROID FINE-NEEDLE ASPIRATION BIOPSY
P-1072 IMPROVED DETECTION RATE OF NOXI-2.5 MUTATIONS IN PATIENTS WITH CONGENITAL THYROID HYPOFUNCTION AND MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION

P-1073 DO CHILDREN AND ADULTS HAVE DIFFERENT RISK PROFILES FOR GRAVES’ DISEASE?
A. Curry, N. E. Burcel, J. H. Romaldini, R. Santos, C. A. Longui, N. E. Bufalo, J. H. Romaldini, R. B. Santos, M. A. Marcello (Shenyang, China)

P-1075 ASSOCIATION STUDY OF INTERLEUKIN 12 AND INTERLEUKIN 11 RECEPTOR ALPHA POLYMORPHISMS IN PAPILLARY THYROID CANCER: A CASE-CONTROL STUDY
Y. G. Eun, I. H. Shin, K. H. Kwon (Masan, Republic of Korea)

P-1076 EXPRESSION OF TWO GENES IN THE TSH SUSCEPTIBILITY REGIONS IN THYROID CANCER: FIND AND TREAT
E. M. Giménez, A. Akdi, R. Matar, A. Vilaalpeced (Barcelona, Spain)

P-1077 USELESSNESS OF BRAF V600E MUTATION DETECTION FOR PROPHYLACTIC EVALUATION OF FINE-NEEDLE ASPIRATIONS FROM THYROID NODULES
M. C. Cortese (Reims, France)

P-1078 SEPT7 AND G3P4 GENE POLYMORPHISMS AND THE EFFECT OF SILENIUM SUPPLEMENTATION ON TPOAB TITERS IN AUTOMMUNE THYROIDITIS

P-1079 ADDICTION CAN BE A MEDIATOR IN OBESITY-RELATED DIFFERENTIATED THYROID CANCER
M. A. Marcella, A. C. Sampao, L. M. Cunha, A. C. Vasquez, L. V. M. Assumpção, R. Cerkovsk, L. S. Ward (Campinas, Brazil)

P-1080 THYROID DISEASES ARE ASSOCIATED WITH DIFFERENTIAL EXPRESSION OF GLUTAMINOLYCATIO AND PROTEOGUTIC IN THE THYROID GLAND
E. Moni, G. Karakiulakis, E. Papakonstantinou (Thessaloniki, Greece)

P-1081 REDUCED THYROIDEROSIS ENZYMATIC ACTIVITY IN THYROID SAMPLES FROM PATIENTS WITH CONGENITAL THYROID HYPOFUNCTION WITH IODIDE ORGANIFICATION DEFECTS
F. R. Maralina, R. F. Pazzani, D. P. Carvalho, G. Moutinho-Neto, I. G. Rubbi (Rio de Janeiro, Brazil)

P-1082 NPK1 POLYMORPHISMS ARE ASSOCIATED WITH GRAVES’ DISEASE IN A UK COHORT
A. L. Mitchell, K. MacArthur, S. H. Pearce (Newcastle-upon-Tyne, United Kingdom)

P-1083 DUAL-GENEF-2 GENE MODIFICATIONS IN CHILDREN WITH HYPOFUNCTION: IDENTIFICATION AND FUNCTIONAL ANALYSIS OF NEW VARIANTS AND MUTATIONS
A. Molina, G. de Marco, L. Montanelli, P. Agnelli, B. Bagattini, A. Di Salvo, M. De Sio, F. Nicolai, C. Ciaramelli, P. Brozzi, A. Pinchera, P. Vith, M. Tachtschicha (Flo, Italy)

P-1084 MUTY EXPRESSION MAY HELP CHARACTERIZE THYROID CARCINOMAS BUT DOES NOT PREDICT PATIENTS OUICOME
E. C. Morait, J. R. Silva, P. A. Soares, J. Vasques, L. S. Ward (Campinas, Brazil)

P-1085 CARBOY-TERMINAL MUTATIONS IN THE THYROID STIMULATING HORMONE RECEPTOR (TSHR) GENE ASSOCIATED WITH PARTIAL IODIDE ORGANIFICATION DEFECTS
P. Anbrunger, H. Bony-Trinovne, E. van den Akker, I. Riano, M. Ouarzazi, P. Crock, S. L. Dwe, M. Polak, T. J. Visscher, J. C. Maruo (Rotterdam, Netherlands)

P-1086 METABOLOMICS AND THYROID HORMONE SIGNALING
J. M. Paulson, E. D. Kaloyer, A. N. Hallenberg (Boston, United States)

P-1087 ASSOCIATION OF A20G POLYMORPHISM OF EXON 1 CTLA-4 GENE WITH GRAVES’ DISEASE PATIENTS IN INDONESIA: A PRELIMINARY REPORT OF COHORT STUDY
T. G. D. Komar (Serangat, Indonesia)

P-1088 FOXE1 I135M POLYMORPHISM ANALYSIS IN DIFFERENTIATED THYROID CANCER AND AUTOMMUNE THYROID DISEASE

P-1089 GENOM-E WIDE SCAN FOR GENETIC FACTORS UNDERRLYING CHRONIC AUTOMMUNE THYROIDITIS
M. Rahmani, M. Eizary, M. Attey, P. Herydman, M. Tushli, A. Brookes-Wilson, F. Aziz (Tehran, Islamic Republic of Iran)

P-1090 UNNOVELLING TGNASHYETIN AMILYD- BOUNDING AHEAD WITH WALLABIES
S. J. Richardson, D. G. D’Souza, L. K. Pattenden, K. Allard (Bendinilla, Australia)

P-1091 METHYATION STATUS OF SODIUM-KODIDE SYMPORTER (NKH) PROMOTER IN THYROID CANCER

P-1092 FAMILIAL DISALUBRINSACMA HYPERTHYROXICAEMIA (FH) CAUSING INTERFERENCE IN CURRENT IMMUNOADASANS, ASSOCIATED WITH A NOVEL MUTATION IN THE ALBUMIN GENE
N. Schemanm, D. Hasik, F. Goughog, O. Rajayayaraj, J. Schwabe, P. Clark, A. O’talbo, M. Bignell, T. Barrett, K. Chaterre (Cambridge, United Kingdom)

P-1093 COMPREHENSIVE ANALYSIS OF SELECTED CANDIDATE GENES (OSH, TRX1 AND FOXL1) IN PATIENTS WITH FAMILIAL AND SPORADIC FORM OF THYROID HEMANGIOMAS
E. Szczepanek, M. Ruchala, M. Jaroniec, W. Szaflarski, K. Padicek, M. Klimka, M. Zablo, J. Sovaska (Poznan, Poland)
### Epidemiology of thyroid diseases

<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>PREVALENCE OF BRACTEAL DYSFUNCTION AND THYROID DISEASE IN PARTICIPANTS OF PROSTATE CANCER SCREENING CAMPAIGN</td>
<td>R. Y. A. Camargo, E. K. Sommert, M. Parholer, M. Knoblo, G. Montes-Oro (São Paulo, Brazil)</td>
<td>Brazil</td>
</tr>
<tr>
<td>NON-ENDOCRINE AUTONOMOUS DISEASES AND HISTAMINE-5 HYPERTHYROIDISM: A SYSTEMATIC EPIDEMIOLOGICAL AND CLINICAL CHARACTERIZATION</td>
<td>C. Verti, M. G. Santangeli, S. C. Del Duca, L. Gargano, M. Cantani (Maila, Italy)</td>
<td>Italy</td>
</tr>
<tr>
<td>RE-EVALUATION OF THE ROLE OF BODY MASS INDEX ON THE RISK OF DIFFERENTIATED THYROID CANCER</td>
<td>E. Chies, L. Lou, P. Brindel, T. Triunghi, A. Anger, C. Tremonte, I. Dallia, F. De Feyter, P. Gaultier, F. De Vaillant (Villepinte, France)</td>
<td>Belgium</td>
</tr>
<tr>
<td>SINGLE CENTRE 5 YEAR EXPERIENCE OF SCINTIGRAPHIC IMAGING IN NEONATAL HYPOTHYROIDISM</td>
<td>A. De Silva, L. Jong, J. McKay, R. Shabti, G. Soo, D. Nandurkar (Clayton, Australia)</td>
<td>Australia</td>
</tr>
<tr>
<td>THYROID DISFUNCTION IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS</td>
<td>A. P. D. Gisea, M. Ferraro, C. Diogo, J. Palma, J. Vilanova, J. Duran (Porto, Portugal)</td>
<td>Portugal</td>
</tr>
<tr>
<td>FACTORS ASSOCIATED WITH PULMONARY COMPLICATIONS AFTER THYROID SURGERY: AN ANALYSIS OF 19,714 PATIENTS FROM THE ACS NSQIP DATABASE</td>
<td>A. Y. Hayman, D. M. Elang, C. W. Wang, S. Sturgis (Chicago, United States)</td>
<td>United States</td>
</tr>
<tr>
<td>THE REASONS FOR THYROID REOPERATION IN AN ENDOCRINE NODE INFECTED AREA DURING 25 YEARS, 1984-2008 IN GUILLIEN PROVINCE, NORTH OF IRAN</td>
<td>N. Hedayati  Emami (Rasht, Islamic Republic of Iran)</td>
<td>Iran</td>
</tr>
<tr>
<td>COST-ECONOMIC EVALUATION OF RADIODOINE ABLATION FOLLOWING RREVN IN RATHER THAN THE HYPOTHYROID STATE IN SWEDE</td>
<td>L.-L. Hermansson, P. Mehmert, M. Allyn, M. Luster (Solna, Sweden)</td>
<td>Sweden</td>
</tr>
<tr>
<td>TRENDS IN PRIMARY CARE THYROID HORMONE PRESCRIBING IN THE UNITED KINGDOM</td>
<td>A. M. Ghail, P. N. Taylor, R. Chapmanwood, W. Hamilton, C. M. Dayon (Bright, United Kingdom)</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>EPIDEMIOLOGICAL STUDY OF THYROID FUNCTION IN THE POPULATION OF THE KASTORIA PREFECTURE DURING A TIME PERIOD OF 9 YEARS</td>
<td>P. Karapavlidou, I. Patsalidou, E. Chasios (Kastoria, Greece)</td>
<td>Greece</td>
</tr>
<tr>
<td>PREVALENCE OF THYROID DISORDERS IN CHILDREN WITH TYPE 1 DIABETES MELLITUS</td>
<td>N. Khalihi Rouznejad, S. Shahpooor (Tabriz, Islamic Republic of Iran)</td>
<td>Iran</td>
</tr>
<tr>
<td>RELATION BETWEEN THYROID FUNCTION AND GENDER, AGE, BODY MASS INDEX IN SCHOOL CHILDREN LIVING IN A LONG-STANDING HODIOINE REFLECT AREA</td>
<td>N. Khalihi Rouznejad, M. Hashempour (Shahrek, Islamic Republic of Iran)</td>
<td>Iran</td>
</tr>
<tr>
<td>COMPARISON OF THYROID DISORDER IN TWO GROUPS OF SCHOOLCHILDREN LIVING IN TWO NEAR REGIONS WITH LONG-STATE HODIOINE REFLECT</td>
<td>N. Khalihi Rouznejad, O. Pirhaji, M. Hashempour (Isfahan, Iran)</td>
<td>Iran</td>
</tr>
<tr>
<td>HIGH PREVALENCE OF ENDEMIC GOITER IN LAWACHAR AREA, DISTRICT KARAK, OF LOWER HIMALAYAS, PAKISTAN</td>
<td>M. N. Khan Khattak, M. U. Haq, M. M. Ch Towm (Erfangten, Germany)</td>
<td>Pakistan</td>
</tr>
<tr>
<td>EFFECT OF DIFFERENT IODINE CONCENTRATIONS IN HOUSEHOLD SALT ON THYROID VOLUME DISTRIBUTION IN SCHOOL-AGE CHILDREN</td>
<td>Y. Zhang, P. Liu, S. Liu (Harbin, China)</td>
<td>China</td>
</tr>
<tr>
<td>THYROID CARCINOMA FROM 2005 TO 2006 IN FINISTERE, FRANCE: INCIDENCE AND COMPARISON TO MARINE-ARDENNES</td>
<td>J.-M. Maillet, N. Roudaut, E. Sonnet, C. Schyra, V. Korlen (Brest, France)</td>
<td>France</td>
</tr>
<tr>
<td>HYPOCYCLOMUTATIONAL COMPLICATIONS ARE INCREASED IN PATIENTS GREATER THAN 75 YEARS OF AGE</td>
<td>K. A. Maffulli, S. Naas, J. S. Sosa, R. K. Davis, N. M. Carroll, E. A. Falgah (Washington, United States)</td>
<td>United States</td>
</tr>
<tr>
<td>HISPANIC AMERICANS DIAGNOSED WITH THYROID CANCER PRESENT WITH MORE LOCALY ADVANCE DISEASE WHEN COMPARED TO THEIR NON-HISPANIC COUNTERPARTS</td>
<td>T. Mousnyoung, J. Paneroy, H. Du, R. Plote, S. Patel, L. Feghelf (Chicago, United States)</td>
<td>United States</td>
</tr>
<tr>
<td>SCREENING FOR AUTONOMOUS THYROID DISORDERS IN PREGNANT WOMEN: PRELIMINARY RESULTS OF THE FOLLOW-UP STUDY</td>
<td>E. Potlikova, J. Joksa, Z. Tellek, D. Sprinigers, J. Bartkova, Z. Limantova (Prague, Czech Republic)</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>THYROID FUNCTION AND MORTALITY IN EUTHYROID SUBJECTS</td>
<td>A. Ros, T. E. Linea, R. O. Gana, B. H. Wolffenbuttel, S.-J. Bakker (Groningen, Netherlands)</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>THYROID—MOBILE DIAGNOSTIC PLANT FOR THYROID AND PARATHYROID DISEASE SCREENING</td>
<td>E. Bychenkova, A. Bubnov, Y. Fedotov, A. Semenen, A. N psycho, R. Cherlikov, I. Chichik, A. Uspenska (St. Petersburg, Russian Federation)</td>
<td>Russia</td>
</tr>
<tr>
<td>BENEFITS AND DIFFICULTIES OF UNIVERSAL THYROID-DYSFUNCTION SCREENING IN PREGNANCY IN THE CZECH REPUBLIC</td>
<td>D. Springer, Z. Limantova, J. Joksa, E. Potlikova, T. Zima (Prague, Czech Republic)</td>
<td>Czech Republic</td>
</tr>
</tbody>
</table>
**Medullary thyroid carcinoma**

P-1124 A CASE REPORT OF A SPORADIC MEDULLARY THYROID CANCER FINALLY DISCOVERED ON REPEATED F-18 FDG PET
M. Abo, T. Hosote, Y. Kashioki, H. Saito, A. Sasaki, N. Takeoka (Gifu, Japan)

P-1125 RET CODON 1979 MUTATION—NOT AS LOW RISK AS WE THOUGHT
E. M. Alford, G. Cote, T. Riph, E. Grubbs, M. D. Williams, M. I. Hu (Bryanston, United States)

P-1126 NOVEL Germline VARIANTS IN RET PROTO-ONCogene IN A PATIENT WITH BILATERAL PHAECOMIOCYCTOMA AND MULTIPLE MEDULLARY THYROID CANCER
C. Alvarez Ezuda, B. Losamuendo Santamarina, A. Fernandez Martinez, A. Castro, L. F. Pallardo Sanchez, H. Robledo Batanes (Madrid, Spain)

P-1127 MEDULLARY THYROID CARCINOMA (MTC) - RESULTS OF TAILORED TREATMENT

P-1128 CLINICAL MANIFESTATIONS OF MULTIPLE ENDONEURIAL NEUPLASIA 2A IN A FAMILY WITH THE 4J6 RET PROTO-ONCENE MUTATION
G. A. Carvalho, C. Marazzato, T. Testona, L. Kalache, S. Sztal-Mazer, E. Vanzanecolo, H. Graf, T. Costa (Curtiba, Brazil)

P-1129 PERCUTANEOUS ETHANOL INJECTION IN THE TREATMENT OF RECURRENCE HYPERPARATHYROIDISM IN A PATIENT WITH MEN 2A
C. A. Carvalho, C. Marazzato, C. Mora Junior, M. Trippa, S. Sztal-Mazer, T. Costa, L. Gomes, E. Vanzanecolo, H. Graf (Curtiba, Brazil)

P-1130 Germline mutations of RET ONCOGENE IN KOREA WITH MEN 2A, FAMILIAL AND SPORADIC MEDULLARY THYROID CANCER: REVIEW OF LITERATURE

P-1131 Are we able to differentiate micromedullary thyroid cancer from reactive C cell hyperplasia with a pre-operative procalcitonin evaluation?
M. D'herbomez, S. Aubert, E. Leteurtre, C. Do Cao, L. Leclerc, C. De Micco, J.-F. Henry (Marseille, France)

P-1132 EVOLUMLUS (RAD001) INDUCES TUMOR RESPONSE IN A CASE REPORT OF A SPORADIC MEDULLARY THYROID CANCER
M. I. Hu, A. Alavi, S. J. Mandel (Istanbul, Turkey)

P-1133 A KINDRED OF FAMILIAL MEDULLARY THYROID CARCINOMA WITH HIRSCHSPRUNG DISEASE
T. Igarashi, S. Jansson, P. Bumming, J. Nilsson (Gothenburg, Sweden)

P-1134 MULTIPLE ENDOPLASMIC NEUPLASIA TYPE 2B (MEN 2B) AN AGGRESSIVE DISEASE DIFFICULT TO RECOGNIZE
S. Iorcansky, C. Scollo, E. Russo, V. De Falco, M. Santoro, G. Fenzi, M. Urhan (Catania, Italy)

P-1135 THE ROLE OF PREOPERATIVE SOMATOSTATIN RECEPTOR SCINTIGRAPHY IN MEDULLARY THYROID CANCER
S. Iorcansky, J. Nilsson (Gothenburg, Sweden)

P-1136 LATERAL NECK DISSECTION IN MEDULLARY THYROID CARCINOMA

P-1137 MEDULLARY THYROID CANCER: IMPORTANCE AND DETERMINATES OF CENTRAL NECK DISEASE CONTROL
T. M. Lee, G. M. Shihong, P. G. Gauget, R. S. Miller, N. W. Thompson (Ann Arbor, United States)

P-1138 CORRELATION BETWEEN PRIMARY TUMOR CHARACTERISTICS, LIMPS NODE INVASION AND LONG-TERM OUTCOME IN PATIENTS WITH SPORADIC PAFABLE MEDULLARY THYROID CARCINOMA
A. Barbela, C. Do Cao, S. Aubert, M. D'Herbomez, B. Carnaille, E. Leteurtre, J.-L. Peix, J. P. Pochart, F. Batoni (Lille, France)

P-1139 SURGICAL MANAGEMENT OF FAMILIAL MEDULLARY THYROID CARCINOMA WITH EXONS 12-15 RET MUTATION: VALUE OF PREOPERATIVE CT LEVEL TO SELECT PATIENTS FOR CERVICAL LYMPH NODE DISSECTION
J.-M. Pochart, S. Fiuille, C. Delorocourt, H. Labre, A. Dalae, C. Schwartz (Rennes, France)

P-1140 CHOICE OF OPTIMAL VOLUME OF OPERATION ON A MEDULLARY THYROID CARCINOMA
A. T. Ramanacholou, G. I. Lookwee, R. V. Valentayr (Samt Petersburg, Russian Federation)

P-1141 TUMOR STAGE AT DIAGNOSIS IN MEDULLARY THYROID CANCER (MTC): CORRELATION AND CLINICAL OUTCOME IN PATIENTS WITH EITHER ONLY BIOCHEMICAL MARKERS OR MORPHOLOGICAL SIGN OF PERITENTELY RENAL DISEASE
C. Sollka, G. Novko, E. Maigneux, R. Masucci, M. Ledin, G. Giannone, G. Pelegatti (Catania, Italy)

P-1142 MILD HYPERCALCITONINEMIA AND SPORADIC MEDULLARY THYROID DISEASE
F. Sebag, M. Cherveno, E. Soliana, I. Morag, T. Bru, C. De Micco, J.-F. Henry (Marseillle, France)

P-1143 AN OVERVIEW OF MEDULLARY THYROID CARCINOMA SURGICAL MANAGEMENT IN FRANCE

P-1144 ALTERNATIVE SURGICAL STRATEGIES AND CLINICAL OUTCOMES IN THE PATIENTS WITH STAGE CT2a2P3 SPORADIC MEDULLARY THYROID CARCINOMA IN GANSU PROVINCE OF CHINA
M. Shihong, Z. You Cheng (Lanzhou, China)

P-1145 METASTATIC MEDULLARY THYROID CARCINOMA PRESENTED WITH CUSHING'S SYNDROME
T. A. N. Tabbakh, A. Karawagh, T. Nasser (Jeddah, Saudi Arabia)

P-1146 THE ROLE OF FEG PET IMAGING IN PATIENTS WITH MEDULLARY THYROID CARCINOMA
M. Urban, A. Alaraj, S. J. Mandel (Istanbul, Turkey)

P-1147 CALCIUM-CALMODULIN DEPENDENT KINASE II IN ACTIVATED BY MUTATED RET IN MEDULLARY THYROID CARCINOMA
M. Salzino, E. Bianco, V. De Falco, M. Santoro, G. Fenzi, G. Rossi, G. Ansoc (Naples, Italy)

P-1148 MEN 2A IN A FILIPINO KINDRED WITH CODON 1034 MUTATION
J. J. Wahidah (Quezon City, Philippines)
Treatment of Differentiated Thyroid Cancer in the Era of Targeted Therapy

Agenda

Monday 13 September 2010
7.30 – 8.30
Palais des Congrès de Paris
Amphitheatre Havane
Paris, France

Breakfast will be available at 7.00 at Bar Arlequin (adjacent to the Amphitheatre Havane)

7.30 Welcome and Introduction
Martin Schlumberger, MD
Symposium Chair
Institut Gustave Roussy
Villejuif, France

7.35 Epidemiology, Diagnosis, and Unmet Need of DTC
Yasuhiro Ito, MD, PhD
Kuma Hospital
Kobe, Japan

7.50 Inherent Biology and Signaling Pathways in DTC
Johannes Smit, MD, PhD
Leiden University Medical Center
Leiden, Netherlands

8.05 Clinical Development of Targeted Therapies in DTC
Marcia Brose, MD, PhD
University of Pennsylvania
Philadelphia, PA, United States

8.20 Panel Discussion

8.30 Concluding Remarks
Martin Schlumberger, MD
EXHIBITION FLOOR PLAN

LEVEL 3

LIST OF EXHIBITORS

ABBOTT .......................... 09
ASURAGEN ........................ 08
BAYER SCHERING PHARMA ........ 10
BECKMAN COULTER ............... 14
BRAHMS GMBH .................... 19
EEXELIXIS, INC ................. 16
GENZYME ......................... 11
MERCK SERONO SA ............... 12
QUISEL CORPORATION / DIAGNOSTIC HYBRIDS ........................ 02
ROCHE DIAGNOSTICS .......... 01
S. KARGER PUBLISHERS ......... 07
SAURAMPS MEDICAL ............. 15
SCREENING DEVICES CANADA, INC ........................ 03
SUPERSONIC IMAGINE ............ 13
AACE .................................. 20
ATA .................................. 23
AOTA .................................. 22
ENDOCRINE EDUCATION, INC ... 21
EORTC ................................ 25
ETA .................................. 24
LATS ................................ 31
LIGUE CONTRE LE CANCER ...... 29
THYROID FEDERATION
INTERNATIONAL (TFI) ............ 30
LIST OF EXHIBITORS

AACE

BOOTH NUMBER: 08
American Association of Clinical Endocrinologists
245 Riverside Ave, Suite 200
South Amboy, NJ 08879 – USA
Contact person: Pamela H. Smith, CAE
Phone: +1 (908) 313 6500
Fax: +1 (908) 313 6505
Email: membership@aace.com
Website: www.aace.com
AACE is a professional community of medical clinicians and scientists who specialize in the research and treatment of thyroid disease. AACE provides a platform for scientific and public understanding of the biology of the thyroid gland and its disorders, so as to improve methods for prevention, diagnosis, and management.

ATA

BOOTH NUMBER: 23
American Thyroid Association
6000 Leesburg Pike, Suite 350
Falls Church, Virginia 22041 – USA
Contact person: Barbara R. Smith, CAE
Phone: +1 (703) 590 9890
Fax: +1 (703) 590 9895
Email: thyroid@thyroid.org
Website: www.thyroid.org
Founded in 1923, the American Thyroid Association (ATA) is a professional society of thyroid clinicians and scientists who specialize in the research and treatment of thyroid disease. The ATA is dedicated to promoting scientific and public understanding of the biology of the thyroid gland and its disorders, so as to improve methods for prevention, diagnosis, and management.

AOTA

BOOTH NUMBER: 19
Asiatica and Oceania Thyroid Association
Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku
460-8601 Nagoya – Japan
Contact person: Yoshikazu Murata, M.D (Secretary/ Treasurer)
Phone: +81 52 789 3872
Fax: +81 52 789 3873
Email: aota@earthlink.net
Website: http://www.aota.org
AOTA is a non-profit organization of international thyroid societies in Asia and Oceania region.

ASURAGEN

BOOTH NUMBER: 18
2350 Woodward Ave, Suite 100
Austin, TX 78744 – USA
Contact person: Matt Fantone
Phone: +1 512 681 5284
Fax: +1 512 681 5201
Email: mmadameau@asuragen.com
Website: www.asuragen.com
Asuragen, Inc. is a molecular biology service provider and integrated diagnostic company focused on oncology. Asuragen's CLIA-accredited clinical laboratory provides mutational analysis, novel molecular tests and services as a platform for the commercialization of companion diagnostics and other molecular tests for oncology.

BAYER SCHERING PHARMA

BOOTH NUMBER: 16
PO Box 99
Montevideo, Uruguay 11704 – USA
Contact persons: Sunny Yang, Christine Marziano
Email: sunny.yang@bayer.com, christine.marziano@bayer.com
Website: www.bayer.com
As a global pharmaceutical company devoted to discovering new medicines, BAYER SCHERING PHARMA is committed to enhancing health care around the world. Our products span the continuum of care, from nutritional products to medical devices and pharmaceutical therapies. Our comprehensive product line excercises like itself – addressing important health needs for all ages.

ENDOCRINE EDUCATION, INC

BOOTH NUMBER: 17
PO Box 994, 24 Nanagut Av South Dartmouth, MA 02748 – USA
Contact person: Leslie A. De Great
Phone: +1 508 998 5104
Fax: +1 508 998 5104
Email: ldegroot@earthlink.net
Website: www.thyroidmanager.org, www.endoconnect.org
Endocrine Education, Inc. publishes THYROIDMANAGER.ORG, a one-stop source of the latest information on thyroid diseases, THYROIDMANAGER.ORG is authoritative, constantly updated, FREE, and downloadable for personal use and teaching. THYROIDMANAGER is supported by educational grants.

EORTC

BOOTH NUMBER: 25
Avenue Meunier 85
B-2250 Brussels – Belgium
Contact Person: Yelke Minas
Phone: +32 2 799 16 57
Email: vicky.minas@eortc.be
Website: http://www.eortc.be
The aims of the European Organisation for Research and Treatment of Cancer (EORTC) are to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life.

ETA

BOOTH NUMBER: 24
European Thyroid Association
Moorstraat 25
2552KA Bergendal – Germany
Contact Person: Sandra Creulech
Phone: +32 4922 04011
Fax: +32 4922 04019
Email: eurothyroid-association@endoscience.de
Website: www.eurothyroid.com
Founded in 1965, the ETA’s aims are to promote knowledge of the thyroid field (fundamental and clinical) and improve knowledge of the thyroid gland and its diseases. The Annual Meeting, held every year except when the ITCS takes place. Membership (570) comprising honorary, ordinary, junior, corresponding, senior, corporate.

EXELIXIS, INC

BOOTH NUMBER: 15
210 East Grand Avenue
South San Francisco 94083 – USA
Contact Person: John Fye, Pharm. D
Phone: +1 (650) 837 7500
Fax: +1 (650) 837 7510
Email: jfye@exelixis.com
Website: www.exelixis.com
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biologic expertise and integrated research and development capabilities to identify and generate a pipeline of development compounds with significant therapeutic and commercial potential.
GENZYME

Booth Number: 11

Genzyme Corporation Headquarters
500 Kendall Street
Cambridge, MA 02139 – USA
Phone: +1 617 252 7500
Fax: +1 617 252 7500
Website: www.genzyme.com

Genzyme Europe B.V.
Gorinchem 11
1411 DD Naarden - The Netherlands
Phone: +31 (0) 253 609 32 14
Fax: +31 (0) 253 609 32 14

One of the world’s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 12,000 employees in location-spanning the globe and 2009 revenues of $4.5 billion. In 2010, Genzyme was named to the Fortune 500.

With many established products and services helping patients in approximately 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company’s products and services are focused on rare inherited disorders, kidney disease, orthopedics, cancer, transplant and immune disease. Genzyme’s commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative disease, and other areas of unmet medical need.

For more information please go to: www.genzyme.com

LATS

Booth Number: 31

Latin American Thyroid Society
Rua Salinas, 1104 – Mertes
03810-070 Curitiba - Brazil
Contact Person: Hans Graf
Phone: +55 41 3919 2524
Fax: +55 41 2525 0994
Email: banugraf@bighost.com.br
Website: www.lats.org

Latin American Thyroid Society (LATS) is an association of Latin American scientists interested in promoting research in the thyroid field (fundamental and clinical). The aim of the association is to promote research in the thyroid field (fundamental and clinical) and improve knowledge of the thyroid gland and its diseases.

LIGUE CONTRE LE CANCER

Booth Number: 29

16 rue Corvisart
75014 Paris - France
Contact person: Marie Lanta
Phone: +33 (0) 1 53 55 28 84
Fax: +33 (0) 1 53 55 91 49
Email: lantam@ligue-cancer.net
Website: www.ligue-cancer.net

The French League against cancer is an independent NGO which relies on the generosity of the public. The league is a top cancer research funding association in France. The League is also acting through information, prevention and screening actions for and for patients and their loved ones.

MERCK SERONO SA

Booth Number: 85

9, dumont des Mées
13070 Grenoble – Switzerland
Contact Person: Mathis Blomme
Phone: +41 79 301 04 46
Fax: +41 22 414 35 69
Email: beatrice.blomme@merkserono.com
Website: www.merckserono.com

Merck Serono is the division for innovative prescription pharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecule and biopharmaceuticals to help patients with unmet medical needs.

Merck Serono has a broad portfolio of products to treat patients with endocrinological diseases (Glaucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, Thyretain™ (TSI Reporter Bioassay), QuickVue®, Strips A, hyper, pregnancy, Chlamydia, H. pylori and local oral blood.

ROCHE DIAGNOSTICS

Booth Number: 30

Forrestenstrasse 6340 Bottrop – Switzerland
Contact Person: Cornelia Eichner
Email: cornelia.eichner@roche.com
Website: www.roche.com

Headquartered in Basel, Switzerland, Roche is a leader in research-oriented healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world leader in in vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

S. KARGER PUBLISHERS

Booth Number: 27

Alteheinestrasse 39
PO Box
4009 Basel - Switzerland
Contact Person: Stephanie Ripka
Phone: +41 61 381 32 67
Fax: +41 61 381 32 64
Email: s.ripka@karger.ch
Website: www.karger.com

S. Karger Publisher is pleased to present the brand new, thoroughly updated 2nd edition of “Cazevie’s Orbitopathy”. The successful question and answer format is designed to help clinicians caring for patients with GO to efficiently locate the information they need.

Profit from a congress discount on this and many more titles at the Karger booth during the IFC in Paris.

SAURAMPS MEDICAL

Booth Number: 23

121

La librairie
15, boulevard Fléret IV
34000 Montpellier – France
Phone: +33 (0) 4 6763 0090
Fax: +33 (0) 4 6725 9895
Email: librairie-sauramps-medical@wanadoo.fr
Website: www.saurampsmedical.com

PUBLISHER - BOOKSTORE

SAURAMPS MEDICAL deals with medical literature for over 50 years offering books in french and other languages, DVD and FDA enabled items. Strong publishing activities featuring special medical references and more than 500 titles in its catalogue, special bibliographies, worldwide campaigns on nearly 60 medical congresses every year.

SCREENING DEVICES CANADA, INC

Booth Number: 33

2227 Bte 124
Hatfield Pk – Canada, NB, E3T 2P8
Contact Person: Lianne Wyman-Cunningham
Phone: +1 416 477 5072
Fax: +1 306 465 9832
Email: scanningimagine@sicadna.com
Website: www.screeningdevices.ca

ThyroChek® QR System opens the door to accessible and accurate information on thyroid function by providing TSH values in minutes from one drop of blood.

SUPERSONIC IMAGINE

Booth Number: 13

Les Jardins de la Duranne
Bois d’Eau
38157 Aix en Provence Cédex – France
Contact Person: Céline Le Maréchal
Phone: +33 (0) 4 86 19 65 36
Fax: +33 (0) 4 865 07 56 33
Email: celine.lemarechal@supersonicimagine.fr
Website: www.supersonicimagine.fr

SuperSonic Imagine was founded in 2005. Its revolutionary ultrasound system, the Aixplorer®, has an all software-based architecture that allows for great speed, accuracy and feasibility. Only SuperSonic Imagine’s Intuitive View2® technology enables true color Doppler, speckle-tracking, real-time OCT, 3D renders, and true tissue elasticity values in kilopascals - SmartWave Elastography®.

THYROID FEDERATION INTERNATIONAL (TFI)

Booth Number: 30

11, boulevard Henri IV
11, boulevard Henri IV
1202 Geneva – Switzerland
Phone: +41 79 581 05 46
Fax: +41 22 414 30 66
Email: cornelia.eichner@roche.com
Contact person: Cornelia Eichner
Website: www.merckserono.com

Merck Serono is the division for innovative prescription pharmaceuticals of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Basel, Switzerland, Merck is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world leader in in vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
GENERAL INFORMATION

VENUE and DATES
The 14th International Thyroid Congress will be held from Saturday 11 September to Thursday 16 September 2010.

At the PALAIS DES CONGRES DE PARIS
2, Place de la Porte Maillot
Level 3
75017 Paris – France

Metro/RER station: “Porte Maillot”
Several practical and rapid means of transport are at your disposal to get to the meeting place:
- by Metro (line 1)
- RER (line C)
- bus (line 82, 73, 43, 244 and PC)
- car (public car park under the Palais des Congrès) or taxi.
There will be no shuttle buses organized by the Congress from the hotels to the Congress Centre.

CONGRESS OFFICE
Before and after the meeting:
Scientific Programme, Registrations, Accommodation, Exhibition:
ITC 2010 c/o MCI France
24, rue Chauchat – 75009 Paris – France
Tel: +33 (0) 1 53 85 82 51 - Fax: +33 (0) 1 53 85 82 83
e.mail: itc2010@mci-group.com

On-site Secretary: LEVEL 3
Opening hours:
- Saturday 11 September: 7:00 pm - 9:00 pm
- Sunday 12 September: 7:00 am - 7:30 pm
- Monday 13 September: 7:00 am - 7:30 pm
- Tuesday 14 September: 7:00 am - 7:30 pm
- Wednesday 15 September: 7:00 am - 7:30 pm
- Thursday 16 September: 7:00 am - 1:00 pm

OFFICIAL LANGUAGE
The Congress being organized by international Societies, the official language of the congress is English. There will be no simultaneous translation.
REGISTRATION

Access to all congress activities is subject to registration.

Onsite registration fees (all rates include VAT of 19.6%)

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member (AOTA, ATA, ETA, LATS)</td>
<td>520 €</td>
</tr>
<tr>
<td>Non Member</td>
<td>620 €</td>
</tr>
<tr>
<td>Student **</td>
<td>240 €</td>
</tr>
<tr>
<td>Accompanying person</td>
<td>220 €</td>
</tr>
<tr>
<td>10th Meeting of ETA-CRN (ETA Cancer Research Network) (Sat. 11 Sept. – morning)</td>
<td>120 €</td>
</tr>
<tr>
<td>Pre-congress Ultrasonography course (Sat. 11 Sept. – morning)</td>
<td>120 €</td>
</tr>
</tbody>
</table>

* To apply for the member registration fee, you must be a member in good standing of your Sister Thyroid Society.

** To qualify for the student registration fee, the applicant’s registration form must be accompanied by written proof of status.

Social events

- Welcome Reception
  - Saturday 11th September 2010
  - Palais des Congrès – Exhibition area
  - Included in the registration fees

- Congress Dinner
  - Tuesday 14th September 2010
  - Royal Evening in Versailles
  - Optional at 120 € per person

Delegates registration fees include:

- Admission to the scientific sessions
- Access to posters and exhibition areas
- Admission to the Opening Ceremony and Welcome Reception
- Congress documents (final programme, congress bag, abstracts CD-rom)
- Lunch bags (on 12-13-14-15 Sept.), morning and afternoon breaks

Accompanying persons registration fees include:

- Admission to the Opening Ceremony and Welcome Reception
- 2 half-day excursions (V1 and V5)

Terms of payment

The ITC Organising Committees has given mandate to MCI for the organisation of its 14th International Thyroid Congress. MCI is the sole competent company to receive payments for this Congress.

Payments may be made either:

- by credit card (Visa / Master Card / Eurocard / American Express)
- by cheque to the order of ITC 2010 / MCI
- by cash

Name changes & modifications

- A processing fee of 50 € will be charged for changes in registration except for name substitutions which will be treated as new registrations.

Registration cancellation policy

All cancellations must be notified in writing (by mail, fax or e-mail) to the Congress Office according to the following conditions and reimbursement will be processed AFTER the Congress.

- Up to 15th May 2010: 100 € will be withheld for administrative fee
- Cancellations between 16th May 2010 and 20th August 2010: reimbursement of 50% of the registered fees
- After 20th August 2010: no refund. Requests for refunds received by the Congress Office after 15th November 2010 will not be considered.

ACCOMMODATION

If you have used the Congress Office services to handle your accommodation, please do not hesitate to ask the staff for information/assistance.

Please remember:

- No shows on the first night will automatically cancel the entire reservation and involve the loss of the entire deposit
- If you shorten your stay, hotels reserve the right to charge you for the balance of your stay

Cancellation conditions for hotel reservations (for individual reservations)

All cancellations must be notified in writing (by email or fax) to the congress office according to the following conditions:

- Up to 15th May 2010: the 15 € will be withheld for administrative fee
- Cancellations between 16th May and 1st July 2010: 50% of the deposit and reservation fees will be withheld
- After 1st July 2010: no refund.

Other conditions apply to group reservations; please contact the congress office onsite for any question.
PRACTICAL INFORMATION
(by alphabetical order)

■ ABSTRACTS
Selected abstracts are reproduced on a CD-rom distributed on site to all registered delegates. Abstracts will also be published electronically on the Congress web site.

■ BADGES
A name badge will be provided with your registration documents on site. For security and regulation purposes, the wearing of this badge is compulsory at all times both inside the Palais des Congrès and at all official events organized within the context of the congress.

■ BANKS
See currency.

■ BREAKS AND LUNCHES
Morning and afternoon breaks as well as lunch bags on 12-13-14 and 15 September are included in the registration fees. During the breaks, coffee and tea will be available in the exhibition areas.

■ CELLULAR PHONES
Delegates and participants are kindly requested to turn off their mobile phones when entering the meeting rooms and in the poster areas.

■ CERTIFICATE OF ATTENDANCE
Certificates of attendance for pre-registered participants are issued along with the Congress documentation upon arrival.

■ CITY MAP
A city map is provided in the Delegates’ bags.

■ CLIMATE AND CLOTHING
The weather in Paris in September is usually warm and sunny with daily temperatures ranging from 20°C to 25°C. Night temperatures may be milder between 12°C to 16°C.

■ CLOAKROOM
A cloakroom is at the participants disposal. It is located on level 3 in the registration area. Please make sure that no personal belongings are left after the closing each day. Cloakroom fee is at the participant's expense. Opening hours: same as congress office.

■ CME CREDITS
ITC2010 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The Congress ITC2010 is designated for a maximum of, or up to 28 European CME credits (ECMECs).
Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). www.uems.net EACCME credits (ECMECs) are recognised by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category credit, please contact the AMA.

■ CONGRESS BAG
Each participant is entitled to a congress bag that has to be collected at the congress bag counter (level 3) upon presentation of the corresponding voucher.

■ CURRENCY AND EXCHANGE
The conference proceedings arising from political, social, health or economic events or any other unforeseen incidents beyond their control. The congress cancellation conditions shall apply in any case. Registration of a participant entails acceptance of the cancellation conditions. It is recommended that participants obtain adequate cover for travel, health accident and cancellation insurance.
before they depart from their countries. ITC 2010 and MCI as organisers will accept no liability for personal injuries sustained by or for loss or damage to property belonging to congress participants and accompanying persons either during or as a result of the Congress or during all tours and events.

II. LOST AND FOUND

Lost items should be returned to the Congress Welcome Desk (level 3). Should you lose anything, please report to this desk for assistance.

II. POSTERS

See relevant chapter.

II. SMOKING POLICY

Please note that smoking is prohibited by Law within the Congress premises.

II. SPEAKERS PREVIEW ROOM

In order to match with the most recent technology, each room is equipped with a single videoprojector (LCD for computer assisted presentations). For the general organisation, after having pick-up his badge at the welcome desk, each speaker should go to the PREVIEW ROOM, located on level 3, room 315.

Opening hours:
- Saturday September 11th, 2010 from 7:00 to 20:30
- Sunday September 12th, 2010 from 7:00 to 19:30
- Monday September 13th, 2010 from 7:00 to 19:30
- Tuesday September 14th, 2010 from 7:00 to 19:30
- Wednesday September 15th, 2010 from 7:00 to 19:30
- Thursday September 16th, 2010 from 7:00 to 13:00
- Friday September 17th, 2010 from 7:00 to 13:00

II. TELEPHONES

For international calls to France, dial the international code followed by 33 and the correspondent’s number (without the 0).

II. TRANSPORTATION

Official Airline

AIRFRANCE

Air France and its affiliated companies worldwide have been nominated Official airline for the ITC.

Identifier Code 08432AF

Valid for travel from 06/09/10 to 21/09/10

Discounts are applied to a wide range of airfares, in all classes of travel (Espace Première [First], Espace Affaires [Business] and Tempo [Coach] on all Air France flights worldwide.

To access the preferential fares granted for this event, use this link:

www.airfrance-globalmeetings.com

This present document of the event serves to justify the application of the preferential airfare. Keep it with you as you may be asked for it at any point of your journey. To locate your nearest Air France sales point, please consult:

www.airfrance.com

Train

For participants travelling within France to Paris by train on the occasion of the congress, special fares may be obtained with SNCF (French Railway Network).

Metro

The metro is the probably the best and quickest way to travel within the city. It operates from 5:30 am to 0:30 am. Information about the metro can be obtained from the RATP website (see below).

Bus

One way ticket costs 1.60€ and you can buy special passes for 2, 3 or 4 days depending on the duration of your stay at very good value for money. Although slower than the Metro or the RER at certain hours of the day (depending on the traffic density), the RATP buses (they are green) are frequent from 8:00 am to 8:00 pm. The services are more irregular after 8:00 pm. As for the Metro, you should buy a “Carte” or one of the formulas proposed. The lines to Porte Maillot are 82, 73, and the PC (kind of belt line following Paris city limits).

Taxi

The Noctambus service (for night-birds) operates during the night: 10 bus routes lead from the heart of Paris: Chaleté (avenue Victoria or rue Saint-Martin) to the city limits with departures every hour between 1:30 and 5:30 am.

Average fare from central Paris to the Palais des Congrès is 10 €. It is usual to leave a tip of up to 10% of the total fare.

Cars

To reach the Palais des Congrès, exit on the Boulevard périphérique (ring-road surrounding Paris) at the “PORTE MAILLOT”. The car park is under the Convention Centre with direct access to the meeting. Count approx. 29€ per day car park.

Going back from Paris to the airports

Access to Roissy Charles de Gaulle international airport (north of Paris), terminal 1 & terminal 2:
- By RER Express Commuter train: From Chatelet or Gare du Nord Stations, Line B.
- By Air France shuttle bus: Departure beside the Palais des Congrès every 15/20 minutes.

Access to Orly international airport (south of Paris), terminal West (domestic flights) or terminal South (international flights):
- By RER Express Commuter train: From Denfert Rochereau, Line B or Orly Bus.
- By Air France shuttle bus: Departure from Invalides Station.

II. USEFUL TELEPHONE NUMBERS

- Roissy-Charles de Gaulle Airport: 01 48 62 22 80
- Orly Airport 01 49 75 15 15
- Air France: 0820 820 820
- SNCF (French National Railways): 36 35

Taxis services:
- Taxis G7 01 47 39 47 39
- Taxis Bleus 01 49 63 10 10

II. USEFUL WEBSITES


II. VISAS AND PASSPORTS

Every person entering France should be in possession of a valid passport and/or identification card (except for members of the Euro zone). Some countries require a Visa. Please contact the nearest French Embassy or Consulate to your home for further information.
The Local Organising Committee has set up a specific Social Events Programme for the 14th International Thyroid Congress attendees. The different activities will be good opportunities for congress delegates and their spouses or for exhibitors to meet and renew old acquaintances or establish new links.

SOCIAL PROGRAMME

OPENING CEREMONY
(Included in the registration fees)

The Opening Ceremony of the 14th International Thyroid Congress will be held in the Grand Amphitheatre of the Palais des Congrès, on Saturday 11 September, at 6:30 pm. All delegates, accompanying persons and exhibitors are cordially invited to attend.

WELCOME RECEPTION
(Included in the registration fees)

Following the Opening Ceremony, a Welcome Reception will be offered to all attendees on Saturday 11 September, from 7:30 pm to 9:00 pm within the premises of the Palais des Congrès in the exhibition area. Do not miss this get together party. Delegates, spouses and exhibitors are most welcome.

CONGRESS DINNER
ROYAL EVENING IN VERSAILLES

Tuesday 14th September 2010

Programme and seating arrangement: Please visit the Congress Dinner Desk located on level 3 in the Hall Bordeaux to get the programme and to choose your seat no later than Tuesday 14th September, 10:00.

19:15
Departure by coach from the Palais des Congrès (meeting point down the escalators, street level)

23:00
End of the evening and return to Paris, Palais des Congrès, by coach

Dress code: suit and cocktail dress
Non-smoking dinner

Limited number of participants. Please ask the registration desk to check about last minute availabilities

Price per person: 120 €, VAT included

Return transportation by coach from and to the Palais des Congrès will be arranged.
ACCOMPANYING PERSONS’ PROGRAMME

Paris, THE BEST TRIP EVER…

Paris is a dynamic city. A renowned cultural capital and always at the forefront of current affairs: Paris is never short of ideas. Find all your interests satisfied. Paris offers unforgettable visits and walks, museums and many other unmissable, and marvellous things to taste and to experiment.

Optional tours

A specific optional tours programme has been tailor-made for regularly registered participants and accompanying persons. These visits will be an excellent opportunity to discover some of the most outstanding artistic and historic highlights of Paris and its surroundings.

Be guided through the intensity and richness of culture and taste the Parisian art-de-vivre!

Tours programme, description and conditions are indicated here below. To sign up for tours, please tick the corresponding boxes on the registration form and send your payment.

• All tours will be conducted in English.
• All tours depart from and return to the Palais des Congrès de Paris.
• Full day excursions include lunch.
• The organisers reserve the right to cancel tours with less than 10 participants.

For the half-day excursion - V1 and V3 - included in the Accompanying person’s registration fee, please indicate your choice on the relevant section in the web-site.

Saturday, September 11, 2010

V1 Paris City Tour
Departure by coach 10:00 am - Return 1:00 pm
Meet at the congress’ welcome desk
Included in the Accompanying Persons’ fee
Price per person : 42 €

V2 Cité de l’Architecture
Departure by metro 10:30 am - Return 1:00 pm
Meet at the congress’ welcome desk
Price per person : 35 €

V1 bis Paris City Tour
Departure by coach 2:00 pm - Return 5:00 pm
Meet at the congress’ welcome desk
Included in the Accompanying Persons’ fee
Price per person : 42 €

V3 Walking tour of Le Marais district and Carnavalet Museum
Departure by metro 2:00 pm - Return 5:00 pm
Meet at the congress’ welcome desk
Price per person : 35 €

Sunday, September 12, 2010

V4 Walking tour of Montmartre followed by wine tasting
Departure by metro 9:00 am - Return 1:00 pm
Meet at the congress’ welcome desk
Price per person : 52 €

V1 ter Paris City Tour
Departure by coach 10:00 am - Return 1:00 pm
Meet at the congress’ welcome desk
Included in the Accompanying Persons’ fee
Price per person : 42 €

V5 Cruise on the Seine and visit of the Eiffel Tower
Departure by metro 2:00 pm - Return 6:00 pm
Meet at the congress’ welcome desk
Included in the Accompanying Persons’ fee
Price per person : 54 €

V5 Impressionism Day
(Rouen and Giverny)
Departure by coach 8:00 am - Return 6:00 pm
Meet at the congress’ welcome desk
Price per person : 150 €
Monday, September 13, 2010

- **Da Vinci Code Tour**
  - Departure by coach 9:00 am - Return 1:00 pm
  - Meet at the congress’ welcome desk
  - Price per person: 80 €

- **Cooking School: Le Cordon Bleu**
  - Departure by metro 8:30 am - Return 12:00 pm
  - Meet at the congress’ welcome desk
  - Price per person: 90 €

Tuesday, September 14, 2010

- **Walking tour of Montmartre followed by wine tasting**
  - Departure by metro 2:00 pm - Return 6:00 pm
  - Meet at the congress’ welcome desk
  - Price per person: 52 €

Wednesday, September 15, 2010

- **Cruise on the Seine and visit of the Eiffel Tower**
  - Departure by metro 10:00 am - Return 2:00 pm
  - Meet at the congress’ welcome desk
  - Included in the Accompanying Persons’ fee
  - Price per person: 54 €

- **Claude Monet at Giverny**
  - Departure by coach 8:30 am - Return 1:00 pm
  - Meet at the congress’ welcome desk
  - Price per person: 41 €

Thursday, September 16, 2010

- **Versailles Palace**
  - Departure by coach 8:30 am – Return 1:00 pm
  - Meet at the congress’ welcome desk
  - Price per person: 70 €

- **Notre-Dame Cathedral, Conciergerie & Sainte-Chapelle – Classic Paris**
  - Departure by metro 2:00 pm - Return 5:00 pm
  - Meet at the congress’ welcome desk
  - Price per person: 28 €